{"9268d8f6495e6c459fbd82a4ffaea504fd816751": [["associated with ZIKV infection (microcephaly in newborns and Guillain-Barr\u00e9 syndrome in adults [7] [8] [9] ), indicate an urgent need for research into the biology of the pathogen.", [["ZIKV infection", "DISEASE", 16, 30], ["microcephaly", "DISEASE", 32, 44], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 61, 84], ["Guillain-Barr\u00e9", "ORGANISM", 61, 75], ["ZIKV", "SPECIES", 16, 20], ["ZIKV infection", "PROBLEM", 16, 30], ["microcephaly in newborns", "PROBLEM", 32, 56], ["Barr\u00e9 syndrome", "PROBLEM", 70, 84], ["ZIKV", "OBSERVATION_MODIFIER", 16, 20], ["infection", "OBSERVATION", 21, 30], ["microcephaly", "OBSERVATION", 32, 44], ["Barr\u00e9 syndrome", "OBSERVATION", 70, 84], ["pathogen", "OBSERVATION", 171, 179]]]], "PMC7385316": [["MethodsN95 respirators were obtained from hospitals actively using various decontamination techniques, and respirators were donned on a mannequin that was covered in a layer of soft closed-cell foam.", [["cell", "ANATOMY", 189, 193], ["MethodsN95 respirators", "TREATMENT", 0, 22], ["various decontamination techniques", "TREATMENT", 67, 101], ["respirators", "TREATMENT", 107, 118], ["a mannequin", "TREATMENT", 134, 145], ["soft closed-cell foam", "TREATMENT", 177, 198], ["cell foam", "OBSERVATION", 189, 198]]], ["The mannequin was installed in a 0.1-m3 exposure chamber and flooded with polydispersed combustion aerosol.", [["The mannequin", "TREATMENT", 0, 13], ["polydispersed combustion aerosol", "TREATMENT", 74, 106], ["combustion aerosol", "OBSERVATION", 88, 106]]], ["For this study, almost all respirators were 3M 1860 or 1860S models (3M, St Paul, MN).", [["this study", "TEST", 4, 14]]], ["Air was sampled through the mask at 85 L/min and alternated between chamber and mask-occluded sampling, consistent with a method in our prior work.6 Aerosol samples were delivered to a scanning mobility particle sizer (model 3225/3080, TSI, Minneapolis, MN), which characterized particle size distribution from 16.8 nm to 650 nm and provides much more detailed respirator performance information than standard filtration efficiency testing.", [["samples", "ANATOMY", 157, 164], ["the mask", "TREATMENT", 24, 32], ["chamber and mask", "TREATMENT", 68, 84], ["occluded sampling", "PROBLEM", 85, 102], ["Aerosol samples", "TREATMENT", 149, 164], ["a scanning mobility particle sizer", "TEST", 183, 217], ["standard filtration efficiency testing", "TEST", 401, 439], ["occluded", "OBSERVATION", 85, 93], ["consistent with", "UNCERTAINTY", 104, 119], ["particle", "OBSERVATION_MODIFIER", 279, 287], ["size", "OBSERVATION_MODIFIER", 288, 292], ["16.8 nm", "OBSERVATION_MODIFIER", 311, 318]]], ["Incense was burned in a separate combustion chamber and diluted ~50\u00d7 prior to delivery to the exposure chamber.", [["delivery", "TREATMENT", 78, 86], ["the exposure chamber", "TREATMENT", 90, 110], ["burned", "OBSERVATION_MODIFIER", 12, 18], ["combustion chamber", "OBSERVATION", 33, 51]]], ["Using incense aerosol is a more protective assessment because respirators are less effective at capturing combustion aerosol7 compared to sodium chloride.MethodsRespirator decontamination was performed off site using standard hospital processing protocols, and the quantity of masks was limited.", [["sodium chloride", "CHEMICAL", 138, 153], ["sodium chloride", "CHEMICAL", 138, 153], ["aerosol7", "SIMPLE_CHEMICAL", 117, 125], ["sodium chloride", "SIMPLE_CHEMICAL", 138, 153], ["incense aerosol", "TREATMENT", 6, 21], ["a more protective assessment", "TEST", 25, 53], ["sodium chloride", "TEST", 138, 153], ["MethodsRespirator decontamination", "TREATMENT", 154, 187], ["standard hospital processing protocols", "TREATMENT", 217, 255]]], ["The related data are summarized in Table 1.Methods", [["Methods", "TREATMENT", 43, 50]]]], "PMC7498276": [["IntroductionThe availability of nuclear medicine in Sub-Saharan Africa has increased significantly in the past two decades [1].", [["nuclear", "ANATOMY", 32, 39], ["nuclear", "CELLULAR_COMPONENT", 32, 39]]], ["Whilst South Africa has the most advanced nuclear medicine (NM) practices on the continent, spanning over six decades, the growth of NM in most of the other Sub-Saharan African countries is a recent event [1, 2].", [["NM", "DISEASE", 133, 135]]], ["NM diagnostic and treatment procedures are among the most powerful analytic tools for decision-making in the management of cancer, cardiovascular and neurological diseases.", [["cancer", "ANATOMY", 123, 129], ["cardiovascular", "ANATOMY", 131, 145], ["neurological", "ANATOMY", 150, 162], ["cancer", "DISEASE", 123, 129], ["cardiovascular and neurological diseases", "DISEASE", 131, 171], ["cancer", "CANCER", 123, 129], ["cardiovascular", "ANATOMICAL_SYSTEM", 131, 145], ["treatment procedures", "TREATMENT", 18, 38], ["cancer", "PROBLEM", 123, 129], ["cardiovascular and neurological diseases", "PROBLEM", 131, 171], ["cancer", "OBSERVATION", 123, 129], ["neurological diseases", "OBSERVATION", 150, 171]]], ["Appropriate utilisation of NM tools has led to fewer patients undergoing invasive and costly tests and sometimes unnecessary treatments including invasive surgeries [3].", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["costly tests", "TEST", 86, 98], ["unnecessary treatments", "TREATMENT", 113, 135], ["invasive surgeries", "TREATMENT", 146, 164]]], ["The impact of NM on the management of cancer led to the strengthening of NM capacity by the International Atomic Energy Agency (IAEA) among member states in Africa, as a part of international cancer control efforts [1\u20135].", [["cancer", "ANATOMY", 38, 44], ["cancer", "ANATOMY", 192, 198], ["cancer", "DISEASE", 38, 44], ["cancer", "DISEASE", 192, 198], ["cancer", "CANCER", 38, 44], ["cancer", "CANCER", 192, 198], ["the management", "TREATMENT", 20, 34], ["cancer", "PROBLEM", 38, 44], ["NM capacity", "PROBLEM", 73, 84], ["cancer", "OBSERVATION", 38, 44]]], ["However, the growth of NM in Sub-Saharan Africa continues to face many challenges.", [["NM", "DISEASE", 23, 25], ["growth", "OBSERVATION_MODIFIER", 13, 19], ["NM", "OBSERVATION_MODIFIER", 23, 25]]], ["The known barriers include ageing equipment [4], culturally embedded dread of radiation [6], logistic challenges with radionuclide delivery [3, 7, 8], lack of health insurance [9], as well as other systemic barriers that limit health systems in developing countries [2, 10].IntroductionThe incidence of cancer is increasing in most of the African countries [11\u201314].", [["cancer", "ANATOMY", 303, 309], ["cancer", "DISEASE", 303, 309], ["cancer", "CANCER", 303, 309], ["radiation", "TREATMENT", 78, 87], ["radionuclide delivery", "TREATMENT", 118, 139], ["cancer", "PROBLEM", 303, 309], ["cancer", "OBSERVATION", 303, 309], ["increasing", "OBSERVATION_MODIFIER", 313, 323]]], ["The demographic and epidemiological changes are leading to a rise in the non-communicable disease burden on public healthcare in Nigeria, Africa\u2019s most populous country [15].", [["the non-communicable disease burden", "PROBLEM", 69, 104], ["rise", "OBSERVATION_MODIFIER", 61, 65], ["non-communicable", "OBSERVATION_MODIFIER", 73, 89], ["disease", "OBSERVATION", 90, 97]]], ["As a part of the national strategic health plans, NM planners in Nigeria projected that the country would require a minimum of 10 NM centres to provide equitable access to NM services in the country.", [["a minimum of 10 NM centres", "TREATMENT", 114, 140]]], ["Using their intuitive judgement, the sites of the ten NM centres were in tertiary hospitals that will provide radiation oncology services [8].", [["the ten NM centres", "TREATMENT", 46, 64], ["radiation oncology services", "TREATMENT", 110, 137]]], ["It is geographically located in the southwest region of the country at Nigeria\u2019s first tertiary hospital and oldest medical school [16].", [["geographically", "OBSERVATION_MODIFIER", 6, 20]]], ["The second centre was opened in 2007 at the Nation\u2019s capital city, which is geographically in the northern central region of the country.IntroductionBoth centres have a similar complement of NM physicians, which are in tertiary hospitals and major regional referral centres for radiotherapy.", [["radiotherapy", "TREATMENT", 278, 290], ["geographically", "OBSERVATION_MODIFIER", 76, 90], ["northern", "ANATOMY_MODIFIER", 98, 106], ["central", "ANATOMY_MODIFIER", 107, 114], ["region", "ANATOMY_MODIFIER", 115, 121]]], ["However, the centre under review is more established with four radiopharmacists, a dedicated medical physicist and two gamma cameras\u2014including the only hybrid single-photon emission computer tomography/computer tomography (SPECT/CT) scanner in West Africa [17].", [["computer tomography", "TEST", 202, 221], ["SPECT/CT) scanner", "TEST", 223, 240]]], ["Furthermore, it is purpose built to accommodate two positron emission tomography (PET) scanners and a cyclotron and recently expanded from two to ten isolation rooms for radionuclide therapy, making it the largest NM facility in the country.", [["two positron emission tomography", "TEST", 48, 80], ["a cyclotron", "TREATMENT", 100, 111], ["radionuclide therapy", "TREATMENT", 170, 190]]], ["The second centre is equipped with a double-head SPECT camera and has two radiopharmacists and two NM physicians.", [["a double-head SPECT camera", "TREATMENT", 35, 61]]], ["To inform the relevant public health initiatives that will be required to promote NM in Nigeria, this study assessed the pattern of NM imaging services at the first NM centre in Nigeria from January 2010 to December 2018.Referral pattern of patients ::: Subjects and methodsReferral patterns were characterised by the type of referral hospital and referring physician speciality.", [["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["this study", "TEST", 97, 107]]], ["The residential address provided by patients was used to determine the state of residence in Nigeria.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["Subsequently, the geospatial data were generated from the centroid coordinate of each state in Nigeria and was obtained from a digital map of Nigeria.", [["the geospatial data", "TEST", 14, 33]]], ["New columns (latitude and longitude) were created, and the corresponding centroid coordinate of each patient was added.", [["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["New columns (latitude and longitude)", "TREATMENT", 0, 36], ["columns", "OBSERVATION_MODIFIER", 4, 11]]], ["The distance to the nearest hub algorithms was implemented based on the data.", [["the data", "TEST", 68, 76]]], ["Subsequently, the distance travelled to obtain NM scans was estimated.", [["NM scans", "TEST", 47, 55]]], ["A 100 km distance was empirically chosen to categorise the distance travelled to obtain scans into two groups (\u2264100 km or >100 km).Categorisation of radionuclide scans ::: Subjects and methodsWe performed all scans in accordance with the international guidelines as published by the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging.", [["scans", "TEST", 88, 93], ["radionuclide scans", "TEST", 149, 167], ["all scans", "TEST", 205, 214], ["Molecular Imaging", "TEST", 364, 381]]], ["Procedures were characterised according to the common single-photon emission computer tomography (SPECT) scan types (bone, renal, thyroid or whole-body iodine scans or others).", [["bone", "ANATOMY", 117, 121], ["renal", "ANATOMY", 123, 128], ["thyroid", "ANATOMY", 130, 137], ["body", "ANATOMY", 147, 151], ["iodine", "CHEMICAL", 152, 158], ["bone", "TISSUE", 117, 121], ["renal", "ORGAN", 123, 128], ["thyroid", "ORGAN", 130, 137], ["body", "ORGANISM_SUBDIVISION", 147, 151], ["iodine", "SIMPLE_CHEMICAL", 152, 158], ["SPECT) scan types", "TEST", 98, 115], ["bone", "TEST", 117, 121], ["bone", "ANATOMY", 117, 121], ["renal", "ANATOMY", 123, 128], ["thyroid", "ANATOMY", 130, 137]]], ["Less commonly requested SPECT scans include brain, cardiac, lung and gastrointestinal (GI) scans and were grouped under the category \u2018others\u2019.", [["brain", "ANATOMY", 44, 49], ["cardiac", "ANATOMY", 51, 58], ["lung", "ANATOMY", 60, 64], ["gastrointestinal", "ANATOMY", 69, 85], ["GI", "ANATOMY", 87, 89], ["brain, cardiac, lung and gastrointestinal (GI)", "DISEASE", 44, 90], ["brain", "ORGAN", 44, 49], ["cardiac", "ORGAN", 51, 58], ["lung", "ORGAN", 60, 64], ["gastrointestinal", "ORGAN", 69, 85], ["SPECT scans", "TEST", 24, 35], ["brain, cardiac, lung and gastrointestinal (GI) scans", "TEST", 44, 96], ["brain", "ANATOMY", 44, 49], ["cardiac", "ANATOMY", 51, 58], ["lung", "ANATOMY", 60, 64], ["gastrointestinal", "ANATOMY", 69, 85]]], ["Indications for NM scans were further subclassified as follows: common oncologic (cancers of the breast, prostate, cervix and GI tract), less common oncologic (all other cancers) and non-oncologic indications.Statistical analysis ::: Subjects and methodsDescriptive statistics were assessed for the means and standard deviations (SD) for continuous variables, whereas the percentages were assessed for categorical variables.", [["cancers", "ANATOMY", 82, 89], ["breast", "ANATOMY", 97, 103], ["prostate", "ANATOMY", 105, 113], ["cervix", "ANATOMY", 115, 121], ["GI tract", "ANATOMY", 126, 134], ["cancers", "ANATOMY", 170, 177], ["cancers of the breast, prostate, cervix and GI tract", "DISEASE", 82, 134], ["cancers", "DISEASE", 170, 177], ["cancers", "CANCER", 82, 89], ["breast", "CANCER", 97, 103], ["prostate", "CANCER", 105, 113], ["cervix", "CANCER", 115, 121], ["GI tract", "CANCER", 126, 134], ["cancers", "CANCER", 170, 177], ["NM scans", "TEST", 16, 24], ["common oncologic (cancers of the breast, prostate, cervix and GI tract", "PROBLEM", 64, 134], ["all other cancers", "PROBLEM", 160, 177], ["non-oncologic indications", "TREATMENT", 183, 208], ["breast", "ANATOMY", 97, 103], ["prostate", "ANATOMY", 105, 113], ["cervix", "ANATOMY", 115, 121], ["GI tract", "ANATOMY", 126, 134]]], ["All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and the National Cancer Institute\u2019s Joinpoint software.", [["Cancer", "DISEASE", 105, 111], ["All statistical analyses", "TEST", 0, 24], ["SAS version", "TEST", 46, 57]]], ["A statistical significance was set at p < 0.05.Demographic characteristics of patients ::: ResultsTable 1 shows the general characteristic of patients.", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 142, 150]]], ["The mean age was 53.7 \u00b1 16.5 years (range: 0.1\u201393 years), and 58% were done in females.", [["The mean age", "TEST", 0, 12]]], ["The highest proportion of nuclear medicine scans was conducted in persons aged between 51 and 60 years (23.5%).", [["nuclear", "ANATOMY", 26, 33], ["nuclear", "CELLULAR_COMPONENT", 26, 33], ["persons", "ORGANISM", 66, 73], ["persons", "SPECIES", 66, 73], ["nuclear medicine scans", "TEST", 26, 48], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["The paediatric age group accounted for 3.4% of scans performed.Referral patterns ::: ResultsPatients travelled from all but four states in Nigeria (Figure 1), and most (65%) travelled more than 100 km to obtain scans (Figure 2).", [["scans", "TEST", 47, 52], ["scans", "TEST", 211, 216]]], ["Figure 3 shows the speciality of referring physicians during the study period.", [["the study", "TEST", 61, 70]]], ["Surgical specialities and radiation oncology accounted for 59% and 33.5% of total referrals, respectively.Characteristics of nuclear medicine scans ::: ResultsBone scanning with technetium-99m (99mTc)-labelled diphosphonates was the most common procedure (88.2%), followed by renal scans (7.3%), whereas pertechnetate thyroid scans and whole-body iodine (WBI) scans using radioactive iodine-131 (131I) accounted for 2.5% and 1.7% of scanning procedures, respectively (Table 1).", [["nuclear", "ANATOMY", 125, 132], ["Bone", "ANATOMY", 159, 163], ["renal", "ANATOMY", 276, 281], ["thyroid", "ANATOMY", 318, 325], ["technetium-99m (99mTc)-labelled diphosphonates", "CHEMICAL", 178, 224], ["radioactive iodine-131", "CHEMICAL", 372, 394], ["technetium", "CHEMICAL", 178, 188], ["99mTc", "CHEMICAL", 194, 199], ["diphosphonates", "CHEMICAL", 210, 224], ["pertechnetate", "CHEMICAL", 304, 317], ["iodine", "CHEMICAL", 347, 353], ["iodine-131", "CHEMICAL", 384, 394], ["nuclear", "CELLULAR_COMPONENT", 125, 132], ["Bone", "TISSUE", 159, 163], ["technetium-99m", "SIMPLE_CHEMICAL", 178, 192], ["99mTc)-labelled diphosphonates", "SIMPLE_CHEMICAL", 194, 224], ["renal", "ORGAN", 276, 281], ["pertechnetate", "SIMPLE_CHEMICAL", 304, 317], ["thyroid", "ORGAN", 318, 325], ["whole-body iodine", "SIMPLE_CHEMICAL", 336, 353], ["radioactive iodine-131", "SIMPLE_CHEMICAL", 372, 394], ["nuclear medicine scans", "TEST", 125, 147], ["Bone scanning", "TEST", 159, 172], ["technetium", "TEST", 178, 188], ["renal scans", "TEST", 276, 287], ["pertechnetate thyroid scans", "TEST", 304, 331], ["whole-body iodine (WBI", "TREATMENT", 336, 358], ["scans", "TEST", 360, 365], ["radioactive iodine", "TREATMENT", 372, 390], ["scanning procedures", "TEST", 433, 452], ["Bone", "ANATOMY", 159, 163], ["renal", "ANATOMY", 276, 281], ["thyroid", "ANATOMY", 318, 325]]], ["Overall, 86.3% of scans performed were for oncology indications.", [["scans", "TEST", 18, 23], ["oncology indications", "TREATMENT", 43, 63]]], ["Table 2 shows the common and less common oncology indications for scans.", [["scans", "TEST", 66, 71]]], ["Female breast cancers (44.8%), prostate cancers (30%), cervical cancers (1.7%) and GI cancers (1.5%) were the top four.", [["breast cancers", "ANATOMY", 7, 21], ["prostate cancers", "ANATOMY", 31, 47], ["cervical cancers", "ANATOMY", 55, 71], ["GI cancers", "ANATOMY", 83, 93], ["breast cancers", "DISEASE", 7, 21], ["prostate cancers", "DISEASE", 31, 47], ["cervical cancers", "DISEASE", 55, 71], ["GI cancers", "DISEASE", 83, 93], ["Female breast cancers", "CANCER", 0, 21], ["prostate cancers", "CANCER", 31, 47], ["cervical cancers", "CANCER", 55, 71], ["GI cancers", "CANCER", 83, 93], ["Female breast cancers", "PROBLEM", 0, 21], ["prostate cancers", "PROBLEM", 31, 47], ["cervical cancers", "PROBLEM", 55, 71], ["GI cancers", "PROBLEM", 83, 93], ["breast", "ANATOMY", 7, 13], ["cancers", "OBSERVATION", 14, 21], ["prostate", "ANATOMY", 31, 39], ["cancers", "OBSERVATION", 40, 47], ["cervical", "ANATOMY", 55, 63], ["cancers", "OBSERVATION", 64, 71], ["GI", "ANATOMY", 83, 85], ["cancers", "OBSERVATION", 86, 93]]], ["Among the less common oncologic indications, head and neck cancer was the most common, also accounting for 3.2 % of overall scans.Characteristics of nuclear medicine scans ::: ResultsOnly 585 scans were carried out for non-oncologic indications and are shown in Table 3.", [["head and neck cancer", "ANATOMY", 45, 65], ["nuclear", "ANATOMY", 149, 156], ["head and neck cancer", "DISEASE", 45, 65], ["head and neck cancer", "CANCER", 45, 65], ["nuclear", "CELLULAR_COMPONENT", 149, 156], ["head and neck cancer", "PROBLEM", 45, 65], ["overall scans", "TEST", 116, 129], ["nuclear medicine scans", "TEST", 149, 171], ["scans", "TEST", 192, 197], ["head", "ANATOMY", 45, 49], ["neck", "ANATOMY", 54, 58], ["cancer", "OBSERVATION", 59, 65], ["most common", "OBSERVATION_MODIFIER", 74, 85]]], ["Renal scans (53%) were the most common non-oncologic scans, followed by bone (25.5%) and thyroid (19%) scans.", [["Renal", "ANATOMY", 0, 5], ["bone", "ANATOMY", 72, 76], ["thyroid", "ANATOMY", 89, 96], ["Renal", "ORGAN", 0, 5], ["bone", "TISSUE", 72, 76], ["thyroid", "ORGAN", 89, 96], ["Renal scans", "TEST", 0, 11], ["bone", "TEST", 72, 76], ["thyroid (19%) scans", "TEST", 89, 108], ["bone", "ANATOMY", 72, 76], ["thyroid", "ANATOMY", 89, 96]]], ["Less commonly performed non-oncology scans during the study period included hepatobiliary scans using 99mTc-labelled iminodiacetic acid derivatives, parathyroid scans using the cardiac imaging agent MIBI (hexakis methoxy-isobutyl-isonitrile), lymphoscintigraphy and gastric emptying scan.", [["hepatobiliary", "ANATOMY", 76, 89], ["cardiac", "ANATOMY", 177, 184], ["gastric", "ANATOMY", 266, 273], ["99mTc-labelled iminodiacetic acid", "CHEMICAL", 102, 135], ["hexakis methoxy-isobutyl-isonitrile", "CHEMICAL", 205, 240], ["99mTc", "CHEMICAL", 102, 107], ["iminodiacetic acid", "CHEMICAL", 117, 135], ["hexakis methoxy-isobutyl-isonitrile", "CHEMICAL", 205, 240], ["hepatobiliary", "ORGAN", 76, 89], ["99mTc-labelled iminodiacetic acid derivatives", "SIMPLE_CHEMICAL", 102, 147], ["parathyroid", "ORGAN", 149, 160], ["hexakis methoxy-isobutyl-isonitrile", "SIMPLE_CHEMICAL", 205, 240], ["gastric", "ORGAN", 266, 273], ["non-oncology scans", "TEST", 24, 42], ["the study", "TEST", 50, 59], ["hepatobiliary scans", "TEST", 76, 95], ["99mTc", "TEST", 102, 107], ["labelled iminodiacetic acid derivatives", "TREATMENT", 108, 147], ["parathyroid scans", "TEST", 149, 166], ["the cardiac imaging agent MIBI", "TEST", 173, 203], ["hexakis methoxy", "TREATMENT", 205, 220], ["isobutyl-isonitrile", "TREATMENT", 221, 240], ["lymphoscintigraphy", "TREATMENT", 243, 261], ["gastric emptying scan", "TEST", 266, 287], ["hepatobiliary", "ANATOMY", 76, 89], ["cardiac", "ANATOMY", 177, 184], ["gastric", "ANATOMY", 266, 273]]], ["Technetium-labelled mercapto-acetyl-triglycine (99mTc-MAG3) and technetium labelled-diethylenetriaminepentaacetic acid (99mTc-DTPA) accounted for 90% of renograms, whereas the remainder were 99mTc-DMSA scans (technetium-99m- labelled dimercaptosuccinic acid).", [["Technetium", "CHEMICAL", 0, 10], ["mercapto-acetyl-triglycine", "CHEMICAL", 20, 46], ["99mTc-MAG3", "CHEMICAL", 48, 58], ["technetium labelled-diethylenetriaminepentaacetic acid", "CHEMICAL", 64, 118], ["99mTc-DTPA", "CHEMICAL", 120, 130], ["99mTc-DMSA", "CHEMICAL", 191, 201], ["technetium-99m- labelled dimercaptosuccinic acid", "CHEMICAL", 209, 257], ["Technetium-labelled mercapto-acetyl-triglycine", "CHEMICAL", 0, 46], ["99mTc-MAG3", "CHEMICAL", 48, 58], ["technetium labelled-diethylenetriaminepentaacetic acid", "CHEMICAL", 64, 118], ["99mTc-DTPA", "CHEMICAL", 120, 130], ["99mTc", "CHEMICAL", 191, 196], ["DMSA", "CHEMICAL", 197, 201], ["technetium-99m", "CHEMICAL", 209, 223], ["dimercaptosuccinic acid", "CHEMICAL", 234, 257], ["Technetium-labelled mercapto-acetyl-triglycine", "SIMPLE_CHEMICAL", 0, 46], ["99mTc-MAG3", "SIMPLE_CHEMICAL", 48, 58], ["technetium labelled-diethylenetriaminepentaacetic acid", "SIMPLE_CHEMICAL", 64, 118], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 120, 130], ["99mTc-DMSA", "SIMPLE_CHEMICAL", 191, 201], ["technetium-99m- labelled dimercaptosuccinic acid", "SIMPLE_CHEMICAL", 209, 257], ["Technetium", "TEST", 0, 10], ["labelled mercapto-acetyl", "TEST", 11, 35], ["triglycine", "TEST", 36, 46], ["MAG3", "TEST", 54, 58], ["technetium", "TEST", 64, 74], ["diethylenetriaminepentaacetic acid", "TREATMENT", 84, 118], ["DMSA scans", "TEST", 197, 207], ["technetium", "TEST", 209, 219], ["dimercaptosuccinic acid", "TEST", 234, 257]]], ["Furthermore, an evaluation of non-oncologic indications for scans showed that that scans for the evaluation of pain/inflammation were the most common non-oncologic bone scan followed by scans to evaluate for infection.", [["bone", "ANATOMY", 164, 168], ["pain", "DISEASE", 111, 115], ["inflammation", "DISEASE", 116, 128], ["infection", "DISEASE", 208, 217], ["bone", "TISSUE", 164, 168], ["an evaluation", "TEST", 13, 26], ["scans", "TEST", 60, 65], ["that scans", "TEST", 78, 88], ["the evaluation", "TEST", 93, 107], ["pain", "PROBLEM", 111, 115], ["inflammation", "PROBLEM", 116, 128], ["non-oncologic bone scan", "TEST", 150, 173], ["scans", "TEST", 186, 191], ["infection", "PROBLEM", 208, 217], ["infection", "OBSERVATION", 208, 217]]], ["Notably, all requests for infection imaging were from in-hospital orthopaedic surgeons.Trend analysis ::: ResultsThe trends of scans performed from 2010 to 2018 showed a significant increase in the APC of renal and thyroid scans by 21.4% and 33.6%, respectively.", [["renal", "ANATOMY", 205, 210], ["thyroid", "ANATOMY", 215, 222], ["infection", "DISEASE", 26, 35], ["APC", "GENE_OR_GENE_PRODUCT", 198, 201], ["renal", "ORGAN", 205, 210], ["thyroid", "ORGAN", 215, 222], ["APC", "CELL_TYPE", 198, 201], ["infection imaging", "TEST", 26, 43], ["scans", "TEST", 127, 132], ["renal and thyroid scans", "TEST", 205, 228], ["significant", "OBSERVATION_MODIFIER", 170, 181], ["increase", "OBSERVATION_MODIFIER", 182, 190], ["renal", "ANATOMY", 205, 210], ["thyroid", "ANATOMY", 215, 222]]], ["Conversely, bone scans decreased by 7.7%, but this was not statistically significant.", [["bone", "ANATOMY", 12, 16], ["bone", "TISSUE", 12, 16], ["bone scans", "TEST", 12, 22], ["bone", "ANATOMY", 12, 16]]], ["Furthermore, the analysis of the trend for bone scans showed a significant decrease in the APC for breast cancer (10.9%), whereas bone scans for prostate cancer increased by 5.1%.Trend analysis ::: ResultsOverall, a significant decline in in-hospital requests (APC: 11.6%) and an increase in outside hospital requests (APC: 11.60) were noted (p < 0.05).", [["bone", "ANATOMY", 43, 47], ["breast cancer", "ANATOMY", 99, 112], ["bone", "ANATOMY", 130, 134], ["prostate cancer", "ANATOMY", 145, 160], ["breast cancer", "DISEASE", 99, 112], ["prostate cancer", "DISEASE", 145, 160], ["bone", "TISSUE", 43, 47], ["APC", "GENE_OR_GENE_PRODUCT", 91, 94], ["breast cancer", "CANCER", 99, 112], ["bone", "TISSUE", 130, 134], ["prostate cancer", "CANCER", 145, 160], ["APC", "CELL_TYPE", 91, 94], ["the analysis", "TEST", 13, 25], ["bone scans", "TEST", 43, 53], ["a significant decrease in the APC", "PROBLEM", 61, 94], ["breast cancer", "PROBLEM", 99, 112], ["bone scans", "TEST", 130, 140], ["prostate cancer", "PROBLEM", 145, 160], ["a significant decline", "PROBLEM", 214, 235], ["APC", "TEST", 261, 264], ["APC", "TEST", 319, 322], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["decrease", "OBSERVATION_MODIFIER", 75, 83], ["breast", "ANATOMY", 99, 105], ["cancer", "OBSERVATION", 106, 112], ["bone", "ANATOMY", 130, 134], ["prostate", "ANATOMY", 145, 153], ["cancer", "OBSERVATION", 154, 160], ["significant", "OBSERVATION_MODIFIER", 216, 227], ["decline", "OBSERVATION_MODIFIER", 228, 235], ["increase", "OBSERVATION_MODIFIER", 280, 288]]], ["The volume of scans averaging 486 scans per annum is consistent with the other studies reporting similar low throughput of nuclear medicine departments in Sub-Saharan Africa [2, 4].", [["scans", "TEST", 14, 19], ["the other studies", "TEST", 69, 86], ["consistent with", "UNCERTAINTY", 53, 68]]], ["Besides the specific barriers of NM in Nigeria [4, 6\u20139], general challenges that affect oncology and healthcare delivery significantly impact on NM scans.", [["NM", "DISEASE", 33, 35], ["NM scans", "TEST", 145, 153]]], ["Since the majority of the referrals come from oncologists, radiotherapy equipment downtime and industrial strike actions by health professionals trade unions impact on NM services [18].", [["radiotherapy equipment downtime", "TREATMENT", 59, 90]]], ["External strikes (aviation and logistics) are not only less frequent but also halt NM service delivery.", [["External strikes", "PROBLEM", 0, 16], ["halt NM service delivery", "TREATMENT", 78, 102], ["strikes", "OBSERVATION", 9, 16]]], ["For instance, since the global COVID-19 pandemic started, an import of radionuclides from overseas has been disrupted.", [["the global COVID", "TEST", 20, 36], ["pandemic", "PROBLEM", 40, 48]]], ["The affordability of scans also plays a major role in the utilisation of NM procedures in Nigeria [9].", [["scans", "TEST", 21, 26], ["NM procedures", "TREATMENT", 73, 86]]], ["In our experience, camera downtime as a factor for under utility of NM is infrequent.", [["NM", "DISEASE", 68, 70], ["NM", "MULTI-TISSUE_STRUCTURE", 68, 70]]], ["Its effects are minimised due to the availability of two gamma cameras.DiscussionThe low utility of NM scans could be partly explained by the accessibility of services.", [["NM scans", "TEST", 100, 108]]], ["With only two centres nationwide, patients would have to travel long distances to obtain services [9].", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Although patients travelled from all but four states in the country, the numbers of scans diminished with distance travelled (Figure 1).", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["scans", "TEST", 84, 89], ["diminished", "OBSERVATION_MODIFIER", 90, 100]]], ["The four states without referrals are a part of six states in Nigeria with remarkably high rates of severe malnutrition [19].", [["malnutrition", "DISEASE", 107, 119], ["severe malnutrition", "PROBLEM", 100, 119], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["malnutrition", "OBSERVATION", 107, 119]]], ["Therefore, it is likely that travel distance and socioeconomic factors play a role in the utility of NM services.", [["NM services", "TREATMENT", 101, 112], ["is likely", "UNCERTAINTY", 14, 23]]], ["This could be evaluated in the further studies.DiscussionThe results show that few NM scans were performed for non-oncologic indications.", [["the further studies", "TEST", 27, 46], ["few NM scans", "TEST", 79, 91]]], ["Remarkably, no cardiac imaging was conducted during the period under review.", [["cardiac", "ANATOMY", 15, 22], ["cardiac imaging", "TEST", 15, 30]]], ["The absence of nuclear cardiology imaging may have contributed to the low scan volumes in this study.", [["nuclear", "ANATOMY", 15, 22], ["nuclear", "CELLULAR_COMPONENT", 15, 22], ["nuclear cardiology imaging", "TEST", 15, 41], ["the low scan volumes", "PROBLEM", 66, 86], ["this study", "TEST", 90, 100]]], ["Nuclear cardiology, in general, notably stress myocardial perfusion using single-photon emission computed tomography (SPECT), is underutilised in many developing countries [20\u201322].", [["myocardial", "ANATOMY", 47, 57], ["myocardial", "MULTI-TISSUE_STRUCTURE", 47, 57], ["single-photon emission computed tomography", "TEST", 74, 116], ["SPECT", "TEST", 118, 123]]], ["Myocardial ischaemia appears to be an infrequent cause of hospital deaths in Nigeria despite population-level changes in cardiovascular disease mortality and morbidity [23\u201325].", [["Myocardial", "ANATOMY", 0, 10], ["cardiovascular", "ANATOMY", 121, 135], ["Myocardial ischaemia", "DISEASE", 0, 20], ["deaths", "DISEASE", 67, 73], ["cardiovascular disease", "DISEASE", 121, 143], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 0, 10], ["cardiovascular", "ANATOMICAL_SYSTEM", 121, 135], ["Myocardial ischaemia", "PROBLEM", 0, 20], ["level changes", "PROBLEM", 104, 117], ["cardiovascular disease mortality", "PROBLEM", 121, 153], ["morbidity", "TEST", 158, 167], ["ischaemia", "OBSERVATION", 11, 20], ["appears to be", "UNCERTAINTY", 21, 34], ["cardiovascular", "ANATOMY", 121, 135]]], ["The ability to foster the adoption and expansion of nuclear cardiology in developing countries may be blunted by the marked decline of SPECT cardiology imaging globally [26].DiscussionInfectious diseases continue to be the leading cause of mortality in Sub-Saharan Africa [11].", [["DiscussionInfectious diseases", "DISEASE", 174, 203], ["nuclear", "CELLULAR_COMPONENT", 52, 59], ["SPECT cardiology imaging", "TEST", 135, 159], ["DiscussionInfectious diseases", "PROBLEM", 174, 203], ["marked", "OBSERVATION_MODIFIER", 117, 123]]], ["This proposes that the need for infection imaging will be high.", [["infection", "DISEASE", 32, 41], ["infection imaging", "TEST", 32, 49]]], ["The utility of NM for infection imaging was low and limited to referrals from in-hospital orthopaedic surgeons.", [["infection", "DISEASE", 22, 31], ["NM", "MULTI-TISSUE_STRUCTURE", 15, 17], ["infection imaging", "TEST", 22, 39]]], ["Although in-house orthopaedic surgeons are renown experts in the country and more informed about NM services [27], we do not believe that they are utilising NM scans to the maximum possible.", [["NM scans", "TEST", 157, 165]]], ["Feedback of their dissatisfaction with bone scans for the evaluation of prosthetic joint inspired efforts to introduce technetium-labelled ubiquicidin peptide (99mTc-UBI).", [["bone", "ANATOMY", 39, 43], ["joint", "ANATOMY", 83, 88], ["technetium", "CHEMICAL", 119, 129], ["ubiquicidin peptide", "CHEMICAL", 139, 158], ["99mTc-UBI", "CHEMICAL", 160, 169], ["technetium", "CHEMICAL", 119, 129], ["ubiquicidin peptide", "CHEMICAL", 139, 158], ["99mTc", "CHEMICAL", 160, 165], ["bone", "TISSUE", 39, 43], ["technetium-labelled ubiquicidin peptide", "SIMPLE_CHEMICAL", 119, 158], ["99mTc-UBI", "SIMPLE_CHEMICAL", 160, 169], ["bone scans", "TEST", 39, 49], ["the evaluation", "TEST", 54, 68], ["prosthetic joint", "PROBLEM", 72, 88], ["technetium", "TEST", 119, 129], ["labelled ubiquicidin peptide", "TREATMENT", 130, 158], ["prosthetic joint", "OBSERVATION", 72, 88]]], ["However, the local research studies to evaluate its impact are required.", [["the local research studies", "TEST", 9, 35]]], ["Conducting research has been shown to facilitate the adoption of new techniques in small-scale initiatives [28].", [["new techniques", "TREATMENT", 65, 79], ["small-scale initiatives", "TREATMENT", 83, 106]]], ["Given the recent development of infection-specific radiopharmaceuticals such as 99mTc-UBI [29], advances in SPECT quantification and standardisation of imaging procedures [30], the approaches to raise awareness about NM infection imaging and its potential adoption are needed.DiscussionOverall, the low utility of NM for non-oncologic scans may not be unrelated to the promotion of NM at its founding as an important tool for cancer management [4, 5].", [["cancer", "ANATOMY", 426, 432], ["infection", "DISEASE", 32, 41], ["99mTc-UBI", "CHEMICAL", 80, 89], ["infection", "DISEASE", 220, 229], ["cancer", "DISEASE", 426, 432], ["99mTc", "CHEMICAL", 80, 85], ["99mTc", "SIMPLE_CHEMICAL", 80, 85], ["NM", "MULTI-TISSUE_STRUCTURE", 217, 219], ["NM", "MULTI-TISSUE_STRUCTURE", 314, 316], ["cancer", "CANCER", 426, 432], ["infection", "PROBLEM", 32, 41], ["specific radiopharmaceuticals", "TEST", 42, 71], ["SPECT quantification", "TEST", 108, 128], ["imaging procedures", "TEST", 152, 170], ["NM infection imaging", "TEST", 217, 237], ["non-oncologic scans", "TEST", 321, 340], ["cancer management", "TREATMENT", 426, 443], ["infection", "OBSERVATION", 32, 41]]], ["Furthermore, the studies to explore other unknown factors that play a role in the low throughput of NM services in Nigeria and other Sub-Saharan African countries are warranted.", [["the studies", "TEST", 13, 24], ["NM services", "TREATMENT", 100, 111]]], ["Investigating the challenges of implementation and adoption of NM in sub-Sahara Africa should not be overlooked.DiscussionThe predominant use of diuresis renography among adults in this study is noteworthy.", [["NM", "DISEASE", 63, 65], ["diuresis renography", "TREATMENT", 145, 164], ["this study", "TEST", 181, 191]]], ["It contrasts with the reports from developed countries, where diuresis renography is predominantly used in children for the early detection and management of congenital abnormalities of the kidneys and urinary tracts (CAKUT) [32\u201335].", [["kidneys", "ANATOMY", 190, 197], ["urinary tracts", "ANATOMY", 202, 216], ["congenital abnormalities of the kidneys and urinary tracts", "DISEASE", 158, 216], ["children", "ORGANISM", 107, 115], ["kidneys", "ORGAN", 190, 197], ["urinary tracts", "ORGANISM_SUBDIVISION", 202, 216], ["children", "SPECIES", 107, 115], ["diuresis renography", "TREATMENT", 62, 81], ["the early detection", "TEST", 120, 139], ["management", "TREATMENT", 144, 154], ["congenital abnormalities of the kidneys and urinary tracts", "PROBLEM", 158, 216], ["predominantly", "OBSERVATION_MODIFIER", 85, 98], ["congenital", "OBSERVATION", 158, 168], ["kidneys", "ANATOMY", 190, 197], ["urinary tracts", "ANATOMY", 202, 216]]], ["In Nigeria, CAKUT is responsible for between 7.8% and 17.5% of paediatric admissions and a major cause of chronic kidney disease among children [32, 36\u201338].", [["kidney", "ANATOMY", 114, 120], ["chronic kidney disease", "DISEASE", 106, 128], ["kidney", "ORGAN", 114, 120], ["children", "ORGANISM", 135, 143], ["children", "SPECIES", 135, 143], ["chronic kidney disease", "PROBLEM", 106, 128], ["CAKUT", "OBSERVATION", 12, 17], ["chronic", "OBSERVATION_MODIFIER", 106, 113], ["kidney", "ANATOMY", 114, 120], ["disease", "OBSERVATION", 121, 128]]], ["Coordinated efforts to improve the diagnosis and treatment of renal diseases in childhood are needed and may impact on renal diseases observed in adulthood.", [["renal", "ANATOMY", 62, 67], ["renal", "ANATOMY", 119, 124], ["renal diseases", "DISEASE", 62, 76], ["renal diseases", "DISEASE", 119, 133], ["renal", "ORGAN", 62, 67], ["renal", "ORGAN", 119, 124], ["renal diseases", "PROBLEM", 62, 76], ["renal diseases", "PROBLEM", 119, 133], ["renal", "ANATOMY", 62, 67], ["diseases", "OBSERVATION", 68, 76], ["renal", "ANATOMY", 119, 124], ["diseases", "OBSERVATION", 125, 133]]], ["Opportunities for multidisciplinary research and coordination of public health paediatric care in proximity to NM centres should be explored further.DiscussionThe role of NM in thyroid disease continues to be of interest.", [["thyroid", "ANATOMY", 177, 184], ["thyroid disease", "DISEASE", 177, 192], ["NM", "MULTI-TISSUE_STRUCTURE", 171, 173], ["thyroid", "ORGAN", 177, 184], ["public health paediatric care", "TREATMENT", 65, 94], ["NM centres", "TREATMENT", 111, 121], ["thyroid disease", "PROBLEM", 177, 192], ["thyroid", "ANATOMY", 177, 184], ["disease", "OBSERVATION", 185, 192]]], ["The current role of thyroid scintigraphy for diagnosis is adjunctive [39].", [["thyroid", "ANATOMY", 20, 27], ["thyroid", "ORGAN", 20, 27], ["thyroid scintigraphy", "TEST", 20, 40], ["thyroid", "ANATOMY", 20, 27]]], ["Several radionuclides are used for thyroid imaging, where NM contributes to the treatment of both oncologic and non-oncologic conditions.", [["thyroid", "ANATOMY", 35, 42], ["thyroid", "ORGAN", 35, 42], ["Several radionuclides", "TREATMENT", 0, 21], ["thyroid imaging", "TEST", 35, 50], ["non-oncologic conditions", "TREATMENT", 112, 136], ["radionuclides", "OBSERVATION", 8, 21]]], ["Radioactive iodine (123I) and pertechnetate (99mTcO4-) are the radionuclides used for imaging, whereas 131I is used for treatment.", [["iodine", "CHEMICAL", 12, 18], ["pertechnetate", "CHEMICAL", 30, 43], ["99mTcO4", "CHEMICAL", 45, 52], ["iodine", "CHEMICAL", 12, 18], ["123I", "CHEMICAL", 20, 24], ["pertechnetate", "CHEMICAL", 30, 43], ["99mTcO4", "CHEMICAL", 45, 52], ["Radioactive iodine", "SIMPLE_CHEMICAL", 0, 18], ["123I)", "SIMPLE_CHEMICAL", 20, 25], ["pertechnetate", "SIMPLE_CHEMICAL", 30, 43], ["99mTcO4", "SIMPLE_CHEMICAL", 45, 52], ["131I", "SIMPLE_CHEMICAL", 103, 107], ["Radioactive iodine", "TREATMENT", 0, 18], ["pertechnetate", "TREATMENT", 30, 43], ["imaging", "TEST", 86, 93], ["treatment", "TREATMENT", 120, 129]]], ["Similar to the other reports, this study shows 99mTc-pertechnetate as the main isotope used for thyroid imaging in resource-poor settings.", [["thyroid", "ANATOMY", 96, 103], ["99mTc-pertechnetate", "CHEMICAL", 47, 66], ["99mTc", "CHEMICAL", 47, 52], ["pertechnetate", "CHEMICAL", 53, 66], ["99mTc-pertechnetate", "SIMPLE_CHEMICAL", 47, 66], ["thyroid", "ORGAN", 96, 103], ["this study", "TEST", 30, 40], ["99mTc", "TEST", 47, 52], ["thyroid imaging", "TEST", 96, 111], ["thyroid", "ANATOMY", 96, 103]]], ["Its major indication for use is to evaluate clinically confirmed Graves\u2019 disease.", [["Graves\u2019 disease", "DISEASE", 65, 80], ["Graves\u2019 disease", "CANCER", 65, 80], ["Graves\u2019 disease", "PROBLEM", 65, 80], ["Graves", "OBSERVATION", 65, 71]]], ["Other indications include evaluation of thyroid nodules and thyroiditis to locate ectopic thyroid tissue [39, 40].", [["thyroid nodules", "ANATOMY", 40, 55], ["thyroid tissue", "ANATOMY", 90, 104], ["thyroiditis", "DISEASE", 60, 71], ["ectopic thyroid tissue", "DISEASE", 82, 104], ["thyroid nodules", "CANCER", 40, 55], ["thyroid tissue", "TISSUE", 90, 104], ["evaluation", "TEST", 26, 36], ["thyroid nodules", "PROBLEM", 40, 55], ["thyroiditis", "PROBLEM", 60, 71], ["ectopic thyroid tissue", "PROBLEM", 82, 104], ["thyroid", "ANATOMY", 40, 47], ["nodules", "OBSERVATION", 48, 55], ["thyroiditis", "OBSERVATION", 60, 71], ["ectopic", "OBSERVATION_MODIFIER", 82, 89], ["thyroid", "ANATOMY", 90, 97]]], ["Its low cost, ready availability, rapid imaging and lower absorbed dose are major advantages.", [["rapid imaging", "TEST", 34, 47], ["lower absorbed dose", "TREATMENT", 52, 71], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["For patients undergoing radioactive iodine therapy for benign and overactive goitres, it is routinely used to guide empirical dosing [6, 41].", [["radioactive iodine", "CHEMICAL", 24, 42], ["overactive goitres", "DISEASE", 66, 84], ["iodine", "CHEMICAL", 36, 42], ["patients", "ORGANISM", 4, 12], ["radioactive iodine", "SIMPLE_CHEMICAL", 24, 42], ["patients", "SPECIES", 4, 12], ["radioactive iodine therapy", "TREATMENT", 24, 50], ["benign and overactive goitres", "PROBLEM", 55, 84], ["goitres", "OBSERVATION", 77, 84]]], ["However, personalised radioiodine therapy is best achieved by a radioiodine uptake test [39].DiscussionRadioactive iodine 131I therapy (RAIT) is the first targeted theragnostic radionuclide in NM and plays an important role in thyroid carcinoma treatment [42].", [["thyroid carcinoma", "ANATOMY", 227, 244], ["DiscussionRadioactive iodine", "CHEMICAL", 93, 121], ["NM", "DISEASE", 193, 195], ["thyroid carcinoma", "DISEASE", 227, 244], ["iodine", "CHEMICAL", 115, 121], ["radioiodine", "SIMPLE_CHEMICAL", 22, 33], ["radioiodine", "SIMPLE_CHEMICAL", 64, 75], ["DiscussionRadioactive iodine 131I", "SIMPLE_CHEMICAL", 93, 126], ["NM", "CANCER", 193, 195], ["thyroid carcinoma", "CANCER", 227, 244], ["personalised radioiodine therapy", "TREATMENT", 9, 41], ["a radioiodine uptake test", "TEST", 62, 87], ["DiscussionRadioactive iodine 131I therapy", "TREATMENT", 93, 134], ["thyroid carcinoma treatment", "TREATMENT", 227, 254], ["thyroid", "ANATOMY", 227, 234], ["carcinoma", "OBSERVATION", 235, 244]]], ["The reports of the use of RAIT in Nigeria predate the establishment of the NM imaging facilities [43\u201345].", [["RAIT", "CHEMICAL", 26, 30]]], ["The rising patterns of thyroid and whole-body scintigraphy with 131I (WBI) in this study provide recognition for the impact of NM in Nigeria.", [["thyroid", "ANATOMY", 23, 30], ["body", "ANATOMY", 41, 45], ["NM", "DISEASE", 127, 129], ["thyroid", "ORGAN", 23, 30], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["131I", "SIMPLE_CHEMICAL", 64, 68], ["thyroid and whole-body scintigraphy", "TEST", 23, 58], ["this study", "TEST", 78, 88], ["rising", "OBSERVATION_MODIFIER", 4, 10], ["thyroid", "ANATOMY", 23, 30]]], ["WBI is recommended for staging of patients with suspected metastases from differentiated thyroid carcinomas.", [["metastases", "ANATOMY", 58, 68], ["thyroid carcinomas", "ANATOMY", 89, 107], ["metastases", "DISEASE", 58, 68], ["thyroid carcinomas", "DISEASE", 89, 107], ["patients", "ORGANISM", 34, 42], ["thyroid carcinomas", "CANCER", 89, 107], ["patients", "SPECIES", 34, 42], ["WBI", "TEST", 0, 3], ["staging", "TEST", 23, 30], ["suspected metastases", "PROBLEM", 48, 68], ["differentiated thyroid carcinomas", "PROBLEM", 74, 107], ["metastases", "OBSERVATION", 58, 68], ["differentiated", "OBSERVATION_MODIFIER", 74, 88], ["thyroid", "ANATOMY", 89, 96], ["carcinomas", "OBSERVATION", 97, 107]]], ["The use of the same radionuclide (131I) for diagnosis and treatment has its controversies [46].", [["treatment", "TREATMENT", 58, 67]]], ["However, it remains useful for identifying patients who will benefit from 131I from the other forms of therapy in the case of poorly differentiated or dedifferentiated thyroid carcinoma [42, 46].", [["dedifferentiated thyroid carcinoma", "ANATOMY", 151, 185], ["thyroid carcinoma", "DISEASE", 168, 185], ["patients", "ORGANISM", 43, 51], ["dedifferentiated thyroid carcinoma", "CANCER", 151, 185], ["patients", "SPECIES", 43, 51], ["therapy", "TREATMENT", 103, 110], ["poorly differentiated or dedifferentiated thyroid carcinoma", "PROBLEM", 126, 185], ["poorly differentiated", "OBSERVATION_MODIFIER", 126, 147], ["dedifferentiated", "OBSERVATION_MODIFIER", 151, 167], ["thyroid", "ANATOMY", 168, 175], ["carcinoma", "OBSERVATION", 176, 185]]], ["WBI provides information on nodal and distant metastases for staging of the disease and gives a visual representation for monitoring treatment response and detection of recurrence during follow-up [42, 46].", [["nodal", "ANATOMY", 28, 33], ["metastases", "ANATOMY", 46, 56], ["nodal", "MULTI-TISSUE_STRUCTURE", 28, 33], ["nodal and distant metastases", "PROBLEM", 28, 56], ["the disease", "PROBLEM", 72, 83], ["monitoring treatment", "TREATMENT", 122, 142], ["recurrence", "PROBLEM", 169, 179], ["nodal", "ANATOMY", 28, 33], ["distant", "OBSERVATION_MODIFIER", 38, 45], ["metastases", "OBSERVATION", 46, 56]]], ["Therefore, the routine administration of radioactive iodine 131I without radionuclide imaging is not recommended [40, 42, 46].", [["radioactive iodine", "CHEMICAL", 41, 59], ["iodine", "CHEMICAL", 53, 59], ["radioactive iodine 131I", "SIMPLE_CHEMICAL", 41, 64], ["radioactive iodine 131I", "TREATMENT", 41, 64], ["radionuclide imaging", "TEST", 73, 93]]], ["Opportunities to educate oncologists/endocrinologist on the role of imaging for radioactive iodine therapy must be sustained.DiscussionChallenges with radionuclide supply continue to impact on timely access to NM services and its growth in Nigeria [8].", [["radioactive iodine", "CHEMICAL", 80, 98], ["iodine", "CHEMICAL", 92, 98], ["radioactive iodine", "SIMPLE_CHEMICAL", 80, 98], ["imaging", "TEST", 68, 75], ["radioactive iodine therapy", "TREATMENT", 80, 106], ["NM services", "TREATMENT", 210, 221]]], ["This may contribute to the observed stable imaging trends despite population health evidence shows the need for NM.", [["NM", "TREATMENT", 112, 114], ["stable", "OBSERVATION_MODIFIER", 36, 42]]], ["The decline in bone scan for breast cancer may indicate the impact of evidence-based research on clinical practice.", [["bone", "ANATOMY", 15, 19], ["breast cancer", "ANATOMY", 29, 42], ["breast cancer", "DISEASE", 29, 42], ["bone", "TISSUE", 15, 19], ["breast cancer", "CANCER", 29, 42], ["The decline", "PROBLEM", 0, 11], ["bone scan", "TEST", 15, 24], ["breast cancer", "PROBLEM", 29, 42], ["clinical practice", "TREATMENT", 97, 114], ["decline", "OBSERVATION_MODIFIER", 4, 11], ["bone", "ANATOMY", 15, 19], ["breast", "ANATOMY", 29, 35], ["cancer", "OBSERVATION", 36, 42]]], ["In a prior study, we had shown that bone scan was frequently showed metastases in patients with stage III and IV disease.", [["bone", "ANATOMY", 36, 40], ["metastases", "ANATOMY", 68, 78], ["bone", "TISSUE", 36, 40], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["a prior study", "TEST", 3, 16], ["bone scan", "TEST", 36, 45], ["metastases", "PROBLEM", 68, 78], ["stage III and IV disease", "PROBLEM", 96, 120], ["bone", "ANATOMY", 36, 40], ["metastases", "OBSERVATION", 68, 78], ["stage III", "OBSERVATION_MODIFIER", 96, 105], ["disease", "OBSERVATION", 113, 120]]], ["Hence, the routine use of bone scan for staging is only in these patients [47].", [["bone", "ANATOMY", 26, 30], ["bone", "TISSUE", 26, 30], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["bone scan", "TEST", 26, 35], ["staging", "TEST", 40, 47]]], ["Consistent with global patterns, bone imaging with technetium-labelled diphosphonates was the most common procedure in the centre.", [["bone", "ANATOMY", 33, 37], ["technetium-labelled diphosphonates", "CHEMICAL", 51, 85], ["technetium", "CHEMICAL", 51, 61], ["diphosphonates", "CHEMICAL", 71, 85], ["bone", "TISSUE", 33, 37], ["technetium-labelled diphosphonates", "SIMPLE_CHEMICAL", 51, 85], ["bone imaging", "TEST", 33, 45], ["technetium", "TEST", 51, 61], ["labelled diphosphonates", "TREATMENT", 62, 85], ["global patterns", "OBSERVATION", 16, 31], ["bone", "ANATOMY", 33, 37]]], ["It is well established for staging of patients with prostate, breast, small-cell lung tumours and other cancers which frequently metastasise to bone [48, 49].", [["prostate", "ANATOMY", 52, 60], ["breast", "ANATOMY", 62, 68], ["small-cell lung tumours", "ANATOMY", 70, 93], ["cancers", "ANATOMY", 104, 111], ["bone", "ANATOMY", 144, 148], ["prostate, breast, small-cell lung tumours", "DISEASE", 52, 93], ["cancers", "DISEASE", 104, 111], ["patients", "ORGANISM", 38, 46], ["prostate", "CANCER", 52, 60], ["breast, small-cell lung tumours", "CANCER", 62, 93], ["cancers", "CANCER", 104, 111], ["bone", "TISSUE", 144, 148], ["patients", "SPECIES", 38, 46], ["staging", "TEST", 27, 34], ["prostate, breast, small-cell lung tumours", "PROBLEM", 52, 93], ["other cancers", "PROBLEM", 98, 111], ["prostate", "ANATOMY", 52, 60], ["breast", "ANATOMY", 62, 68], ["small-cell", "OBSERVATION", 70, 80], ["lung", "ANATOMY", 81, 85], ["tumours", "OBSERVATION", 86, 93], ["cancers", "OBSERVATION", 104, 111], ["bone", "ANATOMY", 144, 148]]], ["The top four oncologic indications for NM scans in this study were consistent with country figures [7, 23].DiscussionGeneral advances in imaging are increasingly revealing the limitations of bone scanning, particularly for modifying treatment outcomes and early detection of treatment response in cancers [50\u201352].", [["bone", "ANATOMY", 191, 195], ["cancers", "ANATOMY", 297, 304], ["cancers", "DISEASE", 297, 304], ["bone", "TISSUE", 191, 195], ["cancers", "CANCER", 297, 304], ["NM scans", "TEST", 39, 47], ["this study", "TEST", 51, 61], ["imaging", "TEST", 137, 144], ["bone scanning", "TEST", 191, 204], ["modifying treatment outcomes", "TREATMENT", 223, 251], ["treatment response in cancers", "PROBLEM", 275, 304]]], ["Recent PET tracers are promising for the application of PET in the initial evaluation of several oncologic diseases [53, 54].", [["Recent PET tracers", "TREATMENT", 0, 18], ["PET", "TREATMENT", 56, 59], ["the initial evaluation", "TEST", 63, 85], ["several oncologic diseases", "PROBLEM", 89, 115], ["several", "OBSERVATION_MODIFIER", 89, 96], ["oncologic diseases", "OBSERVATION", 97, 115]]], ["Since automated synthesis systems have increased the reliability, reproducibility and safety of radiopharmaceutical productions [55\u201357], the absence of PET services in Nigeria is largely due to the high cost of investment.", [["automated synthesis systems", "TEST", 6, 33], ["radiopharmaceutical productions", "TEST", 96, 127], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["In the southern hemisphere of Africa, the availability of PET is limited to South Africa and, recently, Kenya.", [["Africa", "OBSERVATION", 30, 36]]], ["Recent advances in SPECT technology are projected to advance SPECT closer to PET imaging [58].", [["SPECT technology", "TEST", 19, 35], ["SPECT", "TEST", 61, 66], ["PET imaging", "TEST", 77, 88]]], ["However, it will require matching advances in SPECT radiopharmacy and affordability within the reach of low-resource countries.", [["SPECT radiopharmacy", "TEST", 46, 65]]], ["Furthermore, the feasibility analysis on the need and utilisation of technological advances in NM technologies (Cyclotron, PET, SPECT) in Africa are warranted in the future.ConclusionNuclear medicine in Nigeria has been sustained for 13 years but appears underexplored and underutilised.", [["Nuclear", "CELLULAR_COMPONENT", 183, 190], ["the feasibility analysis", "TEST", 13, 37]]], ["However, the limited availability of NM services creates unequal access for patients who require these services.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["these services", "TREATMENT", 97, 111]]], ["Differential and contextual factors contribute to the slow growth of NM in Nigeria and increase the complexity of interventions that are required to boost it.", [["NM", "DISEASE", 69, 71], ["contextual factors", "PROBLEM", 17, 35], ["the slow growth of NM in Nigeria", "PROBLEM", 50, 82], ["interventions", "TREATMENT", 114, 127], ["slow", "OBSERVATION_MODIFIER", 54, 58], ["growth", "OBSERVATION_MODIFIER", 59, 65]]], ["Furthermore, the studies to characterise the access gaps and implementation needs are desired.", [["the studies", "TEST", 13, 24]]]], "dae1345c0f14ce2d06147f78edfd9298ecebf938": [["IntroductionA ventricular septal defect (VSD) is an abnormal communication between the left and right ventricle through a defect in the septal wall of the heart.", [["ventricular septal", "ANATOMY", 14, 32], ["left", "ANATOMY", 87, 91], ["right ventricle", "ANATOMY", 96, 111], ["septal wall", "ANATOMY", 136, 147], ["heart", "ANATOMY", 155, 160], ["ventricular septal defect", "DISEASE", 14, 39], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 14, 32], ["right ventricle", "MULTI-TISSUE_STRUCTURE", 96, 111], ["septal wall", "MULTI-TISSUE_STRUCTURE", 136, 147], ["heart", "ORGAN", 155, 160], ["IntroductionA ventricular septal defect", "PROBLEM", 0, 39], ["an abnormal communication between the left and right ventricle", "PROBLEM", 49, 111], ["a defect", "PROBLEM", 120, 128], ["ventricular septal", "ANATOMY", 14, 32], ["defect", "OBSERVATION", 33, 39], ["VSD", "OBSERVATION", 41, 44], ["abnormal", "OBSERVATION_MODIFIER", 52, 60], ["communication", "OBSERVATION", 61, 74], ["left", "ANATOMY_MODIFIER", 87, 91], ["right ventricle", "ANATOMY", 96, 111], ["defect", "OBSERVATION", 122, 128], ["septal", "ANATOMY_MODIFIER", 136, 142], ["wall", "ANATOMY_MODIFIER", 143, 147], ["heart", "ANATOMY", 155, 160]]], ["VSD is a rare but lethal complication of myocardial infarction (MI), it is also referred to as a ventricular septal rupture (VSR).", [["myocardial", "ANATOMY", 41, 51], ["ventricular septal", "ANATOMY", 97, 115], ["myocardial infarction", "DISEASE", 41, 62], ["MI", "DISEASE", 64, 66], ["ventricular septal rupture", "DISEASE", 97, 123], ["VSR", "DISEASE", 125, 128], ["myocardial", "MULTI-TISSUE_STRUCTURE", 41, 51], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 97, 115], ["VSD", "PROBLEM", 0, 3], ["myocardial infarction", "PROBLEM", 41, 62], ["MI", "PROBLEM", 64, 66], ["a ventricular septal rupture", "PROBLEM", 95, 123], ["myocardial", "ANATOMY", 41, 51], ["infarction", "OBSERVATION", 52, 62], ["ventricular septal", "ANATOMY", 97, 115], ["rupture", "OBSERVATION", 116, 123]]], ["A VSR after MI is uncommon and occurs only 1-2% of the time [1] .", [["VSR", "DISEASE", 2, 5], ["MI", "DISEASE", 12, 14], ["VSR", "CANCER", 2, 5], ["MI", "PROBLEM", 12, 14]]], ["The event occurs 2-8 days after an infarction and often leads to cardiogenic shock.", [["infarction", "DISEASE", 35, 45], ["cardiogenic shock", "DISEASE", 65, 82], ["an infarction", "PROBLEM", 32, 45], ["cardiogenic shock", "PROBLEM", 65, 82], ["infarction", "OBSERVATION", 35, 45], ["cardiogenic shock", "OBSERVATION", 65, 82]]], ["Conservative treatment is associated with 94% mortality, while surgical treatment is associated with 47% mortality during the first 30 days [2] .", [["Conservative treatment", "TREATMENT", 0, 22], ["surgical treatment", "TREATMENT", 63, 81]]], ["Making a decision to perform surgery is complicated by the critical preoperative condition of the patients and the myocardial tissues necrosis.", [["myocardial tissues", "ANATOMY", 115, 133], ["myocardial tissues necrosis", "DISEASE", 115, 142], ["patients", "ORGANISM", 98, 106], ["myocardial tissues", "TISSUE", 115, 133], ["patients", "SPECIES", 98, 106], ["surgery", "TREATMENT", 29, 36], ["the myocardial tissues necrosis", "PROBLEM", 111, 142], ["myocardial tissues", "ANATOMY", 115, 133], ["necrosis", "OBSERVATION", 134, 142]]], ["Patients with a right ventricular infarction or cardiogenic shock and a ventricular septal rupture have high in-hospital mortality rate [3] .", [["right ventricular", "ANATOMY", 16, 33], ["ventricular septal", "ANATOMY", 72, 90], ["right ventricular infarction", "DISEASE", 16, 44], ["cardiogenic shock", "DISEASE", 48, 65], ["ventricular septal rupture", "DISEASE", 72, 98], ["Patients", "ORGANISM", 0, 8], ["ventricular", "MULTI-TISSUE_STRUCTURE", 22, 33], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 72, 90], ["Patients", "SPECIES", 0, 8], ["a right ventricular infarction", "PROBLEM", 14, 44], ["cardiogenic shock", "PROBLEM", 48, 65], ["a ventricular septal rupture", "PROBLEM", 70, 98], ["right ventricular", "ANATOMY", 16, 33], ["infarction", "OBSERVATION", 34, 44], ["cardiogenic shock", "OBSERVATION", 48, 65], ["ventricular septal", "ANATOMY", 72, 90], ["rupture", "OBSERVATION", 91, 98], ["high", "OBSERVATION_MODIFIER", 104, 108]]], ["Here we are presenting a case of VSD post myocardial infarction, which subsequently lead to multisystem organ failure.Case PresentationA 65-year-old Caucasian male with past medical history significant for hepatitis and HIV complicated by multiple pneumocystis pneumonia (PCP) infections [not on highly active antiretroviral therapy (HAART)] initially presented to the emergency room for evaluation for severe depression after his cat passed away.", [["myocardial", "ANATOMY", 42, 52], ["organ", "ANATOMY", 104, 109], ["myocardial infarction", "DISEASE", 42, 63], ["multisystem organ failure", "DISEASE", 92, 117], ["hepatitis", "DISEASE", 206, 215], ["HIV", "DISEASE", 220, 223], ["pneumocystis pneumonia", "DISEASE", 248, 270], ["PCP", "DISEASE", 272, 275], ["infections", "DISEASE", 277, 287], ["depression", "DISEASE", 410, 420], ["myocardial", "MULTI-TISSUE_STRUCTURE", 42, 52], ["organ", "ORGAN", 104, 109], ["male", "ORGANISM", 159, 163], ["HIV", "ORGANISM", 220, 223], ["cat", "ORGANISM", 431, 434], ["HIV", "SPECIES", 220, 223], ["HIV", "SPECIES", 220, 223], ["VSD", "PROBLEM", 33, 36], ["myocardial infarction", "PROBLEM", 42, 63], ["multisystem organ failure", "PROBLEM", 92, 117], ["hepatitis", "PROBLEM", 206, 215], ["HIV", "PROBLEM", 220, 223], ["multiple pneumocystis pneumonia", "PROBLEM", 239, 270], ["PCP) infections", "PROBLEM", 272, 287], ["highly active antiretroviral therapy", "TREATMENT", 296, 332], ["evaluation", "TEST", 388, 398], ["severe depression", "PROBLEM", 403, 420], ["myocardial", "ANATOMY", 42, 52], ["infarction", "OBSERVATION", 53, 63], ["multisystem", "OBSERVATION_MODIFIER", 92, 103], ["organ", "ANATOMY", 104, 109], ["failure", "OBSERVATION", 110, 117], ["hepatitis", "OBSERVATION", 206, 215], ["multiple", "OBSERVATION_MODIFIER", 239, 247], ["pneumocystis", "OBSERVATION_MODIFIER", 248, 260], ["pneumonia", "OBSERVATION", 261, 270], ["severe", "OBSERVATION_MODIFIER", 403, 409], ["depression", "OBSERVATION", 410, 420]]], ["The patient stated that he had a sense of depression for three weeks prior to his admission.", [["depression", "DISEASE", 42, 52], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["depression", "PROBLEM", 42, 52]]], ["He conveyed that during that three-week stretch, he experienced decreased appetite, unintentional weight loss of roughly 20 pounds, and suicidal ideation.", [["decreased appetite", "DISEASE", 64, 82], ["weight loss", "DISEASE", 98, 109], ["suicidal ideation", "DISEASE", 136, 153], ["decreased appetite", "PROBLEM", 64, 82], ["unintentional weight loss", "PROBLEM", 84, 109], ["suicidal ideation", "PROBLEM", 136, 153]]], ["Furthermore, during that time frame, he also complained of progressively worsening shortness of breath associated with a cough productive of yellow-whitish sputum, diffuse body aches, weakness, and bilateral lower extremity edema.", [["sputum", "ANATOMY", 156, 162], ["body", "ANATOMY", 172, 176], ["lower extremity edema", "ANATOMY", 208, 229], ["shortness of breath", "DISEASE", 83, 102], ["cough", "DISEASE", 121, 126], ["body aches", "DISEASE", 172, 182], ["weakness", "DISEASE", 184, 192], ["lower extremity edema", "DISEASE", 208, 229], ["body", "ORGANISM_SUBDIVISION", 172, 176], ["lower extremity", "ORGANISM_SUBDIVISION", 208, 223], ["edema", "PATHOLOGICAL_FORMATION", 224, 229], ["progressively worsening shortness of breath", "PROBLEM", 59, 102], ["a cough productive of yellow-whitish sputum", "PROBLEM", 119, 162], ["diffuse body aches", "PROBLEM", 164, 182], ["weakness", "PROBLEM", 184, 192], ["bilateral lower extremity edema", "PROBLEM", 198, 229], ["diffuse", "OBSERVATION_MODIFIER", 164, 171], ["body aches", "ANATOMY", 172, 182], ["weakness", "OBSERVATION", 184, 192], ["bilateral", "ANATOMY_MODIFIER", 198, 207], ["lower", "ANATOMY_MODIFIER", 208, 213], ["extremity", "ANATOMY", 214, 223], ["edema", "OBSERVATION", 224, 229]]], ["The patient denied coming into contact with individuals who were ill and denied exposure to the COVID-19 virus.", [["patient", "ORGANISM", 4, 11], ["individuals", "ORGANISM", 44, 55], ["COVID-19 virus", "ORGANISM", 96, 110], ["patient", "SPECIES", 4, 11], ["COVID-19 virus", "SPECIES", 96, 110], ["the COVID", "TEST", 92, 101]]], ["The patient revealed that he had a significant history of substance abuse spanning the last 10 years.", [["substance abuse", "DISEASE", 58, 73], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["He admitted to the use of Marijuana and Cocaine, with his last use being 10 days prior to his admission.", [["Marijuana", "CHEMICAL", 26, 35], ["Cocaine", "CHEMICAL", 40, 47], ["Cocaine", "CHEMICAL", 40, 47], ["Cocaine", "SIMPLE_CHEMICAL", 40, 47]]], ["The patient's urine drug screen (UDS) was positive for cannabinoids.", [["urine", "ANATOMY", 14, 19], ["cannabinoids", "CHEMICAL", 55, 67], ["cannabinoids", "CHEMICAL", 55, 67], ["patient", "ORGANISM", 4, 11], ["urine", "ORGANISM_SUBSTANCE", 14, 19], ["patient", "SPECIES", 4, 11], ["The patient's urine drug screen", "TEST", 0, 31], ["UDS", "TEST", 33, 36], ["cannabinoids", "PROBLEM", 55, 67]]], ["Moreover, he denied the use of IV drug use.Case PresentationUpon evaluation in the emergency room, the patient was found to be afebrile with an oral temperature of 36.4 C, normotensive with a blood pressure of 114/90, saturating at 94% on room air, and with a heart rate of 100 bpm.", [["oral", "ANATOMY", 144, 148], ["blood", "ANATOMY", 192, 197], ["heart", "ANATOMY", 260, 265], ["patient", "ORGANISM", 103, 110], ["oral", "ORGANISM_SUBDIVISION", 144, 148], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["heart", "ORGAN", 260, 265], ["patient", "SPECIES", 103, 110], ["afebrile", "PROBLEM", 127, 135], ["an oral temperature", "TEST", 141, 160], ["normotensive", "PROBLEM", 172, 184], ["a blood pressure", "TEST", 190, 206], ["a heart rate", "TEST", 258, 270], ["heart", "ANATOMY", 260, 265]]], ["Electrocardiogram (EKG) shows normal sinus rhythm.", [["sinus", "ANATOMY", 37, 42], ["sinus", "ORGAN", 37, 42], ["Electrocardiogram", "TEST", 0, 17], ["EKG", "TEST", 19, 22], ["sinus rhythm", "OBSERVATION", 37, 49]]], ["His complete blood count (CBC) revealed no leukocytosis with a white blood cell (WBC) count of 8.7 K/uL (4.8-10.8 K/uL).", [["blood", "ANATOMY", 13, 18], ["white blood cell", "ANATOMY", 63, 79], ["WBC", "ANATOMY", 81, 84], ["leukocytosis", "DISEASE", 43, 55], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["white blood cell", "CELL", 63, 79], ["WBC", "CELL", 81, 84], ["His complete blood count", "TEST", 0, 24], ["CBC", "TEST", 26, 29], ["leukocytosis", "PROBLEM", 43, 55], ["a white blood cell", "TEST", 61, 79], ["WBC", "TEST", 81, 84], ["count", "TEST", 86, 91], ["K", "TEST", 99, 100], ["uL", "TEST", 101, 103], ["K/uL", "TEST", 114, 118], ["no", "UNCERTAINTY", 40, 42], ["leukocytosis", "OBSERVATION", 43, 55]]], ["Troponin was negative.", [["Troponin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Troponin", "PROTEIN", 0, 8], ["Troponin", "TEST", 0, 8]]], ["The patient's chest X-ray revealed bilateral reticular opacities (left significantly greater than right) with small bilateral pleural effusions.", [["reticular opacities", "ANATOMY", 45, 64], ["pleural effusions", "ANATOMY", 126, 143], ["pleural effusions", "DISEASE", 126, 143], ["patient", "ORGANISM", 4, 11], ["reticular opacities", "PATHOLOGICAL_FORMATION", 45, 64], ["pleural effusions", "PATHOLOGICAL_FORMATION", 126, 143], ["patient", "SPECIES", 4, 11], ["The patient's chest X-ray", "TEST", 0, 25], ["bilateral reticular opacities", "PROBLEM", 35, 64], ["small bilateral pleural effusions", "PROBLEM", 110, 143], ["chest", "ANATOMY", 14, 19], ["bilateral", "ANATOMY_MODIFIER", 35, 44], ["reticular", "ANATOMY_MODIFIER", 45, 54], ["opacities", "OBSERVATION", 55, 64], ["left", "ANATOMY_MODIFIER", 66, 70], ["significantly", "OBSERVATION_MODIFIER", 71, 84], ["greater", "OBSERVATION_MODIFIER", 85, 92], ["right", "ANATOMY_MODIFIER", 98, 103], ["small", "OBSERVATION_MODIFIER", 110, 115], ["bilateral", "ANATOMY_MODIFIER", 116, 125], ["pleural", "ANATOMY", 126, 133], ["effusions", "OBSERVATION", 134, 143]]], ["After review of his comprehensive metabolic panel (CMP), the patient was noted to have an elevated creatinine of 2.28 mg/dL (0.7-1.2 mg/dL).", [["creatinine", "CHEMICAL", 99, 109], ["creatinine", "CHEMICAL", 99, 109], ["patient", "ORGANISM", 61, 68], ["creatinine", "SIMPLE_CHEMICAL", 99, 109], ["patient", "SPECIES", 61, 68], ["his comprehensive metabolic panel", "TEST", 16, 49], ["CMP", "TEST", 51, 54], ["an elevated creatinine", "PROBLEM", 87, 109], ["elevated", "OBSERVATION", 90, 98]]], ["Arterial blood gas (ABG) studies revealed a partial pressure of oxygen (PO2) of 46 mmHg (>80 mmHg) and a partial pressure of carbon dioxide (PCO2) of 23.6 mmHg (35-45 mmHg).Case PresentationUpon admission to the hospital, the patient was noted to have acute kidney injury (AKI) with a creatinine 2.28 mg/dL (0.7-1.2 mg/dL).", [["Arterial blood", "ANATOMY", 0, 14], ["kidney", "ANATOMY", 258, 264], ["oxygen", "CHEMICAL", 64, 70], ["PO2", "CHEMICAL", 72, 75], ["carbon dioxide", "CHEMICAL", 125, 139], ["acute kidney injury", "DISEASE", 252, 271], ["AKI", "DISEASE", 273, 276], ["creatinine", "CHEMICAL", 285, 295], ["oxygen", "CHEMICAL", 64, 70], ["carbon dioxide", "CHEMICAL", 125, 139], ["PCO2", "CHEMICAL", 141, 145], ["creatinine", "CHEMICAL", 285, 295], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["PO2", "SIMPLE_CHEMICAL", 72, 75], ["carbon dioxide", "SIMPLE_CHEMICAL", 125, 139], ["patient", "ORGANISM", 226, 233], ["kidney", "ORGAN", 258, 264], ["creatinine", "SIMPLE_CHEMICAL", 285, 295], ["patient", "SPECIES", 226, 233], ["Arterial blood gas", "TEST", 0, 18], ["ABG", "TEST", 20, 23], ["PO2", "TEST", 72, 75], ["mmHg", "TEST", 83, 87], ["a partial pressure", "TEST", 103, 121], ["carbon dioxide", "TEST", 125, 139], ["PCO2", "TEST", 141, 145], ["acute kidney injury", "PROBLEM", 252, 271], ["AKI", "PROBLEM", 273, 276], ["a creatinine", "TEST", 283, 295], ["partial", "OBSERVATION_MODIFIER", 44, 51], ["pressure", "OBSERVATION_MODIFIER", 52, 60], ["partial", "OBSERVATION_MODIFIER", 105, 112], ["pressure", "OBSERVATION_MODIFIER", 113, 121], ["carbon dioxide", "OBSERVATION", 125, 139], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["kidney", "ANATOMY", 258, 264], ["injury", "OBSERVATION", 265, 271], ["AKI", "OBSERVATION", 273, 276]]], ["Further evaluation via ultrasound revealed a left renal cyst.", [["left renal cyst", "ANATOMY", 45, 60], ["left renal cyst", "DISEASE", 45, 60], ["renal cyst", "CANCER", 50, 60], ["Further evaluation", "TEST", 0, 18], ["ultrasound", "TEST", 23, 33], ["a left renal cyst", "PROBLEM", 43, 60], ["left", "ANATOMY_MODIFIER", 45, 49], ["renal", "ANATOMY", 50, 55], ["cyst", "OBSERVATION", 56, 60]]], ["Ultimately, the patient's creatinine mildly improved during the course of his treatment to 1.97 mg/dL.", [["creatinine", "CHEMICAL", 26, 36], ["creatinine", "CHEMICAL", 26, 36], ["patient", "ORGANISM", 16, 23], ["creatinine", "SIMPLE_CHEMICAL", 26, 36], ["patient", "SPECIES", 16, 23], ["the patient's creatinine", "TEST", 12, 36], ["his treatment", "TREATMENT", 74, 87], ["mildly", "OBSERVATION_MODIFIER", 37, 43], ["improved", "OBSERVATION_MODIFIER", 44, 52]]], ["After undergoing a more thorough work-up, the patient was found to be positive for COVID-19.", [["patient", "ORGANISM", 46, 53], ["COVID-19", "DNA", 83, 91], ["patient", "SPECIES", 46, 53], ["COVID", "TEST", 83, 88], ["positive", "OBSERVATION", 70, 78]]], ["He also had a transthoracic echocardiogram, which showed a left ventricular ejection fraction (LVEF) of 30-35%, ischemic cardiomyopathy, and muscular ventricular septal defects with left to right shunting and severely elevated pulmonary artery systolic pressure as seen in Video 1.VIDEO 1: Transthoracic echocardiogram shows systolic left-toright flow at the muscular ventricular septal defect (VSD) with color flow mappingView video here: https://vimeo.com/441202606VIDEO 1: Transthoracic echocardiogram shows systolic left-toright flow at the muscular ventricular septal defect (VSD) with color flow mappingOver time, the patient's bilirubin and aspartate transaminase/alanine transaminase (AST/ALT) continued to rise, peaking at an AST of 2,365 U/L (15-41 U/L) and an ALT of 1167 U/L (17-63 U/L).", [["left ventricular", "ANATOMY", 59, 75], ["muscular ventricular septal", "ANATOMY", 141, 168], ["pulmonary artery", "ANATOMY", 227, 243], ["left-toright", "ANATOMY", 334, 346], ["muscular ventricular septal", "ANATOMY", 359, 386], ["left-toright", "ANATOMY", 520, 532], ["muscular ventricular septal", "ANATOMY", 545, 572], ["ischemic cardiomyopathy", "DISEASE", 112, 135], ["ventricular septal defects", "DISEASE", 150, 176], ["elevated pulmonary artery systolic pressure", "DISEASE", 218, 261], ["ventricular septal defect", "DISEASE", 368, 393], ["ventricular septal defect", "DISEASE", 554, 579], ["bilirubin", "CHEMICAL", 634, 643], ["aspartate", "CHEMICAL", 648, 657], ["alanine", "CHEMICAL", 671, 678], ["bilirubin", "CHEMICAL", 634, 643], ["aspartate", "CHEMICAL", 648, 657], ["alanine", "CHEMICAL", 671, 678], ["ventricular", "MULTI-TISSUE_STRUCTURE", 64, 75], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 150, 168], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 227, 243], ["muscular ventricular septal", "MULTI-TISSUE_STRUCTURE", 359, 386], ["muscular ventricular septal", "MULTI-TISSUE_STRUCTURE", 545, 572], ["patient", "ORGANISM", 624, 631], ["bilirubin", "GENE_OR_GENE_PRODUCT", 634, 643], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 648, 670], ["alanine", "AMINO_ACID", 671, 678], ["transaminase", "GENE_OR_GENE_PRODUCT", 679, 691], ["AST", "SIMPLE_CHEMICAL", 693, 696], ["ALT", "SIMPLE_CHEMICAL", 697, 700], ["bilirubin", "PROTEIN", 634, 643], ["aspartate transaminase", "PROTEIN", 648, 670], ["alanine transaminase", "PROTEIN", 671, 691], ["AST", "PROTEIN", 693, 696], ["ALT", "PROTEIN", 697, 700], ["patient", "SPECIES", 624, 631], ["a transthoracic echocardiogram", "TEST", 12, 42], ["a left ventricular ejection fraction", "TEST", 57, 93], ["LVEF", "TEST", 95, 99], ["ischemic cardiomyopathy", "PROBLEM", 112, 135], ["muscular ventricular septal defects", "PROBLEM", 141, 176], ["left to right shunting", "PROBLEM", 182, 204], ["severely elevated pulmonary artery systolic pressure", "PROBLEM", 209, 261], ["Transthoracic echocardiogram", "TEST", 290, 318], ["systolic left-toright flow at the muscular ventricular septal defect", "PROBLEM", 325, 393], ["color flow mapping", "TEST", 405, 423], ["Transthoracic echocardiogram", "TEST", 476, 504], ["systolic left-toright flow", "PROBLEM", 511, 537], ["the muscular ventricular septal defect", "PROBLEM", 541, 579], ["the patient's bilirubin", "TEST", 620, 643], ["aspartate transaminase", "TEST", 648, 670], ["alanine transaminase", "TEST", 671, 691], ["AST", "TEST", 693, 696], ["ALT", "TEST", 697, 700], ["an AST", "TEST", 732, 738], ["U/L", "TEST", 748, 751], ["an ALT", "TEST", 768, 774], ["U/L", "TEST", 783, 786], ["left ventricular", "ANATOMY", 59, 75], ["ejection fraction", "OBSERVATION", 76, 93], ["ischemic", "OBSERVATION_MODIFIER", 112, 120], ["cardiomyopathy", "OBSERVATION", 121, 135], ["muscular ventricular", "ANATOMY", 141, 161], ["septal", "ANATOMY_MODIFIER", 162, 168], ["defects", "OBSERVATION", 169, 176], ["left", "ANATOMY_MODIFIER", 182, 186], ["right", "ANATOMY_MODIFIER", 190, 195], ["shunting", "OBSERVATION", 196, 204], ["severely", "OBSERVATION_MODIFIER", 209, 217], ["elevated", "OBSERVATION", 218, 226], ["pulmonary artery", "ANATOMY", 227, 243], ["systolic pressure", "OBSERVATION", 244, 261], ["systolic", "OBSERVATION", 325, 333], ["left", "ANATOMY_MODIFIER", 334, 338], ["toright flow", "OBSERVATION", 339, 351], ["muscular ventricular", "ANATOMY", 359, 379], ["septal", "ANATOMY_MODIFIER", 380, 386], ["defect", "OBSERVATION", 387, 393], ["VSD", "OBSERVATION", 395, 398], ["color flow", "OBSERVATION", 405, 415], ["systolic", "OBSERVATION", 511, 519], ["left", "ANATOMY_MODIFIER", 520, 524], ["toright flow", "OBSERVATION", 525, 537], ["muscular ventricular", "ANATOMY", 545, 565], ["septal", "ANATOMY_MODIFIER", 566, 572], ["defect", "OBSERVATION", 573, 579], ["VSD", "OBSERVATION", 581, 584], ["color flow", "OBSERVATION", 591, 601]]], ["The patient's international normalised ratio (INR) also became elevated reaching a maximum of 7.0 with a prothrombin time (PT) of 37.8 seconds (12.6-14.6 sec).", [["patient", "ORGANISM", 4, 11], ["prothrombin", "GENE_OR_GENE_PRODUCT", 105, 116], ["prothrombin", "PROTEIN", 105, 116], ["patient", "SPECIES", 4, 11], ["The patient's international normalised ratio", "TEST", 0, 44], ["INR", "TEST", 46, 49], ["elevated", "PROBLEM", 63, 71], ["a prothrombin time", "TEST", 103, 121], ["PT", "TEST", 123, 125]]], ["Evidently, the patient was in fulminant hepatic failure.", [["hepatic", "ANATOMY", 40, 47], ["fulminant hepatic failure", "DISEASE", 30, 55], ["patient", "ORGANISM", 15, 22], ["hepatic", "ORGAN", 40, 47], ["patient", "SPECIES", 15, 22], ["fulminant hepatic failure", "PROBLEM", 30, 55], ["fulminant", "OBSERVATION_MODIFIER", 30, 39], ["hepatic", "ANATOMY", 40, 47], ["failure", "OBSERVATION", 48, 55]]], ["Furthermore, he was also in renal failure with a blood urea nitrogen (BUN) > 130 mg/dL (8-20 mg/dL).", [["renal", "ANATOMY", 28, 33], ["blood", "ANATOMY", 49, 54], ["renal failure", "DISEASE", 28, 41], ["blood urea nitrogen", "CHEMICAL", 49, 68], ["urea", "CHEMICAL", 55, 59], ["nitrogen", "CHEMICAL", 60, 68], ["renal", "ORGAN", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["urea nitrogen", "SIMPLE_CHEMICAL", 55, 68], ["BUN", "SIMPLE_CHEMICAL", 70, 73], ["renal failure", "PROBLEM", 28, 41], ["a blood urea nitrogen", "TEST", 47, 68], ["BUN", "TEST", 70, 73], ["renal", "ANATOMY", 28, 33], ["failure", "OBSERVATION", 34, 41]]], ["Also, the patient was found to have an elevated D-dimer of > 5,000 ng/ml (0-230 ng/ml).", [["patient", "ORGANISM", 10, 17], ["D-dimer", "GENE_OR_GENE_PRODUCT", 48, 55], ["D-dimer", "PROTEIN", 48, 55], ["patient", "SPECIES", 10, 17], ["an elevated D-dimer", "PROBLEM", 36, 55], ["elevated", "OBSERVATION", 39, 47]]], ["However, the patient was unable to receive anticoagulation due to his elevated INR.", [["patient", "ORGANISM", 13, 20], ["INR", "PROTEIN", 79, 82], ["patient", "SPECIES", 13, 20], ["anticoagulation", "TREATMENT", 43, 58], ["his elevated INR", "PROBLEM", 66, 82]]], ["On physical examination, he had multiple petechiae and ecchymoses throughout his body, was severely jaundiced, but was awake, alert and oriented to date, place and person (AAOx3).", [["petechiae", "ANATOMY", 41, 50], ["body", "ANATOMY", 81, 85], ["petechiae", "DISEASE", 41, 50], ["ecchymoses", "DISEASE", 55, 65], ["petechiae", "PATHOLOGICAL_FORMATION", 41, 50], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["person", "SPECIES", 164, 170], ["physical examination", "TEST", 3, 23], ["multiple petechiae", "PROBLEM", 32, 50], ["ecchymoses throughout his body", "PROBLEM", 55, 85], ["severely jaundiced", "PROBLEM", 91, 109], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["petechiae", "OBSERVATION", 41, 50], ["ecchymoses", "OBSERVATION", 55, 65], ["body", "ANATOMY", 81, 85], ["severely", "OBSERVATION_MODIFIER", 91, 99], ["jaundiced", "OBSERVATION", 100, 109]]], ["No cardiac murmur was appreciated on examination.", [["cardiac", "ANATOMY", 3, 10], ["cardiac murmur", "DISEASE", 3, 17], ["cardiac", "ORGAN", 3, 10], ["cardiac murmur", "PROBLEM", 3, 17], ["examination", "TEST", 37, 48], ["cardiac", "ANATOMY", 3, 10], ["murmur", "OBSERVATION", 11, 17]]], ["An extensive conversation was held with the patient with regards to goals of care in which patient made himself do-not-resuscitate/do-not-intubate (DNR/DNI).", [["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 91, 98]]], ["Both cardiology and nephrology were on board as he was treated symptomatically.VIDEO 1: Transthoracic echocardiogram shows systolic left-toright flow at the muscular ventricular septal defect (VSD) with color flow mappingDuring hospital course, the patient became dyspneic and was subsequently started on 2 mg of IV morphine for comfort as per family discussion.", [["left-toright", "ANATOMY", 132, 144], ["muscular ventricular septal", "ANATOMY", 157, 184], ["ventricular septal defect", "DISEASE", 166, 191], ["dyspneic", "DISEASE", 264, 272], ["morphine", "CHEMICAL", 316, 324], ["morphine", "CHEMICAL", 316, 324], ["muscular ventricular septal", "MULTI-TISSUE_STRUCTURE", 157, 184], ["patient", "ORGANISM", 249, 256], ["morphine", "SIMPLE_CHEMICAL", 316, 324], ["patient", "SPECIES", 249, 256], ["Transthoracic echocardiogram", "TEST", 88, 116], ["systolic left-toright flow", "PROBLEM", 123, 149], ["the muscular ventricular septal defect", "PROBLEM", 153, 191], ["dyspneic", "PROBLEM", 264, 272], ["IV morphine", "TREATMENT", 313, 324], ["systolic", "OBSERVATION", 123, 131], ["left", "ANATOMY_MODIFIER", 132, 136], ["toright flow", "OBSERVATION", 137, 149], ["muscular ventricular", "ANATOMY", 157, 177], ["septal", "ANATOMY_MODIFIER", 178, 184], ["defect", "OBSERVATION", 185, 191], ["VSD", "OBSERVATION", 193, 196], ["color flow", "OBSERVATION", 203, 213], ["dyspneic", "OBSERVATION", 264, 272]]], ["The next morning, the patient was found unresponsive with dilated pupils and no brain stem reflexes and was pronounced dead.DiscussionVentricular septal defect (VSD) is a rare mechanical complication of myocardial infarction, especially in the era of reperfusion therapy [2] .", [["brain stem", "ANATOMY", 80, 90], ["Ventricular septal", "ANATOMY", 134, 152], ["myocardial", "ANATOMY", 203, 213], ["Ventricular septal defect", "DISEASE", 134, 159], ["myocardial infarction", "DISEASE", 203, 224], ["patient", "ORGANISM", 22, 29], ["brain stem", "TISSUE", 80, 90], ["Ventricular septal", "MULTI-TISSUE_STRUCTURE", 134, 152], ["myocardial", "MULTI-TISSUE_STRUCTURE", 203, 213], ["patient", "SPECIES", 22, 29], ["unresponsive", "PROBLEM", 40, 52], ["dilated pupils", "PROBLEM", 58, 72], ["brain stem reflexes", "PROBLEM", 80, 99], ["dead", "PROBLEM", 119, 123], ["Ventricular septal defect", "PROBLEM", 134, 159], ["VSD", "PROBLEM", 161, 164], ["a rare mechanical complication", "PROBLEM", 169, 199], ["myocardial infarction", "PROBLEM", 203, 224], ["reperfusion therapy", "TREATMENT", 251, 270], ["dilated", "OBSERVATION", 58, 65], ["no", "UNCERTAINTY", 77, 79], ["brain stem", "ANATOMY", 80, 90], ["septal", "ANATOMY_MODIFIER", 146, 152], ["defect", "OBSERVATION", 153, 159], ["VSD", "OBSERVATION", 161, 164], ["rare", "OBSERVATION_MODIFIER", 171, 175], ["mechanical", "OBSERVATION_MODIFIER", 176, 186], ["complication", "OBSERVATION", 187, 199], ["myocardial", "ANATOMY", 203, 213], ["infarction", "OBSERVATION", 214, 224]]], ["It usually occurs days two to seven following a transmural infarction secondary to complete occlusion of any of the coronary vessels with septal branches supplying the interventricular septum in the absence of collaterals.", [["coronary vessels", "ANATOMY", 116, 132], ["septal branches", "ANATOMY", 138, 153], ["interventricular septum", "ANATOMY", 168, 191], ["collaterals", "ANATOMY", 210, 221], ["infarction", "DISEASE", 59, 69], ["coronary vessels", "MULTI-TISSUE_STRUCTURE", 116, 132], ["septal branches", "MULTI-TISSUE_STRUCTURE", 138, 153], ["interventricular septum", "MULTI-TISSUE_STRUCTURE", 168, 191], ["a transmural infarction", "PROBLEM", 46, 69], ["transmural", "OBSERVATION_MODIFIER", 48, 58], ["infarction", "OBSERVATION", 59, 69], ["complete", "OBSERVATION_MODIFIER", 83, 91], ["occlusion", "OBSERVATION", 92, 101], ["coronary vessels", "ANATOMY", 116, 132], ["septal", "ANATOMY_MODIFIER", 138, 144], ["branches", "ANATOMY_MODIFIER", 145, 153], ["interventricular septum", "ANATOMY", 168, 191], ["collaterals", "OBSERVATION", 210, 221]]], ["Occlusion of the left anterior descending artery is the most common cause [2] .", [["left anterior descending artery", "ANATOMY", 17, 48], ["anterior descending artery", "MULTI-TISSUE_STRUCTURE", 22, 48], ["Occlusion of the left anterior descending artery", "TREATMENT", 0, 48], ["left anterior descending artery", "ANATOMY", 17, 48]]], ["Ventricular septal rupture (VSR) can occur following both anterior and inferior MI.", [["Ventricular septal", "ANATOMY", 0, 18], ["anterior", "ANATOMY", 58, 66], ["Ventricular septal rupture", "DISEASE", 0, 26], ["VSR", "DISEASE", 28, 31], ["anterior and inferior MI", "DISEASE", 58, 82], ["Ventricular septal", "MULTI-TISSUE_STRUCTURE", 0, 18], ["anterior", "MULTI-TISSUE_STRUCTURE", 58, 66], ["Ventricular septal rupture", "PROBLEM", 0, 26], ["both anterior and inferior MI", "PROBLEM", 53, 82], ["septal", "ANATOMY_MODIFIER", 12, 18], ["rupture", "OBSERVATION", 19, 26], ["anterior", "OBSERVATION_MODIFIER", 58, 66], ["inferior", "OBSERVATION_MODIFIER", 71, 79], ["MI", "OBSERVATION", 80, 82]]], ["Typically, the defect due to anterior MI is apical and simple.", [["MI", "DISEASE", 38, 40], ["the defect", "PROBLEM", 11, 21], ["anterior MI", "PROBLEM", 29, 40], ["defect", "OBSERVATION", 15, 21], ["anterior", "ANATOMY_MODIFIER", 29, 37], ["MI", "OBSERVATION", 38, 40], ["apical", "ANATOMY_MODIFIER", 44, 50], ["simple", "OBSERVATION_MODIFIER", 55, 61]]], ["VSR secondary to inferior MI tends to be a more complex lesion with more significant tissue destruction.", [["lesion", "ANATOMY", 56, 62], ["tissue", "ANATOMY", 85, 91], ["VSR", "DISEASE", 0, 3], ["inferior MI", "DISEASE", 17, 28], ["tissue", "TISSUE", 85, 91], ["VSR", "PROBLEM", 0, 3], ["inferior MI", "PROBLEM", 17, 28], ["a more complex lesion", "PROBLEM", 41, 62], ["significant tissue destruction", "PROBLEM", 73, 103], ["inferior", "OBSERVATION_MODIFIER", 17, 25], ["MI", "OBSERVATION", 26, 28], ["more", "OBSERVATION_MODIFIER", 43, 47], ["complex", "OBSERVATION_MODIFIER", 48, 55], ["lesion", "OBSERVATION", 56, 62], ["more", "OBSERVATION_MODIFIER", 68, 72], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["tissue", "OBSERVATION_MODIFIER", 85, 91], ["destruction", "OBSERVATION", 92, 103]]], ["It has been reported as a complication of right ventricular infarction [3] .", [["right ventricular", "ANATOMY", 42, 59], ["right ventricular infarction", "DISEASE", 42, 70], ["ventricular", "MULTI-TISSUE_STRUCTURE", 48, 59], ["right ventricular infarction", "PROBLEM", 42, 70], ["right ventricular", "ANATOMY", 42, 59], ["infarction", "OBSERVATION", 60, 70]]], ["Cardiac rupture occurring 24 hours after MI is the result of dissecting intramural hematoma.", [["Cardiac", "ANATOMY", 0, 7], ["intramural hematoma", "ANATOMY", 72, 91], ["Cardiac rupture", "DISEASE", 0, 15], ["MI", "DISEASE", 41, 43], ["hematoma", "DISEASE", 83, 91], ["Cardiac", "ORGAN", 0, 7], ["intramural hematoma", "PATHOLOGICAL_FORMATION", 72, 91], ["Cardiac rupture", "PROBLEM", 0, 15], ["MI", "PROBLEM", 41, 43], ["dissecting intramural hematoma", "PROBLEM", 61, 91], ["rupture", "OBSERVATION", 8, 15], ["dissecting", "OBSERVATION_MODIFIER", 61, 71], ["intramural", "OBSERVATION_MODIFIER", 72, 82], ["hematoma", "OBSERVATION", 83, 91]]], ["The subacute course which occurs within a week after myocardial infarction is the result of a cascade of pathological events that starts with ischemia of the myocardium then coagulative necrosis then neutrophilic infiltration with subsequent macrophages infiltration and removal of necrotic tissue leading to the weakening of the tissue culminating in complications such as a ventricular free wall rupture, interventricular septum rupture, or a papillary muscle rupture.", [["myocardial", "ANATOMY", 53, 63], ["myocardium", "ANATOMY", 158, 168], ["neutrophilic", "ANATOMY", 200, 212], ["macrophages", "ANATOMY", 242, 253], ["necrotic tissue", "ANATOMY", 282, 297], ["tissue", "ANATOMY", 330, 336], ["ventricular free wall", "ANATOMY", 376, 397], ["interventricular septum", "ANATOMY", 407, 430], ["papillary muscle", "ANATOMY", 445, 461], ["myocardial infarction", "DISEASE", 53, 74], ["ischemia", "DISEASE", 142, 150], ["necrosis", "DISEASE", 186, 194], ["necrotic", "DISEASE", 282, 290], ["ventricular free wall rupture", "DISEASE", 376, 405], ["interventricular septum rupture", "DISEASE", 407, 438], ["papillary muscle rupture", "DISEASE", 445, 469], ["myocardial", "MULTI-TISSUE_STRUCTURE", 53, 63], ["myocardium", "ORGAN", 158, 168], ["macrophages", "CELL", 242, 253], ["necrotic tissue", "TISSUE", 282, 297], ["tissue", "TISSUE", 330, 336], ["interventricular septum", "MULTI-TISSUE_STRUCTURE", 407, 430], ["papillary muscle", "TISSUE", 445, 461], ["myocardial infarction", "PROBLEM", 53, 74], ["pathological events", "PROBLEM", 105, 124], ["ischemia of the myocardium", "PROBLEM", 142, 168], ["coagulative necrosis", "PROBLEM", 174, 194], ["neutrophilic infiltration", "PROBLEM", 200, 225], ["subsequent macrophages infiltration", "PROBLEM", 231, 266], ["removal", "TREATMENT", 271, 278], ["necrotic tissue", "PROBLEM", 282, 297], ["the weakening of the tissue", "PROBLEM", 309, 336], ["complications", "PROBLEM", 352, 365], ["a ventricular free wall rupture", "PROBLEM", 374, 405], ["interventricular septum rupture", "PROBLEM", 407, 438], ["a papillary muscle rupture", "PROBLEM", 443, 469], ["subacute", "OBSERVATION_MODIFIER", 4, 12], ["course", "OBSERVATION_MODIFIER", 13, 19], ["myocardial", "ANATOMY", 53, 63], ["infarction", "OBSERVATION", 64, 74], ["myocardium", "ANATOMY", 158, 168], ["coagulative", "OBSERVATION_MODIFIER", 174, 185], ["necrosis", "OBSERVATION", 186, 194], ["neutrophilic", "OBSERVATION_MODIFIER", 200, 212], ["infiltration", "OBSERVATION", 213, 225], ["macrophages infiltration", "OBSERVATION", 242, 266], ["removal", "OBSERVATION_MODIFIER", 271, 278], ["necrotic tissue", "OBSERVATION", 282, 297], ["weakening", "OBSERVATION", 313, 322], ["tissue", "OBSERVATION", 330, 336], ["complications", "OBSERVATION", 352, 365], ["ventricular", "ANATOMY", 376, 387], ["free", "OBSERVATION_MODIFIER", 388, 392], ["wall", "ANATOMY_MODIFIER", 393, 397], ["rupture", "OBSERVATION", 398, 405], ["interventricular septum", "ANATOMY", 407, 430], ["rupture", "OBSERVATION", 431, 438], ["papillary muscle", "ANATOMY", 445, 461], ["rupture", "OBSERVATION", 462, 469]]], ["A much rarer type can occur >2 weeks following perforation of thinned aneurysmal myocardium [4] .DiscussionVentricular septal rupture complicates 0.2% of acute MIs, compared with 1-2% before thrombolysis was introduced [2] .", [["aneurysmal myocardium", "ANATOMY", 70, 91], ["Ventricular septal", "ANATOMY", 107, 125], ["aneurysmal myocardium", "DISEASE", 70, 91], ["Ventricular septal rupture", "DISEASE", 107, 133], ["MIs", "DISEASE", 160, 163], ["Ventricular septal", "MULTI-TISSUE_STRUCTURE", 107, 125], ["perforation of thinned aneurysmal myocardium", "PROBLEM", 47, 91], ["Ventricular septal rupture", "PROBLEM", 107, 133], ["acute MIs", "PROBLEM", 154, 163], ["thrombolysis", "TREATMENT", 191, 203], ["perforation", "OBSERVATION", 47, 58], ["thinned", "OBSERVATION_MODIFIER", 62, 69], ["aneurysmal", "OBSERVATION", 70, 80], ["myocardium", "ANATOMY", 81, 91], ["septal", "ANATOMY_MODIFIER", 119, 125], ["rupture", "OBSERVATION", 126, 133]]], ["Multiple observational studies identified severe risk factors that increase the risk of cardiac rupture, including rupture of the interventricular septum, first incidence of MI, ST-segment elevation, female sex, previous stroke, positive initial cardiac biomarkers, older age (>70), and higher heart rate.", [["cardiac", "ANATOMY", 88, 95], ["interventricular septum", "ANATOMY", 130, 153], ["cardiac", "ANATOMY", 246, 253], ["heart", "ANATOMY", 294, 299], ["cardiac rupture", "DISEASE", 88, 103], ["rupture of the interventricular septum", "DISEASE", 115, 153], ["MI", "DISEASE", 174, 176], ["stroke", "DISEASE", 221, 227], ["cardiac", "ORGAN", 88, 95], ["interventricular septum", "MULTI-TISSUE_STRUCTURE", 130, 153], ["cardiac", "ORGAN", 246, 253], ["heart", "ORGAN", 294, 299], ["Multiple observational studies", "TEST", 0, 30], ["severe risk factors", "PROBLEM", 42, 61], ["cardiac rupture", "PROBLEM", 88, 103], ["rupture of the interventricular septum", "PROBLEM", 115, 153], ["MI", "PROBLEM", 174, 176], ["ST-segment elevation", "PROBLEM", 178, 198], ["previous stroke", "PROBLEM", 212, 227], ["positive initial cardiac biomarkers", "PROBLEM", 229, 264], ["higher heart rate", "PROBLEM", 287, 304], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["cardiac", "ANATOMY", 88, 95], ["rupture", "OBSERVATION", 96, 103], ["rupture", "OBSERVATION", 115, 122], ["interventricular septum", "ANATOMY", 130, 153], ["MI", "OBSERVATION", 174, 176], ["segment", "ANATOMY_MODIFIER", 181, 188], ["elevation", "OBSERVATION_MODIFIER", 189, 198], ["stroke", "OBSERVATION", 221, 227], ["cardiac", "ANATOMY", 246, 253], ["heart", "ANATOMY", 294, 299]]], ["On the other hand, a history of MI with primary percutaneous coronary intervention (PCI) and the use of low-molecular-weight heparin and beta-blockers during the first 24 hours were identified as protective factors for cardiac rupture [4] [5] [6] [7] .DiscussionPatients with a ruptured septum may present with a wide range of symptoms and signs, ranging from mild dyspnea at exertion to severe cardiogenic shock.", [["percutaneous", "ANATOMY", 48, 60], ["coronary", "ANATOMY", 61, 69], ["cardiac", "ANATOMY", 219, 226], ["septum", "ANATOMY", 287, 293], ["MI", "DISEASE", 32, 34], ["heparin", "CHEMICAL", 125, 132], ["cardiac rupture", "DISEASE", 219, 234], ["ruptured septum", "DISEASE", 278, 293], ["dyspnea", "DISEASE", 365, 372], ["cardiogenic shock", "DISEASE", 395, 412], ["coronary", "MULTI-TISSUE_STRUCTURE", 61, 69], ["low-molecular-weight heparin", "SIMPLE_CHEMICAL", 104, 132], ["beta-blockers", "GENE_OR_GENE_PRODUCT", 137, 150], ["cardiac", "ORGAN", 219, 226], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 235, 250], ["septum", "MULTI-TISSUE_STRUCTURE", 287, 293], ["beta", "PROTEIN", 137, 141], ["MI", "PROBLEM", 32, 34], ["primary percutaneous coronary intervention", "TREATMENT", 40, 82], ["PCI", "TREATMENT", 84, 87], ["low-molecular-weight heparin", "TREATMENT", 104, 132], ["beta-blockers", "TREATMENT", 137, 150], ["cardiac rupture", "PROBLEM", 219, 234], ["a ruptured septum", "PROBLEM", 276, 293], ["a wide range of symptoms", "PROBLEM", 311, 335], ["signs", "PROBLEM", 340, 345], ["mild dyspnea", "PROBLEM", 360, 372], ["severe cardiogenic shock", "PROBLEM", 388, 412], ["coronary", "ANATOMY", 61, 69], ["rupture", "OBSERVATION", 227, 234], ["ruptured", "OBSERVATION", 278, 286], ["mild", "OBSERVATION_MODIFIER", 360, 364], ["dyspnea", "OBSERVATION", 365, 372], ["severe", "OBSERVATION_MODIFIER", 388, 394], ["cardiogenic shock", "OBSERVATION", 395, 412]]], ["When the onset of hemodynamic compromise is immediate, hypotension and tachycardia are present.", [["hypotension", "DISEASE", 55, 66], ["tachycardia", "DISEASE", 71, 82], ["hemodynamic compromise", "PROBLEM", 18, 40], ["hypotension", "PROBLEM", 55, 66], ["tachycardia", "PROBLEM", 71, 82], ["hemodynamic compromise", "OBSERVATION", 18, 40], ["tachycardia", "OBSERVATION", 71, 82]]], ["Biventricular heart failure with predominant right-sided failure may be present.", [["heart", "ANATOMY", 14, 19], ["heart failure", "DISEASE", 14, 27], ["heart", "ORGAN", 14, 19], ["Biventricular heart failure", "PROBLEM", 0, 27], ["predominant right-sided failure", "PROBLEM", 33, 64], ["heart", "ANATOMY", 14, 19], ["failure", "OBSERVATION", 20, 27], ["predominant", "OBSERVATION_MODIFIER", 33, 44], ["right", "ANATOMY_MODIFIER", 45, 50], ["sided", "ANATOMY_MODIFIER", 51, 56], ["failure", "OBSERVATION", 57, 64], ["may be", "UNCERTAINTY", 65, 71]]], ["Rupture of the septum leads to left to right shunt with subsequent right ventricular failure that can progress to pulmonary edema and biventricular failure.", [["septum", "ANATOMY", 15, 21], ["right shunt", "ANATOMY", 39, 50], ["right ventricular", "ANATOMY", 67, 84], ["pulmonary", "ANATOMY", 114, 123], ["Rupture of the septum", "DISEASE", 0, 21], ["right ventricular failure", "DISEASE", 67, 92], ["pulmonary edema", "DISEASE", 114, 129], ["biventricular failure", "DISEASE", 134, 155], ["septum", "MULTI-TISSUE_STRUCTURE", 15, 21], ["ventricular", "MULTI-TISSUE_STRUCTURE", 73, 84], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 114, 129], ["Rupture of the septum leads", "PROBLEM", 0, 27], ["left to right shunt", "TREATMENT", 31, 50], ["subsequent right ventricular failure", "PROBLEM", 56, 92], ["pulmonary edema", "PROBLEM", 114, 129], ["biventricular failure", "PROBLEM", 134, 155], ["septum", "ANATOMY_MODIFIER", 15, 21], ["left", "ANATOMY_MODIFIER", 31, 35], ["right", "ANATOMY_MODIFIER", 39, 44], ["shunt", "OBSERVATION", 45, 50], ["right ventricular", "ANATOMY", 67, 84], ["failure", "OBSERVATION", 85, 92], ["pulmonary", "ANATOMY", 114, 123], ["edema", "OBSERVATION", 124, 129], ["biventricular", "ANATOMY", 134, 147], ["failure", "OBSERVATION", 148, 155]]], ["On physical exam, a new cardiac murmur is nearly always present.", [["cardiac", "ANATOMY", 24, 31], ["cardiac murmur", "DISEASE", 24, 38], ["cardiac", "ORGAN", 24, 31], ["physical exam", "TEST", 3, 16], ["a new cardiac murmur", "PROBLEM", 18, 38], ["new", "OBSERVATION_MODIFIER", 20, 23], ["cardiac", "ANATOMY", 24, 31], ["murmur", "OBSERVATION", 32, 38]]], ["The new murmur is typically harsh, loud, and holosystolic, and is heard best at the lower left and usually right sternal borders.", [["lower left", "ANATOMY", 84, 94], ["right sternal borders", "ANATOMY", 107, 128], ["The new murmur", "PROBLEM", 0, 14], ["loud", "PROBLEM", 35, 39], ["holosystolic", "PROBLEM", 45, 57], ["new", "OBSERVATION_MODIFIER", 4, 7], ["murmur", "OBSERVATION", 8, 14], ["typically", "OBSERVATION_MODIFIER", 18, 27], ["harsh", "OBSERVATION_MODIFIER", 28, 33], ["loud", "OBSERVATION_MODIFIER", 35, 39], ["holosystolic", "OBSERVATION", 45, 57], ["lower", "ANATOMY_MODIFIER", 84, 89], ["left", "ANATOMY_MODIFIER", 90, 94], ["usually", "ANATOMY_MODIFIER", 99, 106], ["right", "ANATOMY_MODIFIER", 107, 112], ["sternal", "ANATOMY", 113, 120], ["borders", "ANATOMY_MODIFIER", 121, 128]]], ["In some cases, the murmur is heard best at the apex and may be mistaken for acute mitral regurgitation.", [["mitral", "ANATOMY", 82, 88], ["mitral regurgitation", "DISEASE", 82, 102], ["apex", "ORGAN", 47, 51], ["mitral regurgitation", "PATHOLOGICAL_FORMATION", 82, 102], ["the murmur", "PROBLEM", 15, 25], ["acute mitral regurgitation", "PROBLEM", 76, 102], ["murmur", "OBSERVATION", 19, 25], ["apex", "ANATOMY_MODIFIER", 47, 51], ["may be mistaken for", "UNCERTAINTY", 56, 75], ["acute mitral", "OBSERVATION", 76, 88], ["regurgitation", "OBSERVATION", 89, 102]]], ["A thrill can be detected in up to 50% of patients; right ventricular lift and a hyperdynamic precordium may also be noted.DiscussionDiagnosis is confirmed by transthoracic echocardiography, which will show disrupted ventricular septum with evidence of left-to-right shunt by color Doppler, left cardiac catheterization (evidence of left-to-right shunt by ventriculography).", [["right ventricular", "ANATOMY", 51, 68], ["ventricular septum", "ANATOMY", 216, 234], ["left", "ANATOMY", 252, 256], ["left cardiac", "ANATOMY", 290, 302], ["left", "ANATOMY", 332, 336], ["patients", "ORGANISM", 41, 49], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 51, 68], ["ventricular septum", "MULTI-TISSUE_STRUCTURE", 216, 234], ["cardiac", "ORGAN", 295, 302], ["patients", "SPECIES", 41, 49], ["right ventricular lift", "PROBLEM", 51, 73], ["a hyperdynamic precordium", "PROBLEM", 78, 103], ["transthoracic echocardiography", "TEST", 158, 188], ["disrupted ventricular septum", "PROBLEM", 206, 234], ["color Doppler", "TEST", 275, 288], ["left cardiac catheterization", "TEST", 290, 318], ["left-to-right shunt", "TREATMENT", 332, 351], ["ventriculography", "TEST", 355, 371], ["thrill", "OBSERVATION", 2, 8], ["right ventricular", "ANATOMY", 51, 68], ["lift", "OBSERVATION", 69, 73], ["hyperdynamic", "OBSERVATION", 80, 92], ["precordium", "ANATOMY", 93, 103], ["may also be", "UNCERTAINTY", 104, 115], ["ventricular septum", "ANATOMY", 216, 234], ["left", "ANATOMY_MODIFIER", 252, 256], ["right", "ANATOMY_MODIFIER", 260, 265], ["shunt", "OBSERVATION", 266, 271], ["left", "ANATOMY_MODIFIER", 290, 294], ["cardiac", "ANATOMY", 295, 302], ["catheterization", "OBSERVATION", 303, 318], ["left", "ANATOMY_MODIFIER", 332, 336], ["right", "ANATOMY_MODIFIER", 340, 345], ["shunt", "OBSERVATION", 346, 351]]], ["If done, pulmonary artery catheterization can reveal step up in the oxygen saturation in the right ventricle and pulmonary artery compared to the right atrium.DiscussionPost MI VSD has a high in-hospital mortality rate.", [["pulmonary artery", "ANATOMY", 9, 25], ["right ventricle", "ANATOMY", 93, 108], ["pulmonary artery", "ANATOMY", 113, 129], ["right atrium", "ANATOMY", 146, 158], ["oxygen", "CHEMICAL", 68, 74], ["oxygen", "CHEMICAL", 68, 74], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 9, 25], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["right ventricle", "MULTI-TISSUE_STRUCTURE", 93, 108], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 113, 129], ["right atrium", "MULTI-TISSUE_STRUCTURE", 146, 158], ["pulmonary artery catheterization", "TEST", 9, 41], ["the oxygen saturation", "TEST", 64, 85], ["Post MI VSD", "PROBLEM", 169, 180], ["pulmonary artery", "ANATOMY", 9, 25], ["oxygen saturation", "OBSERVATION", 68, 85], ["right ventricle", "ANATOMY", 93, 108], ["pulmonary artery", "ANATOMY", 113, 129], ["right atrium", "ANATOMY", 146, 158]]], ["Cardiogenic shock is an independent predictor of in-hospital mortality.", [["Cardiogenic shock", "DISEASE", 0, 17], ["Cardiogenic shock", "PROBLEM", 0, 17], ["shock", "OBSERVATION", 12, 17]]], ["These patients often require mechanical circulatory support [4] .", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["mechanical circulatory support", "TREATMENT", 29, 59]]], ["In-hospital mortality is about 45% in patients who were surgically treated compared to 90% who were medically treated [2] .", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["Patients usually require initial afterload reduction prior to definitive intervention, with the timing of intervention being an important factor in survival [6] .DiscussionTreatment of post-MI VSD is challenging.", [["MI", "DISEASE", 190, 192], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["initial afterload reduction", "TREATMENT", 25, 52], ["definitive intervention", "TREATMENT", 62, 85], ["intervention", "TREATMENT", 106, 118], ["post-MI VSD", "PROBLEM", 185, 196], ["VSD", "OBSERVATION", 193, 196]]], ["The timing of intervention and the treatment approach continues to be an area of debate, depending on the type and size of the defect, clinical condition of the patient, and technical expertise [8] [9] [10] .", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["intervention", "TREATMENT", 14, 26], ["the treatment approach", "TREATMENT", 31, 53], ["the defect", "PROBLEM", 123, 133], ["size", "OBSERVATION_MODIFIER", 115, 119], ["defect", "OBSERVATION", 127, 133]]], ["Surgical management has been the standard treatment.", [["Surgical management", "TREATMENT", 0, 19], ["the standard treatment", "TREATMENT", 29, 51]]], ["However, the trans-catheter approach has increasingly become an alternative modality to surgical repair, especially in patients that are at high risk for surgery.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["the trans-catheter approach", "TREATMENT", 9, 36], ["surgical repair", "TREATMENT", 88, 103], ["surgery", "TREATMENT", 154, 161], ["catheter", "OBSERVATION", 19, 27], ["surgical repair", "OBSERVATION", 88, 103], ["surgery", "OBSERVATION", 154, 161]]], ["Immediate surgical closure is associated with high mortality due to hemodynamic instability and friable tissue surrounding the septal defect in the acute phase of an MI.", [["tissue", "ANATOMY", 104, 110], ["septal", "ANATOMY", 127, 133], ["MI", "DISEASE", 166, 168], ["friable tissue", "TISSUE", 96, 110], ["septal", "MULTI-TISSUE_STRUCTURE", 127, 133], ["Immediate surgical closure", "TREATMENT", 0, 26], ["high mortality", "PROBLEM", 46, 60], ["hemodynamic instability", "PROBLEM", 68, 91], ["friable tissue", "PROBLEM", 96, 110], ["the septal defect", "PROBLEM", 123, 140], ["an MI", "PROBLEM", 163, 168], ["surgical closure", "OBSERVATION", 10, 26], ["hemodynamic instability", "OBSERVATION", 68, 91], ["friable tissue", "OBSERVATION", 96, 110], ["septal", "ANATOMY_MODIFIER", 127, 133], ["defect", "OBSERVATION", 134, 140], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["phase", "OBSERVATION_MODIFIER", 154, 159], ["MI", "OBSERVATION", 166, 168]]], ["A systemic review looking at the differences between management options found no significant difference in the mortality among patient who had early trans-catheter approach compared with initial surgical closure group but the overall mortality among all trans-catheter approach and late transcatheter approach groups were significantly lower when compared with the late surgical closure group [8] .", [["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["A systemic review", "TEST", 0, 17], ["management options", "TREATMENT", 53, 71], ["early trans-catheter approach", "TREATMENT", 143, 172], ["initial surgical closure group", "TREATMENT", 187, 217], ["all trans-catheter approach", "TREATMENT", 250, 277], ["late transcatheter approach groups", "TREATMENT", 282, 316], ["the late surgical closure group", "TREATMENT", 361, 392], ["catheter", "OBSERVATION", 155, 163], ["catheter", "OBSERVATION", 260, 268]]], ["Our patient had a VSD due to an old undiagnosed MI.", [["MI", "DISEASE", 48, 50], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a VSD", "PROBLEM", 16, 21], ["an old undiagnosed MI", "PROBLEM", 29, 50], ["VSD", "OBSERVATION", 18, 21], ["MI", "OBSERVATION", 48, 50]]], ["He was in compensated heart failure at first and was treated with medical management.", [["heart", "ANATOMY", 22, 27], ["heart failure", "DISEASE", 22, 35], ["He", "ORGANISM", 0, 2], ["heart", "ORGAN", 22, 27], ["compensated heart failure", "PROBLEM", 10, 35], ["medical management", "TREATMENT", 66, 84], ["compensated", "OBSERVATION_MODIFIER", 10, 21], ["heart", "ANATOMY", 22, 27], ["failure", "OBSERVATION", 28, 35]]], ["Later on, he developed respiratory complications related to COVID-19 infection as well as hepatic failure in addition to cardiomyopathy that made him a poor surgical candidate.ConclusionsVentricular septal defect is a known however rare complication of myocardial infarction.", [["respiratory", "ANATOMY", 23, 34], ["hepatic", "ANATOMY", 90, 97], ["Ventricular septal", "ANATOMY", 187, 205], ["myocardial", "ANATOMY", 253, 263], ["respiratory complications", "DISEASE", 23, 48], ["COVID-19", "CHEMICAL", 60, 68], ["infection", "DISEASE", 69, 78], ["hepatic failure", "DISEASE", 90, 105], ["cardiomyopathy", "DISEASE", 121, 135], ["Ventricular septal defect", "DISEASE", 187, 212], ["myocardial infarction", "DISEASE", 253, 274], ["hepatic", "ORGAN", 90, 97], ["Ventricular septal", "MULTI-TISSUE_STRUCTURE", 187, 205], ["myocardial", "MULTI-TISSUE_STRUCTURE", 253, 263], ["respiratory complications", "PROBLEM", 23, 48], ["COVID-19 infection", "PROBLEM", 60, 78], ["hepatic failure", "PROBLEM", 90, 105], ["cardiomyopathy", "PROBLEM", 121, 135], ["Ventricular septal defect", "PROBLEM", 187, 212], ["myocardial infarction", "PROBLEM", 253, 274], ["respiratory", "ANATOMY", 23, 34], ["complications", "OBSERVATION", 35, 48], ["infection", "OBSERVATION", 69, 78], ["hepatic", "ANATOMY", 90, 97], ["failure", "OBSERVATION", 98, 105], ["cardiomyopathy", "OBSERVATION", 121, 135], ["Ventricular septal", "ANATOMY", 187, 205], ["defect", "OBSERVATION", 206, 212], ["myocardial", "ANATOMY", 253, 263], ["infarction", "OBSERVATION", 264, 274]]], ["Symptoms range from mild dyspnea to overt cardiogenic shock.", [["dyspnea", "DISEASE", 25, 32], ["cardiogenic shock", "DISEASE", 42, 59], ["Symptoms range", "PROBLEM", 0, 14], ["mild dyspnea", "PROBLEM", 20, 32], ["overt cardiogenic shock", "PROBLEM", 36, 59], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["dyspnea", "OBSERVATION", 25, 32], ["overt", "OBSERVATION_MODIFIER", 36, 41], ["cardiogenic shock", "OBSERVATION", 42, 59]]], ["Our study highlights a fortunate patient in which a VSD secondary to myocardial infarction (MI) did not result in catastrophic outcome during the initial admission for MI.", [["myocardial", "ANATOMY", 69, 79], ["myocardial infarction", "DISEASE", 69, 90], ["MI", "DISEASE", 92, 94], ["MI", "DISEASE", 168, 170], ["patient", "ORGANISM", 33, 40], ["myocardial", "MULTI-TISSUE_STRUCTURE", 69, 79], ["patient", "SPECIES", 33, 40], ["Our study", "TEST", 0, 9], ["a VSD", "PROBLEM", 50, 55], ["myocardial infarction", "PROBLEM", 69, 90], ["MI", "PROBLEM", 92, 94], ["MI", "PROBLEM", 168, 170], ["VSD", "OBSERVATION", 52, 55], ["myocardial", "ANATOMY", 69, 79], ["infarction", "OBSERVATION", 80, 90], ["catastrophic", "OBSERVATION_MODIFIER", 114, 126]]], ["Bringing awareness to this fatal complication may result in health care providers recognizing it quicker and acting accordingly.", [["this fatal complication", "PROBLEM", 22, 45]]], ["More research studies should be geared towards optimal ways to detect and manage VSDs secondary to myocardial infarctions.Additional Information DisclosuresHuman subjects: Consent was obtained by all participants in this study.Conflicts of interest:In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.", [["myocardial", "ANATOMY", 99, 109], ["VSDs", "DISEASE", 81, 85], ["myocardial infarctions", "DISEASE", 99, 121], ["myocardial", "MULTI-TISSUE_STRUCTURE", 99, 109], ["Human", "ORGANISM", 156, 161], ["Human", "SPECIES", 156, 161], ["participants", "SPECIES", 200, 212], ["research studies", "TEST", 5, 21], ["VSDs", "PROBLEM", 81, 85], ["myocardial infarctions", "PROBLEM", 99, 121], ["this study", "TEST", 216, 226], ["financial support", "TREATMENT", 395, 412], ["myocardial", "ANATOMY", 99, 109], ["infarctions", "OBSERVATION", 110, 121]]]], "84f7dcdcfb8c678c895d41dbb439b4e0e8acfd77": [["1Exercise in isolating during novel coronavirus 19 -A case report of bilateral ocular trauma from elastic resistant bandsSibley D (1), Abdalla H (1), Gupta A (1), Ho J (1,2).Introduction:The novel coronavirus (COVID-19), has become a worldwide pandemic (1) .", [["ocular", "ANATOMY", 79, 85], ["ocular trauma", "DISEASE", 79, 92], ["COVID-19", "CHEMICAL", 210, 218], ["Gupta A", "CHEMICAL", 150, 157], ["coronavirus", "ORGANISM", 36, 47], ["ocular", "ORGAN", 79, 85], ["coronavirus", "ORGANISM", 197, 208], ["COVID-19", "ORGANISM", 210, 218], ["bilateral ocular trauma", "PROBLEM", 69, 92], ["elastic resistant bands", "PROBLEM", 98, 121], ["COVID", "TEST", 210, 215], ["bilateral", "ANATOMY_MODIFIER", 69, 78], ["ocular", "ANATOMY", 79, 85], ["trauma", "OBSERVATION", 86, 92], ["elastic resistant bands", "OBSERVATION", 98, 121]]], ["Social distancing measures implemented to prevent disease spread have included the closure of gymnasiums worldwide.", [["gymnasiums", "DISEASE", 94, 104], ["Social distancing measures", "TREATMENT", 0, 26], ["disease spread", "PROBLEM", 50, 64], ["the closure of gymnasiums worldwide", "TREATMENT", 79, 114], ["closure", "OBSERVATION", 83, 90]]], ["As a result, the public have turned to home exercise equipment.", [["home exercise equipment", "TREATMENT", 39, 62]]], ["We have found a corresponding increase in patients attending a central London ophthalmic A&E with bilateral ocular trauma from elastic resistance bands.", [["ocular", "ANATOMY", 108, 114], ["ocular trauma", "DISEASE", 108, 121], ["patients", "ORGANISM", 42, 50], ["ocular", "ORGAN", 108, 114], ["patients", "SPECIES", 42, 50], ["bilateral ocular trauma", "PROBLEM", 98, 121], ["elastic resistance bands", "PROBLEM", 127, 151], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["bilateral", "ANATOMY_MODIFIER", 98, 107], ["ocular", "ANATOMY", 108, 114], ["trauma", "OBSERVATION", 115, 121], ["elastic resistance", "OBSERVATION", 127, 145]]], ["In this case report we described two cases presenting within two weeks during the UK lockdown.Case 1:A 41-year-old female presented to the A&E after a resistance band had slipped and hit both eyes.", [["eyes", "ANATOMY", 192, 196], ["UK", "GENE_OR_GENE_PRODUCT", 82, 84], ["female", "ORGANISM", 115, 121], ["eyes", "ORGAN", 192, 196], ["a resistance band", "PROBLEM", 149, 166], ["slipped and hit both eyes", "PROBLEM", 171, 196], ["slipped", "OBSERVATION", 171, 178], ["both", "ANATOMY_MODIFIER", 187, 191], ["eyes", "ANATOMY", 192, 196]]], ["She has no previous ophthalmic or medical history.", [["no", "UNCERTAINTY", 8, 10]]], ["Her unaided Snellen visual acuity was 6/12 in both eyes, this improved to 6/9 with pinhole in both eyes.", [["eyes", "ANATOMY", 51, 55], ["eyes", "ANATOMY", 99, 103], ["eyes", "ORGAN", 51, 55], ["eyes", "ORGAN", 99, 103], ["eyes", "ANATOMY", 51, 55], ["both eyes", "ANATOMY", 94, 103]]], ["Her intraocular pressures were within normal limits at 10mmHg bilaterally.", [["intraocular", "ANATOMY", 4, 15], ["Her intraocular pressures", "TEST", 0, 25], ["intraocular pressures", "OBSERVATION", 4, 25], ["normal limits", "OBSERVATION", 38, 51], ["bilaterally", "ANATOMY_MODIFIER", 62, 73]]], ["On examination of the anterior segment the right eye had a 0.8mm hyphaema.", [["anterior segment", "ANATOMY", 22, 38], ["right eye", "ANATOMY", 43, 52], ["hyphaema", "DISEASE", 65, 73], ["anterior segment", "MULTI-TISSUE_STRUCTURE", 22, 38], ["eye", "ORGAN", 49, 52], ["examination", "TEST", 3, 14], ["a 0.8mm hyphaema", "PROBLEM", 57, 73], ["anterior", "ANATOMY_MODIFIER", 22, 30], ["segment", "ANATOMY_MODIFIER", 31, 38], ["right", "ANATOMY_MODIFIER", 43, 48], ["eye", "ANATOMY", 49, 52], ["0.8mm", "OBSERVATION_MODIFIER", 59, 64], ["hyphaema", "OBSERVATION", 65, 73]]], ["The left eye had a 1mm hyphaema with 2 clock hours of iridodialysis from 4 to 6 o'clock.", [["left eye", "ANATOMY", 4, 12], ["hyphaema", "DISEASE", 23, 31], ["eye", "ORGAN", 9, 12], ["a 1mm hyphaema", "PROBLEM", 17, 31], ["iridodialysis", "TEST", 54, 67], ["left", "ANATOMY_MODIFIER", 4, 8], ["eye", "ANATOMY", 9, 12], ["1mm", "OBSERVATION_MODIFIER", 19, 22], ["hyphaema", "OBSERVATION", 23, 31]]], ["Dilated fundoscopy of both eyes revealed peripheral commotio retinae with no retinal tears found on indented examination.", [["eyes", "ANATOMY", 27, 31], ["peripheral commotio retinae", "ANATOMY", 41, 68], ["retinal", "ANATOMY", 77, 84], ["retinal tears", "DISEASE", 77, 90], ["eyes", "ORGAN", 27, 31], ["retinae", "MULTI-TISSUE_STRUCTURE", 61, 68], ["retinal tears", "PATHOLOGICAL_FORMATION", 77, 90], ["Dilated fundoscopy of both eyes", "TEST", 0, 31], ["peripheral commotio retinae", "PROBLEM", 41, 68], ["retinal tears", "PROBLEM", 77, 90], ["indented examination", "TEST", 100, 120], ["both", "ANATOMY_MODIFIER", 22, 26], ["eyes", "ANATOMY", 27, 31], ["peripheral", "ANATOMY_MODIFIER", 41, 51], ["commotio retinae", "OBSERVATION", 52, 68], ["no", "UNCERTAINTY", 74, 76], ["retinal", "ANATOMY", 77, 84], ["tears", "OBSERVATION", 85, 90]]], ["She was treated with bed rest, a tapering course of G. Dexamethasone 0.1% beginning at 6 times a day and G. Cyclopentolate 1% three times a day.", [["Cyclopentolate", "CHEMICAL", 108, 122], ["Dexamethasone", "CHEMICAL", 55, 68], ["Dexamethasone", "SIMPLE_CHEMICAL", 55, 68], ["bed rest", "TREATMENT", 21, 29], ["a tapering course of G. Dexamethasone", "TREATMENT", 31, 68], ["Cyclopentolate", "TREATMENT", 108, 122]]], ["She will require review within two weeks to monitor her progress and annual lifelong monitoring of the left eye for the development of angle recession glaucoma.Case 2:A 19-year-old male former personal trainer sustained a resistance band injury across both eyes.", [["left eye", "ANATOMY", 103, 111], ["eyes", "ANATOMY", 257, 261], ["glaucoma", "DISEASE", 151, 159], ["eye", "ORGAN", 108, 111], ["eyes", "ORGAN", 257, 261], ["annual lifelong monitoring", "TEST", 69, 95], ["angle recession glaucoma", "PROBLEM", 135, 159], ["a resistance band injury", "PROBLEM", 220, 244], ["left", "ANATOMY_MODIFIER", 103, 107], ["eye", "ANATOMY", 108, 111], ["angle recession", "OBSERVATION", 135, 150], ["glaucoma", "OBSERVATION", 151, 159], ["resistance band", "OBSERVATION", 222, 237], ["injury", "OBSERVATION", 238, 244], ["both", "ANATOMY_MODIFIER", 252, 256], ["eyes", "ANATOMY", 257, 261]]], ["His unaided visual acuity on presentation was 6/6 on the right and 2/60 on the left 3 with no improvement with pinhole.", [["right", "ANATOMY", 57, 62], ["right", "ANATOMY_MODIFIER", 57, 62], ["left", "ANATOMY_MODIFIER", 79, 83], ["no", "UNCERTAINTY", 91, 93], ["improvement", "OBSERVATION", 94, 105]]], ["His intraocular pressure was 15 and 24mmHg in the right and left eye respectively.", [["intraocular", "ANATOMY", 4, 15], ["right", "ANATOMY", 50, 55], ["left eye", "ANATOMY", 60, 68], ["intraocular", "MULTI-TISSUE_STRUCTURE", 4, 15], ["eye", "ORGAN", 65, 68], ["His intraocular pressure", "TEST", 0, 24], ["intraocular pressure", "OBSERVATION", 4, 24], ["right", "ANATOMY_MODIFIER", 50, 55], ["left", "ANATOMY_MODIFIER", 60, 64], ["eye", "ANATOMY", 65, 68]]], ["Examination of the anterior segment of the right eye showed red blood cell deposits on the inferior corneal endothelium, the left eye had a 1mm hyphaemia, that had settled nasally due to the patient laying on his right-hand side ( Figure 1 ).", [["anterior segment", "ANATOMY", 19, 35], ["right eye", "ANATOMY", 43, 52], ["red blood cell", "ANATOMY", 60, 74], ["inferior corneal endothelium", "ANATOMY", 91, 119], ["left eye", "ANATOMY", 125, 133], ["right-hand", "ANATOMY", 213, 223], ["hyphaemia", "DISEASE", 144, 153], ["anterior segment", "MULTI-TISSUE_STRUCTURE", 19, 35], ["eye", "ORGAN", 49, 52], ["red blood cell", "CELL", 60, 74], ["inferior corneal endothelium", "TISSUE", 91, 119], ["eye", "ORGAN", 130, 133], ["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 191, 198], ["Examination of the anterior segment of the right eye", "TEST", 0, 52], ["red blood cell deposits", "PROBLEM", 60, 83], ["a 1mm hyphaemia", "PROBLEM", 138, 153], ["anterior", "ANATOMY_MODIFIER", 19, 27], ["segment", "ANATOMY_MODIFIER", 28, 35], ["right", "ANATOMY_MODIFIER", 43, 48], ["eye", "ANATOMY", 49, 52], ["red blood cell deposits", "OBSERVATION", 60, 83], ["inferior", "ANATOMY_MODIFIER", 91, 99], ["corneal endothelium", "ANATOMY", 100, 119], ["left", "ANATOMY_MODIFIER", 125, 129], ["eye", "ANATOMY", 130, 133], ["1mm", "OBSERVATION_MODIFIER", 140, 143], ["hyphaemia", "OBSERVATION", 144, 153], ["right", "ANATOMY_MODIFIER", 213, 218], ["hand", "ANATOMY", 219, 223]]], ["Dilated fundoscopy showed inferior peripheral commotio retinae on the right eye.", [["inferior peripheral commotio retinae", "ANATOMY", 26, 62], ["right eye", "ANATOMY", 70, 79], ["retinae", "MULTI-TISSUE_STRUCTURE", 55, 62], ["eye", "ORGAN", 76, 79], ["Dilated fundoscopy", "TEST", 0, 18], ["inferior peripheral commotio retinae on the right eye", "PROBLEM", 26, 79], ["inferior", "ANATOMY_MODIFIER", 26, 34], ["peripheral", "ANATOMY_MODIFIER", 35, 45], ["commotio retinae", "OBSERVATION", 46, 62], ["right", "ANATOMY_MODIFIER", 70, 75], ["eye", "ANATOMY", 76, 79]]], ["The left eye had a vitreous haemorrhage with peripheral commotio retinae and intra-retinal haemorrhages and an inferior retinal tear (Figure 2 ).", [["left eye", "ANATOMY", 4, 12], ["vitreous", "ANATOMY", 19, 27], ["peripheral commotio retinae", "ANATOMY", 45, 72], ["intra-retinal", "ANATOMY", 77, 90], ["inferior retinal tear", "ANATOMY", 111, 132], ["vitreous haemorrhage", "DISEASE", 19, 39], ["haemorrhages", "DISEASE", 91, 103], ["inferior retinal tear", "DISEASE", 111, 132], ["eye", "ORGAN", 9, 12], ["retinae", "MULTI-TISSUE_STRUCTURE", 65, 72], ["retinal", "MULTI-TISSUE_STRUCTURE", 120, 127], ["a vitreous haemorrhage", "PROBLEM", 17, 39], ["peripheral commotio retinae", "PROBLEM", 45, 72], ["intra-retinal haemorrhages", "PROBLEM", 77, 103], ["an inferior retinal tear", "PROBLEM", 108, 132], ["left", "ANATOMY_MODIFIER", 4, 8], ["eye", "ANATOMY", 9, 12], ["vitreous haemorrhage", "OBSERVATION", 19, 39], ["peripheral", "ANATOMY_MODIFIER", 45, 55], ["commotio retinae", "OBSERVATION", 56, 72], ["intra-retinal", "ANATOMY", 77, 90], ["haemorrhages", "OBSERVATION", 91, 103], ["inferior", "ANATOMY_MODIFIER", 111, 119], ["retinal", "ANATOMY", 120, 127], ["tear", "OBSERVATION", 128, 132]]], ["The patient was treated with bed rest, a tapering course of G. Dexamethasone 0.1% starting six times a day and G. CyclopentolateConclusionThis case report describes the complex bilateral ocular injuries from elastic home exercise bands, requiring both short-and long-term management.", [["ocular", "ANATOMY", 187, 193], ["Cyclopentolate", "CHEMICAL", 114, 128], ["ocular injuries", "DISEASE", 187, 202], ["Dexamethasone", "CHEMICAL", 63, 76], ["patient", "ORGANISM", 4, 11], ["Dexamethasone", "SIMPLE_CHEMICAL", 63, 76], ["patient", "SPECIES", 4, 11], ["bed rest", "TREATMENT", 29, 37], ["a tapering course of G. Dexamethasone", "TREATMENT", 39, 76], ["the complex bilateral ocular injuries", "PROBLEM", 165, 202], ["elastic home exercise bands", "TREATMENT", 208, 235], ["long-term management", "TREATMENT", 262, 282], ["bilateral", "ANATOMY_MODIFIER", 177, 186], ["ocular", "ANATOMY", 187, 193], ["injuries", "OBSERVATION", 194, 202]]], ["There are sparse case reports of ocular injuries from elastic exercise bands causing unilateral retinal detachment (2), hyphaema (3) and lens dislocation (4).", [["ocular", "ANATOMY", 33, 39], ["retinal", "ANATOMY", 96, 103], ["lens", "ANATOMY", 137, 141], ["ocular injuries", "DISEASE", 33, 48], ["retinal detachment", "DISEASE", 96, 114], ["hyphaema", "DISEASE", 120, 128], ["lens dislocation", "DISEASE", 137, 153], ["retinal", "MULTI-TISSUE_STRUCTURE", 96, 103], ["ocular injuries", "PROBLEM", 33, 48], ["elastic exercise bands", "PROBLEM", 54, 76], ["unilateral retinal detachment", "PROBLEM", 85, 114], ["hyphaema (3) and lens dislocation", "PROBLEM", 120, 153], ["sparse", "OBSERVATION_MODIFIER", 10, 16], ["ocular", "ANATOMY", 33, 39], ["injuries", "OBSERVATION", 40, 48], ["elastic", "OBSERVATION_MODIFIER", 54, 61], ["exercise bands", "OBSERVATION", 62, 76], ["unilateral", "ANATOMY_MODIFIER", 85, 95], ["retinal", "ANATOMY", 96, 103], ["detachment", "OBSERVATION", 104, 114], ["lens", "ANATOMY", 137, 141], ["dislocation", "OBSERVATION", 142, 153]]], ["Our case report is the first where both cases have 4 bilateral injury requiring treatment.", [["4 bilateral injury", "PROBLEM", 51, 69], ["treatment", "TREATMENT", 80, 89], ["bilateral", "ANATOMY_MODIFIER", 53, 62], ["injury", "OBSERVATION", 63, 69]]], ["The bilateral involvement is explained through the mechanism of injury where the exercise band slips, often from under the foot, and strikes both eyes.", [["foot", "ANATOMY", 123, 127], ["eyes", "ANATOMY", 146, 150], ["foot", "ORGANISM_SUBDIVISION", 123, 127], ["eyes", "ORGAN", 146, 150], ["injury", "PROBLEM", 64, 70], ["the exercise band slips", "PROBLEM", 77, 100], ["bilateral", "ANATOMY_MODIFIER", 4, 13], ["involvement", "OBSERVATION", 14, 25], ["injury", "OBSERVATION", 64, 70], ["band slips", "OBSERVATION", 90, 100], ["foot", "ANATOMY", 123, 127], ["both eyes", "ANATOMY", 141, 150]]], ["Interestingly both cases had asymmetrical injuries with the left eye being more affected than the right.", [["left eye", "ANATOMY", 60, 68], ["injuries", "DISEASE", 42, 50], ["eye", "ORGAN", 65, 68], ["asymmetrical injuries", "PROBLEM", 29, 50], ["the left eye", "PROBLEM", 56, 68], ["asymmetrical", "OBSERVATION_MODIFIER", 29, 41], ["injuries", "OBSERVATION", 42, 50], ["left", "ANATOMY_MODIFIER", 60, 64], ["eye", "ANATOMY", 65, 68], ["more", "OBSERVATION_MODIFIER", 75, 79], ["affected", "OBSERVATION", 80, 88], ["right", "ANATOMY_MODIFIER", 98, 103]]], ["This highlights the need for clinicians to ensure both eyes are adequately assessed as the apparently unaffected eye may still have injuries.", [["eyes", "ANATOMY", 55, 59], ["eye", "ANATOMY", 113, 116], ["eyes", "ORGAN", 55, 59], ["eye", "ORGAN", 113, 116], ["injuries", "PROBLEM", 132, 140], ["injuries", "OBSERVATION", 132, 140]]], ["This case report is also unusual in that all cases presented within quick succession due to increased home exercise during COVID-19 isolation.", [["COVID-19 isolation", "TREATMENT", 123, 141]]], ["We wish to raise public awareness of the potential ocular risks arising from home exercise and the need for adequate eye protection.ConclusionThe Authors declare that there is no conflict of interest in the publication of this article.ConclusionThe authors received no financial support for the research authorship and/or publication of this article.ConclusionWritten consent was obtained for publication of the images in this article Anterior segment photo of a hyphaemia that settled nasally due to posturing on the righthand side.Figure 2:Colour fundus photo demonstrating inferior commotio retinae, intra-retinal haemorrhages and a traumatic retinal tear.", [["ocular", "ANATOMY", 51, 57], ["eye", "ANATOMY", 117, 120], ["righthand", "ANATOMY", 518, 527], ["fundus", "ANATOMY", 549, 555], ["inferior commotio retinae", "ANATOMY", 576, 601], ["intra-retinal", "ANATOMY", 603, 616], ["retinal", "ANATOMY", 646, 653], ["hyphaemia", "DISEASE", 463, 472], ["posturing", "DISEASE", 501, 510], ["haemorrhages", "DISEASE", 617, 629], ["retinal tear", "DISEASE", 646, 658], ["eye", "ORGAN", 117, 120], ["fundus", "MULTI-TISSUE_STRUCTURE", 549, 555], ["retinae", "MULTI-TISSUE_STRUCTURE", 594, 601], ["retinal", "MULTI-TISSUE_STRUCTURE", 646, 653], ["home exercise", "TREATMENT", 77, 90], ["financial support", "TREATMENT", 269, 286], ["the images", "TEST", 408, 418], ["a hyphaemia", "PROBLEM", 461, 472], ["posturing on the righthand side", "PROBLEM", 501, 532], ["Colour fundus photo", "TEST", 542, 561], ["inferior commotio retinae", "PROBLEM", 576, 601], ["intra-retinal haemorrhages", "PROBLEM", 603, 629], ["a traumatic retinal tear", "PROBLEM", 634, 658], ["no", "UNCERTAINTY", 176, 178], ["hyphaemia", "OBSERVATION", 463, 472], ["posturing", "OBSERVATION", 501, 510], ["inferior", "ANATOMY_MODIFIER", 576, 584], ["commotio retinae", "ANATOMY", 585, 601], ["intra-retinal", "ANATOMY", 603, 616], ["haemorrhages", "OBSERVATION", 617, 629], ["traumatic", "OBSERVATION_MODIFIER", 636, 645], ["retinal", "ANATOMY", 646, 653], ["tear", "OBSERVATION", 654, 658]]]], "PMC7295484": [["Why is everyone in a state of panic?This is a time of uncertainties \u2013 all individuals are uncertain about their health and economic outcomes.", [["panic", "DISEASE", 30, 35], ["panic", "PROBLEM", 30, 35]]], ["Also, there is overwhelming misinformation, stigma, prolonged isolation, and disruption of daily routines.", [["overwhelming misinformation", "PROBLEM", 15, 42], ["stigma", "PROBLEM", 44, 50], ["prolonged isolation", "TREATMENT", 52, 71], ["disruption of daily routines", "TREATMENT", 77, 105], ["overwhelming", "OBSERVATION_MODIFIER", 15, 27], ["misinformation", "OBSERVATION", 28, 42], ["prolonged isolation", "OBSERVATION", 52, 71]]], ["Fear and anxiety had led to suicides, communal disharmony, and crimes against essential service providers (Sharma et al., 2020).Why should mental health workers reach out?Not only individuals with confirmed or suspected COVID-19 but several other vulnerable groups (e.g. health care workers, persons with mental illness etc.), despite remaining uninfected, will continue to suffer from psychological infirmity.", [["Fear", "DISEASE", 0, 4], ["anxiety", "DISEASE", 9, 16], ["disharmony", "DISEASE", 47, 57], ["persons", "ORGANISM", 292, 299], ["persons", "SPECIES", 292, 299], ["Fear", "PROBLEM", 0, 4], ["anxiety", "PROBLEM", 9, 16], ["psychological infirmity", "PROBLEM", 386, 409]]], ["Therefore, we need an intervention plan to address mental-health problems during the pandemic (Das, 2020).What should be the possible objectives of psychiatric intervention?", [["psychiatric", "DISEASE", 148, 159], ["an intervention plan", "TREATMENT", 19, 39], ["mental-health problems", "PROBLEM", 51, 73], ["psychiatric intervention", "TREATMENT", 148, 172]]]], "a110f5802f51a669f77a647df0cd0dff1fda97c3": [["INTRODUCTIONThe COVID-19 pandemic is a new critical emerging human disease, where no vaccines, or monoclonal antibodies (mAbs), or drugs are currently available for preventative measures or therapy.", [["human", "ORGANISM", 61, 66], ["monoclonal antibodies", "PROTEIN", 98, 119], ["mAbs", "PROTEIN", 121, 125], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["vaccines", "TREATMENT", 85, 93], ["monoclonal antibodies (mAbs", "TREATMENT", 98, 125], ["drugs", "TREATMENT", 131, 136], ["preventative measures", "TREATMENT", 165, 186], ["therapy", "TREATMENT", 190, 197]]], ["Active vaccination, as the first choice, requires the induction of an immune response against a given agent by a susceptible individual for the purpose of preventing or treating the disease.", [["Active vaccination", "TREATMENT", 0, 18], ["agent", "TREATMENT", 102, 107], ["the disease", "PROBLEM", 178, 189], ["disease", "OBSERVATION", 182, 189]]], ["Development of an effective vaccine can take time to be fully validated for use.", [["an effective vaccine", "TREATMENT", 15, 35], ["effective", "OBSERVATION_MODIFIER", 18, 27], ["vaccine", "OBSERVATION", 28, 35]]], ["The duration of effectiveness of a vaccine must be established, so is its capability and effectiveness as a public health tool can be established.", [["a vaccine", "TREATMENT", 33, 42]]], ["Moreover, to develop an effective and appropriate of vaccine to the SARS-CoV-2 virus, it is advisable to target the spiky crown of the virus to prevent viral propagation via entry of the virus into the cell and to target the viral development machinery.", [["cell", "ANATOMY", 202, 206], ["SARS", "DISEASE", 68, 72], ["SARS-CoV-2 virus", "ORGANISM", 68, 84], ["cell", "CELL", 202, 206], ["CoV-2 virus", "SPECIES", 73, 84], ["SARS-CoV-2 virus", "SPECIES", 68, 84], ["vaccine", "TREATMENT", 53, 60], ["the SARS", "TEST", 64, 72], ["CoV", "TEST", 73, 76], ["virus", "PROBLEM", 79, 84], ["the virus", "PROBLEM", 131, 140], ["viral propagation", "PROBLEM", 152, 169], ["the virus into the cell", "PROBLEM", 183, 206]]], ["Trials underway in the UK indicate that there is promising progress with the development of an effective vaccine.", [["UK", "GENE_OR_GENE_PRODUCT", 23, 25], ["an effective vaccine", "TREATMENT", 92, 112]]], ["In addition, the use of J o u r n a l P r e -p r o o f available drug therapies, such as dexamethasone to treat lung inflammation or the antiviral Remdesivir, can reduce mortality.", [["lung", "ANATOMY", 112, 116], ["dexamethasone", "CHEMICAL", 89, 102], ["lung inflammation", "DISEASE", 112, 129], ["Remdesivir", "CHEMICAL", 147, 157], ["dexamethasone", "CHEMICAL", 89, 102], ["dexamethasone", "SIMPLE_CHEMICAL", 89, 102], ["lung", "ORGAN", 112, 116], ["Remdesivir", "SIMPLE_CHEMICAL", 147, 157], ["J o u r n", "TREATMENT", 24, 33], ["drug therapies", "TREATMENT", 65, 79], ["dexamethasone", "TREATMENT", 89, 102], ["lung inflammation", "PROBLEM", 112, 129], ["the antiviral Remdesivir", "TREATMENT", 133, 157], ["lung", "ANATOMY", 112, 116], ["inflammation", "OBSERVATION", 117, 129]]], ["More data are expected in the future with the use of other relevant drugs.INTRODUCTIONCOVID-19 convalescent plasma (CCP) therapy involves the use of circulating antibodies (Abs) administration from recovered COVID 19 patients, in particular after 2 -4weeks recovery, as a practical strategy to provide immediate passive immunity in susceptible recipients in need.INTRODUCTIONThe success of therapeutic use of convalescent plasma in Ebola cases is well established [1, 2] and this has led many investigators worldwide to pursue developing COVID-19 convalescent plasma programs for compassionate and emergency use [3] [4] [5] [6] [7] [8] [9] [10] .INTRODUCTIONCurrently, to respond to the COVID-19 pandemic crisis many countries have adopted widespread public health initiatives for the testing, tracking, tracing, and isolation of those that are at risk of transmitting the SARS-CoV-2 virus.", [["plasma", "ANATOMY", 108, 114], ["plasma", "ANATOMY", 422, 428], ["plasma", "ANATOMY", 560, 566], ["Ebola", "DISEASE", 432, 437], ["SARS", "DISEASE", 873, 877], ["[3] [4] [5] [6] [7] [8] [9]", "CHEMICAL", 612, 639], ["convalescent", "ORGANISM", 95, 107], ["plasma", "ORGANISM_SUBSTANCE", 108, 114], ["patients", "ORGANISM", 217, 225], ["recipients", "ORGANISM", 344, 354], ["convalescent", "ORGANISM", 409, 421], ["plasma", "ORGANISM_SUBSTANCE", 422, 428], ["Ebola", "ORGANISM", 432, 437], ["convalescent", "ORGANISM", 547, 559], ["plasma", "ORGANISM_SUBSTANCE", 560, 566], ["[3] [4] [5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 612, 644], ["SARS-CoV-2 virus", "ORGANISM", 873, 889], ["circulating antibodies", "PROTEIN", 149, 171], ["Abs", "PROTEIN", 173, 176], ["patients", "SPECIES", 217, 225], ["CoV-2 virus", "SPECIES", 878, 889], ["SARS-CoV-2 virus", "SPECIES", 873, 889], ["other relevant drugs", "TREATMENT", 53, 73], ["INTRODUCTIONCOVID", "TEST", 74, 91], ["convalescent plasma (CCP) therapy", "TREATMENT", 95, 128], ["circulating antibodies", "TREATMENT", 149, 171], ["a practical strategy", "TREATMENT", 270, 290], ["immediate passive immunity", "TREATMENT", 302, 328], ["convalescent plasma in Ebola cases", "TREATMENT", 409, 443], ["COVID", "TEST", 538, 543], ["the testing", "TEST", 781, 792], ["tracing", "TEST", 804, 811], ["the SARS", "PROBLEM", 869, 877], ["CoV-2 virus", "PROBLEM", 878, 889]]], ["Through these initiatives, it has become possible to identify recovered COVID-19 individuals who can participate in large CCP programs.", [["large CCP programs", "TREATMENT", 116, 134]]], ["Currently in the USA and other countries, multiple randomized control trials are underway to evaluate the efficacy of CCP therapy.", [["CCP", "SIMPLE_CHEMICAL", 118, 121], ["multiple randomized control trials", "TREATMENT", 42, 76], ["CCP therapy", "TREATMENT", 118, 129]]], ["Such programs are highly complex undertakings and have required rigorous risk assessments, and detailed planning in order to ensure that there are the required resources and staff available to perform the targeted donor recruitment, plasma collection, testing, and product inventory management required [3] .", [["plasma", "ANATOMY", 233, 239], ["plasma", "ORGANISM_SUBSTANCE", 233, 239], ["rigorous risk assessments", "TEST", 64, 89], ["the targeted donor recruitment", "TREATMENT", 201, 231], ["plasma collection", "TEST", 233, 250], ["testing", "TEST", 252, 259]]], ["Establishing appropriate SARS-CoV-2 antibody titres for donor selection, evaluating concerns over residual levels of virus antigen in asymptomatic individuals and the need to adopt pathogen inactivation processes as part of standardizing apheresis collections are some of the additional challenges facing the rapid establishment of CCP programs.J o u r n a l P r e -p r o o fAt the time of preparing this article, more than 53,000 people in the United States have received COVID-19 convalescent plasma (www.uscovidplasma.org) and controlled clinical trials of CCP are underway around the world.", [["people", "ORGANISM", 431, 437], ["plasma", "ORGANISM_SUBSTANCE", 495, 501], ["virus antigen", "PROTEIN", 117, 130], ["people", "SPECIES", 431, 437], ["appropriate SARS", "TEST", 13, 29], ["CoV", "TEST", 30, 33], ["antibody titres", "TEST", 36, 51], ["donor selection", "TREATMENT", 56, 71], ["residual levels of virus antigen", "PROBLEM", 98, 130], ["asymptomatic individuals", "PROBLEM", 134, 158], ["pathogen inactivation processes", "TREATMENT", 181, 212], ["standardizing apheresis collections", "TREATMENT", 224, 259], ["CCP programs", "TREATMENT", 332, 344], ["COVID", "TREATMENT", 473, 478]]], ["Given the lack of other therapies available, many countries are making available CCP under \"Expanded Access\" or compassionate use programs, while at the same time conducting the clinical trials that will establish if CCP has any clinical benefit in patients affected by the disease.", [["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["other therapies", "TREATMENT", 18, 33], ["the disease", "PROBLEM", 270, 281], ["disease", "OBSERVATION", 274, 281]]], ["While limited studies have reported on the effectiveness of CCP in treating patients with severe disease [7, 11] , these studies have served in guiding important decisions around donor selection and appropriate source and dose of neutralizing antibodies in CCP products.", [["patients", "ORGANISM", 76, 84], ["neutralizing antibodies", "PROTEIN", 230, 253], ["CCP products", "PROTEIN", 257, 269], ["patients", "SPECIES", 76, 84], ["limited studies", "TEST", 6, 21], ["severe disease", "PROBLEM", 90, 104], ["these studies", "TEST", 115, 128], ["donor selection", "TREATMENT", 179, 194], ["neutralizing antibodies in CCP products", "TREATMENT", 230, 269], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["disease", "OBSERVATION", 97, 104]]], ["Importantly, as evidence emerges from large multi-site clinical trials, new indications for the collection, production and use of CCP will emerge which will allow for more targeted use of this product.J o u r n a l P r e -p r o o fGlobal concern over the potential for \"second\" or \"third\" waves of infection to occur before effective vaccines or drug therapies are available has many looking at other biological sources for large-scale production of neutralizing SARS-CoV-2 antibodies.", [["infection", "DISEASE", 298, 307], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 463, 484], ["neutralizing SARS-CoV-2 antibodies", "PROTEIN", 450, 484], ["SARS-CoV", "SPECIES", 463, 471], ["large multi-site clinical trials", "TREATMENT", 38, 70], ["the collection", "PROBLEM", 92, 106], ["CCP", "TREATMENT", 130, 133], ["this product", "TREATMENT", 188, 200], ["fGlobal", "PROBLEM", 230, 237], ["\"second\"", "PROBLEM", 269, 277], ["\"third\" waves of infection", "PROBLEM", 281, 307], ["effective vaccines", "TREATMENT", 324, 342], ["drug therapies", "TREATMENT", 346, 360], ["neutralizing SARS", "PROBLEM", 450, 467], ["CoV", "TEST", 468, 471], ["large", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 298, 307]]], ["This report summarizes some of the novel strategies for developing alternative safe sources of therapeutic autologous antibodies from COVID -19 infected patients, and provides some original thoughts on how to rapidly implement a safe passive immunity in those COVID-19 patients who are most in need of intervention.ALTERNATIVE SOURCES OF COVID-19 ANTIBODIES FOR CLINICAL USETo support the development of guidelines for COVID-19 management, systematic reviews and meta-analyses on the use of convalescent plasma in COVID-19 and other severe respiratory viral infections, including influenza and Ebola viral infections, have been performed [6] [7] [8] [9] .", [["plasma", "ANATOMY", 504, 510], ["COVID-19", "CHEMICAL", 514, 522], ["respiratory viral infections", "DISEASE", 540, 568], ["influenza", "DISEASE", 580, 589], ["Ebola viral infections", "DISEASE", 594, 616], ["COVID -19", "ORGANISM", 134, 143], ["patients", "ORGANISM", 153, 161], ["patients", "ORGANISM", 269, 277], ["convalescent", "ORGANISM", 491, 503], ["plasma", "ORGANISM_SUBSTANCE", 504, 510], ["Ebola viral", "ORGANISM", 594, 605], ["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 638, 653], ["therapeutic autologous antibodies", "PROTEIN", 95, 128], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 269, 277], ["Ebola viral", "SPECIES", 594, 605], ["COVID-19", "SPECIES", 514, 522], ["therapeutic autologous antibodies", "TREATMENT", 95, 128], ["intervention", "TREATMENT", 302, 314], ["COVID", "TEST", 338, 343], ["CLINICAL USETo support", "TREATMENT", 362, 384], ["COVID-19 management", "TREATMENT", 419, 438], ["systematic reviews", "TEST", 440, 458], ["convalescent plasma in COVID", "TEST", 491, 519], ["other severe respiratory viral infections", "PROBLEM", 527, 568], ["influenza", "PROBLEM", 580, 589], ["Ebola viral infections", "PROBLEM", 594, 616], ["severe", "OBSERVATION_MODIFIER", 533, 539], ["respiratory", "ANATOMY", 540, 551], ["viral infections", "OBSERVATION", 552, 568]]], ["Intriguingly, in one meta-analysis the quality of evidence was very low for iii) Affinity Column Preparation of Antibody Hyperconcentrate -Affinity columns can be used to remove either the COVID-19 viral antigen or its antibodies from COVID-19 patients, blood products or the circulation of recovered COVID-19 donors to produce a hyperconcentrate for therapeutic use.", [["blood", "ANATOMY", 254, 259], ["patients", "ORGANISM", 244, 252], ["blood", "ORGANISM_SUBSTANCE", 254, 259], ["donors", "ORGANISM", 310, 316], ["COVID-19 viral antigen", "PROTEIN", 189, 211], ["antibodies", "PROTEIN", 219, 229], ["patients", "SPECIES", 244, 252], ["Affinity Column Preparation", "TREATMENT", 81, 108], ["Antibody Hyperconcentrate -Affinity columns", "TREATMENT", 112, 155], ["the COVID", "TEST", 185, 194], ["viral antigen", "TEST", 198, 211], ["its antibodies", "TEST", 215, 229], ["COVID", "TEST", 235, 240], ["blood products", "TREATMENT", 254, 268]]], ["Such procedures, purposely designed by some manufacturers of affinity columns to removal FIX antibodies, have been already developed and used with success in Malmo, Sweden and can be easily adopted to COVID-19 antibody removal.", [["COVID-19", "CHEMICAL", 201, 209], ["FIX antibodies", "GENE_OR_GENE_PRODUCT", 89, 103], ["FIX antibodies", "PROTEIN", 89, 103], ["Such procedures", "TREATMENT", 0, 15], ["affinity columns", "TREATMENT", 61, 77], ["removal FIX antibodies", "TREATMENT", 81, 103], ["COVID-19 antibody removal", "TREATMENT", 201, 226]]], ["In fact, a capture ELISA, with a plate coated with recombinant ACE-2, or its complexes with S-Protein or its S1 subunit, as a specific and storage this makes RBCs readily available to be used as delivery systems.", [["RBCs", "ANATOMY", 158, 162], ["ACE-2", "GENE_OR_GENE_PRODUCT", 63, 68], ["S-Protein", "GENE_OR_GENE_PRODUCT", 92, 101], ["RBCs", "CELL", 158, 162], ["recombinant ACE-2", "PROTEIN", 51, 68], ["S-Protein", "PROTEIN", 92, 101], ["S1 subunit", "PROTEIN", 109, 119], ["RBCs", "CELL_TYPE", 158, 162], ["a capture ELISA", "TEST", 9, 24], ["a plate coated with recombinant ACE", "TREATMENT", 31, 66], ["S-Protein", "TREATMENT", 92, 101], ["RBCs", "PROBLEM", 158, 162], ["capture ELISA", "OBSERVATION", 11, 24]]], ["The emergence of stem-cell derived RBCs provides further opportunities for developing customized antibody delivery systems for immune therapy [13] .", [["stem-cell", "ANATOMY", 17, 26], ["RBCs", "ANATOMY", 35, 39], ["stem-cell", "CELL", 17, 26], ["RBCs", "CELL", 35, 39], ["stem-cell derived RBCs", "CELL_TYPE", 17, 39], ["stem-cell derived RBCs", "TREATMENT", 17, 39], ["developing customized antibody delivery systems", "TREATMENT", 75, 122], ["immune therapy", "TREATMENT", 127, 141]]], ["Currently, several drug-loading techniques such as encapsulation and surface conjugation have been used for the effective treatment of infections, cancer, and chronic autoimmune diseases [13] .", [["surface", "ANATOMY", 69, 76], ["cancer", "ANATOMY", 147, 153], ["infections", "DISEASE", 135, 145], ["cancer", "DISEASE", 147, 153], ["chronic autoimmune diseases", "DISEASE", 159, 186], ["cancer", "CANCER", 147, 153], ["several drug-loading techniques", "TREATMENT", 11, 42], ["encapsulation and surface conjugation", "TREATMENT", 51, 88], ["infections", "PROBLEM", 135, 145], ["cancer", "PROBLEM", 147, 153], ["chronic autoimmune diseases", "PROBLEM", 159, 186], ["infections", "OBSERVATION", 135, 145], ["cancer", "OBSERVATION", 147, 153], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["autoimmune", "OBSERVATION", 167, 177]]], ["More recently, there is progressive evolution in the use of inhalable drug delivery systems for lung cancer therapy.", [["lung cancer", "ANATOMY", 96, 107], ["lung cancer", "DISEASE", 96, 107], ["lung cancer", "CANCER", 96, 107], ["inhalable drug delivery systems", "TREATMENT", 60, 91], ["lung cancer therapy", "TREATMENT", 96, 115], ["progressive", "OBSERVATION_MODIFIER", 24, 35], ["evolution", "OBSERVATION_MODIFIER", 36, 45], ["lung", "ANATOMY", 96, 100], ["cancer", "OBSERVATION", 101, 107]]], ["Inhalation offers many advantages as it J o u r n a l P r e -p r o o f is a non-invasive method of drug administration as well as provides for localized delivery of anti-cancer drugs to lung tumors.", [["anti-cancer", "ANATOMY", 165, 176], ["lung tumors", "ANATOMY", 186, 197], ["lung tumors", "DISEASE", 186, 197], ["lung tumors", "CANCER", 186, 197], ["a non-invasive method", "TREATMENT", 74, 95], ["drug administration", "TREATMENT", 99, 118], ["anti-cancer drugs", "TREATMENT", 165, 182], ["lung tumors", "PROBLEM", 186, 197], ["lung", "ANATOMY", 186, 190], ["tumors", "OBSERVATION", 191, 197]]], ["Currently various inhalable colloidal systems exist for tumor-targeted drug delivery including polymeric, lipid, hybrid and inorganic nanocarriers.", [["tumor", "ANATOMY", 56, 61], ["tumor", "DISEASE", 56, 61], ["tumor", "CANCER", 56, 61], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["inorganic nanocarriers", "SIMPLE_CHEMICAL", 124, 146], ["various inhalable colloidal systems", "TREATMENT", 10, 45], ["tumor", "PROBLEM", 56, 61], ["targeted drug delivery", "TREATMENT", 62, 84], ["polymeric, lipid", "TREATMENT", 95, 111], ["hybrid", "TREATMENT", 113, 119], ["inorganic nanocarriers", "TREATMENT", 124, 146], ["tumor", "OBSERVATION", 56, 61], ["inorganic nanocarriers", "OBSERVATION", 124, 146]]], ["These approaches for enhanced delivery of nanocarriers to lung cancer cells were illustrated by the recent advances of inhalable microparticlesbased drug delivery systems for lung cancer therapy including: large porous, solid lipid and drug-complex microparticles [14] .", [["lung cancer cells", "ANATOMY", 58, 75], ["lung cancer", "ANATOMY", 175, 186], ["lung cancer", "DISEASE", 58, 69], ["lung cancer", "DISEASE", 175, 186], ["lung cancer cells", "CELL", 58, 75], ["lung cancer", "CANCER", 175, 186], ["solid lipid", "SIMPLE_CHEMICAL", 220, 231], ["lung cancer cells", "CELL_TYPE", 58, 75], ["enhanced delivery of nanocarriers", "TREATMENT", 21, 54], ["lung cancer cells", "PROBLEM", 58, 75], ["inhalable microparticlesbased drug delivery systems", "TREATMENT", 119, 170], ["lung cancer therapy", "TREATMENT", 175, 194], ["large porous, solid lipid and drug-complex microparticles", "TREATMENT", 206, 263], ["lung", "ANATOMY", 58, 62], ["cancer", "OBSERVATION", 63, 69], ["lung", "ANATOMY", 175, 179], ["cancer", "OBSERVATION", 180, 186], ["large porous", "OBSERVATION_MODIFIER", 206, 218]]], ["Despite enormous progress in this field, nevertheless,s little is done in the direction of the potential application of RBC-based DDS in transfusion therapy in particular hypoxia that appears to be a common feature of COVID-19 patients even in the preclinical stages.", [["RBC", "ANATOMY", 120, 123], ["hypoxia", "DISEASE", 171, 178], ["RBC", "CELL", 120, 123], ["patients", "ORGANISM", 227, 235], ["RBC", "CELL_TYPE", 120, 123], ["patients", "SPECIES", 227, 235], ["RBC-based DDS", "TREATMENT", 120, 133], ["transfusion therapy", "TREATMENT", 137, 156], ["particular hypoxia", "PROBLEM", 160, 178], ["COVID", "TEST", 218, 223], ["transfusion therapy", "OBSERVATION", 137, 156], ["appears to be", "UNCERTAINTY", 184, 197]]], ["Hence, deserved to be explored further by investigators with appropriate know how as a research protocol.CONCLUSIONSIn countries without access to advanced blood-processing technologies, choices may initially be restricted to convalescent plasmapheresis using modern apheresis tools that provide leukoreduced plasma for the treatment of COVID-19 patients.", [["blood", "ANATOMY", 156, 161], ["plasma", "ANATOMY", 309, 315], ["COVID", "DISEASE", 337, 342], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["plasma", "ORGANISM_SUBSTANCE", 309, 315], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 346, 354], ["a research protocol", "TREATMENT", 85, 104], ["advanced blood-processing technologies", "TREATMENT", 147, 185], ["convalescent plasmapheresis", "TREATMENT", 226, 253], ["modern apheresis tools", "TREATMENT", 260, 282], ["leukoreduced plasma", "TREATMENT", 296, 315], ["the treatment of COVID", "TREATMENT", 320, 342]]], ["As ongoing clinical trials establish the optimal conditions for CCP therapy, data on effective neutralizing antibody concentrations and dose will help inform the development of more efficient plasmapheresis protocols.", [["CCP therapy", "TREATMENT", 64, 75], ["effective neutralizing antibody concentrations", "TREATMENT", 85, 131], ["more efficient plasmapheresis protocols", "TREATMENT", 177, 216]]], ["The use of two units of plasma, or plasma from two different individuals and /or even preparation of pools of immunoglobulins containing antibodies from various individuals may emerge as the most effective therapy.", [["plasma", "ANATOMY", 24, 30], ["plasma", "ANATOMY", 35, 41], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 110, 125], ["immunoglobulins", "PROTEIN", 110, 125], ["antibodies", "PROTEIN", 137, 147], ["plasma", "TREATMENT", 24, 30], ["plasma", "TREATMENT", 35, 41], ["immunoglobulins containing antibodies", "TREATMENT", 110, 147]]], ["Cryosupernatant plasma or pools of cryosupernatant plasma may also be considered as evidence on the effectiveness of these protocols is collected.", [["plasma", "ANATOMY", 16, 22], ["cryosupernatant plasma", "ANATOMY", 35, 57], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["cryosupernatant plasma", "TREATMENT", 35, 57], ["these protocols", "TREATMENT", 117, 132]]], ["In technologically more advanced countries, additional options for pathogen inactivated and sterilized convalescent plasma or blood products such as This commentary has introduced various alternatives to the current use of COVID-19 convalescent plasma to treat COVID-19 patients.", [["plasma", "ANATOMY", 116, 122], ["blood", "ANATOMY", 126, 131], ["plasma", "ANATOMY", 245, 251], ["COVID", "DISEASE", 261, 266], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["convalescent", "ORGANISM", 232, 244], ["plasma", "ORGANISM_SUBSTANCE", 245, 251], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["pathogen", "PROBLEM", 67, 75], ["sterilized convalescent plasma", "TREATMENT", 92, 122], ["blood products", "TREATMENT", 126, 140], ["COVID", "TREATMENT", 223, 228], ["COVID", "TEST", 261, 266]]], ["While the proposed technological options may, in some cases, be theoretical, the growing concern over the rapid spread of the SARS-CoV-2 virus has prompted many to pursue innovative and creative solutions to reduce the mortality and morbidity resulting from the current global pandemic.CONCLUSIONSJ o u r n a l P r e -p r o o f", [["SARS", "DISEASE", 126, 130], ["SARS-CoV-2 virus", "ORGANISM", 126, 142], ["CoV-2 virus", "SPECIES", 131, 142], ["SARS-CoV-2 virus", "SPECIES", 126, 142], ["the SARS", "PROBLEM", 122, 130], ["CoV-2 virus", "PROBLEM", 131, 142], ["innovative and creative solutions", "TREATMENT", 171, 204], ["morbidity", "PROBLEM", 233, 242]]]], "ac7d8fb495888876f03df56a1d3a3faa1f05e770": [["stage, as described for DIII and stem peptide inhibitors of class II fusion proteins.", [["DIII", "GENE_OR_GENE_PRODUCT", 24, 28], ["class II fusion proteins", "GENE_OR_GENE_PRODUCT", 60, 84], ["DIII", "PROTEIN", 24, 28], ["class II fusion proteins", "PROTEIN", 60, 84], ["DIII and stem peptide inhibitors", "TREATMENT", 24, 56], ["class II fusion proteins", "PROBLEM", 60, 84]]], ["Collectively, our results demonstrate that hantavirus Gc shares not only structural, but also mechanistic similarity with class II viral fusion proteins, and will hopefully help in developing novel therapeutic strategies against hantaviruses.IntroductionThe genus Hantavirus of the family Bunyaviridae comprises diverse viruses that are highly pathogenic to humans.", [["hantavirus", "DISEASE", 43, 53], ["hantaviruses", "DISEASE", 229, 241], ["Hantavirus", "DISEASE", 264, 274], ["Bunyaviridae", "DISEASE", 289, 301], ["hantavirus", "ORGANISM", 43, 53], ["Gc", "GENE_OR_GENE_PRODUCT", 54, 56], ["hantaviruses", "ORGANISM", 229, 241], ["humans", "ORGANISM", 358, 364], ["Gc", "PROTEIN", 54, 56], ["class II viral fusion proteins", "PROTEIN", 122, 152], ["humans", "SPECIES", 358, 364], ["hantavirus", "SPECIES", 43, 53], ["humans", "SPECIES", 358, 364], ["hantavirus", "PROBLEM", 43, 53], ["class II viral fusion proteins", "PROBLEM", 122, 152], ["novel therapeutic strategies", "TREATMENT", 192, 220], ["hantaviruses", "PROBLEM", 229, 241], ["the family Bunyaviridae", "TREATMENT", 278, 301], ["diverse viruses", "PROBLEM", 312, 327], ["hantavirus", "OBSERVATION", 43, 53], ["genus Hantavirus", "OBSERVATION", 258, 274], ["diverse", "OBSERVATION_MODIFIER", 312, 319], ["viruses", "OBSERVATION", 320, 327]]], ["In Asia and Europe the Hantaan, Seoul and PUUV viruses cause hemorrhagic fever with renal syndrome, while in America ANDV and Sin Nombre virus can lead to hantavirus pulmonary syndrome with mortality rates above 30% [1] [2] [3] [4] [5] .", [["renal", "ANATOMY", 84, 89], ["pulmonary", "ANATOMY", 166, 175], ["PUUV viruses", "DISEASE", 42, 54], ["hemorrhagic fever", "DISEASE", 61, 78], ["renal syndrome", "DISEASE", 84, 98], ["hantavirus pulmonary syndrome", "DISEASE", 155, 184], ["Hantaan", "ORGANISM", 23, 30], ["PUUV viruses", "ORGANISM", 42, 54], ["renal", "ORGAN", 84, 89], ["America ANDV", "ORGANISM", 109, 121], ["Sin Nombre virus", "ORGANISM", 126, 142], ["pulmonary", "ORGAN", 166, 175], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 216, 235], ["PUUV viruses", "SPECIES", 42, 54], ["Sin Nombre virus", "SPECIES", 126, 142], ["hemorrhagic fever", "PROBLEM", 61, 78], ["renal syndrome", "PROBLEM", 84, 98], ["Sin Nombre virus", "TREATMENT", 126, 142], ["hantavirus pulmonary syndrome", "PROBLEM", 155, 184], ["mortality rates", "TEST", 190, 205], ["renal", "ANATOMY", 84, 89], ["syndrome", "OBSERVATION", 90, 98], ["pulmonary", "ANATOMY", 166, 175], ["syndrome", "OBSERVATION", 176, 184]]], ["Hantaviruses are currently the most lethal human pathogenic viruses known to occur in America and, due to the lack of Food and Drug Administration (FDA)-approved preventive or therapeutic measures [6, 7] , they have been classified as category A pathogens.", [["Hantaviruses", "DISEASE", 0, 12], ["Hantaviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["Hantaviruses", "TREATMENT", 0, 12], ["the most lethal human pathogenic viruses", "PROBLEM", 27, 67], ["Drug Administration", "TREATMENT", 127, 146], ["viruses", "OBSERVATION", 60, 67]]], ["Like other members of the Bunyaviridae family, hantaviruses have a tri-segmented single strand RNA genome of negative polarity packaged by the nucleoprotein into viral ribonucleocapsids, which are also associated to the viral RNA-dependent RNA polymerase [8] .", [["hantaviruses", "ORGANISM", 47, 59], ["ribonucleocapsids", "GENE_OR_GENE_PRODUCT", 168, 185], ["tri-segmented single strand RNA genome", "DNA", 67, 105], ["viral ribonucleocapsids", "PROTEIN", 162, 185], ["viral RNA", "RNA", 220, 229], ["RNA polymerase", "PROTEIN", 240, 254], ["viral ribonucleocapsids", "PROBLEM", 162, 185], ["the viral RNA-dependent RNA polymerase", "PROBLEM", 216, 254], ["negative polarity", "OBSERVATION_MODIFIER", 109, 126], ["viral ribonucleocapsids", "OBSERVATION", 162, 185], ["viral RNA", "OBSERVATION", 220, 229]]], ["A lipid membrane, which further envelopes the viral ribonucleocapsids, anchors the viral Gn and Gc glycoproteins.", [["lipid membrane", "ANATOMY", 2, 16], ["lipid membrane", "CELLULAR_COMPONENT", 2, 16], ["Gn", "GENE_OR_GENE_PRODUCT", 89, 91], ["Gc glycoproteins", "GENE_OR_GENE_PRODUCT", 96, 112], ["viral ribonucleocapsids", "PROTEIN", 46, 69], ["viral Gn and Gc glycoproteins", "PROTEIN", 83, 112], ["A lipid membrane", "TREATMENT", 0, 16], ["the viral ribonucleocapsids", "PROBLEM", 42, 69], ["the viral Gn and Gc glycoproteins", "PROBLEM", 79, 112], ["lipid membrane", "OBSERVATION", 2, 16], ["viral ribonucleocapsids", "OBSERVATION", 46, 69], ["viral Gn", "OBSERVATION", 83, 91], ["Gc glycoproteins", "OBSERVATION", 96, 112]]], ["This viral envelope is derived from a host cell membrane during the budding process of the virus [9, 10] .", [["cell membrane", "ANATOMY", 43, 56], ["cell membrane", "CELLULAR_COMPONENT", 43, 56], ["This viral envelope", "PROBLEM", 0, 19], ["a host cell membrane", "TREATMENT", 36, 56], ["the virus", "PROBLEM", 87, 96], ["host cell membrane", "OBSERVATION", 38, 56]]], ["To infect new cells, hantaviruses bind to cell surface receptors [11] [12] [13] [14] , and are subsequently taken up by endocytosis [15, 16] .", [["cells", "ANATOMY", 14, 19], ["cell surface", "ANATOMY", 42, 54], ["cells", "CELL", 14, 19], ["hantaviruses", "ORGANISM", 21, 33], ["cell", "CELL", 42, 46], ["cell surface receptors", "PROTEIN", 42, 64], ["new cells", "PROBLEM", 10, 19], ["hantaviruses bind", "PROBLEM", 21, 38], ["cell surface receptors", "TEST", 42, 64]]], ["A crucial step in viral cell entry is the fusion of the virus with an endosomal membrane of the host, escaping from its degradation in lysosomes.", [["cell", "ANATOMY", 24, 28], ["endosomal membrane", "ANATOMY", 70, 88], ["lysosomes", "ANATOMY", 135, 144], ["viral cell", "CELL", 18, 28], ["endosomal membrane", "CELLULAR_COMPONENT", 70, 88], ["lysosomes", "CELLULAR_COMPONENT", 135, 144], ["A crucial step in viral cell entry", "PROBLEM", 0, 34], ["the virus", "PROBLEM", 52, 61], ["its degradation in lysosomes", "PROBLEM", 116, 144], ["crucial", "OBSERVATION_MODIFIER", 2, 9], ["step", "OBSERVATION_MODIFIER", 10, 14], ["viral cell entry", "OBSERVATION", 18, 34], ["virus", "OBSERVATION", 56, 61], ["endosomal membrane", "OBSERVATION", 70, 88], ["host", "OBSERVATION_MODIFIER", 96, 100], ["degradation", "OBSERVATION_MODIFIER", 120, 131]]], ["Yet, little is known about the fusion process of hantaviruses; however, our recent data show that the low pH of endosomes triggers a non-reversible fusion process, in which the Gc protein inserts into target membranes and forms a highly stable post-fusion homotrimer [17] .IntroductionIn general, virus-cell membrane fusion is thought to be accomplished by multiple steps [reviewed in 18, 19] .", [["endosomes", "ANATOMY", 112, 121], ["membranes", "ANATOMY", 208, 217], ["cell membrane", "ANATOMY", 303, 316], ["hantaviruses", "DISEASE", 49, 61], ["endosomes", "CELLULAR_COMPONENT", 112, 121], ["Gc", "GENE_OR_GENE_PRODUCT", 177, 179], ["membranes", "CELLULAR_COMPONENT", 208, 217], ["cell", "CELL", 303, 307], ["Gc protein", "PROTEIN", 177, 187], ["hantaviruses", "PROBLEM", 49, 61], ["the low pH of endosomes", "PROBLEM", 98, 121], ["a non-reversible fusion process", "PROBLEM", 131, 162], ["the Gc protein", "TEST", 173, 187], ["virus-cell membrane fusion", "TREATMENT", 297, 323], ["hantaviruses", "OBSERVATION", 49, 61], ["non-reversible fusion", "OBSERVATION", 133, 154], ["stable", "OBSERVATION_MODIFIER", 237, 243], ["cell membrane fusion", "OBSERVATION", 303, 323]]], ["After the activation, viral fusion proteins insert a fusion peptide or fusion loop into a target membrane.", [["membrane", "ANATOMY", 97, 105], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["viral fusion proteins", "PROTEIN", 22, 43], ["fusion loop", "PROTEIN", 71, 82], ["the activation", "TREATMENT", 6, 20], ["viral fusion proteins", "TREATMENT", 22, 43], ["a fusion peptide", "TREATMENT", 51, 67], ["fusion loop", "TREATMENT", 71, 82], ["fusion loop", "OBSERVATION", 71, 82]]], ["At this intermediate stage, the fusion peptide is located at one end of the fusion protein while the opposite end is anchored to the viral envelope membrane by a transmembrane region, thereby bridging the viral and cellular membranes.", [["membrane", "ANATOMY", 148, 156], ["transmembrane region", "ANATOMY", 162, 182], ["cellular membranes", "ANATOMY", 215, 233], ["envelope membrane", "CELLULAR_COMPONENT", 139, 156], ["transmembrane", "CELLULAR_COMPONENT", 162, 175], ["cellular membranes", "CELLULAR_COMPONENT", 215, 233], ["fusion protein", "PROTEIN", 76, 90], ["opposite end", "PROTEIN", 101, 113], ["transmembrane region", "PROTEIN", 162, 182], ["the fusion peptide", "TREATMENT", 28, 46], ["the fusion protein", "TREATMENT", 72, 90], ["a transmembrane region", "TREATMENT", 160, 182], ["bridging the viral and cellular membranes", "PROBLEM", 192, 233], ["fusion", "OBSERVATION", 32, 38], ["fusion protein", "OBSERVATION", 76, 90], ["viral envelope membrane", "OBSERVATION", 133, 156], ["viral", "OBSERVATION", 205, 210], ["cellular membranes", "OBSERVATION", 215, 233]]], ["By undergoing additional conformational changes, the fusion protein is thought to pull both anchors together, until it reaches a hairpin-like conformation in which both membrane-inserted domains are located at the same end of the protein.", [["membrane", "ANATOMY", 169, 177], ["membrane", "CELLULAR_COMPONENT", 169, 177], ["fusion protein", "PROTEIN", 53, 67], ["membrane-inserted domains", "PROTEIN", 169, 194], ["additional conformational changes", "PROBLEM", 14, 47], ["the fusion protein", "TREATMENT", 49, 67], ["a hairpin-like conformation", "PROBLEM", 127, 154], ["hairpin", "OBSERVATION", 129, 136]]], ["Once the opposed membranes have been brought into a close distance by the introduction of local membrane curvature, the fusion of the outer leaflets of the membranes produces a hemifusion intermediate, followed by the full fusion of the membranes.", [["membranes", "ANATOMY", 17, 26], ["membrane", "ANATOMY", 96, 104], ["outer leaflets", "ANATOMY", 134, 148], ["membranes", "ANATOMY", 156, 165], ["membranes", "ANATOMY", 237, 246], ["membranes", "CELLULAR_COMPONENT", 17, 26], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["outer leaflets", "CELLULAR_COMPONENT", 134, 148], ["membranes", "CELLULAR_COMPONENT", 156, 165], ["membranes", "CELLULAR_COMPONENT", 237, 246], ["local membrane curvature", "TREATMENT", 90, 114], ["the fusion of the outer leaflets of the membranes", "TREATMENT", 116, 165], ["the full fusion of the membranes", "TREATMENT", 214, 246], ["membrane curvature", "OBSERVATION", 96, 114], ["fusion", "OBSERVATION", 120, 126], ["outer", "ANATOMY_MODIFIER", 134, 139], ["leaflets", "ANATOMY_MODIFIER", 140, 148], ["membranes", "ANATOMY_MODIFIER", 156, 165], ["full fusion", "OBSERVATION", 218, 229]]], ["The fusion culminates in the formation of a fusion pore through which the virus can deliver its ribonucleocapsids into the cell cytosol to initiate replication.", [["pore", "ANATOMY", 51, 55], ["cell cytosol", "ANATOMY", 123, 135], ["ribonucleocapsids", "GENE_OR_GENE_PRODUCT", 96, 113], ["cell cytosol", "CELLULAR_COMPONENT", 123, 135], ["ribonucleocapsids", "PROTEIN", 96, 113], ["The fusion", "TREATMENT", 0, 10], ["a fusion pore", "TREATMENT", 42, 55], ["the virus", "PROBLEM", 70, 79], ["the cell cytosol", "TREATMENT", 119, 135], ["fusion", "OBSERVATION", 4, 10], ["fusion", "OBSERVATION", 44, 50]]], ["Viral fusion proteins are currently grouped into at least three different classes based on their molecular structures: class I fusion proteins have a high alpha helical content, class II proteins consist principally of beta sheets, while class III fusion proteins include characteristics from the first two classes [reviewed in [19] [20] [21] .", [["beta sheets", "GENE_OR_GENE_PRODUCT", 219, 230], ["class III fusion proteins", "GENE_OR_GENE_PRODUCT", 238, 263], ["[19] [20] [21]", "SIMPLE_CHEMICAL", 328, 342], ["Viral fusion proteins", "PROTEIN", 0, 21], ["class I fusion proteins", "PROTEIN", 119, 142], ["alpha helical", "PROTEIN", 155, 168], ["class II proteins", "PROTEIN", 178, 195], ["beta sheets", "PROTEIN", 219, 230], ["class III fusion proteins", "PROTEIN", 238, 263], ["Viral fusion proteins", "PROBLEM", 0, 21], ["class I fusion proteins", "PROBLEM", 119, 142], ["a high alpha helical content", "PROBLEM", 148, 176], ["beta sheets", "TEST", 219, 230], ["fusion", "OBSERVATION", 6, 12], ["high alpha helical content", "OBSERVATION_MODIFIER", 150, 176]]], ["Early in silico and in vitro analyses suggested that the Gc glycoprotein of hantaviruses shares structural similarity with class II fusion proteins [22, 23] .", [["Gc glycoprotein", "GENE_OR_GENE_PRODUCT", 57, 72], ["class II fusion proteins", "GENE_OR_GENE_PRODUCT", 123, 147], ["Gc glycoprotein", "PROTEIN", 57, 72], ["class II fusion proteins", "PROTEIN", 123, 147], ["vitro analyses", "TEST", 23, 37], ["the Gc glycoprotein of hantaviruses", "PROBLEM", 53, 88], ["class II fusion proteins", "TEST", 123, 147]]], ["This notion has also been proposed for other members of the Bunyaviridae [24] [25] [26] [27] [28] , and the crystal structure of Gc from Rift Valley Fever virus (RVFV) ultimately confirmed this notion for phleboviruses [29] .IntroductionClass II fusion proteins are composed of three domains (I-III) and a stem region that connects the ectodomain to the transmembrane anchor [30] [31] [32] [33] [34] .", [["stem region", "ANATOMY", 306, 317], ["transmembrane", "ANATOMY", 354, 367], ["Bunyaviridae", "DISEASE", 60, 72], ["Rift Valley Fever", "DISEASE", 137, 154], ["[24] [25] [26] [27] [28]", "SIMPLE_CHEMICAL", 73, 97], ["Gc", "ORGANISM", 129, 131], ["Rift Valley Fever virus", "ORGANISM", 137, 160], ["RVFV", "ORGANISM", 162, 166], ["Class II", "GENE_OR_GENE_PRODUCT", 237, 245], ["I-III", "GENE_OR_GENE_PRODUCT", 293, 298], ["transmembrane", "CELLULAR_COMPONENT", 354, 367], ["[30] [31] [32] [33] [34]", "SIMPLE_CHEMICAL", 375, 399], ["Gc", "PROTEIN", 129, 131], ["Class II fusion proteins", "PROTEIN", 237, 261], ["I-III", "PROTEIN", 293, 298], ["stem region", "PROTEIN", 306, 317], ["ectodomain", "PROTEIN", 336, 346], ["Rift Valley Fever virus", "SPECIES", 137, 160], ["Rift Valley Fever virus", "SPECIES", 137, 160], ["RVFV", "SPECIES", 162, 166], ["the crystal structure of Gc", "PROBLEM", 104, 131], ["Rift Valley Fever virus", "PROBLEM", 137, 160], ["phleboviruses", "PROBLEM", 205, 218], ["IntroductionClass II fusion proteins", "TREATMENT", 225, 261], ["a stem region", "PROBLEM", 304, 317], ["stem", "ANATOMY", 306, 310], ["region", "ANATOMY_MODIFIER", 311, 317]]], ["To adopt a hairpin-like structure, DIII moves towards the fusion loop [35, 36] , while the stem region, which is connected to the transmembrane anchor, is thought to follow the movement of DIII by folding against the trimeric core formed by the fusion protein [37] [38] [39] .", [["stem region", "ANATOMY", 91, 102], ["transmembrane", "ANATOMY", 130, 143], ["DIII", "GENE_OR_GENE_PRODUCT", 35, 39], ["transmembrane", "CELLULAR_COMPONENT", 130, 143], ["DIII", "GENE_OR_GENE_PRODUCT", 189, 193], ["DIII", "PROTEIN", 35, 39], ["stem region", "PROTEIN", 91, 102], ["transmembrane anchor", "PROTEIN", 130, 150], ["DIII", "PROTEIN", 189, 193], ["trimeric core", "PROTEIN", 217, 230], ["fusion protein", "PROTEIN", 245, 259], ["a hairpin-like structure", "PROBLEM", 9, 33], ["the fusion loop", "TREATMENT", 54, 69], ["the fusion protein", "TEST", 241, 259], ["hairpin", "OBSERVATION", 11, 18], ["stem", "ANATOMY", 91, 95], ["region", "ANATOMY_MODIFIER", 96, 102]]], ["The extensive conformational changes that occur during the fusion process offer opportunities to disrupt the fusion cascade, thereby blocking viral infection.", [["viral infection", "DISEASE", 142, 157], ["The extensive conformational changes", "PROBLEM", 0, 36], ["the fusion process", "TREATMENT", 55, 73], ["the fusion cascade", "TREATMENT", 105, 123], ["blocking viral infection", "PROBLEM", 133, 157], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["conformational", "OBSERVATION", 14, 28], ["fusion", "OBSERVATION", 109, 115], ["infection", "OBSERVATION", 148, 157]]], ["Ligands that bind selectively to an intermediate form of the fusion protein preceding its post-fusion conformation can delay or inhibit viral entry.", [["fusion protein", "PROTEIN", 61, 75], ["the fusion protein", "TREATMENT", 57, 75]]], ["In the case of human immunodeficiency virus 1, which has a fusion protein with a class I fold, there is a licensed drug based on a 20-residue peptide [reviewed in 40, 41] .", [["human immunodeficiency virus", "DISEASE", 15, 43], ["human immunodeficiency virus 1", "ORGANISM", 15, 45], ["fusion protein", "PROTEIN", 59, 73], ["class I fold", "PROTEIN", 81, 93], ["human immunodeficiency virus", "SPECIES", 15, 43], ["human immunodeficiency virus 1", "SPECIES", 15, 45], ["human immunodeficiency virus", "PROBLEM", 15, 43], ["a fusion protein", "TREATMENT", 57, 73]]], ["This peptide comprises a partial sequence of the outer layer of the trimeric post-fusion hairpin conformation of gp41 and binds to the trimeric core of the fusion protein in its extended intermediate conformation, preventing the foldback reaction [reviewed in 42, 43] .", [["outer layer", "ANATOMY", 49, 60], ["gp41", "AMINO_ACID", 113, 117], ["trimeric post-fusion hairpin conformation", "PROTEIN", 68, 109], ["gp41", "PROTEIN", 113, 117], ["trimeric core", "PROTEIN", 135, 148], ["fusion protein", "PROTEIN", 156, 170], ["the trimeric post-fusion hairpin conformation of gp41", "TREATMENT", 64, 117], ["the foldback reaction", "PROBLEM", 225, 246], ["outer", "OBSERVATION_MODIFIER", 49, 54], ["layer", "OBSERVATION_MODIFIER", 55, 60], ["fusion hairpin", "OBSERVATION", 82, 96], ["fusion protein", "OBSERVATION", 156, 170], ["intermediate conformation", "OBSERVATION", 187, 212]]], ["Among class II proteins, DIII and the stem region form the outer layer of the trimeric post-fusion conformation [35] [36] [37] .", [["stem region", "ANATOMY", 38, 49], ["outer layer", "ANATOMY", 59, 70], ["class II proteins", "GENE_OR_GENE_PRODUCT", 6, 23], ["DIII", "GENE_OR_GENE_PRODUCT", 25, 29], ["outer layer", "CELLULAR_COMPONENT", 59, 70], ["class II proteins", "PROTEIN", 6, 23], ["DIII", "PROTEIN", 25, 29], ["stem region", "PROTEIN", 38, 49], ["trimeric post-fusion conformation", "PROTEIN", 78, 111], ["stem", "ANATOMY_MODIFIER", 38, 42], ["region", "ANATOMY_MODIFIER", 43, 49], ["outer", "ANATOMY_MODIFIER", 59, 64], ["layer", "ANATOMY_MODIFIER", 65, 70], ["trimeric", "ANATOMY_MODIFIER", 78, 86], ["post-fusion", "OBSERVATION", 87, 98]]], ["Liao & Kielian (2005) showed that the addition of soluble DIII with or without the stem region of Semliki Forest virus E1 protein and soluble DIII of Dengue virus type 2 (DV2) E protein inhibit the entry of the respective virus into cells and confirmed a common inhibitory mechanism of class I and class II fusion proteins [44] .", [["cells", "ANATOMY", 233, 238], ["DIII", "GENE_OR_GENE_PRODUCT", 58, 62], ["Semliki Forest virus E1", "ORGANISM", 98, 121], ["Dengue virus type 2", "ORGANISM", 150, 169], ["DV2) E protein", "GENE_OR_GENE_PRODUCT", 171, 185], ["cells", "CELL", 233, 238], ["class I", "GENE_OR_GENE_PRODUCT", 286, 293], ["class II", "GENE_OR_GENE_PRODUCT", 298, 306], ["DIII", "PROTEIN", 58, 62], ["stem region", "PROTEIN", 83, 94], ["Semliki Forest virus E1 protein", "PROTEIN", 98, 129], ["DIII", "PROTEIN", 142, 146], ["Dengue virus type 2 (DV2) E protein", "PROTEIN", 150, 185], ["class I and class II fusion proteins", "PROTEIN", 286, 322], ["Semliki Forest virus", "SPECIES", 98, 118], ["Dengue virus", "SPECIES", 150, 162], ["Semliki Forest virus", "SPECIES", 98, 118], ["Dengue virus", "SPECIES", 150, 162], ["soluble DIII", "TREATMENT", 50, 62], ["the stem region", "PROBLEM", 79, 94], ["Semliki Forest virus E1 protein", "TREATMENT", 98, 129], ["Dengue virus type 2 (DV2) E protein inhibit", "PROBLEM", 150, 193], ["stem", "ANATOMY", 83, 87], ["Semliki Forest", "OBSERVATION", 98, 112]]], ["Other studies have shown that peptides derived from the stem region of the fusion protein of flavi-and phleboviruses also inhibit viral cell entry [45, 46] .", [["stem region", "ANATOMY", 56, 67], ["cell", "ANATOMY", 136, 140], ["flavi", "GENE_OR_GENE_PRODUCT", 93, 98], ["phleboviruses", "GENE_OR_GENE_PRODUCT", 103, 116], ["cell", "CELL", 136, 140], ["fusion protein", "PROTEIN", 75, 89], ["flavi", "PROTEIN", 93, 98], ["Other studies", "TEST", 0, 13], ["the fusion protein", "TEST", 71, 89], ["flavi", "TEST", 93, 98], ["phleboviruses", "PROBLEM", 103, 116], ["viral cell entry", "TEST", 130, 146], ["stem", "ANATOMY_MODIFIER", 56, 60], ["fusion", "OBSERVATION", 75, 81], ["viral cell", "OBSERVATION", 130, 140]]], ["The binding of stem peptides to fusion proteins is thought to prevent the post-fusion conformation as in the case of DIII; however, their amphipathic characteristics seem to allow binding to the virus before attachment to the cell, and are hence thought to be carried on the virus into endosomes [47, 48] .", [["cell", "ANATOMY", 226, 230], ["endosomes", "ANATOMY", 286, 295], ["DIII", "GENE_OR_GENE_PRODUCT", 117, 121], ["cell", "CELL", 226, 230], ["endosomes", "CELLULAR_COMPONENT", 286, 295], ["fusion proteins", "PROTEIN", 32, 47], ["DIII", "PROTEIN", 117, 121], ["stem peptides", "TREATMENT", 15, 28], ["fusion proteins", "PROBLEM", 32, 47], ["the post-fusion conformation", "PROBLEM", 70, 98], ["stem peptides", "OBSERVATION", 15, 28]]], ["This characteristic provides an advantage for the delivery of the inhibitor to the site of virus-cell membrane fusion when this process occurs in a closed endosomal compartment.", [["cell membrane", "ANATOMY", 97, 110], ["endosomal compartment", "ANATOMY", 155, 176], ["cell membrane", "CELLULAR_COMPONENT", 97, 110], ["endosomal compartment", "CELLULAR_COMPONENT", 155, 176], ["the delivery of the inhibitor", "TREATMENT", 46, 75], ["virus-cell membrane fusion", "TREATMENT", 91, 117], ["virus", "OBSERVATION", 91, 96], ["cell membrane fusion", "OBSERVATION", 97, 117], ["endosomal compartment", "OBSERVATION", 155, 176]]], ["Here, we hypothesized that if hantavirus Gc shares mechanistic similarity with class II fusion proteins, then it should be inhibited with strategies used for other class II fusion proteins.", [["hantavirus Gc", "ORGANISM", 30, 43], ["class II fusion proteins", "GENE_OR_GENE_PRODUCT", 79, 103], ["class II fusion proteins", "GENE_OR_GENE_PRODUCT", 164, 188], ["hantavirus Gc", "PROTEIN", 30, 43], ["class II fusion proteins", "PROTEIN", 79, 103], ["class II fusion proteins", "PROTEIN", 164, 188], ["hantavirus Gc", "PROBLEM", 30, 43], ["class II fusion proteins", "PROBLEM", 79, 103], ["other class II fusion proteins", "TREATMENT", 158, 188]]], ["To test this hypothesis, we predicted and produced DIII and the stem region of ANDV Gc and assessed them for ANDV inhibition.", [["stem region", "ANATOMY", 64, 75], ["DIII", "GENE_OR_GENE_PRODUCT", 51, 55], ["ANDV Gc", "GENE_OR_GENE_PRODUCT", 79, 86], ["ANDV", "GENE_OR_GENE_PRODUCT", 109, 113], ["DIII", "PROTEIN", 51, 55], ["ANDV Gc", "PROTEIN", 79, 86], ["ANDV", "SPECIES", 79, 83], ["ANDV", "SPECIES", 109, 113], ["ANDV inhibition", "TREATMENT", 109, 124]]], ["Our results show that indeed both, recombinant DIII and synthetic stem peptides, interfered with the ANDV infection, acting at late stages of the ANDV fusion process.Preparation of DIII expression plasmidsFor the PCR amplification of the predicted DIII and DIIIS sequences we used the cloned cDNA of the M segment from ANDV isolate CHI-7913 [49] and from PUUV strain K27 cloned into pWRG/PUUV-M(s2) expression plasmid [50] (kindly provided by Jay Hooper, USAMRIID, USA), GenBank accession numbers AAO86638 and L08754, respectively.", [["infection", "DISEASE", 106, 115], ["CHI-7913", "CHEMICAL", 332, 340], ["DIII", "GENE_OR_GENE_PRODUCT", 47, 51], ["ANDV", "GENE_OR_GENE_PRODUCT", 101, 105], ["ANDV", "GENE_OR_GENE_PRODUCT", 146, 150], ["DIII", "GENE_OR_GENE_PRODUCT", 181, 185], ["DIII", "GENE_OR_GENE_PRODUCT", 248, 252], ["PUUV", "ORGANISM", 355, 359], ["pWRG", "GENE_OR_GENE_PRODUCT", 383, 387], ["recombinant DIII", "PROTEIN", 35, 51], ["DIII expression plasmids", "DNA", 181, 205], ["DIII and DIIIS sequences", "DNA", 248, 272], ["cloned cDNA", "DNA", 285, 296], ["M segment", "DNA", 304, 313], ["pWRG/PUUV-M(s2) expression plasmid", "DNA", 383, 417], ["ANDV", "SPECIES", 101, 105], ["ANDV", "SPECIES", 146, 150], ["ANDV", "SPECIES", 319, 323], ["CHI-7913", "SPECIES", 332, 340], ["PUUV strain K27", "SPECIES", 355, 370], ["synthetic stem peptides", "TREATMENT", 56, 79], ["the ANDV infection", "PROBLEM", 97, 115], ["the ANDV fusion process", "TREATMENT", 142, 165], ["DIII expression plasmids", "TREATMENT", 181, 205], ["the PCR amplification", "TEST", 209, 230], ["CHI", "TEST", 332, 335], ["PUUV strain K27", "TEST", 355, 370], ["infection", "OBSERVATION", 106, 115], ["fusion", "OBSERVATION", 151, 157]]], ["The PCR products were cloned into pET28a, which gave rise to fusion proteins with an N-terminal tag of 34 residues including polyhistidine (His-tag).", [["polyhistidine", "CHEMICAL", 125, 138], ["N", "CHEMICAL", 85, 86], ["polyhistidine", "CHEMICAL", 125, 138], ["His", "CHEMICAL", 140, 143], ["pET28a", "GENE_OR_GENE_PRODUCT", 34, 40], ["polyhistidine", "SIMPLE_CHEMICAL", 125, 138], ["PCR products", "DNA", 4, 16], ["pET28a", "PROTEIN", 34, 40], ["fusion proteins", "PROTEIN", 61, 76], ["N-terminal tag", "PROTEIN", 85, 99], ["polyhistidine (His-tag", "PROTEIN", 125, 147], ["The PCR products", "TREATMENT", 0, 16], ["fusion proteins", "TREATMENT", 61, 76], ["polyhistidine", "TEST", 125, 138]]], ["For the preparation of DIII without the His-tag, the PCR product of ANDV DIII was cloned into pGST-Parallel-1 [51] .", [["DIII", "GENE_OR_GENE_PRODUCT", 23, 27], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 68, 77], ["DIII", "PROTEIN", 23, 27], ["His-tag", "PROTEIN", 40, 47], ["ANDV DIII", "PROTEIN", 68, 77], ["pGST", "PROTEIN", 94, 98], ["ANDV", "SPECIES", 68, 72], ["the His-tag", "TREATMENT", 36, 47], ["the PCR", "TEST", 49, 56]]], ["The expression product of this plasmid contained an N-terminal tag of 314 residues including a Glutathione S transferase (GST) affinity tag followed by a cleavage site for the tobacco etch virus (TEV) protease.", [["plasmid", "ANATOMY", 31, 38], ["Glutathione", "CHEMICAL", 95, 106], ["N", "CHEMICAL", 52, 53], ["Glutathione", "CHEMICAL", 95, 106], ["S", "CHEMICAL", 107, 108], ["Glutathione S transferase", "GENE_OR_GENE_PRODUCT", 95, 120], ["GST", "GENE_OR_GENE_PRODUCT", 122, 125], ["tobacco etch virus", "ORGANISM", 176, 194], ["plasmid", "DNA", 31, 38], ["N-terminal tag", "PROTEIN", 52, 66], ["Glutathione S transferase (GST) affinity tag", "PROTEIN", 95, 139], ["tobacco etch virus (TEV) protease", "PROTEIN", 176, 209], ["tobacco etch virus", "SPECIES", 176, 194], ["this plasmid", "TREATMENT", 26, 38], ["an N-terminal tag of 314 residues", "TREATMENT", 49, 82], ["a Glutathione S transferase (GST) affinity tag", "TREATMENT", 93, 139], ["a cleavage site", "PROBLEM", 152, 167]]], ["After cleavage with TEV protease, 7 residues from the GST-fusion protein remained fused to the N-terminal of DIII, corresponding to the sequence GAMDPEF.Expression and purification of DIII proteinsThe expression of recombinant DIII proteins was performed as established before [52] .", [["GST", "GENE_OR_GENE_PRODUCT", 54, 57], ["DIII", "GENE_OR_GENE_PRODUCT", 109, 113], ["DIII", "GENE_OR_GENE_PRODUCT", 184, 188], ["DIII", "GENE_OR_GENE_PRODUCT", 227, 231], ["TEV protease", "PROTEIN", 20, 32], ["GST", "PROTEIN", 54, 57], ["fusion protein", "PROTEIN", 58, 72], ["DIII", "PROTEIN", 109, 113], ["GAMDPEF", "PROTEIN", 145, 152], ["DIII proteins", "PROTEIN", 184, 197], ["recombinant DIII proteins", "PROTEIN", 215, 240], ["TEV protease", "TREATMENT", 20, 32], ["7 residues", "TREATMENT", 34, 44], ["the GST-fusion protein", "TREATMENT", 50, 72], ["the sequence GAMDPEF", "TEST", 132, 152], ["DIII proteins", "PROBLEM", 184, 197], ["recombinant DIII proteins", "PROBLEM", 215, 240]]], ["In brief, His-tagged fusion proteins were expressed in Escherichia coli (E.coli) BL21, which was transformed with the different pET28a/DIII plasmids.", [["His", "CHEMICAL", 10, 13], ["Escherichia coli", "ORGANISM", 55, 71], ["E.coli) BL21", "ORGANISM", 73, 85], ["pET28a", "GENE_OR_GENE_PRODUCT", 128, 134], ["DIII", "GENE_OR_GENE_PRODUCT", 135, 139], ["His-tagged fusion proteins", "PROTEIN", 10, 36], ["pET28a/DIII plasmids", "DNA", 128, 148], ["Escherichia coli", "SPECIES", 55, 71], ["Escherichia coli", "SPECIES", 55, 71], ["BL21", "SPECIES", 81, 85], ["His-tagged fusion proteins", "TEST", 10, 36], ["Escherichia coli (E.coli) BL21", "PROBLEM", 55, 85], ["the different pET28a/DIII plasmids", "TREATMENT", 114, 148], ["Escherichia coli", "OBSERVATION", 55, 71]]], ["The isopropyl-beta-D-thiogalactopyranosideinduced bacteria were lysed by sonication in buffer containing 20 mM Tris, 50 mM NaCl, and 0.2 mM phenylmethanesulfonylfluoride, pH 8.", [["isopropyl-beta-D-thiogalactopyranosideinduced", "CHEMICAL", 4, 49], ["NaCl", "CHEMICAL", 123, 127], ["phenylmethanesulfonylfluoride", "CHEMICAL", 140, 169], ["isopropyl-beta-D-thiogalactopyranosideinduced", "CHEMICAL", 4, 49], ["Tris", "CHEMICAL", 111, 115], ["NaCl", "CHEMICAL", 123, 127], ["phenylmethanesulfonylfluoride", "CHEMICAL", 140, 169], ["isopropyl-beta-D-thiogalactopyranosideinduced bacteria", "SIMPLE_CHEMICAL", 4, 58], ["phenylmethanesulfonylfluoride", "SIMPLE_CHEMICAL", 140, 169], ["The isopropyl", "TREATMENT", 0, 13], ["beta-D-thiogalactopyranosideinduced bacteria", "TREATMENT", 14, 58], ["NaCl", "TREATMENT", 123, 127], ["pH", "TEST", 171, 173]]], ["Lysis was performed by sonication on ice and soluble proteins were purified through the ion exchange resin Bio-Rex 70 (Bio-Rad Laboratories) followed by tandem ultrafiltration on devices with 30 kDa and 3 kDa of molecular weight cut-off.", [["soluble proteins", "PROTEIN", 45, 61], ["Lysis", "TREATMENT", 0, 5], ["ice and soluble proteins", "TREATMENT", 37, 61], ["the ion exchange resin Bio", "TREATMENT", 84, 110], ["tandem ultrafiltration on devices", "TREATMENT", 153, 186], ["30 kDa", "TREATMENT", 192, 198]]], ["Recombinant, untagged DIII was produced following a similar purification procedure described elsewhere [53] , with some modifications.", [["DIII", "GENE_OR_GENE_PRODUCT", 22, 26], ["untagged DIII", "PROTEIN", 13, 26], ["a similar purification procedure", "TREATMENT", 50, 82]]], ["Briefly, E. coli Origami 2(DE3) (Novagen), were transformed with pGST-Parallel-1/DIII, and expression was induced, and bacteria were pelleted and lysed as described above.", [["E. coli Origami 2", "ORGANISM", 9, 26], ["DE3", "GENE_OR_GENE_PRODUCT", 27, 30], ["Novagen", "GENE_OR_GENE_PRODUCT", 33, 40], ["pGST-Parallel-1", "GENE_OR_GENE_PRODUCT", 65, 80], ["DIII", "GENE_OR_GENE_PRODUCT", 81, 85], ["pGST", "PROTEIN", 65, 69], ["DIII", "PROTEIN", 81, 85], ["E. coli Origami", "SPECIES", 9, 24], ["E. coli", "SPECIES", 9, 16], ["E. coli Origami 2(DE3) (Novagen)", "TREATMENT", 9, 41], ["pGST", "TEST", 65, 69], ["bacteria", "PROBLEM", 119, 127], ["coli Origami", "OBSERVATION", 12, 24]]], ["The clarified supernatant was purified on glutathione-Sepharose 4B (GE Healthcare), and the bound protein was eluted with 20 mM reduced glutathione (Sigma-Aldrich).", [["supernatant", "ANATOMY", 14, 25], ["glutathione", "CHEMICAL", 42, 53], ["glutathione", "CHEMICAL", 136, 147], ["glutathione", "CHEMICAL", 42, 53], ["reduced glutathione", "CHEMICAL", 128, 147], ["glutathione", "SIMPLE_CHEMICAL", 42, 53], ["glutathione", "SIMPLE_CHEMICAL", 136, 147], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 149, 162], ["glutathione-Sepharose 4B", "TREATMENT", 42, 66], ["the bound protein", "PROBLEM", 88, 105], ["20 mM reduced glutathione", "TREATMENT", 122, 147]]], ["His6-tagged TEV protease was used to cleave off the GST moiety, and the GST moiety and the TEV protease were removed by sequential passage through glutathione-sepharose 4B and Ni-NTA (Qiagen) resins.", [["glutathione", "CHEMICAL", 147, 158], ["Ni-NTA", "CHEMICAL", 176, 182], ["glutathione", "CHEMICAL", 147, 158], ["Ni-NTA", "CHEMICAL", 176, 182], ["His6", "GENE_OR_GENE_PRODUCT", 0, 4], ["TEV", "GENE_OR_GENE_PRODUCT", 12, 15], ["GST", "GENE_OR_GENE_PRODUCT", 52, 55], ["GST", "GENE_OR_GENE_PRODUCT", 72, 75], ["glutathione", "SIMPLE_CHEMICAL", 147, 158], ["-sepharose 4B", "SIMPLE_CHEMICAL", 158, 171], ["Ni-NTA", "SIMPLE_CHEMICAL", 176, 182], ["Qiagen", "SIMPLE_CHEMICAL", 184, 190], ["His6", "PROTEIN", 0, 4], ["TEV protease", "PROTEIN", 12, 24], ["GST moiety", "PROTEIN", 52, 62], ["GST moiety", "PROTEIN", 72, 82], ["TEV protease", "PROTEIN", 91, 103], ["His6-tagged TEV protease", "TREATMENT", 0, 24], ["the GST moiety", "TREATMENT", 48, 62], ["the GST moiety", "TREATMENT", 68, 82], ["the TEV protease", "TREATMENT", 87, 103], ["glutathione-sepharose 4B", "TREATMENT", 147, 171], ["Ni-NTA (Qiagen) resins", "TREATMENT", 176, 198]]], ["Eventually, DIII was concentrated using an ultrafiltration device with 3 kDa cutoff, and further purified on a HiLoad 16/60 Superdex 200 prep grade column (GE Healthcare).DIII protein analysisProteins were analyzed by standard Tris-glycine SDS-polyacrylamide gel electrophoresis using 4-12% or 15% gels.", [["Tris-glycine", "CHEMICAL", 227, 239], ["Tris-glycine", "CHEMICAL", 227, 239], ["polyacrylamide", "CHEMICAL", 244, 258], ["DIII", "GENE_OR_GENE_PRODUCT", 12, 16], ["DIII", "GENE_OR_GENE_PRODUCT", 171, 175], ["Tris-glycine", "SIMPLE_CHEMICAL", 227, 239], ["DIII", "PROTEIN", 12, 16], ["DIII protein analysisProteins", "PROTEIN", 171, 200], ["an ultrafiltration device", "TREATMENT", 40, 65], ["a HiLoad 16/60 Superdex", "TREATMENT", 109, 132], ["DIII protein analysisProteins", "TEST", 171, 200], ["standard Tris-glycine SDS", "TREATMENT", 218, 243], ["polyacrylamide gel electrophoresis", "TREATMENT", 244, 278]]], ["For irreversible reduction, 8 mM dithiothreitol was added, the proteins were heated to 95\u00b0C for 3 min, and subsequently alkylated by incubation with 24 mM iodoacetamide for 15 min at 37\u00b0C. Circular dichroism measurements were performed using a spectropolarimeter (Jasco-J600), and 5 scans were recorded at room temperature between 190 and 260 nm, using a 1 mm optical pass cuvette.", [["dithiothreitol", "CHEMICAL", 33, 47], ["iodoacetamide", "CHEMICAL", 155, 168], ["dithiothreitol", "CHEMICAL", 33, 47], ["iodoacetamide", "CHEMICAL", 155, 168], ["dithiothreitol", "SIMPLE_CHEMICAL", 33, 47], ["iodoacetamide", "SIMPLE_CHEMICAL", 155, 168], ["irreversible reduction", "TREATMENT", 4, 26], ["8 mM dithiothreitol", "TREATMENT", 28, 47], ["the proteins", "TEST", 59, 71], ["24 mM iodoacetamide", "TREATMENT", 149, 168], ["Circular dichroism measurements", "TEST", 189, 220], ["5 scans", "TEST", 281, 288], ["a 1 mm optical pass cuvette", "TREATMENT", 353, 380], ["irreversible", "OBSERVATION_MODIFIER", 4, 16], ["reduction", "OBSERVATION_MODIFIER", 17, 26]]], ["Measured values of ellipticity were converted into ellipticity per amino acid residue.", [["amino acid", "CHEMICAL", 67, 77], ["amino acid", "CHEMICAL", 67, 77], ["amino acid", "AMINO_ACID", 67, 77], ["ellipticity", "TEST", 19, 30], ["amino acid residue", "TREATMENT", 67, 85], ["ellipticity", "OBSERVATION_MODIFIER", 19, 30], ["ellipticity", "OBSERVATION_MODIFIER", 51, 62], ["amino acid residue", "OBSERVATION", 67, 85]]], ["For deconvolution of the spectra, different databases of CONTIN and CDSSTR servers [54] [55] [56] were used.PeptidesPeptides spanning the predicted stem region of ANDV Gc were synthesized (New England Peptides).", [["stem region", "ANATOMY", 148, 159], ["ANDV Gc", "GENE_OR_GENE_PRODUCT", 163, 170], ["CONTIN", "DNA", 57, 63], ["ANDV Gc", "PROTEIN", 163, 170], ["PeptidesPeptides", "TREATMENT", 108, 124], ["New England Peptides", "TREATMENT", 189, 209], ["stem", "ANATOMY_MODIFIER", 148, 152], ["region", "ANATOMY_MODIFIER", 153, 159], ["New", "OBSERVATION_MODIFIER", 189, 192]]], ["The N-terminal R1 peptide comprised the sequence HLERVTGFNQIDSDKVYDD GAPP, and the C-terminal R2 peptide comprised the sequence TFKCWFTKSGEWLLGILN GN.", [["GAPP", "PROTEIN", 69, 73], ["the sequence HLERVTGFNQIDSDKVYDD GAPP", "TEST", 36, 73], ["the C-terminal R2 peptide", "TREATMENT", 79, 104]]], ["Two additional peptides were used, R2.1 and R2.2, comprising either the first ten residues or the last ten residues of the R2 peptide, respectively.", [["Two additional peptides", "TEST", 0, 23], ["peptides", "OBSERVATION", 15, 23]]], ["To avoid the introduction of additional charges, the C-terminal of R2.1 was amide-modified, and the N-terminal of R.2.2 was acidmodified, comprising the sequences TFKCWFTKSG and EWLLGILNGN, respectively.", [["R2.1", "CHEMICAL", 67, 71], ["C", "CHEMICAL", 53, 54], ["amide", "CHEMICAL", 76, 81], ["N", "CHEMICAL", 100, 101], ["R2.1", "PROTEIN", 67, 71], ["N-terminal", "PROTEIN", 100, 110], ["R.2.2", "PROTEIN", 114, 119], ["EWLLGILNGN", "PROTEIN", 178, 188], ["additional charges", "TREATMENT", 29, 47], ["the C-terminal of R2.1", "TREATMENT", 49, 71]]], ["The NN peptide comprising the sequence QLVTARQKLKDAEKAVEVDPDDVNKSTLQRRAAV STLETKLG, derived from the ANDV nucleoprotein, was used as control.", [["ANDV", "GENE_OR_GENE_PRODUCT", 101, 105], ["QLVTARQKLKDAEKAVEVDPDDVNKSTLQRRAAV STLETKLG", "DNA", 39, 82], ["ANDV nucleoprotein", "PROTEIN", 101, 119], ["ANDV", "SPECIES", 101, 105], ["The NN peptide", "TREATMENT", 0, 14], ["the ANDV nucleoprotein", "TREATMENT", 97, 119]]], ["Such nucleoprotein-based peptide was chosen to limit the possibility of inter-or intramolecular interactions with the fusion protein that may occur during its conformational changes in the fusion process.", [["fusion protein", "PROTEIN", 118, 132], ["Such nucleoprotein-based peptide", "TREATMENT", 0, 32], ["inter-or intramolecular interactions", "PROBLEM", 72, 108], ["the fusion protein", "PROBLEM", 114, 132], ["its conformational changes in the fusion process", "PROBLEM", 155, 203], ["fusion", "OBSERVATION", 189, 195]]], ["This NN peptide of 42 residues was used as control of both short R peptides and longer DIII fragments.", [["DIII fragments", "PROTEIN", 87, 101], ["This NN peptide of 42 residues", "TREATMENT", 0, 30], ["both short R peptides and longer DIII fragments", "PROBLEM", 54, 101]]], ["All peptides were soluble in HNE buffer (10 mM HEPES, 130 mM NaCl, 0,1 mM EDTA, pH 7.4), except peptides R2 and R2.2, which were dissolved in 10 mM borate buffer (pH 9).Virus and cellsANDV isolate CHI-7913 (kindly provided by H\u00e9ctor Galeno, Instituto de Salud P\u00fablica, Chile) was propagated in Vero E6 cells (ATTC) as described before [57] .", [["Vero E6 cells", "ANATOMY", 294, 307], ["ATTC", "ANATOMY", 309, 313], ["NaCl", "CHEMICAL", 61, 65], ["CHI-7913", "CHEMICAL", 197, 205], ["HEPES", "CHEMICAL", 47, 52], ["NaCl", "CHEMICAL", 61, 65], ["EDTA", "CHEMICAL", 74, 78], ["borate", "CHEMICAL", 148, 154], ["HNE", "SIMPLE_CHEMICAL", 29, 32], ["EDTA", "SIMPLE_CHEMICAL", 74, 78], ["R2.2", "SIMPLE_CHEMICAL", 112, 116], ["Virus", "ORGANISM", 169, 174], ["CHI-7913", "CELL", 197, 205], ["Vero E6 cells", "CELL", 294, 307], ["ATTC", "CELL", 309, 313], ["Vero E6 cells", "CELL_LINE", 294, 307], ["ATTC", "CELL_LINE", 309, 313], ["CHI-7913", "SPECIES", 197, 205], ["Vero E6", "SPECIES", 294, 301], ["All peptides", "TREATMENT", 0, 12], ["soluble in HNE buffer", "TREATMENT", 18, 39], ["HEPES", "TEST", 47, 52], ["NaCl", "TEST", 61, 65], ["EDTA", "TEST", 74, 78], ["pH", "TEST", 80, 82], ["peptides", "TEST", 96, 104], ["Virus", "PROBLEM", 169, 174], ["CHI", "TEST", 197, 200], ["Vero E6 cells", "TREATMENT", 294, 307]]], ["All work involving the infectious virus was performed under biosafety level 3 conditions (Centro de Investigaciones M\u00e9dicas, Pontificia Universidad Cat\u00f3lica de Chile, Chile).", [["the infectious virus", "PROBLEM", 19, 39]]], ["293FT cells (Invitrogen) were propagated in DMEM supplemented with 10% fetal calf serum (FCS).", [["293FT cells", "ANATOMY", 0, 11], ["fetal calf serum", "ANATOMY", 71, 87], ["293FT cells", "CELL", 0, 11], ["Invitrogen", "ORGANISM", 13, 23], ["fetal calf", "ORGANISM_SUBSTANCE", 71, 81], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["FCS", "ORGANISM_SUBSTANCE", 89, 92], ["293FT cells", "CELL_LINE", 0, 11], ["calf", "SPECIES", 77, 81], ["Invitrogen", "TEST", 13, 23]]], ["CHO-K1 cells (ATTC) were grown in F12-K medium containing 10% FCS.ANDV infectivity titrationThe infection of Vero E6 cells by ANDV (multiplicity of infection (MOI) = 0.1) was quantified by flow cytometry as formerly established [57] .", [["CHO-K1 cells", "ANATOMY", 0, 12], ["ATTC", "ANATOMY", 14, 18], ["Vero E6 cells", "ANATOMY", 109, 122], ["F12-K", "CHEMICAL", 34, 39], ["infection", "DISEASE", 96, 105], ["infection", "DISEASE", 148, 157], ["CHO-K1 cells", "CELL", 0, 12], ["ATTC", "CELL", 14, 18], ["F12-K", "CELL", 34, 39], ["ANDV", "GENE_OR_GENE_PRODUCT", 66, 70], ["Vero E6 cells", "CELL", 109, 122], ["CHO-K1 cells", "CELL_LINE", 0, 12], ["ATTC", "CELL_LINE", 14, 18], ["Vero E6 cells", "CELL_LINE", 109, 122], ["ANDV", "SPECIES", 66, 70], ["Vero E6", "SPECIES", 109, 116], ["ANDV", "SPECIES", 126, 130], ["CHO-K1 cells", "TEST", 0, 12], ["ATTC", "TEST", 14, 18], ["ANDV infectivity titration", "TREATMENT", 66, 92], ["The infection of Vero E6 cells", "PROBLEM", 92, 122], ["infection", "PROBLEM", 148, 157], ["flow cytometry", "TEST", 189, 203], ["K1 cells", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 148, 157]]], ["Briefly, cells were incubated with ANDV for 1 h at 37\u00b0C in the presence and absence of protein or peptide inhibitor candidates.", [["cells", "ANATOMY", 9, 14], ["ANDV", "CHEMICAL", 35, 39], ["ANDV", "CHEMICAL", 35, 39], ["cells", "CELL", 9, 14], ["ANDV", "SIMPLE_CHEMICAL", 35, 39], ["peptide inhibitor candidates", "TREATMENT", 98, 126]]], ["Subsequently, cells were washed and infection was allowed to proceed for 16 h.", [["cells", "ANATOMY", 14, 19], ["infection", "DISEASE", 36, 45], ["cells", "CELL", 14, 19], ["infection", "PROBLEM", 36, 45], ["infection", "OBSERVATION", 36, 45]]], ["Cells were next fixed with 2% (w/v) paraformaldehyde for virus inactivation, and permeabilized with 0.1% Triton X-100.", [["Cells", "ANATOMY", 0, 5], ["Triton X-100", "CHEMICAL", 105, 117], ["paraformaldehyde", "CHEMICAL", 36, 52], ["Triton X-100", "CHEMICAL", 105, 117], ["Cells", "CELL", 0, 5], ["/v) paraformaldehyde", "SIMPLE_CHEMICAL", 32, 52], ["Triton X-100", "SIMPLE_CHEMICAL", 105, 117], ["Cells", "TEST", 0, 5], ["w/v) paraformaldehyde", "TREATMENT", 31, 52], ["virus inactivation", "TREATMENT", 57, 75]]], ["For immunofluorescence staining, cells were incubated for 45 min with anti-ANDV N monoclonal antibody (mAb) 7B3/F6 [58] and then the primary antibody was detected with goat antimouse immunoglobulin conjugated to Alexa 555 (Life Technologies). !10.000 cells of each condition were analyzed using a flow cytometer (FACS CAN II, Becton Dickinson).", [["cells", "ANATOMY", 33, 38], ["cells", "ANATOMY", 251, 256], ["Alexa 555", "CHEMICAL", 212, 221], ["Alexa 555", "CHEMICAL", 212, 221], ["cells", "CELL", 33, 38], ["Alexa 555", "SIMPLE_CHEMICAL", 212, 221], ["cells", "CELL", 251, 256], ["anti-ANDV N monoclonal antibody", "PROTEIN", 70, 101], ["mAb", "PROTEIN", 103, 106], ["7B3", "PROTEIN", 108, 111], ["F6", "PROTEIN", 112, 114], ["primary antibody", "PROTEIN", 133, 149], ["goat antimouse immunoglobulin", "PROTEIN", 168, 197], ["Alexa 555", "PROTEIN", 212, 221], ["goat", "SPECIES", 168, 172], ["goat", "SPECIES", 168, 172], ["immunofluorescence staining", "TEST", 4, 31], ["cells", "TEST", 33, 38], ["anti-ANDV N monoclonal antibody (mAb", "TEST", 70, 106], ["the primary antibody", "TEST", 129, 149], ["goat antimouse immunoglobulin", "TREATMENT", 168, 197], ["Alexa", "TREATMENT", 212, 217], ["a flow cytometer", "TEST", 295, 311]]], ["The standard deviation of at least n = 3 experiments is indicated as the error bar of each value.ANDV infectivity titrationProduction of simian immunodeficiency virus (SIV) vectors pseudotyped with vesicular stomatitis virus (VSV) G protein or ANDV glycoproteins and transduction SIV vectors bearing the VSV glycoprotein were prepared as indicated elsewhere [59] .", [["simian immunodeficiency virus", "DISEASE", 137, 166], ["vesicular stomatitis", "DISEASE", 198, 218], ["ANDV", "GENE_OR_GENE_PRODUCT", 97, 101], ["simian immunodeficiency virus", "ORGANISM", 137, 166], ["SIV", "ORGANISM", 168, 171], ["vesicular stomatitis virus", "ORGANISM", 198, 224], ["VSV", "ORGANISM", 226, 229], [") G protein", "GENE_OR_GENE_PRODUCT", 229, 240], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 244, 262], ["SIV", "ORGANISM", 280, 283], ["VSV", "ORGANISM", 304, 307], ["vesicular stomatitis virus (VSV) G protein", "PROTEIN", 198, 240], ["ANDV glycoproteins", "PROTEIN", 244, 262], ["VSV glycoprotein", "PROTEIN", 304, 320], ["simian immunodeficiency virus", "SPECIES", 137, 166], ["vesicular stomatitis virus", "SPECIES", 198, 224], ["ANDV", "SPECIES", 97, 101], ["simian immunodeficiency virus", "SPECIES", 137, 166], ["SIV", "SPECIES", 168, 171], ["stomatitis virus", "SPECIES", 208, 224], ["VSV", "SPECIES", 226, 229], ["ANDV", "SPECIES", 244, 248], ["SIV", "SPECIES", 280, 283], ["VSV", "SPECIES", 304, 307], ["ANDV infectivity titrationProduction", "TREATMENT", 97, 133], ["simian immunodeficiency virus", "PROBLEM", 137, 166], ["vesicular stomatitis virus", "PROBLEM", 198, 224], ["G protein", "TEST", 231, 240], ["ANDV glycoproteins", "TREATMENT", 244, 262], ["transduction SIV vectors", "TREATMENT", 267, 291], ["the VSV glycoprotein", "TREATMENT", 300, 320], ["simian immunodeficiency", "OBSERVATION", 137, 160], ["vesicular stomatitis", "OBSERVATION", 198, 218]]], ["Briefly, 293FT cells were transfected with 8 \u03bcg of plasmid coding for SIV Gag-Pol (pSIV3+), 8 \u03bcg of plasmid encoding GFP as an RNA minigenome (pGAE1.0) [60] , and 4 \u03bcg of plasmid coding for the envelope protein G of VSV (pVSV-G, Clontech).", [["293FT cells", "ANATOMY", 9, 20], ["plasmid", "ANATOMY", 51, 58], ["plasmid", "ANATOMY", 100, 107], ["plasmid", "ANATOMY", 171, 178], ["293FT cells", "CELL", 9, 20], ["SIV", "ORGANISM", 70, 73], ["Gag-Pol", "GENE_OR_GENE_PRODUCT", 74, 81], ["GFP", "GENE_OR_GENE_PRODUCT", 117, 120], ["VSV", "ORGANISM", 216, 219], ["pVSV-G", "GENE_OR_GENE_PRODUCT", 221, 227], ["Clontech", "GENE_OR_GENE_PRODUCT", 229, 237], ["293FT cells", "CELL_LINE", 9, 20], ["SIV Gag", "PROTEIN", 70, 77], ["Pol", "PROTEIN", 78, 81], ["SIV3", "PROTEIN", 84, 88], ["plasmid", "DNA", 100, 107], ["GFP", "DNA", 117, 120], ["envelope protein G", "PROTEIN", 194, 212], ["pVSV", "PROTEIN", 221, 225], ["Clontech", "PROTEIN", 229, 237], ["VSV", "SPECIES", 216, 219], ["plasmid coding", "TREATMENT", 51, 65], ["SIV Gag", "TEST", 70, 77], ["plasmid encoding GFP", "TREATMENT", 100, 120], ["plasmid coding", "TREATMENT", 171, 185], ["the envelope protein G", "TEST", 190, 212], ["VSV", "TEST", 216, 219], ["pVSV", "TEST", 221, 225]]], ["Alternatively, the plasmid pI.18/GPC coding for ANDV glycoproteins was used to generate SIV vectors pseudotyped with ANDV glycoproteins.", [["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 48, 66], ["SIV", "ORGANISM", 88, 91], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 117, 135], ["plasmid pI.18", "DNA", 19, 32], ["GPC", "DNA", 33, 36], ["ANDV glycoproteins", "PROTEIN", 48, 66], ["ANDV glycoproteins", "PROTEIN", 117, 135], ["ANDV", "SPECIES", 48, 52], ["SIV", "SPECIES", 88, 91], ["ANDV", "SPECIES", 117, 121], ["the plasmid pI", "TEST", 15, 29], ["GPC", "PROBLEM", 33, 36], ["ANDV glycoproteins", "TREATMENT", 48, 66], ["SIV vectors pseudotyped", "TREATMENT", 88, 111], ["ANDV glycoproteins", "TREATMENT", 117, 135]]], ["At 48 h post-transfection, supernatants containing pseudotyped particles were concentrated by centrifugation at 100,000 g for 75 min.", [["supernatants", "ANATOMY", 27, 39], ["pseudotyped", "ORGANISM", 51, 62], ["supernatants containing pseudotyped particles", "TREATMENT", 27, 72]]], ["Different dilutions of VSV-G pseudotyped SIV vectors were incubated for 1 h with Vero E6 cells in the presence and absence of protein or peptide inhibitor candidates.", [["cells", "ANATOMY", 89, 94], ["VSV-G pseudotyped", "ORGANISM", 23, 40], ["SIV", "ORGANISM", 41, 44], ["Vero E6 cells", "CELL", 81, 94], ["Vero E6 cells", "CELL_LINE", 81, 94], ["VSV-G pseudotyped SIV", "SPECIES", 23, 44], ["Vero E6", "SPECIES", 81, 88], ["Different dilutions", "TREATMENT", 0, 19], ["VSV-G pseudotyped SIV vectors", "TREATMENT", 23, 52], ["Vero E6 cells", "TREATMENT", 81, 94], ["peptide inhibitor candidates", "TREATMENT", 137, 165], ["E6 cells", "OBSERVATION", 86, 94]]], ["Three days later, the expression of GFP in transduced cells was analyzed by flow cytometry (FACScan, Becton Dickinson). !10.000 cells were counted for each experimental condition.CytotoxicityA cell proliferation assay was used to assess cytotoxicity of the Gc domains and peptides as described by the manufacturer (CellTiter96, Promega).", [["cells", "ANATOMY", 54, 59], ["cells", "ANATOMY", 128, 133], ["cell", "ANATOMY", 193, 197], ["GFP", "GENE_OR_GENE_PRODUCT", 36, 39], ["cells", "CELL", 54, 59], ["cells", "CELL", 128, 133], ["A cell", "CELL", 191, 197], ["GFP", "PROTEIN", 36, 39], ["transduced cells", "CELL_LINE", 43, 59], ["Gc domains", "PROTEIN", 257, 267], ["GFP in transduced cells", "PROBLEM", 36, 59], ["flow cytometry", "TEST", 76, 90], ["FACScan", "TEST", 92, 99], ["CytotoxicityA cell proliferation assay", "TEST", 179, 217], ["cytotoxicity of the Gc domains and peptides", "PROBLEM", 237, 280], ["cell proliferation", "OBSERVATION", 193, 211]]], ["Briefly, Gc domains and peptides were incubated with Vero E6 cells for 18 h at 37\u00b0C, and the conversion of tetrazolium to formazan was assessed by measuring the absorbance at 570 nm in a microplate reader (Synergy 4, BioTek).Cell-cell fusion assayA three-color based cell-cell fusion assay was performed as established before [22] .", [["cells", "ANATOMY", 61, 66], ["Cell", "ANATOMY", 225, 229], ["cell", "ANATOMY", 230, 234], ["cell", "ANATOMY", 267, 271], ["cell", "ANATOMY", 272, 276], ["tetrazolium", "CHEMICAL", 107, 118], ["formazan", "CHEMICAL", 122, 130], ["tetrazolium", "CHEMICAL", 107, 118], ["formazan", "CHEMICAL", 122, 130], ["Vero E6 cells", "CELL", 53, 66], ["tetrazolium", "SIMPLE_CHEMICAL", 107, 118], ["formazan", "SIMPLE_CHEMICAL", 122, 130], ["Cell", "CELL", 225, 229], ["cell", "CELL", 230, 234], ["cell", "CELL", 267, 271], ["cell", "CELL", 272, 276], ["Gc domains", "PROTEIN", 9, 19], ["Vero E6 cells", "CELL_LINE", 53, 66], ["Vero E6", "SPECIES", 53, 60], ["Gc domains and peptides", "PROBLEM", 9, 32], ["Vero E6 cells", "TREATMENT", 53, 66], ["tetrazolium", "TREATMENT", 107, 118], ["formazan", "TREATMENT", 122, 130], ["a microplate reader (Synergy", "TREATMENT", 185, 213], ["Cell-cell fusion assayA", "TEST", 225, 248], ["color based cell-cell fusion assay", "TEST", 255, 289], ["cell fusion", "OBSERVATION", 230, 241], ["cell fusion", "OBSERVATION", 272, 283]]], ["Briefly, 48 h after the transfection of Vero E6 cells with pI.18/GPC [59] or pWRG/PUUV-M(s2) [50] coding for the glycoproteins of ANDV and PUUV, respectively, the cells were incubated with low pH media (E-MEM, 20 mM sodium succinate, pH 5.5) for 5 min at 37\u00b0C. Three hours later, the cell cytoplasm was stained with 5-chloromethylfluorescein diacetate (CellTracker Green CMFDA, Invitrogen), cell nuclei with DAPI (Life Technologies), and Gc was labeled by anti-Gc mAb 2H4/F6 [61] , and anti-mouse immunoglobulin conjugated to Alexa555 (Invitrogen).", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 163, 168], ["cell cytoplasm", "ANATOMY", 284, 298], ["cell nuclei", "ANATOMY", 391, 402], ["E-MEM", "CHEMICAL", 203, 208], ["sodium succinate", "CHEMICAL", 216, 232], ["5-chloromethylfluorescein diacetate", "CHEMICAL", 316, 351], ["CellTracker Green CMFDA", "CHEMICAL", 353, 376], ["Alexa555", "CHEMICAL", 526, 534], ["sodium succinate", "CHEMICAL", 216, 232], ["5-chloromethylfluorescein diacetate", "CHEMICAL", 316, 351], ["CellTracker Green CMFDA", "CHEMICAL", 353, 376], ["DAPI", "CHEMICAL", 408, 412], ["Alexa555", "CHEMICAL", 526, 534], ["Vero E6 cells", "CELL", 40, 53], ["pWRG", "GENE_OR_GENE_PRODUCT", 77, 81], ["ANDV", "GENE_OR_GENE_PRODUCT", 130, 134], ["PUUV", "ORGANISM", 139, 143], ["cells", "CELL", 163, 168], ["sodium succinate", "SIMPLE_CHEMICAL", 216, 232], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 284, 298], ["5-chloromethylfluorescein diacetate", "SIMPLE_CHEMICAL", 316, 351], ["CellTracker Green CMFDA", "SIMPLE_CHEMICAL", 353, 376], ["Invitrogen", "SIMPLE_CHEMICAL", 378, 388], ["cell nuclei", "CELL", 391, 402], ["DAPI", "SIMPLE_CHEMICAL", 408, 412], ["anti-mouse immunoglobulin conjugated", "SIMPLE_CHEMICAL", 486, 522], ["Alexa555", "SIMPLE_CHEMICAL", 526, 534], ["Invitrogen", "SIMPLE_CHEMICAL", 536, 546], ["Vero E6 cells", "CELL_LINE", 40, 53], ["ANDV", "PROTEIN", 130, 134], ["Gc", "PROTEIN", 438, 440], ["anti-Gc mAb", "PROTEIN", 456, 467], ["2H4", "PROTEIN", 468, 471], ["F6", "PROTEIN", 472, 474], ["anti-mouse immunoglobulin", "PROTEIN", 486, 511], ["Alexa555", "PROTEIN", 526, 534], ["anti-mouse", "SPECIES", 486, 496], ["Vero E6", "SPECIES", 40, 47], ["ANDV", "SPECIES", 130, 134], ["PUUV", "SPECIES", 139, 143], ["Vero E6 cells", "PROBLEM", 40, 53], ["pI", "TEST", 59, 61], ["GPC", "TEST", 65, 68], ["pWRG/PUUV", "TEST", 77, 86], ["the glycoproteins", "TEST", 109, 126], ["ANDV", "TEST", 130, 134], ["PUUV", "PROBLEM", 139, 143], ["low pH media", "TREATMENT", 189, 201], ["mM sodium succinate", "TEST", 213, 232], ["pH", "TEST", 234, 236], ["the cell cytoplasm", "TEST", 280, 298], ["5-chloromethylfluorescein diacetate", "TREATMENT", 316, 351], ["CellTracker", "TREATMENT", 353, 364], ["DAPI (Life Technologies", "TREATMENT", 408, 431], ["Gc", "TEST", 438, 440], ["anti-mouse immunoglobulin", "TREATMENT", 486, 511], ["Alexa555", "TREATMENT", 526, 534], ["PUUV", "OBSERVATION", 82, 86], ["PUUV", "OBSERVATION", 139, 143], ["cell cytoplasm", "OBSERVATION", 284, 298], ["cell nuclei", "OBSERVATION", 391, 402]]], ["The fusion index of Gc-expressing cells was calculated by the formula:Cell-cell fusion assayFor each sample, approximately 200 nuclei per field were counted (20x magnification), and the mean fusion index of five fields was calculated (n = 3).ANDV infection mediated by virus-plasma membrane fusionVero E6 cells were pre-chilled on ice for 10 min with 20 mM NH 4 Cl.", [["cells", "ANATOMY", 34, 39], ["Cell-cell", "ANATOMY", 70, 79], ["sample", "ANATOMY", 101, 107], ["nuclei", "ANATOMY", 127, 133], ["plasma membrane", "ANATOMY", 275, 290], ["Vero E6 cells", "ANATOMY", 297, 310], ["infection", "DISEASE", 247, 256], ["NH 4 Cl", "CHEMICAL", 357, 364], ["NH 4 Cl", "CHEMICAL", 357, 364], ["Gc", "GENE_OR_GENE_PRODUCT", 20, 22], ["cells", "CELL", 34, 39], ["Cell-cell", "CELL", 70, 79], ["ANDV", "GENE_OR_GENE_PRODUCT", 242, 246], ["plasma", "ORGANISM_SUBSTANCE", 275, 281], ["membrane", "CELLULAR_COMPONENT", 282, 290], ["Vero E6 cells", "CELL", 297, 310], ["NH 4 Cl", "SIMPLE_CHEMICAL", 357, 364], ["Gc-expressing cells", "CELL_LINE", 20, 39], ["Vero E6 cells", "CELL_LINE", 297, 310], ["ANDV", "SPECIES", 242, 246], ["Vero E6", "SPECIES", 297, 304], ["The fusion index", "TEST", 0, 16], ["expressing cells", "PROBLEM", 23, 39], ["Cell-cell fusion assay", "TEST", 70, 92], ["each sample", "TEST", 96, 107], ["the mean fusion index", "TEST", 182, 203], ["ANDV infection", "PROBLEM", 242, 256], ["virus", "PROBLEM", 269, 274], ["plasma membrane fusion", "TREATMENT", 275, 297], ["Vero E6 cells", "PROBLEM", 297, 310], ["fusion", "OBSERVATION", 4, 10], ["infection", "OBSERVATION", 247, 256]]], ["The adsorption of ANDV (MOI = 0.2) was performed at 4\u00b0C for 1h.", [["ANDV", "CHEMICAL", 18, 22], ["ANDV", "CHEMICAL", 18, 22], ["ANDV", "SIMPLE_CHEMICAL", 18, 22], ["ANDV (MOI", "TREATMENT", 18, 27]]], ["Next, cells were washed, and the fusion of the virus with the plasma membrane was triggered by incubation in low pH media (E-MEM, 20 mM sodium succinate, pH 5.5) for 5 min at 37\u00b0C in the presence and absence of inhibitor candidates.", [["cells", "ANATOMY", 6, 11], ["plasma membrane", "ANATOMY", 62, 77], ["E-MEM", "CHEMICAL", 123, 128], ["sodium succinate", "CHEMICAL", 136, 152], ["sodium succinate", "CHEMICAL", 136, 152], ["cells", "CELL", 6, 11], ["plasma membrane", "CELLULAR_COMPONENT", 62, 77], ["sodium succinate", "SIMPLE_CHEMICAL", 136, 152], ["the virus", "PROBLEM", 43, 52], ["the plasma membrane", "TREATMENT", 58, 77], ["20 mM sodium succinate", "TREATMENT", 130, 152], ["pH", "TEST", 154, 156], ["inhibitor candidates", "TREATMENT", 211, 231]]], ["Next, cells were washed, and infection was followed by incubation for 16 h at 37\u00b0C in the presence of 20 mM NH 4 Cl.", [["cells", "ANATOMY", 6, 11], ["infection", "DISEASE", 29, 38], ["NH 4 Cl", "CHEMICAL", 108, 115], ["NH 4 Cl", "CHEMICAL", 108, 115], ["cells", "CELL", 6, 11], ["NH 4 Cl", "SIMPLE_CHEMICAL", 108, 115], ["infection", "PROBLEM", 29, 38], ["infection", "OBSERVATION", 29, 38]]], ["Subsequently, viral infection was assessed as described above.Acid-induced Gc homotrimerizationThe multimerization state of Gc was assessed by sucrose gradient centrifugation as previously established [17] .", [["viral infection", "DISEASE", 14, 29], ["Acid-", "CHEMICAL", 62, 67], ["sucrose", "CHEMICAL", 143, 150], ["sucrose", "CHEMICAL", 143, 150], ["Gc", "GENE_OR_GENE_PRODUCT", 75, 77], ["Gc", "GENE_OR_GENE_PRODUCT", 124, 126], ["sucrose", "SIMPLE_CHEMICAL", 143, 150], ["Gc", "PROTEIN", 124, 126], ["viral infection", "PROBLEM", 14, 29], ["Acid-", "TEST", 62, 67], ["sucrose gradient centrifugation", "TREATMENT", 143, 174], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29], ["Gc homotrimerization", "OBSERVATION", 75, 95]]], ["Briefly, ANDV was treated at pH 5.5 to allow for the rearrangement of glycoproteins on the viral envelope.", [["ANDV", "CHEMICAL", 9, 13], ["ANDV", "SIMPLE_CHEMICAL", 9, 13], ["glycoproteins", "PROTEIN", 70, 83], ["ANDV", "SPECIES", 9, 13], ["pH", "TEST", 29, 31], ["the rearrangement of glycoproteins", "PROBLEM", 49, 83], ["the viral envelope", "TREATMENT", 87, 105]]], ["Where indicated, DIII or R2 were added to the virus during its low pH incubation during 30 min at 37\u00b0C. Subsequently, viral glycoproteins were extracted by 1% Triton X-100 and separated in a gradient of 7-15% (w/v) sucrose by centrifugation at 150,000 g for 16 h.", [["Triton X-100", "CHEMICAL", 159, 171], ["sucrose", "CHEMICAL", 215, 222], ["sucrose", "CHEMICAL", 215, 222], ["DIII", "GENE_OR_GENE_PRODUCT", 17, 21], ["R2", "GENE_OR_GENE_PRODUCT", 25, 27], ["Triton X-100", "SIMPLE_CHEMICAL", 159, 171], ["sucrose", "SIMPLE_CHEMICAL", 215, 222], ["DIII", "PROTEIN", 17, 21], ["R2", "PROTEIN", 25, 27], ["viral glycoproteins", "PROTEIN", 118, 137], ["the virus", "PROBLEM", 42, 51], ["its low pH incubation", "TREATMENT", 59, 80], ["viral glycoproteins", "TREATMENT", 118, 137], ["viral glycoproteins", "OBSERVATION", 118, 137]]], ["Fractions were collected, and the presence of Gc in each fraction was assessed by western blot analysis using anti-Gc mAb 2H4/F6 [61] .", [["Gc", "GENE_OR_GENE_PRODUCT", 46, 48], ["Gc", "PROTEIN", 46, 48], ["anti-Gc mAb", "PROTEIN", 110, 121], ["2H4", "PROTEIN", 122, 125], ["Gc in each fraction", "PROBLEM", 46, 65], ["blot analysis", "TEST", 90, 103], ["anti-Gc mAb", "TREATMENT", 110, 121]]], ["The molecular mass of each fraction was assessed by the Coomassie staining of a molecular marker (Gel filtration standard, Bio-Rad) that was applied to the same sedimentation gradient.", [["Coomassie", "CHEMICAL", 56, 65], ["Coomassie", "SIMPLE_CHEMICAL", 56, 65], ["The molecular mass of each fraction", "PROBLEM", 0, 35], ["the Coomassie staining", "TEST", 52, 74], ["a molecular marker (Gel filtration", "TREATMENT", 78, 112], ["Bio-Rad)", "TREATMENT", 123, 131], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["sedimentation gradient", "OBSERVATION", 161, 183]]], ["The experimental molecular mass of the marker was next plotted against the log of its theoretical molecular mass in the panel above the western blots of the gradient.", [["The experimental molecular mass", "PROBLEM", 0, 31], ["its theoretical molecular mass", "PROBLEM", 82, 112], ["experimental", "OBSERVATION_MODIFIER", 4, 16], ["molecular", "OBSERVATION_MODIFIER", 17, 26], ["mass", "OBSERVATION", 27, 31], ["molecular", "OBSERVATION_MODIFIER", 98, 107], ["mass", "OBSERVATION", 108, 112], ["gradient", "OBSERVATION_MODIFIER", 157, 165]]], ["The stability of the Gc homotrimer was further tested by trypsin digestion as indicated before [17] .", [["Gc", "GENE_OR_GENE_PRODUCT", 21, 23], ["trypsin", "GENE_OR_GENE_PRODUCT", 57, 64], ["Gc homotrimer", "PROTEIN", 21, 34], ["trypsin", "PROTEIN", 57, 64], ["the Gc homotrimer", "TREATMENT", 17, 34], ["stability", "OBSERVATION_MODIFIER", 4, 13]]], ["Briefly, well-characterized VLPs projecting ANDV glycoproteins were prepared as described elsewhere [62] and were incubated for 30 min at pH 5.5.", [["VLPs", "ORGANISM", 28, 32], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 44, 62], ["VLPs", "PROTEIN", 28, 32], ["ANDV glycoproteins", "PROTEIN", 44, 62], ["ANDV", "SPECIES", 44, 48], ["pH", "TEST", 138, 140]]], ["After the acidification, VLPs were incubated with TCPK trypsin (Sigma) for the indicated times.", [["VLPs", "ORGANISM", 25, 29], ["TCPK trypsin", "GENE_OR_GENE_PRODUCT", 50, 62], ["TCPK trypsin", "PROTEIN", 50, 62], ["the acidification", "PROBLEM", 6, 23], ["VLPs", "TREATMENT", 25, 29], ["TCPK trypsin", "TREATMENT", 50, 62]]], ["Finally, digestion was stopped by adding sample buffer and heating to 95\u00b0C for 10 min.", [["sample buffer", "TREATMENT", 41, 54]]], ["The digestion of Gc was tested by western blot analysis, using anti-Gc mAb as described above.Cell-based hemifusion assayIn this assay, the transfer of monosialotetrahexosylganglioside (GM1) from an effector cell to a target cell was measured as described before for SNARE proteins [63] .", [["Cell", "ANATOMY", 94, 98], ["effector cell", "ANATOMY", 199, 212], ["cell", "ANATOMY", 225, 229], ["monosialotetrahexosylganglioside", "CHEMICAL", 152, 184], ["monosialotetrahexosylganglioside", "CHEMICAL", 152, 184], ["Gc", "GENE_OR_GENE_PRODUCT", 17, 19], ["anti-Gc mAb", "GENE_OR_GENE_PRODUCT", 63, 74], ["Cell", "CELL", 94, 98], ["monosialotetrahexosylganglioside", "GENE_OR_GENE_PRODUCT", 152, 184], ["GM1", "GENE_OR_GENE_PRODUCT", 186, 189], ["cell", "CELL", 208, 212], ["cell", "CELL", 225, 229], ["SNARE", "GENE_OR_GENE_PRODUCT", 267, 272], ["Gc", "PROTEIN", 17, 19], ["anti-Gc mAb", "PROTEIN", 63, 74], ["monosialotetrahexosylganglioside", "PROTEIN", 152, 184], ["GM1", "PROTEIN", 186, 189], ["effector cell", "CELL_TYPE", 199, 212], ["SNARE proteins", "PROTEIN", 267, 281], ["The digestion of Gc", "PROBLEM", 0, 19], ["blot analysis", "TEST", 42, 55], ["anti-Gc mAb", "TREATMENT", 63, 74], ["this assay", "TEST", 124, 134], ["monosialotetrahexosylganglioside (GM1", "TREATMENT", 152, 189], ["an effector cell", "PROBLEM", 196, 212], ["SNARE proteins", "TEST", 267, 281], ["effector cell", "OBSERVATION", 199, 212]]], ["To adapt this assay to measure the ANDV glycoprotein-mediated GM1 transfer, 293FT cells (GM1 + ) were transfected with pI.18/GPC [59] using Lipofectamine 2000 (Invitrogen), as indicated by the manufacturer.", [["293FT cells", "ANATOMY", 76, 87], ["ANDV glycoprotein", "GENE_OR_GENE_PRODUCT", 35, 52], ["GM1", "GENE_OR_GENE_PRODUCT", 62, 65], ["293FT cells", "CELL", 76, 87], ["GM1 +", "CELL", 89, 94], ["Invitrogen", "SIMPLE_CHEMICAL", 160, 170], ["ANDV glycoprotein", "PROTEIN", 35, 52], ["GM1", "PROTEIN", 62, 65], ["293FT cells", "CELL_LINE", 76, 87], ["GM1", "PROTEIN", 89, 92], ["ANDV", "SPECIES", 35, 39], ["this assay", "TEST", 9, 19], ["the ANDV glycoprotein", "TEST", 31, 52], ["GM1", "TEST", 89, 92], ["pI", "TEST", 119, 121], ["GPC", "TEST", 125, 128], ["Lipofectamine", "TREATMENT", 140, 153]]], ["Forty-five h post-transfection, the cells were detached from the plates, and resuspended in supplemented DMEM.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41]]], ["At the same time, target CHO-K1 cells (GM1 -) were trypsinized and labeled with 40 \u03bcM 7-amino-4-chloromethylcoumarin (CellTracker Blue CMAC, Invitrogen) in supplemented 12-K medium for 40 min at 37\u00b0C. The excess dye was then removed by replacing the dye-containing media with supplemented F12-K medium and subsequent incubation for 30 min.", [["CHO-K1 cells", "ANATOMY", 25, 37], ["7-amino-4-chloromethylcoumarin", "CHEMICAL", 86, 116], ["CellTracker Blue CMAC", "CHEMICAL", 118, 139], ["12-K", "CHEMICAL", 169, 173], ["F12-K", "CHEMICAL", 289, 294], ["7-amino-4-chloromethylcoumarin", "CHEMICAL", 86, 116], ["CellTracker Blue CMAC", "CHEMICAL", 118, 139], ["CHO-K1 cells", "CELL", 25, 37], ["GM1", "CELL", 39, 42], ["7-amino-4-chloromethylcoumarin", "SIMPLE_CHEMICAL", 86, 116], ["CellTracker Blue CMAC", "SIMPLE_CHEMICAL", 118, 139], ["Invitrogen", "SIMPLE_CHEMICAL", 141, 151], ["CHO-K1 cells", "CELL_LINE", 25, 37], ["GM1", "CELL_LINE", 39, 42], ["target CHO-K1 cells", "TEST", 18, 37], ["GM1", "TEST", 39, 42], ["amino", "TREATMENT", 88, 93], ["chloromethylcoumarin (CellTracker Blue CMAC", "TREATMENT", 96, 139], ["The excess dye", "TREATMENT", 201, 215], ["the dye-containing media", "TREATMENT", 246, 270], ["supplemented F12-K medium", "TREATMENT", 276, 301], ["excess dye", "OBSERVATION", 205, 215]]], ["After washing with PBS, target cells were resuspended in supplemented DMEM.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["target cells", "CELL_TYPE", 24, 36], ["PBS", "TREATMENT", 19, 22], ["target cells", "PROBLEM", 24, 36]]], ["Next, effector cells (transfected 293FT cells) and CMAC-labeled target cells (CHO-K1 cells) were combined in a ratio of 1:4 (effector:target) for 3 h.", [["effector cells", "ANATOMY", 6, 20], ["293FT cells", "ANATOMY", 34, 45], ["cells", "ANATOMY", 71, 76], ["CHO-K1 cells", "ANATOMY", 78, 90], ["effector cells", "CELL", 6, 20], ["transfected 293FT cells", "CELL", 22, 45], ["CMAC", "CELL", 51, 55], ["cells", "CELL", 71, 76], ["CHO-K1 cells", "CELL", 78, 90], ["effector cells", "CELL_TYPE", 6, 20], ["transfected 293FT cells", "CELL_LINE", 22, 45], ["CMAC-labeled target cells", "CELL_LINE", 51, 76], ["CHO-K1 cells", "CELL_LINE", 78, 90], ["effector cells", "TEST", 6, 20], ["cells", "TEST", 40, 45], ["CMAC", "TEST", 51, 55], ["a ratio", "TEST", 109, 116], ["effector cells", "OBSERVATION", 6, 20]]], ["Then, the fusion protein was activated by incubating the cells in low pH media (DMEM, sodium succinate 20 mM, 10% FCS, pH 5.5) for 5 min at 37\u00b0C. This medium was replaced with supplemented DMEM, pH 7.4 and after 30 min of incubation the cells were fixed with 4% paraformaldehyde.", [["cells", "ANATOMY", 57, 62], ["cells", "ANATOMY", 237, 242], ["sodium succinate", "CHEMICAL", 86, 102], ["sodium succinate", "CHEMICAL", 86, 102], ["paraformaldehyde", "CHEMICAL", 262, 278], ["cells", "CELL", 57, 62], ["sodium succinate", "SIMPLE_CHEMICAL", 86, 102], ["cells", "CELL", 237, 242], ["paraformaldehyde", "SIMPLE_CHEMICAL", 262, 278], ["fusion protein", "PROTEIN", 10, 24], ["the fusion protein", "TREATMENT", 6, 24], ["low pH media", "TREATMENT", 66, 78], ["sodium succinate", "TEST", 86, 102], ["pH", "TEST", 119, 121], ["supplemented DMEM", "TREATMENT", 176, 193], ["pH", "TEST", 195, 197], ["4% paraformaldehyde", "TREATMENT", 259, 278]]], ["For fluorescence staining, cells were incubated for 30 min with 5 \u03bcg/ml of cholera toxin \u03b2-subunit (CTX) conjugated to Alexa Fluor 488 (Invitrogen) at 37\u00b0C, washed with PBS, and mounted with DABCO.", [["cells", "ANATOMY", 27, 32], ["cholera toxin \u03b2-subunit", "CHEMICAL", 75, 98], ["CTX", "CHEMICAL", 100, 103], ["Alexa Fluor 488", "CHEMICAL", 119, 134], ["DABCO", "CHEMICAL", 191, 196], ["Alexa Fluor 488", "CHEMICAL", 119, 134], ["DABCO", "CHEMICAL", 191, 196], ["cells", "CELL", 27, 32], ["cholera toxin \u03b2-subunit", "SIMPLE_CHEMICAL", 75, 98], ["CTX", "SIMPLE_CHEMICAL", 100, 103], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 119, 134], ["Invitrogen", "SIMPLE_CHEMICAL", 136, 146], ["DABCO", "SIMPLE_CHEMICAL", 191, 196], ["cholera toxin \u03b2-subunit", "PROTEIN", 75, 98], ["Alexa Fluor 488", "PROTEIN", 119, 134], ["Alexa Fluor 488", "SPECIES", 119, 134], ["fluorescence staining", "TEST", 4, 25], ["cholera toxin \u03b2-subunit (CTX", "TREATMENT", 75, 103], ["Alexa Fluor", "TREATMENT", 119, 130], ["PBS", "TREATMENT", 169, 172], ["DABCO", "TREATMENT", 191, 196]]], ["Cells were examined by confocal microscopy (Fluorview FV1000, Olympus and single plane images from 10 different microscopic fields were taken in each condition.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["confocal microscopy", "TEST", 23, 42], ["Olympus", "TEST", 62, 69], ["single plane images", "TEST", 74, 93]]], ["The percentage of GM1 transfer was calculated using the formula:Cell-based hemifusion assaywhere N a corresponds to the number of cells positive for CMAC and GM1, while N b corresponds to the number of cells positive for GM1 that are furthermore in contact with at least one target cell.", [["Cell", "ANATOMY", 64, 68], ["cells", "ANATOMY", 130, 135], ["cells", "ANATOMY", 202, 207], ["cell", "ANATOMY", 282, 286], ["GM1", "GENE_OR_GENE_PRODUCT", 18, 21], ["Cell", "CELL", 64, 68], ["cells", "CELL", 130, 135], ["CMAC", "GENE_OR_GENE_PRODUCT", 149, 153], ["GM1", "GENE_OR_GENE_PRODUCT", 158, 161], ["N b", "GENE_OR_GENE_PRODUCT", 169, 172], ["cells", "CELL", 202, 207], ["GM1", "GENE_OR_GENE_PRODUCT", 221, 224], ["cell", "CELL", 282, 286], ["CMAC", "PROTEIN", 149, 153], ["GM1", "PROTEIN", 158, 161], ["N b", "PROTEIN", 169, 172], ["GM1", "PROTEIN", 221, 224], ["CMAC", "TEST", 149, 153], ["GM1", "TEST", 158, 161], ["GM1", "PROBLEM", 221, 224], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["target cell", "OBSERVATION", 275, 286]]], ["Cells were considered positive for GM1 transfer when the fluorescent label was detected at the full circumference of the cells.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 121, 126], ["Cells", "CELL", 0, 5], ["GM1", "GENE_OR_GENE_PRODUCT", 35, 38], ["cells", "CELL", 121, 126], ["Cells", "TEST", 0, 5], ["the fluorescent label", "TEST", 53, 74]]], ["The standard deviation of at least n = 3 experiments was calculated and was indicated as an error bar for each value.Statistical analysisA Student\u00b4s t-test was performed for statistical evaluation of n!3 independent epxeriments: \u00c3\u00c3\u00c3 , P < 0.00025; \u00c3\u00c3 , P < 0.0025; \u00c3 , P < 0.025.Prediction of DIII and stem fragments with inhibitory potentialFor the hantavirus Gc protein, we predicted DIII and the stem region by sequence alignments with known class II fusion proteins and subsequent model derivation.", [["stem fragments", "ANATOMY", 302, 316], ["stem region", "ANATOMY", 399, 410], ["DIII", "GENE_OR_GENE_PRODUCT", 293, 297], ["Gc", "GENE_OR_GENE_PRODUCT", 361, 363], ["DIII", "GENE_OR_GENE_PRODUCT", 386, 390], ["DIII", "PROTEIN", 293, 297], ["hantavirus Gc protein", "PROTEIN", 350, 371], ["DIII", "PROTEIN", 386, 390], ["stem region", "DNA", 399, 410], ["class II fusion proteins", "PROTEIN", 445, 469], ["Statistical analysisA Student\u00b4s t-test", "TEST", 117, 155], ["statistical evaluation", "TEST", 174, 196], ["\u00c3\u00c3", "TEST", 248, 250], ["P", "TEST", 253, 254], ["\u00c3", "TEST", 265, 266], ["P", "TEST", 269, 270], ["Prediction of DIII and stem fragments", "PROBLEM", 279, 316], ["the hantavirus Gc protein", "TEST", 346, 371], ["known class II fusion proteins", "TREATMENT", 439, 469], ["subsequent model derivation", "TREATMENT", 474, 501], ["stem fragments", "OBSERVATION", 302, 316], ["stem", "ANATOMY", 399, 403]]], ["These proteins included among others the more recently crystallized RVFV Gc [29] .", [["RVFV Gc", "PROTEIN", 68, 75]]], ["None of the new sequence alignments achieved a higher sequence identity, greater cysteine match or model validation scores compared to the alignment used for the original Gc model structure [23] , which is based on the pre-fusion structure of the tick-borne encephalitis virus (TBEV) E protein (PDBid: 1SVB) [31] .", [["encephalitis", "DISEASE", 258, 270], ["cysteine", "CHEMICAL", 81, 89], ["cysteine", "AMINO_ACID", 81, 89], ["tick-borne encephalitis virus", "ORGANISM", 247, 276], ["TBEV", "ORGANISM", 278, 282], ["tick-borne encephalitis virus (TBEV) E protein", "PROTEIN", 247, 293], ["PDBid", "PROTEIN", 295, 300], ["1SVB", "PROTEIN", 302, 306], ["tick-borne encephalitis virus", "SPECIES", 247, 276], ["tick-borne encephalitis virus", "SPECIES", 247, 276], ["TBEV", "SPECIES", 278, 282], ["the new sequence alignments", "TEST", 8, 35], ["model validation scores", "TEST", 99, 122], ["the tick", "TEST", 243, 251], ["tick", "ANATOMY", 247, 251]]], ["For this reason, we used the alignment from the original ANDV Gc model [23] to identify a putative DIII in ANDV Gc (Fig 1A and 1B) .", [["DIII", "GENE_OR_GENE_PRODUCT", 99, 103], ["ANDV Gc", "GENE_OR_GENE_PRODUCT", 107, 114], ["DIII", "PROTEIN", 99, 103], ["ANDV Gc", "PROTEIN", 107, 114]]], ["The sequence that was derived from this model (residues Asp315-Leu414) was termed ANDV DIII, and served as template to predict a putative DIII in Gc of other hantaviruses such as PUUV.", [["ANDV DIII", "GENE_OR_GENE_PRODUCT", 82, 91], ["DIII", "GENE_OR_GENE_PRODUCT", 138, 142], ["hantaviruses", "ORGANISM", 158, 170], ["PUUV", "ORGANISM", 179, 183], ["ANDV DIII", "PROTEIN", 82, 91], ["DIII", "PROTEIN", 138, 142], ["Gc", "PROTEIN", 146, 148], ["hantaviruses", "OBSERVATION", 158, 170], ["PUUV", "OBSERVATION", 179, 183]]], ["We subsequently defined the putative stem region in ANDV Gc as the sequence encompassing residues Leu414-Asn456, which corresponded to the region between the C-terminal end of the predicted DIII and the predicted Gc transmembrane region obtained by the TMpred server [64] (Fig 1C) .Production and characterization of ANDV DIII and stem fragmentsThe production of DIII from different class II fusion proteins, including those of flaviviruses and alphaviruses, has been previously established in E. coli [52, [67] [68] [69] [70] [71] .", [["stem region", "ANATOMY", 37, 48], ["stem fragments", "ANATOMY", 331, 345], ["C", "CHEMICAL", 158, 159], ["Gc", "GENE_OR_GENE_PRODUCT", 57, 59], ["DIII", "GENE_OR_GENE_PRODUCT", 190, 194], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 317, 326], ["DIII", "GENE_OR_GENE_PRODUCT", 363, 367], ["E. coli", "ORGANISM", 494, 501], ["putative stem region", "DNA", 28, 48], ["Gc", "PROTEIN", 57, 59], ["C-terminal end", "PROTEIN", 158, 172], ["DIII", "PROTEIN", 190, 194], ["Gc transmembrane region", "PROTEIN", 213, 236], ["ANDV DIII", "PROTEIN", 317, 326], ["stem fragments", "PROTEIN", 331, 345], ["DIII", "PROTEIN", 363, 367], ["class II fusion proteins", "PROTEIN", 383, 407], ["E. coli", "SPECIES", 494, 501], ["ANDV", "SPECIES", 52, 56], ["ANDV", "SPECIES", 317, 321], ["E. coli", "SPECIES", 494, 501], ["Leu414", "TEST", 98, 104], ["ANDV DIII and stem fragments", "PROBLEM", 317, 345], ["The production of DIII", "PROBLEM", 345, 367], ["different class II fusion proteins", "PROBLEM", 373, 407], ["flaviviruses", "PROBLEM", 428, 440], ["alphaviruses", "PROBLEM", 445, 457], ["E. coli", "TEST", 494, 501], ["putative stem", "OBSERVATION", 28, 41], ["region", "ANATOMY_MODIFIER", 42, 48], ["region", "ANATOMY_MODIFIER", 139, 145], ["stem fragments", "OBSERVATION", 331, 345]]], ["The feasibility of preparing soluble DIII from flavi-and alphaviruses in a prokaryotic expression system retaining the native structure may be related to its globular IgG-like fold and lack of glycosylation [44] .", [["DIII", "GENE_OR_GENE_PRODUCT", 37, 41], ["flavi", "GENE_OR_GENE_PRODUCT", 47, 52], ["alphaviruses", "ORGANISM", 57, 69], ["IgG", "GENE_OR_GENE_PRODUCT", 167, 170], ["DIII", "PROTEIN", 37, 41], ["flavi", "PROTEIN", 47, 52], ["globular IgG", "PROTEIN", 158, 170], ["preparing soluble DIII", "TREATMENT", 19, 41], ["flavi", "TEST", 47, 52], ["alphaviruses", "PROBLEM", 57, 69], ["a prokaryotic expression system", "TREATMENT", 73, 104], ["its globular IgG", "PROBLEM", 154, 170], ["alphaviruses", "OBSERVATION", 57, 69], ["native structure", "OBSERVATION", 119, 135], ["may be related to", "UNCERTAINTY", 136, 153], ["globular", "OBSERVATION_MODIFIER", 158, 166], ["IgG", "OBSERVATION", 167, 170]]], ["The purification of DIII is generally achieved from inclusion bodies followed by refolding [44, 71] , or from the supernatant of the cell lysate [52, [67] [68] [69] [70] .", [["supernatant", "ANATOMY", 114, 125], ["cell lysate", "ANATOMY", 133, 144], ["DIII", "GENE_OR_GENE_PRODUCT", 20, 24], ["cell", "CELL", 133, 137], ["DIII", "PROTEIN", 20, 24], ["The purification of DIII", "PROBLEM", 0, 24], ["the cell lysate", "TEST", 129, 144]]], ["Here, we prepared three recombinant DIII proteins; DIII derived from ANDV Gc with or without N-terminal His-tag (ANDV hDIII, ANDV DIII), and DIII from PUUV Gc with N-terminal His-tag (PUUV hDIII).", [["N-", "CHEMICAL", 93, 95], ["His", "CHEMICAL", 104, 107], ["N-", "CHEMICAL", 164, 166], ["His", "CHEMICAL", 175, 178], ["DIII", "GENE_OR_GENE_PRODUCT", 36, 40], ["DIII", "GENE_OR_GENE_PRODUCT", 51, 55], ["ANDV Gc", "ORGANISM", 69, 76], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 125, 134], ["DIII", "GENE_OR_GENE_PRODUCT", 141, 145], ["recombinant DIII proteins", "PROTEIN", 24, 49], ["DIII", "PROTEIN", 51, 55], ["ANDV Gc", "PROTEIN", 69, 76], ["N-terminal His-tag", "PROTEIN", 93, 111], ["ANDV", "PROTEIN", 113, 117], ["hDIII", "PROTEIN", 118, 123], ["ANDV", "PROTEIN", 125, 129], ["DIII", "PROTEIN", 130, 134], ["DIII", "PROTEIN", 141, 145], ["PUUV Gc", "PROTEIN", 151, 158], ["N-terminal His-tag", "PROTEIN", 164, 182], ["PUUV hDIII", "PROTEIN", 184, 194], ["ANDV Gc", "TEST", 69, 76], ["PUUV Gc", "TEST", 151, 158]]], ["The proteins were obtained from the supernatant of E. coli BL21 or Origami 2(DE3) cells, and eluted after their purification as a single peak detected by absorbance at 280 nm.", [["supernatant", "ANATOMY", 36, 47], ["BL21", "ANATOMY", 59, 63], ["Origami 2(DE3) cells", "ANATOMY", 67, 87], ["E. coli BL21", "CELL", 51, 63], ["Origami 2", "CELL", 67, 76], ["DE3) cells", "CELL", 77, 87], ["Origami 2(DE3) cells", "CELL_LINE", 67, 87], ["E. coli BL21", "SPECIES", 51, 63], ["E. coli", "SPECIES", 51, 58], ["The proteins", "TEST", 0, 12], ["E. coli BL21", "TREATMENT", 51, 63], ["Origami 2(DE3) cells", "TREATMENT", 67, 87], ["their purification", "TEST", 106, 124]]], ["Fig 2A shows an elution profile example of purified ANDV DIII from the last size exclusion chromatography column together with the homogeneity of the preparation assessed by SDS-PAGE.", [["ANDV DIII", "GENE_OR_GENE_PRODUCT", 52, 61], ["ANDV DIII", "PROTEIN", 52, 61], ["ANDV", "SPECIES", 52, 56], ["the last size exclusion chromatography column", "TREATMENT", 67, 112]]], ["Because the predicted ANDV and PUUV DIII sequences contain eight highly conserved cysteine residues, the DIII proteins were next characterized for the presence of disulfide bridges by reduction and subsequent alkylation.", [["cysteine", "CHEMICAL", 82, 90], ["disulfide", "CHEMICAL", 163, 172], ["ANDV", "GENE_OR_GENE_PRODUCT", 22, 26], ["PUUV", "ORGANISM", 31, 35], ["DIII", "GENE_OR_GENE_PRODUCT", 36, 40], ["cysteine", "AMINO_ACID", 82, 90], ["DIII", "GENE_OR_GENE_PRODUCT", 105, 109], ["ANDV and PUUV DIII sequences", "DNA", 22, 50], ["DIII proteins", "PROTEIN", 105, 118], ["disulfide bridges", "PROTEIN", 163, 180], ["ANDV", "SPECIES", 22, 26], ["PUUV", "SPECIES", 31, 35], ["PUUV DIII sequences", "TEST", 31, 50], ["conserved cysteine residues", "TREATMENT", 72, 99], ["the DIII proteins", "TEST", 101, 118], ["disulfide bridges", "TREATMENT", 163, 180], ["subsequent alkylation", "TREATMENT", 198, 219], ["cysteine residues", "OBSERVATION", 82, 99], ["disulfide bridges", "OBSERVATION", 163, 180], ["alkylation", "OBSERVATION", 209, 219]]], ["An increase in the electrophoretic mobility could be detected for reduced ANDV DIII, ANDV hDIII and PUUV hDIII compared to its unreduced control (Fig 2B) , indicating that the cysteines seemed to be arranged in disulfide bridges.", [["cysteines", "CHEMICAL", 176, 185], ["disulfide", "CHEMICAL", 211, 220], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 74, 83], ["ANDV DIII", "PROTEIN", 74, 83], ["ANDV hDIII", "PROTEIN", 85, 95], ["PUUV hDIII", "PROTEIN", 100, 110], ["disulfide bridges", "PROTEIN", 211, 228], ["ANDV", "SPECIES", 74, 78], ["ANDV", "SPECIES", 85, 89], ["PUUV", "SPECIES", 100, 104], ["An increase in the electrophoretic mobility", "PROBLEM", 0, 43], ["reduced ANDV DIII", "PROBLEM", 66, 83], ["PUUV hDIII", "TREATMENT", 100, 110], ["the cysteines", "PROBLEM", 172, 185], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["electrophoretic mobility", "OBSERVATION", 19, 43], ["PUUV", "OBSERVATION", 100, 104]]], ["We next explored the presence of secondary structure elements in DIII from hantaviruses by circular dichroism.", [["DIII", "GENE_OR_GENE_PRODUCT", 65, 69], ["secondary structure elements", "DNA", 33, 61], ["DIII", "PROTEIN", 65, 69], ["secondary structure elements", "PROBLEM", 33, 61], ["secondary structure elements", "OBSERVATION", 33, 61], ["circular dichroism", "OBSERVATION", 91, 109]]], ["The spectra showed a unique negative maximum at 209 nm (Fig 2C) , confirming the presence of secondary structure.", [["secondary structure", "PROBLEM", 93, 112], ["secondary structure", "OBSERVATION", 93, 112]]], ["Deconvolution of the circular dichroism spectra into four components by different servers [54] [55] [56] indicated that DIII contained 40-41% \u03b2-sheets,~60% random coils and turns with an \u03b1-helical content close to zero.", [["DIII", "GENE_OR_GENE_PRODUCT", 120, 124], ["DIII", "PROTEIN", 120, 124], ["Deconvolution of the circular dichroism spectra into four components", "PROBLEM", 0, 68], ["DIII", "TEST", 120, 124], ["sheets", "TEST", 144, 150], ["random coils", "TREATMENT", 156, 168], ["an \u03b1-helical content", "TREATMENT", 184, 204], ["circular", "OBSERVATION_MODIFIER", 21, 29]]], ["This composition coincides with the high content of \u03b2-sheets and turns observed in DIII of class II fusion proteins [31] .", [["DIII of class II", "GENE_OR_GENE_PRODUCT", 83, 99], ["DIII", "PROTEIN", 83, 87], ["class II fusion proteins", "PROTEIN", 91, 115], ["\u03b2-sheets", "TREATMENT", 52, 60]]], ["Taking these data together, the monomeric form of recombinant ANDV DIII in solution, the presence of disulfide bridges, the secondary structure content, and the solubility of the recombinant protein (>20 mg/ml) indicate that DIII was folded.Production and characterization of ANDV DIII and stem fragmentsIn addition, we also produced a protein spanning the predicted DIII and stem region of ANDV Gc, including an N-terminal His-tag (ANDV hDIIIS).", [["stem fragments", "ANATOMY", 290, 304], ["stem region", "ANATOMY", 376, 387], ["disulfide", "CHEMICAL", 101, 110], ["N-", "CHEMICAL", 413, 415], ["His", "CHEMICAL", 424, 427], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 62, 71], ["DIII", "GENE_OR_GENE_PRODUCT", 225, 229], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 276, 285], ["DIII", "GENE_OR_GENE_PRODUCT", 367, 371], ["ANDV Gc", "GENE_OR_GENE_PRODUCT", 391, 398], ["recombinant ANDV DIII", "PROTEIN", 50, 71], ["disulfide bridges", "PROTEIN", 101, 118], ["recombinant protein", "PROTEIN", 179, 198], ["DIII", "PROTEIN", 225, 229], ["ANDV DIII", "PROTEIN", 276, 285], ["stem fragments", "PROTEIN", 290, 304], ["DIII", "PROTEIN", 367, 371], ["stem region", "PROTEIN", 376, 387], ["ANDV Gc", "PROTEIN", 391, 398], ["N-terminal His-tag", "PROTEIN", 413, 431], ["ANDV hDIIIS", "PROTEIN", 433, 444], ["ANDV", "SPECIES", 62, 66], ["ANDV", "SPECIES", 276, 280], ["recombinant ANDV DIII in solution", "TREATMENT", 50, 83], ["disulfide bridges", "PROBLEM", 101, 118], ["the secondary structure content", "PROBLEM", 120, 151], ["the recombinant protein", "TREATMENT", 175, 198], ["ANDV DIII and stem fragments", "PROBLEM", 276, 304], ["a protein", "TEST", 334, 343], ["ANDV Gc", "TEST", 391, 398], ["disulfide bridges", "OBSERVATION", 101, 118], ["secondary structure content", "OBSERVATION", 124, 151], ["stem fragments", "OBSERVATION", 290, 304], ["stem", "ANATOMY", 376, 380]]], ["However, we did not obtain enough ANDV hDIIIS for its purification, presumably due to the poor solubility of this protein.Production and characterization of ANDV DIII and stem fragmentsTo overcome this difficulty, we generated the predicted Gc stem region separately in two synthetic peptides, one spanning the N-terminal part (R1 peptide) and the other spanning the Cterminal part (R2 peptide) (Fig 1C) .", [["stem fragments", "ANATOMY", 171, 185], ["N", "CHEMICAL", 311, 312], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 157, 166], ["ANDV hDIIIS", "PROTEIN", 34, 45], ["ANDV DIII", "PROTEIN", 157, 166], ["stem fragments", "PROTEIN", 171, 185], ["Gc stem region", "DNA", 241, 255], ["N-terminal part", "PROTEIN", 311, 326], ["Cterminal part", "PROTEIN", 367, 381], ["ANDV", "SPECIES", 34, 38], ["ANDV", "SPECIES", 157, 161], ["the poor solubility of this protein", "PROBLEM", 86, 121], ["ANDV DIII and stem fragments", "PROBLEM", 157, 185], ["stem fragments", "OBSERVATION", 171, 185], ["Gc stem", "OBSERVATION", 241, 248], ["terminal", "ANATOMY_MODIFIER", 313, 321]]], ["We also used a negative control peptide comprising a region of the ANDV nucleoprotein (NN peptide).Inhibition of ANDV cell entry by exogenous DIII and stem fragmentsOnce the predicted DIII and stem fragments were synthesized, purified, and characterized, we measured their inhibitory activity against ANDV during virus cell entry via the native, endosomal infection route.", [["cell", "ANATOMY", 118, 122], ["stem fragments", "ANATOMY", 151, 165], ["stem fragments", "ANATOMY", 193, 207], ["cell", "ANATOMY", 319, 323], ["endosomal", "ANATOMY", 346, 355], ["infection", "DISEASE", 356, 365], ["ANDV nucleoprotein", "GENE_OR_GENE_PRODUCT", 67, 85], ["ANDV cell", "CELL", 113, 122], ["DIII", "GENE_OR_GENE_PRODUCT", 142, 146], ["DIII", "GENE_OR_GENE_PRODUCT", 184, 188], ["ANDV", "SIMPLE_CHEMICAL", 301, 305], ["cell", "CELL", 319, 323], ["endosomal", "CELLULAR_COMPONENT", 346, 355], ["ANDV nucleoprotein", "PROTEIN", 67, 85], ["DIII", "PROTEIN", 142, 146], ["stem fragments", "PROTEIN", 151, 165], ["DIII", "PROTEIN", 184, 188], ["stem fragments", "DNA", 193, 207], ["ANDV", "SPECIES", 301, 305], ["a negative control peptide", "TREATMENT", 13, 39], ["the ANDV nucleoprotein (NN peptide", "TREATMENT", 63, 97], ["ANDV cell entry", "TREATMENT", 113, 128], ["exogenous DIII and stem fragments", "PROBLEM", 132, 165], ["stem fragments", "PROBLEM", 193, 207], ["ANDV during virus cell entry", "PROBLEM", 301, 329], ["endosomal infection route", "PROBLEM", 346, 371], ["ANDV cell entry", "OBSERVATION", 113, 128], ["exogenous DIII", "OBSERVATION", 132, 146], ["stem fragments", "OBSERVATION", 151, 165], ["stem fragments", "OBSERVATION", 193, 207], ["endosomal infection", "OBSERVATION", 346, 365]]], ["For this purpose, ANDV was incubated with Vero E6 cells in the presence of the Gc fragments.", [["Vero E6 cells", "ANATOMY", 42, 55], ["ANDV", "SIMPLE_CHEMICAL", 18, 22], ["Vero E6 cells", "CELL", 42, 55], ["Vero E6 cells", "CELL_LINE", 42, 55], ["Gc fragments", "DNA", 79, 91], ["ANDV", "SPECIES", 18, 22], ["Vero E6", "SPECIES", 42, 49], ["ANDV", "TREATMENT", 18, 22], ["Vero E6 cells", "TREATMENT", 42, 55], ["the Gc fragments", "PROBLEM", 75, 91], ["E6 cells", "OBSERVATION", 47, 55], ["Gc fragments", "OBSERVATION", 79, 91]]], ["After 1 h incubation, the cells were washed and the infection monitored after 16 h based on an earlier established protocol [57] .", [["cells", "ANATOMY", 26, 31], ["infection", "DISEASE", 52, 61], ["cells", "CELL", 26, 31], ["the cells", "TREATMENT", 22, 31], ["the infection", "PROBLEM", 48, 61], ["infection", "OBSERVATION", 52, 61]]], ["ANDV DIII and ANDV hDIII reduced ANDV infection up to 60%, at 3-4 \u03bcM (Fig 3A) .", [["hDIII", "CHEMICAL", 19, 24], ["infection", "DISEASE", 38, 47], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 0, 9], ["ANDV", "GENE_OR_GENE_PRODUCT", 14, 18], ["ANDV DIII", "PROTEIN", 0, 9], ["ANDV hDIII", "PROTEIN", 14, 24], ["ANDV", "SPECIES", 0, 4], ["ANDV", "SPECIES", 14, 18], ["ANDV", "SPECIES", 33, 37], ["ANDV infection", "PROBLEM", 33, 47], ["infection", "OBSERVATION", 38, 47]]], ["The N-terminal His-tag did not further improve inhibition of viral infection, as observed for the alpha-and flavivirus DIII proteins [44] .", [["viral infection", "DISEASE", 61, 76], ["His", "CHEMICAL", 15, 18], ["alpha-", "GENE_OR_GENE_PRODUCT", 98, 104], ["N-terminal His-tag", "PROTEIN", 4, 22], ["alpha-and flavivirus DIII proteins", "PROTEIN", 98, 132], ["viral infection", "PROBLEM", 61, 76], ["the alpha-and flavivirus DIII proteins", "TEST", 94, 132], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infection", "OBSERVATION", 67, 76]]], ["Interestingly, PUUV hDIII did not show any cross-inhibition of ANDV.", [["PUUV", "ORGANISM", 15, 19], ["ANDV", "SIMPLE_CHEMICAL", 63, 67], ["PUUV hDIII", "PROTEIN", 15, 25], ["ANDV", "PROTEIN", 63, 67], ["PUUV", "SPECIES", 15, 19], ["ANDV", "SPECIES", 63, 67], ["PUUV", "OBSERVATION", 15, 19]]], ["This result was unexpected since cross-reactivity by DIII has been reported within the alphavirus and flavivirus genera [44, 72] .", [["DIII", "GENE_OR_GENE_PRODUCT", 53, 57], ["DIII", "PROTEIN", 53, 57]]], ["It is likely that the absence of cross-inhibition was due to the presence of the N-terminal His-tag in PUUV DIII (see results below; Fig 4C) .Inhibition of ANDV cell entry by exogenous DIII and stem fragmentsNext, we tested whether the ANDV stem peptides also impair ANDV infection.", [["cell", "ANATOMY", 161, 165], ["stem fragments", "ANATOMY", 194, 208], ["infection", "DISEASE", 272, 281], ["His", "CHEMICAL", 92, 95], ["ANDV cell", "CELL", 156, 165], ["DIII", "GENE_OR_GENE_PRODUCT", 185, 189], ["ANDV", "GENE_OR_GENE_PRODUCT", 267, 271], ["N-terminal His-tag", "PROTEIN", 81, 99], ["PUUV DIII", "PROTEIN", 103, 112], ["DIII", "PROTEIN", 185, 189], ["stem fragments", "PROTEIN", 194, 208], ["ANDV", "SPECIES", 236, 240], ["ANDV", "SPECIES", 267, 271], ["ANDV cell entry", "TREATMENT", 156, 171], ["exogenous DIII and stem fragments", "PROBLEM", 175, 208], ["the ANDV stem peptides", "TREATMENT", 232, 254], ["ANDV infection", "PROBLEM", 267, 281], ["ANDV cell entry", "OBSERVATION", 156, 171], ["exogenous DIII", "OBSERVATION", 175, 189], ["stem fragments", "OBSERVATION", 194, 208], ["infection", "OBSERVATION", 272, 281]]], ["The R2 peptide, comprising the C-terminal part of the predicted Gc stem region, blocked the infection of cells by ANDV up to 55% at 20 \u03bcM (Fig 3B) .", [["cells", "ANATOMY", 105, 110], ["infection", "DISEASE", 92, 101], ["C", "CHEMICAL", 31, 32], ["cells", "CELL", 105, 110], ["C-terminal part", "PROTEIN", 31, 46], ["Gc stem region", "PROTEIN", 64, 78], ["ANDV", "SPECIES", 114, 118], ["The R2 peptide", "TEST", 0, 14], ["the infection of cells", "PROBLEM", 88, 110], ["ANDV", "TEST", 114, 118], ["terminal", "ANATOMY_MODIFIER", 33, 41], ["Gc stem", "OBSERVATION", 64, 71], ["infection", "OBSERVATION", 92, 101]]], ["In contrast, the R1 peptide spanning the N-terminal part of the predicted Gc stem, did not show any reduction of ANDV infection, similar to the negative control NN peptide (Fig 3B) .", [["Gc stem", "ANATOMY", 74, 81], ["infection", "DISEASE", 118, 127], ["ANDV", "GENE_OR_GENE_PRODUCT", 113, 117], ["N-terminal part", "PROTEIN", 41, 56], ["Gc stem", "CELL_LINE", 74, 81], ["ANDV", "SPECIES", 113, 117], ["the R1 peptide", "TEST", 13, 27], ["ANDV infection", "PROBLEM", 113, 127], ["Gc stem", "OBSERVATION", 74, 81], ["reduction", "OBSERVATION_MODIFIER", 100, 109], ["infection", "OBSERVATION", 118, 127]]], ["To test whether a specific region of R2 was required for inhibition, we further tested two different parts of R2 (see Fig 1C) .", [["R2", "GENE_OR_GENE_PRODUCT", 37, 39], ["R2", "DNA", 37, 39], ["R2", "DNA", 110, 112]]], ["The N-terminal R2.1 and C-terminal R2.2 peptides both showed similar reducing effects on viral infection (Fig 3B) .Inhibition of ANDV cell entry by exogenous DIII and stem fragmentsTo further explore the specificity of the Gc fragments on viral inhibition, we used as a model the unrelated vesicular stomatitis virus (VSV).", [["cell", "ANATOMY", 134, 138], ["stem fragments", "ANATOMY", 167, 181], ["viral infection", "DISEASE", 89, 104], ["vesicular stomatitis", "DISEASE", 290, 310], ["C", "CHEMICAL", 24, 25], ["ANDV cell", "CELL", 129, 138], ["DIII", "GENE_OR_GENE_PRODUCT", 158, 162], ["vesicular stomatitis virus", "ORGANISM", 290, 316], ["VSV", "ORGANISM", 318, 321], ["N-terminal R2.1", "PROTEIN", 4, 19], ["DIII", "PROTEIN", 158, 162], ["stem fragments", "PROTEIN", 167, 181], ["Gc fragments", "DNA", 223, 235], ["vesicular stomatitis virus", "SPECIES", 290, 316], ["stomatitis virus", "SPECIES", 300, 316], ["VSV", "SPECIES", 318, 321], ["The N-terminal R2.1", "TEST", 0, 19], ["C-terminal R2.2 peptides", "TEST", 24, 48], ["viral infection", "PROBLEM", 89, 104], ["ANDV cell entry", "TREATMENT", 129, 144], ["exogenous DIII and stem fragments", "PROBLEM", 148, 181], ["the Gc fragments", "PROBLEM", 219, 235], ["viral inhibition", "TREATMENT", 239, 255], ["a model the unrelated vesicular stomatitis virus", "PROBLEM", 268, 316], ["similar", "OBSERVATION_MODIFIER", 61, 68], ["reducing", "OBSERVATION_MODIFIER", 69, 77], ["viral infection", "OBSERVATION", 89, 104], ["ANDV cell entry", "OBSERVATION", 129, 144], ["exogenous DIII", "OBSERVATION", 148, 162], ["stem fragments", "OBSERVATION", 167, 181], ["vesicular stomatitis virus", "OBSERVATION", 290, 316]]], ["While VSV enters cells by endocytosis and low pH-triggered fusion, this virus achieves fusion by a different class of fusion protein (class III).", [["cells", "ANATOMY", 17, 22], ["VSV", "ORGANISM", 6, 9], ["cells", "CELL", 17, 22], ["fusion protein", "PROTEIN", 118, 132], ["class III", "PROTEIN", 134, 143], ["VSV", "SPECIES", 6, 9], ["endocytosis", "TEST", 26, 37], ["low pH", "PROBLEM", 42, 48], ["fusion", "TREATMENT", 59, 65], ["this virus achieves fusion", "TREATMENT", 67, 93], ["low pH", "OBSERVATION_MODIFIER", 42, 48]]], ["To analyze VSV-mediated entry, SIV vectors [24] were pseudotyped with the envelope glycoprotein G of VSV and the transduction of cells by this vector was evaluated by the expression of the GFP reporter gene.", [["cells", "ANATOMY", 129, 134], ["VSV", "ORGANISM", 11, 14], ["SIV", "ORGANISM", 31, 34], ["pseudotyped", "ORGANISM", 53, 64], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 83, 97], ["VSV", "ORGANISM", 101, 104], ["cells", "CELL", 129, 134], ["GFP", "GENE_OR_GENE_PRODUCT", 189, 192], ["envelope glycoprotein G", "PROTEIN", 74, 97], ["GFP reporter gene", "DNA", 189, 206], ["VSV", "SPECIES", 11, 14], ["SIV", "SPECIES", 31, 34], ["VSV", "SPECIES", 101, 104], ["the envelope glycoprotein G of VSV", "TREATMENT", 70, 104], ["the transduction of cells", "TREATMENT", 109, 134]]], ["Neither ANDV DIII nor the ANDV stem peptides altered cell transduction at any tested concentrations up to 6 \u03bcM and 60 \u03bcM, respectively (Fig 3C) .", [["cell", "ANATOMY", 53, 57], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 8, 17], ["cell", "CELL", 53, 57], ["ANDV DIII", "PROTEIN", 8, 17], ["ANDV", "SPECIES", 8, 12], ["ANDV", "SPECIES", 26, 30], ["altered cell transduction", "PROBLEM", 45, 70]]], ["In contrast, when the pH of the endocytic route was neutralized with the weak base ammonium chloride, VSV-G mediated transduction was blocked up to 80% (Fig 3C) .", [["ammonium chloride", "CHEMICAL", 83, 100], ["ammonium chloride", "CHEMICAL", 83, 100], ["ammonium chloride", "SIMPLE_CHEMICAL", 83, 100], ["VSV-G", "SIMPLE_CHEMICAL", 102, 107], ["the weak base ammonium chloride", "TREATMENT", 69, 100], ["VSV-G mediated transduction", "TREATMENT", 102, 129]]], ["On the other hand, when SIV vectors were pseudotyped with ANDV glycoproteins, the DIII and R2 fragments produced~40% and~30% of inhibition of these vectors at 6 \u03bcM and 20 \u03bcM, respectively ( Fig 3D) , corroborating that the inhibitory fragments were active in this system.Inhibition of ANDV cell entry by exogenous DIII and stem fragmentsNone of the Gc-derived peptides and recombinant domains abrogated the viability of cells when they were incubated with Vero E6 cells (Fig 3E) , indicating that the reduction of ANDV infection was not due to a cytopathic effect of the Gc-derived fragments.Inhibition of ANDV cell entry by exogenous DIII and stem fragmentsIt was previously reported that flavivirus stem peptides bind to the virus before it enters the cell, helping its delivery into endosomal compartments [47] .", [["cell", "ANATOMY", 290, 294], ["stem fragments", "ANATOMY", 323, 337], ["cells", "ANATOMY", 420, 425], ["Vero E6 cells", "ANATOMY", 456, 469], ["fragments", "ANATOMY", 582, 591], ["cell", "ANATOMY", 611, 615], ["stem fragments", "ANATOMY", 644, 658], ["cell", "ANATOMY", 754, 758], ["endosomal compartments", "ANATOMY", 786, 808], ["infection", "DISEASE", 519, 528], ["SIV", "ORGANISM", 24, 27], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 58, 76], ["DIII", "GENE_OR_GENE_PRODUCT", 82, 86], ["ANDV cell", "CELL", 285, 294], ["DIII", "GENE_OR_GENE_PRODUCT", 314, 318], ["cells", "CELL", 420, 425], ["Vero E6 cells", "CELL", 456, 469], ["Fig 3E", "CELL", 471, 477], ["ANDV", "GENE_OR_GENE_PRODUCT", 514, 518], ["ANDV cell", "CELL", 606, 615], ["DIII", "GENE_OR_GENE_PRODUCT", 635, 639], ["flavivirus stem peptides", "GENE_OR_GENE_PRODUCT", 690, 714], ["cell", "CELL", 754, 758], ["endosomal", "CELLULAR_COMPONENT", 786, 795], ["ANDV glycoproteins", "PROTEIN", 58, 76], ["DIII and R2 fragments", "DNA", 82, 103], ["DIII", "PROTEIN", 314, 318], ["stem fragments", "PROTEIN", 323, 337], ["Gc", "PROTEIN", 349, 351], ["recombinant domains", "PROTEIN", 373, 392], ["Vero E6 cells", "CELL_LINE", 456, 469], ["Gc-derived fragments", "DNA", 571, 591], ["DIII", "PROTEIN", 635, 639], ["stem fragments", "PROTEIN", 644, 658], ["SIV", "SPECIES", 24, 27], ["ANDV", "SPECIES", 58, 62], ["Vero E6", "SPECIES", 456, 463], ["ANDV", "SPECIES", 514, 518], ["SIV vectors", "TREATMENT", 24, 35], ["ANDV glycoproteins", "TREATMENT", 58, 76], ["the DIII and R2 fragments", "PROBLEM", 78, 103], ["the inhibitory fragments", "PROBLEM", 219, 243], ["ANDV cell entry", "TREATMENT", 285, 300], ["exogenous DIII and stem fragments", "PROBLEM", 304, 337], ["the Gc", "TEST", 345, 351], ["Vero E6 cells", "TEST", 456, 469], ["ANDV infection", "PROBLEM", 514, 528], ["a cytopathic effect", "PROBLEM", 544, 563], ["the Gc-derived fragments", "PROBLEM", 567, 591], ["ANDV cell entry", "TREATMENT", 606, 621], ["exogenous DIII and stem fragments", "PROBLEM", 625, 658], ["flavivirus stem peptides", "PROBLEM", 690, 714], ["the virus", "PROBLEM", 723, 732], ["inhibitory fragments", "OBSERVATION", 223, 243], ["ANDV cell entry", "OBSERVATION", 285, 300], ["exogenous DIII", "OBSERVATION", 304, 318], ["stem fragments", "OBSERVATION", 323, 337], ["reduction", "OBSERVATION_MODIFIER", 501, 510], ["infection", "OBSERVATION", 519, 528], ["cytopathic", "OBSERVATION_MODIFIER", 546, 556], ["derived fragments", "OBSERVATION", 574, 591], ["ANDV cell entry", "OBSERVATION", 606, 621], ["exogenous DIII", "OBSERVATION", 625, 639], ["stem fragments", "OBSERVATION", 644, 658], ["flavivirus", "OBSERVATION", 690, 700]]], ["Based on this observation, we compared the inhibition of ANDV by (a) pre-incubation of the virus with the R2 peptide, or (b) co-incubating the R2 peptide with the virus during its adsorption to cells.", [["cells", "ANATOMY", 194, 199], ["ANDV", "CHEMICAL", 57, 61], ["ANDV", "SIMPLE_CHEMICAL", 57, 61], ["cells", "CELL", 194, 199], ["ANDV", "SPECIES", 57, 61], ["this observation", "TEST", 9, 25], ["the virus", "PROBLEM", 87, 96], ["the R2 peptide", "TEST", 102, 116], ["the virus", "PROBLEM", 159, 168], ["virus", "OBSERVATION", 163, 168]]], ["Comparing the results of both experimental designs, a similar dose-dependent inhibition could be observed (Fig 3F) , coinciding with the results obtained for flaviviruses (47) .", [["dependent inhibition", "PROBLEM", 67, 87], ["flaviviruses", "PROBLEM", 158, 170]]], ["Based on this result, it seems plausible that binding of the R2 peptide to ANDV may occur very fast, making longer incubation times unnecessary.Inhibition of ANDV cell entry by exogenous DIII and stem fragmentsTaken together, our data demonstrate that the exogenous fragments derived from ANDV Gc, comprising the predicted DIII or the C-terminal part of the predicted stem region, abrogate the entry of ANDV into cells.Exogenous DIII and stem fragments block cell-cell fusionThe inhibitory potential of the Gc fragments was next tested in a cell-cell fusion assay driven by the ANDV glycoproteins [22] .", [["cell", "ANATOMY", 163, 167], ["stem fragments", "ANATOMY", 196, 210], ["stem region", "ANATOMY", 368, 379], ["cells", "ANATOMY", 413, 418], ["stem fragments", "ANATOMY", 438, 452], ["cell", "ANATOMY", 459, 463], ["cell", "ANATOMY", 464, 468], ["cell", "ANATOMY", 541, 545], ["cell", "ANATOMY", 546, 550], ["ANDV", "CHEMICAL", 75, 79], ["C", "CHEMICAL", 335, 336], ["ANDV", "GENE_OR_GENE_PRODUCT", 75, 79], ["ANDV cell", "CELL", 158, 167], ["DIII", "GENE_OR_GENE_PRODUCT", 187, 191], ["ANDV Gc", "GENE_OR_GENE_PRODUCT", 289, 296], ["DIII", "GENE_OR_GENE_PRODUCT", 323, 327], ["ANDV", "GENE_OR_GENE_PRODUCT", 403, 407], ["cells", "CELL", 413, 418], ["DIII", "GENE_OR_GENE_PRODUCT", 429, 433], ["stem", "CELL", 438, 442], ["cell", "CELL", 459, 463], ["cell", "CELL", 464, 468], ["cell", "CELL", 541, 545], ["cell", "CELL", 546, 550], ["DIII", "PROTEIN", 187, 191], ["stem fragments", "PROTEIN", 196, 210], ["ANDV Gc", "PROTEIN", 289, 296], ["DIII", "PROTEIN", 323, 327], ["C-terminal part", "PROTEIN", 335, 350], ["ANDV", "PROTEIN", 403, 407], ["DIII", "PROTEIN", 429, 433], ["Gc fragments", "DNA", 507, 519], ["ANDV glycoproteins", "PROTEIN", 578, 596], ["ANDV", "SPECIES", 403, 407], ["ANDV cell entry", "TREATMENT", 158, 173], ["exogenous DIII and stem fragments", "PROBLEM", 177, 210], ["our data", "TEST", 226, 234], ["the exogenous fragments", "PROBLEM", 252, 275], ["ANDV Gc", "TEST", 289, 296], ["Exogenous DIII and stem fragments block cell-cell fusion", "TREATMENT", 419, 475], ["the Gc fragments", "PROBLEM", 503, 519], ["a cell-cell fusion assay", "TEST", 539, 563], ["ANDV cell entry", "OBSERVATION", 158, 173], ["exogenous DIII", "OBSERVATION", 177, 191], ["stem fragments", "OBSERVATION", 196, 210], ["exogenous fragments", "OBSERVATION", 256, 275], ["terminal", "ANATOMY_MODIFIER", 337, 345], ["predicted stem", "OBSERVATION", 358, 372], ["stem fragments", "OBSERVATION", 438, 452], ["cell fusion", "OBSERVATION", 464, 475], ["Gc fragments", "OBSERVATION", 507, 519]]], ["Therefore, we transfected Vero E6 cells with a plasmid in the presence of exogenous DIII or stem peptides.", [["Vero E6 cells", "ANATOMY", 26, 39], ["plasmid", "ANATOMY", 47, 54], ["Vero E6 cells", "CELL", 26, 39], ["DIII", "GENE_OR_GENE_PRODUCT", 84, 88], ["Vero E6 cells", "CELL_LINE", 26, 39], ["DIII", "PROTEIN", 84, 88], ["Vero E6", "SPECIES", 26, 33], ["Vero E6 cells", "TREATMENT", 26, 39], ["a plasmid", "TREATMENT", 45, 54], ["Vero E6 cells", "OBSERVATION", 26, 39], ["exogenous DIII", "OBSERVATION", 74, 88], ["stem peptides", "OBSERVATION", 92, 105]]], ["Transduction was assessed by GFP reporter gene expression using flow cytometry, and 100% transduction defined as transduction in the absence of Gc-derived fragments (Mock).", [["fragments", "ANATOMY", 155, 164], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["GFP reporter gene", "DNA", 29, 46], ["Gc", "PROTEIN", 144, 146], ["flow cytometry", "TEST", 64, 78]]], ["(E) Cytotoxicity analysis of Gc DIII proteins and stem peptides on Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 67, 80], ["Gc DIII", "GENE_OR_GENE_PRODUCT", 29, 36], ["Vero E6 cells", "CELL", 67, 80], ["Gc DIII proteins", "PROTEIN", 29, 45], ["Vero E6 cells", "CELL_LINE", 67, 80], ["Vero E6", "SPECIES", 67, 74], ["Cytotoxicity analysis", "TEST", 4, 25], ["Gc DIII proteins", "TEST", 29, 45], ["stem peptides", "TEST", 50, 63], ["Vero E6 cells", "TREATMENT", 67, 80], ["stem peptides", "OBSERVATION", 50, 63], ["E6 cells", "OBSERVATION", 72, 80]]], ["(F) ANDV inhibition by the R2 stem peptide through pre-incubation (pre-R2) or co-incubation (co-R2).", [["F) ANDV", "SIMPLE_CHEMICAL", 1, 8], ["ANDV inhibition", "TREATMENT", 4, 19], ["co-incubation", "PROBLEM", 78, 91], ["R2 stem", "ANATOMY", 27, 34]]], ["For pre-incubation, ANDV was coding for the ANDV glycoproteins, and incubated the cells 48 h post-transfection with low pH media for 5 min at 37\u00b0C, as described in Materials and Methods.", [["cells", "ANATOMY", 82, 87], ["ANDV", "SIMPLE_CHEMICAL", 20, 24], ["cells", "CELL", 82, 87], ["ANDV", "DNA", 20, 24], ["ANDV glycoproteins", "PROTEIN", 44, 62], ["ANDV", "SPECIES", 20, 24], ["ANDV", "SPECIES", 44, 48], ["pre-incubation", "TREATMENT", 4, 18], ["the ANDV glycoproteins", "TREATMENT", 40, 62], ["low pH media", "TREATMENT", 116, 128]]], ["The acidification of the media allows the activation of the viral Gc fusion protein on the plasma membrane of cells, thereby triggering the formation of syncytia.", [["plasma membrane", "ANATOMY", 91, 106], ["cells", "ANATOMY", 110, 115], ["syncytia", "ANATOMY", 153, 161], ["Gc", "GENE_OR_GENE_PRODUCT", 66, 68], ["plasma membrane", "CELLULAR_COMPONENT", 91, 106], ["cells", "CELL", 110, 115], ["syncytia", "CELL", 153, 161], ["viral Gc fusion protein", "PROTEIN", 60, 83], ["The acidification of the media", "PROBLEM", 0, 30], ["the viral Gc fusion protein", "PROBLEM", 56, 83], ["syncytia", "PROBLEM", 153, 161], ["acidification", "OBSERVATION_MODIFIER", 4, 17], ["viral Gc fusion", "OBSERVATION", 60, 75], ["syncytia", "OBSERVATION", 153, 161]]], ["When the ANDV Gc fragments were incorporated in the low pH incubation step, ANDV DIII and ANDV hDIII diminished the glycoprotein-mediated fusion activity by~70% at 25 \u03bcM and 50 \u03bcM, respectively (Fig 4A) .", [["hDIII", "CHEMICAL", 95, 100], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 76, 85], ["ANDV hDIII", "SIMPLE_CHEMICAL", 90, 100], ["ANDV Gc fragments", "DNA", 9, 26], ["ANDV DIII", "PROTEIN", 76, 85], ["ANDV hDIII", "PROTEIN", 90, 100], ["glycoprotein", "PROTEIN", 116, 128], ["ANDV", "SPECIES", 9, 13], ["ANDV", "SPECIES", 76, 80], ["ANDV", "SPECIES", 90, 94], ["the ANDV Gc fragments", "PROBLEM", 5, 26], ["ANDV DIII", "TEST", 76, 85], ["the glycoprotein", "TREATMENT", 112, 128]]], ["In concordance with the results obtained with infectious ANDV (Fig 3A) , the PUUV hDIII did not achieve cross-inhibition of ANDV glycoproteins (Fig 4A) .", [["PUUV", "ORGANISM", 77, 81], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 124, 142], ["PUUV hDIII", "PROTEIN", 77, 87], ["ANDV glycoproteins", "PROTEIN", 124, 142], ["ANDV", "SPECIES", 57, 61], ["PUUV", "SPECIES", 77, 81], ["ANDV", "SPECIES", 124, 128], ["the PUUV hDIII", "TEST", 73, 87]]], ["On the other hand, the ANDV R2 stem peptides impaired the ANDV glycoprotein fusion activity up to 75% at 20 \u03bcM (Fig 4B) .Cross-inhibition of hantaviruses by exogenous DIII and stem fragmentsThe ANDV-derived Gc fragments were likewise tested for their potential to cross-inhibit other hantaviruses such as PUUV.", [["stem fragments", "ANATOMY", 176, 190], ["hantaviruses", "DISEASE", 141, 153], ["ANDV glycoprotein", "GENE_OR_GENE_PRODUCT", 58, 75], ["DIII", "GENE_OR_GENE_PRODUCT", 167, 171], ["PUUV", "ORGANISM", 305, 309], ["ANDV glycoprotein", "PROTEIN", 58, 75], ["DIII", "PROTEIN", 167, 171], ["stem fragments", "PROTEIN", 176, 190], ["ANDV-derived Gc fragments", "DNA", 194, 219], ["ANDV", "SPECIES", 23, 27], ["ANDV", "SPECIES", 58, 62], ["the ANDV R2 stem peptides", "TEST", 19, 44], ["the ANDV glycoprotein fusion activity", "TEST", 54, 91], ["hantaviruses", "PROBLEM", 141, 153], ["stem fragments", "PROBLEM", 176, 190], ["Gc fragments", "PROBLEM", 207, 219], ["hantaviruses", "OBSERVATION", 141, 153], ["exogenous DIII", "OBSERVATION", 157, 171], ["stem fragments", "OBSERVATION", 176, 190], ["hantaviruses", "OBSERVATION", 284, 296], ["PUUV", "OBSERVATION", 305, 309]]], ["Therefore, we performed a cell-cell fusion assay driven by the PUUV glycoproteins.", [["cell", "ANATOMY", 26, 30], ["cell", "ANATOMY", 31, 35], ["cell", "CELL", 26, 30], ["cell", "CELL", 31, 35], ["PUUV", "ORGANISM", 63, 67], ["PUUV glycoproteins", "PROTEIN", 63, 81], ["a cell-cell fusion assay", "TREATMENT", 24, 48], ["PUUV glycoproteins", "OBSERVATION", 63, 81]]], ["In this assay, PUUV hDIII blocked the PUUV glycoprotein-mediated fusion process, reducing fusion up to 65% at 25 \u03bcM (Fig 4C) .", [["hDIII", "CHEMICAL", 20, 25], ["PUUV", "ORGANISM", 15, 19], ["hDIII", "GENE_OR_GENE_PRODUCT", 20, 25], ["PUUV", "ORGANISM", 38, 42], ["PUUV hDIII", "PROTEIN", 15, 25], ["PUUV glycoprotein", "PROTEIN", 38, 55], ["PUUV", "SPECIES", 15, 19], ["the PUUV glycoprotein-mediated fusion process", "TREATMENT", 34, 79], ["reducing fusion", "TREATMENT", 81, 96], ["PUUV", "OBSERVATION", 38, 42]]], ["This result coincides with the concentration range in which the ANDV DIII proteins block the ANDV glycoprotein fusion activity and confirms the activity of PUUV hDIII.", [["ANDV DIII", "GENE_OR_GENE_PRODUCT", 64, 73], ["ANDV glycoprotein", "GENE_OR_GENE_PRODUCT", 93, 110], ["PUUV", "ORGANISM", 156, 160], ["ANDV DIII proteins", "PROTEIN", 64, 82], ["ANDV glycoprotein", "PROTEIN", 93, 110], ["PUUV hDIII", "PROTEIN", 156, 166], ["ANDV", "SPECIES", 64, 68], ["PUUV", "SPECIES", 156, 160], ["the ANDV DIII proteins block", "TREATMENT", 60, 88], ["the ANDV glycoprotein fusion activity", "TREATMENT", 89, 126], ["PUUV", "OBSERVATION", 156, 160]]], ["When we tested the ANDV DIII proteins for cross-inhibition, we found that ANDV DIII, but not ANDV hDIII, blocked PUUV glycoprotein-mediated fusion up to 50% (Fig 4C) .", [["ANDV DIII", "GENE_OR_GENE_PRODUCT", 19, 28], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 74, 83], ["ANDV hDIII", "GENE_OR_GENE_PRODUCT", 93, 103], ["PUUV glycoprotein", "GENE_OR_GENE_PRODUCT", 113, 130], ["ANDV DIII proteins", "PROTEIN", 19, 37], ["ANDV DIII", "PROTEIN", 74, 83], ["ANDV hDIII", "PROTEIN", 93, 103], ["PUUV glycoprotein", "PROTEIN", 113, 130], ["ANDV", "SPECIES", 19, 23], ["ANDV", "SPECIES", 74, 78], ["ANDV", "SPECIES", 93, 97], ["ANDV DIII", "PROBLEM", 74, 83], ["PUUV glycoprotein", "TREATMENT", 113, 130], ["mediated fusion", "TREATMENT", 131, 146]]], ["These results, together with the data on absent crossreaction of PUUV hDIII with ANDV, suggest that the hantavirus DIII proteins without the Nterminal His-tag have cross-inhibiting activity; however the N-terminal His-tag of these domains seems to interfere in the inhibition.", [["His", "CHEMICAL", 151, 154], ["His", "CHEMICAL", 214, 217], ["PUUV", "ORGANISM", 65, 69], ["hDIII", "GENE_OR_GENE_PRODUCT", 70, 75], ["ANDV", "GENE_OR_GENE_PRODUCT", 81, 85], ["hantavirus", "ORGANISM", 104, 114], ["DIII", "GENE_OR_GENE_PRODUCT", 115, 119], ["PUUV hDIII", "PROTEIN", 65, 75], ["ANDV", "PROTEIN", 81, 85], ["hantavirus DIII proteins", "PROTEIN", 104, 128], ["Nterminal His-tag", "PROTEIN", 141, 158], ["N-terminal His-tag", "PROTEIN", 203, 221], ["the data", "TEST", 29, 37], ["the hantavirus DIII proteins", "PROBLEM", 100, 128], ["PUUV", "OBSERVATION", 65, 69]]], ["Thus so far, this notion remains to be corroborated with PUUV DIII lacking the N-terminal His-tag.Cross-inhibition of hantaviruses by exogenous DIII and stem fragmentsWhen we tested the ANDV stem peptides to block PUUV-mediated fusion, we found that they also had a cross-inhibition function (Fig 4D) .", [["stem fragments", "ANATOMY", 153, 167], ["hantaviruses", "DISEASE", 118, 130], ["PUUV", "ORGANISM", 57, 61], ["DIII", "GENE_OR_GENE_PRODUCT", 62, 66], ["hantaviruses", "ORGANISM", 118, 130], ["DIII", "GENE_OR_GENE_PRODUCT", 144, 148], ["PUUV", "GENE_OR_GENE_PRODUCT", 214, 218], ["PUUV DIII", "PROTEIN", 57, 66], ["N-terminal His-tag", "PROTEIN", 79, 97], ["DIII", "PROTEIN", 144, 148], ["stem fragments", "PROTEIN", 153, 167], ["ANDV", "SPECIES", 186, 190], ["PUUV DIII", "TREATMENT", 57, 66], ["the N-terminal His-tag", "TREATMENT", 75, 97], ["hantaviruses", "PROBLEM", 118, 130], ["stem fragments", "PROBLEM", 153, 167], ["the ANDV stem peptides", "TREATMENT", 182, 204], ["PUUV-mediated fusion", "TREATMENT", 214, 234], ["hantaviruses", "OBSERVATION", 118, 130], ["stem fragments", "OBSERVATION", 153, 167]]], ["Among them, the R2.1 peptide reached the highest cross-reduction result of~70% at 20 \u03bcM, in line with the observation that this peptide also achieved the highest inhibition value of ANDV-mediated cell-cell fusion.", [["cell", "ANATOMY", 196, 200], ["cell", "ANATOMY", 201, 205], ["ANDV", "SIMPLE_CHEMICAL", 182, 186], ["cell", "CELL", 196, 200], ["cell", "CELL", 201, 205], ["ANDV", "PROTEIN", 182, 186], ["this peptide", "TEST", 123, 135], ["ANDV", "TEST", 182, 186], ["mediated cell-cell fusion", "TREATMENT", 187, 212], ["cell fusion", "OBSERVATION", 201, 212]]], ["Collectively, these results on hantavirus cross-inhibition suggest that residues in DIII and stem fragments are involved in intramolecular interactions.", [["stem fragments", "ANATOMY", 93, 107], ["hantavirus", "ORGANISM", 31, 41], ["DIII", "GENE_OR_GENE_PRODUCT", 84, 88], ["DIII", "PROTEIN", 84, 88], ["stem fragments", "PROTEIN", 93, 107], ["hantavirus cross-inhibition", "TREATMENT", 31, 58], ["residues in DIII and stem fragments", "PROBLEM", 72, 107], ["stem fragments", "OBSERVATION", 93, 107], ["intramolecular interactions", "OBSERVATION", 124, 151]]], ["Some of these residues seem to be conserved between ANDV and PUUV (Fig 1D) , allowing for the cross-interaction with exogenous DIII and stem fragments from a different hantavirus.Exogenous DIII and stem fragments block the fusion processANDV cell entry can be blocked at different steps such as receptor binding and membrane fusion.", [["stem fragments", "ANATOMY", 136, 150], ["stem fragments", "ANATOMY", 198, 212], ["cell", "ANATOMY", 242, 246], ["membrane", "ANATOMY", 316, 324], ["hantavirus", "DISEASE", 168, 178], ["DIII", "GENE_OR_GENE_PRODUCT", 127, 131], ["DIII", "GENE_OR_GENE_PRODUCT", 189, 193], ["cell", "CELL", 242, 246], ["membrane", "CELLULAR_COMPONENT", 316, 324], ["DIII", "PROTEIN", 127, 131], ["stem fragments", "PROTEIN", 136, 150], ["DIII", "PROTEIN", 189, 193], ["exogenous DIII and stem fragments", "PROBLEM", 117, 150], ["a different hantavirus", "PROBLEM", 156, 178], ["Exogenous DIII and stem fragments block", "TREATMENT", 179, 218], ["the fusion processANDV cell entry", "TREATMENT", 219, 252], ["receptor binding and membrane fusion", "TREATMENT", 295, 331], ["PUUV", "OBSERVATION", 61, 65], ["stem fragments", "OBSERVATION", 136, 150], ["stem fragments", "OBSERVATION", 198, 212], ["membrane fusion", "OBSERVATION", 316, 331]]], ["For hantaviruses, the envelope glycoprotein or the specific domain involved in binding to receptors has not yet been identified.", [["envelope glycoprotein", "PROTEIN", 22, 43], ["hantaviruses", "PROBLEM", 4, 16], ["the envelope glycoprotein", "TREATMENT", 18, 43], ["hantaviruses", "OBSERVATION", 4, 16]]], ["To discard a possible effect of the ANDV inhibitors in steps preceding virus-cell membrane fusion, we incubated the cells with ANDV DIII or the R2 peptide for 1 h before the addition of the virus.", [["cell membrane", "ANATOMY", 77, 90], ["cells", "ANATOMY", 116, 121], ["ANDV", "SIMPLE_CHEMICAL", 36, 40], ["cell membrane", "CELLULAR_COMPONENT", 77, 90], ["cells", "CELL", 116, 121], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 127, 136], ["ANDV DIII", "PROTEIN", 127, 136], ["ANDV", "SPECIES", 127, 131], ["the ANDV inhibitors", "TREATMENT", 32, 51], ["virus-cell membrane fusion", "TREATMENT", 71, 97], ["ANDV DIII", "TREATMENT", 127, 136], ["the R2 peptide", "TREATMENT", 140, 154], ["the virus", "PROBLEM", 186, 195], ["cell membrane fusion", "OBSERVATION", 77, 97], ["virus", "OBSERVATION", 190, 195]]], ["Unbound fragments were subsequently washed out, and cells were then infected with ANDV.", [["fragments", "ANATOMY", 8, 17], ["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["ANDV", "SPECIES", 82, 86], ["Unbound fragments", "PROBLEM", 0, 17], ["ANDV", "TREATMENT", 82, 86], ["fragments", "OBSERVATION", 8, 17]]], ["The addition of neither DIII nor R2 at 10 and 20 \u03bcM, respectively, before the cells were incubated with ANDV led to a significant decrease in virus infection (Fig 5A) .", [["cells", "ANATOMY", 78, 83], ["ANDV", "CHEMICAL", 104, 108], ["decrease in virus infection", "DISEASE", 130, 157], ["ANDV", "CHEMICAL", 104, 108], ["DIII", "GENE_OR_GENE_PRODUCT", 24, 28], ["cells", "CELL", 78, 83], ["ANDV", "SIMPLE_CHEMICAL", 104, 108], ["DIII", "PROTEIN", 24, 28], ["R2", "PROTEIN", 33, 35], ["ANDV", "SPECIES", 104, 108], ["a significant decrease in virus infection", "PROBLEM", 116, 157], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["decrease", "OBSERVATION_MODIFIER", 130, 138], ["virus infection", "OBSERVATION", 142, 157]]], ["These data emphasize that the pre-incubation of DIII and stem fragments did not abrogate early steps in virus infection such as receptor binding or cellular signaling pathways.", [["stem fragments", "ANATOMY", 57, 71], ["cellular", "ANATOMY", 148, 156], ["infection", "DISEASE", 110, 119], ["DIII", "GENE_OR_GENE_PRODUCT", 48, 52], ["cellular", "CELL", 148, 156], ["DIII", "PROTEIN", 48, 52], ["the pre-incubation of DIII and stem fragments", "PROBLEM", 26, 71], ["virus infection", "PROBLEM", 104, 119], ["receptor binding", "PROBLEM", 128, 144], ["cellular signaling pathways", "PROBLEM", 148, 175], ["stem fragments", "OBSERVATION", 57, 71]]], ["Furthermore, the results coincide with data obtained with stem peptides derived from DV2, where the pre-incubation of cells with these peptides also did not affect infection by DV2 [47] .", [["cells", "ANATOMY", 118, 123], ["infection", "DISEASE", 164, 173], ["DV2", "GENE_OR_GENE_PRODUCT", 85, 88], ["cells", "CELL", 118, 123], ["stem peptides", "TEST", 58, 71], ["the pre-incubation of cells", "TREATMENT", 96, 123], ["these peptides", "PROBLEM", 129, 143], ["infection", "PROBLEM", 164, 173]]], ["Next, we asked whether the DIII and stem fragments interfered directly in the virus-cell fusion process.", [["stem fragments", "ANATOMY", 36, 50], ["cell", "ANATOMY", 84, 88], ["DIII", "GENE_OR_GENE_PRODUCT", 27, 31], ["cell", "CELL", 84, 88], ["DIII", "PROTEIN", 27, 31], ["stem fragments", "DNA", 36, 50], ["the DIII and stem fragments", "PROBLEM", 23, 50], ["cell fusion process", "TREATMENT", 84, 103], ["stem fragments", "OBSERVATION", 36, 50], ["cell fusion", "OBSERVATION", 84, 95]]], ["To test this, we assessed inhibition in a fusion infection assay, fusing ANDV with the plasma membrane.", [["plasma membrane", "ANATOMY", 87, 102], ["infection", "DISEASE", 49, 58], ["ANDV", "GENE_OR_GENE_PRODUCT", 73, 77], ["plasma membrane", "CELLULAR_COMPONENT", 87, 102], ["ANDV", "PROTEIN", 73, 77], ["ANDV", "SPECIES", 73, 77], ["a fusion infection assay", "TEST", 40, 64], ["the plasma membrane", "TREATMENT", 83, 102]]], ["Therefore, ANDV was pre-bound to cells at 4\u00b0C and then ANDV DIII or R2 were added during the 5 min low pH pulse that triggers fusion.", [["cells", "ANATOMY", 33, 38], ["ANDV", "SIMPLE_CHEMICAL", 11, 15], ["cells", "CELL", 33, 38], ["C", "SIMPLE_CHEMICAL", 44, 45], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 55, 64], ["R2", "GENE_OR_GENE_PRODUCT", 68, 70], ["ANDV", "PROTEIN", 11, 15], ["ANDV DIII", "PROTEIN", 55, 64], ["R2", "PROTEIN", 68, 70], ["ANDV", "SPECIES", 11, 15], ["ANDV", "SPECIES", 55, 59], ["ANDV DIII or R2", "TREATMENT", 55, 70], ["low pH pulse", "PROBLEM", 99, 111], ["fusion", "OBSERVATION", 126, 132]]], ["The blockade of this viral entry pathway was highly efficient in the case of the R2 peptide, reaching over 95% of inhibition at 20 \u03bcM (Fig 5B) .", [["this viral entry pathway", "PROBLEM", 16, 40], ["the R2 peptide", "TREATMENT", 77, 91]]], ["Recombinant DIII led to a lower inhibition efficiency of 70% at 20 \u03bcM, result that in comparison to that obtained with R2 could be explained by the short incubation time in this experimental design.", [["DIII", "GENE_OR_GENE_PRODUCT", 12, 16], ["Recombinant DIII", "PROTEIN", 0, 16], ["a lower inhibition efficiency", "PROBLEM", 24, 53]]], ["Compared to inhibition of the normal entry route of the virus, higher concentrations of ANDV DIII might have been necessary for inhibition since more input virus was used to reach similar levels of infection (MOI = 0.2).", [["ANDV", "CHEMICAL", 88, 92], ["infection", "DISEASE", 198, 207], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 88, 97], ["ANDV DIII", "PROTEIN", 88, 97], ["ANDV", "SPECIES", 88, 92], ["the virus", "PROBLEM", 52, 61], ["ANDV DIII", "TREATMENT", 88, 97], ["more input virus", "PROBLEM", 145, 161], ["infection", "PROBLEM", 198, 207], ["MOI", "TEST", 209, 212], ["infection", "OBSERVATION", 198, 207]]], ["Taking these data together, our results confirm that the exogenous DIII and stem fragments function specifically during the viral fusion process.Exogenous DIII and stem fragments do not affect Gc homotrimer formationSince the fusion process involves multiple steps, we next assessed at which specific stage the Gc fragments interfere in this process.", [["stem fragments", "ANATOMY", 76, 90], ["stem fragments", "ANATOMY", 164, 178], ["fragments", "ANATOMY", 314, 323], ["DIII", "GENE_OR_GENE_PRODUCT", 67, 71], ["DIII", "GENE_OR_GENE_PRODUCT", 155, 159], ["Gc homotrimer", "GENE_OR_GENE_PRODUCT", 193, 206], ["Gc", "GENE_OR_GENE_PRODUCT", 311, 313], ["DIII", "PROTEIN", 67, 71], ["DIII", "PROTEIN", 155, 159], ["Gc fragments", "DNA", 311, 323], ["the exogenous DIII and stem fragments function", "PROBLEM", 53, 99], ["the viral fusion process", "TREATMENT", 120, 144], ["Exogenous DIII and stem fragments", "PROBLEM", 145, 178], ["Gc homotrimer formation", "PROBLEM", 193, 216], ["the fusion process", "PROBLEM", 222, 240], ["the Gc fragments", "PROBLEM", 307, 323], ["stem fragments", "OBSERVATION", 76, 90], ["viral fusion", "OBSERVATION", 124, 136], ["stem fragments", "OBSERVATION", 164, 178], ["fusion", "OBSERVATION", 226, 232], ["multiple", "OBSERVATION_MODIFIER", 250, 258], ["Gc fragments", "OBSERVATION", 311, 323]]], ["To this end, we started analyzing the trimerization of Gc using an earlier protocol [17] .", [["Gc", "PROTEIN", 55, 57], ["an earlier protocol", "TREATMENT", 64, 83]]], ["ANDV was therefore incubated at neutral or low pH with or without DIII.", [["ANDV", "SIMPLE_CHEMICAL", 0, 4], ["DIII", "GENE_OR_GENE_PRODUCT", 66, 70], ["DIII", "PROTEIN", 66, 70], ["ANDV", "SPECIES", 0, 4], ["DIII", "PROBLEM", 66, 70]]], ["Subsequently, the viral glycoproteins were extracted from the virus and applied to a sucrose gradient (7-15%) to evaluate their molecular mass.", [["sucrose", "CHEMICAL", 85, 92], ["sucrose", "CHEMICAL", 85, 92], ["sucrose", "SIMPLE_CHEMICAL", 85, 92], ["viral glycoproteins", "PROTEIN", 18, 37], ["the viral glycoproteins", "TREATMENT", 14, 37], ["the virus", "TREATMENT", 58, 67], ["a sucrose gradient", "TREATMENT", 83, 101], ["their molecular mass", "PROBLEM", 122, 142], ["viral glycoproteins", "OBSERVATION", 18, 37], ["molecular", "ANATOMY", 128, 137], ["mass", "OBSERVATION", 138, 142]]], ["After ultracentrifugation, each fraction was examined by western blot analysis for the presence of Gc.", [["blot analysis", "TEST", 65, 78]]], ["Gradient sedimentation at pH 7.4 led to the detection of Gc in fractions corresponding to the molecular mass of Gc monomers of~50 kDa (fractions 5-7), in the presence or absence of ANDV DIII (Fig 6A) .", [["ANDV DIII", "GENE_OR_GENE_PRODUCT", 181, 190], ["Gc", "PROTEIN", 57, 59], ["Gc monomers", "PROTEIN", 112, 123], ["ANDV DIII", "PROTEIN", 181, 190], ["Gradient sedimentation", "TEST", 0, 22], ["pH", "TEST", 26, 28], ["the detection", "TEST", 40, 53], ["Gc in fractions", "PROBLEM", 57, 72], ["the molecular mass", "PROBLEM", 90, 108], ["sedimentation", "OBSERVATION_MODIFIER", 9, 22], ["mass", "OBSERVATION", 104, 108], ["Gc monomers", "OBSERVATION", 112, 123]]], ["Two Gc migration bands could be observed in the reducing electrophoretic system, which may correspond to different oxidation forms of Gc as described earlier [73] .", [["Gc", "GENE_OR_GENE_PRODUCT", 134, 136], ["Gc", "PROTEIN", 134, 136], ["Two Gc migration bands", "TREATMENT", 0, 22], ["Gc", "OBSERVATION_MODIFIER", 4, 6], ["migration bands", "OBSERVATION", 7, 22], ["electrophoretic system", "OBSERVATION", 57, 79], ["may correspond to", "UNCERTAINTY", 87, 104], ["different oxidation", "OBSERVATION", 105, 124]]], ["Only the lower molecular mass band was previously found to shift from Gc monomers at neutral pH to Gc trimers at low pH [17] .", [["Gc monomers", "SIMPLE_CHEMICAL", 70, 81], ["Gc trimers", "GENE_OR_GENE_PRODUCT", 99, 109], ["Gc trimers", "PROTEIN", 99, 109], ["the lower molecular mass band", "PROBLEM", 5, 34], ["Gc trimers", "TEST", 99, 109], ["lower", "OBSERVATION_MODIFIER", 9, 14], ["mass", "OBSERVATION", 25, 29]]], ["When we incubated ANDV at pH 5.5, in the presence or absence of the DIII inhibitor, the lower molecular mass band of Gc shifted from the fractions corresponding to monomers and was found in fractions corresponding to Gc homotrimers (fractions 11-12; Fig 6A) .", [["ANDV", "SIMPLE_CHEMICAL", 18, 22], ["DIII", "GENE_OR_GENE_PRODUCT", 68, 72], ["DIII", "PROTEIN", 68, 72], ["Gc", "PROTEIN", 117, 119], ["Gc homotrimers", "PROTEIN", 217, 231], ["pH", "TEST", 26, 28], ["the DIII inhibitor", "TREATMENT", 64, 82], ["the lower molecular mass band of Gc", "PROBLEM", 84, 119], ["Gc homotrimers", "TEST", 217, 231], ["fractions", "TEST", 233, 242], ["mass", "OBSERVATION", 104, 108]]], ["This result indicates that ANDV DIII abrogated neither Gc fusion activation, nor Gc trimerization.Exogenous DIII and stem fragments prevent the formation of a stable Gc post-fusion trimerThe post-fusion conformation of ANDV Gc corresponds to a highly stable homotrimer [17] .", [["stem fragments", "ANATOMY", 117, 131], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 27, 36], ["Gc", "GENE_OR_GENE_PRODUCT", 55, 57], ["Gc", "GENE_OR_GENE_PRODUCT", 81, 83], ["DIII", "GENE_OR_GENE_PRODUCT", 108, 112], ["ANDV Gc", "GENE_OR_GENE_PRODUCT", 219, 226], ["ANDV DIII", "PROTEIN", 27, 36], ["Gc", "PROTEIN", 81, 83], ["DIII", "PROTEIN", 108, 112], ["Gc post-fusion trimer", "PROTEIN", 166, 187], ["ANDV Gc", "PROTEIN", 219, 226], ["ANDV", "SPECIES", 27, 31], ["ANDV DIII", "TREATMENT", 27, 36], ["Gc fusion activation", "TREATMENT", 55, 75], ["Gc trimerization", "TREATMENT", 81, 97], ["Exogenous DIII and stem fragments", "PROBLEM", 98, 131], ["ANDV Gc", "PROBLEM", 219, 226], ["stem fragments", "OBSERVATION", 117, 131], ["stable", "OBSERVATION_MODIFIER", 159, 165]]], ["In this context, we next explored the stability of the Gc homotrimer formed in the presence of exogenous DIII and stem fragments by assessing its resistance to protease digestion.", [["stem fragments", "ANATOMY", 114, 128], ["Gc", "GENE_OR_GENE_PRODUCT", 55, 57], ["DIII", "GENE_OR_GENE_PRODUCT", 105, 109], ["Gc homotrimer", "PROTEIN", 55, 68], ["DIII", "PROTEIN", 105, 109], ["protease", "PROTEIN", 160, 168], ["the Gc homotrimer", "TREATMENT", 51, 68], ["exogenous DIII and stem fragments", "PROBLEM", 95, 128], ["protease digestion", "PROBLEM", 160, 178], ["exogenous DIII", "OBSERVATION", 95, 109], ["stem fragments", "OBSERVATION", 114, 128]]], ["For this experimental approach we used ANDV-like particles (VLPs) [62] , since they can be purified to higher concentrations than the virus.", [["VLPs", "ORGANISM", 60, 64], ["this experimental approach", "TREATMENT", 4, 30], ["ANDV-like particles (VLPs", "TREATMENT", 39, 64], ["the virus", "PROBLEM", 130, 139]]], ["These VLPs resemble the viral envelope by exposing the Gn and Gc glycoproteins.", [["VLPs", "ORGANISM", 6, 10], ["Gn", "GENE_OR_GENE_PRODUCT", 55, 57], ["Gc glycoproteins", "GENE_OR_GENE_PRODUCT", 62, 78], ["Gn and Gc glycoproteins", "PROTEIN", 55, 78], ["These VLPs", "TEST", 0, 10], ["the viral envelope", "PROBLEM", 20, 38], ["viral envelope", "OBSERVATION", 24, 38], ["Gn", "OBSERVATION", 55, 57], ["Gc glycoproteins", "OBSERVATION", 62, 78]]], ["To test their trypsin resistance, the VLPs were first incubated at neutral or low pH in the presence or absence of the inhibitors, and subsequently subjected to digestion with trypsin for different incubation times.", [["trypsin", "GENE_OR_GENE_PRODUCT", 14, 21], ["VLPs", "ORGANISM", 38, 42], ["trypsin", "GENE_OR_GENE_PRODUCT", 176, 183], ["trypsin", "PROTEIN", 14, 21], ["trypsin", "PROTEIN", 176, 183], ["the VLPs", "TEST", 34, 42], ["low pH", "PROBLEM", 78, 84], ["the inhibitors", "TREATMENT", 115, 129], ["trypsin", "TREATMENT", 176, 183], ["low pH", "OBSERVATION_MODIFIER", 78, 84]]], ["As expected, the neutral pH form of Gc was fully degraded within 30 min, while the low pH form of Gc was largely resistant to digestion (Fig 6B) .", [["Gc", "GENE_OR_GENE_PRODUCT", 36, 38], ["Gc", "GENE_OR_GENE_PRODUCT", 98, 100], ["Gc", "PROTEIN", 36, 38], ["Gc", "PROTEIN", 98, 100], ["the neutral pH", "TEST", 13, 27], ["Gc", "TEST", 36, 38], ["the low pH form of Gc", "PROBLEM", 79, 100]]], ["In contrast, Gc lost its trypsin resistance and digestion could be observed when ANDV DIII or the R2 peptide was co-incubated with VLPs during the low pH incubation step, indicating that they interfered in the formation of a stable Gc homotrimer (Fig 6B) .", [["Gc", "GENE_OR_GENE_PRODUCT", 13, 15], ["trypsin", "GENE_OR_GENE_PRODUCT", 25, 32], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 81, 90], ["Gc", "PROTEIN", 13, 15], ["trypsin", "PROTEIN", 25, 32], ["ANDV DIII", "PROTEIN", 81, 90], ["Gc homotrimer", "PROTEIN", 232, 245], ["ANDV", "SPECIES", 81, 85], ["digestion", "PROBLEM", 48, 57], ["the R2 peptide", "TREATMENT", 94, 108], ["VLPs", "TREATMENT", 131, 135], ["the low pH incubation step", "PROBLEM", 143, 169], ["a stable Gc homotrimer", "TREATMENT", 223, 245], ["stable", "OBSERVATION_MODIFIER", 225, 231]]], ["Some residual Gc could be detected, most likely because the DIII or stem fragments did not block all Gc molecules, which coincides with the inhibitory results (Figs 3A and 3B and 5B) .", [["stem fragments", "ANATOMY", 68, 82], ["Gc", "GENE_OR_GENE_PRODUCT", 14, 16], ["DIII", "GENE_OR_GENE_PRODUCT", 60, 64], ["Gc", "PROTEIN", 14, 16], ["DIII", "PROTEIN", 60, 64], ["Gc molecules", "PROTEIN", 101, 113], ["Some residual", "PROBLEM", 0, 13], ["Gc", "TEST", 14, 16], ["stem fragments", "PROBLEM", 68, 82], ["residual", "OBSERVATION_MODIFIER", 5, 13], ["most likely", "UNCERTAINTY", 36, 47], ["stem fragments", "OBSERVATION", 68, 82]]], ["The formation of a stable homotrimer was however not prevented when the control peptide NN was added before acidification, nor when either the NN peptide, DIII or the R2 peptide was added after the low pH incubation, confirming the specificity of the assay.", [["NN", "CHEMICAL", 88, 90], ["DIII", "GENE_OR_GENE_PRODUCT", 155, 159], ["DIII", "PROTEIN", 155, 159], ["a stable homotrimer", "TREATMENT", 17, 36], ["the control peptide NN", "TREATMENT", 68, 90], ["the R2 peptide", "TREATMENT", 163, 177], ["the low pH incubation", "TREATMENT", 194, 215], ["the assay", "TEST", 247, 256], ["stable", "OBSERVATION_MODIFIER", 19, 25], ["homotrimer", "OBSERVATION", 26, 36]]], ["Together, these data suggest that the exogenous DIII and stem fragments prevented the formation of a stable post-fusion hairpin structure, presumably by direct binding to Gc in its extended intermediate conformation.Exogenous DIII arrests the fusion process in a step preceding the hemifusion intermediateThe presence of exogenous Gc fragments interfered neither with the activation of ANDV Gc nor with its homotrimerization; however it did not allow the formation of a stable post-fusion structure.", [["stem fragments", "ANATOMY", 57, 71], ["DIII", "GENE_OR_GENE_PRODUCT", 48, 52], ["Gc", "GENE_OR_GENE_PRODUCT", 171, 173], ["DIII", "GENE_OR_GENE_PRODUCT", 226, 230], ["Gc", "GENE_OR_GENE_PRODUCT", 331, 333], ["DIII", "PROTEIN", 48, 52], ["stem fragments", "PROTEIN", 57, 71], ["Gc", "PROTEIN", 171, 173], ["DIII", "PROTEIN", 226, 230], ["exogenous Gc fragments", "PROTEIN", 321, 343], ["Gc", "PROTEIN", 391, 393], ["post-fusion structure", "PROTEIN", 477, 498], ["ANDV", "SPECIES", 386, 390], ["these data", "TEST", 10, 20], ["the exogenous DIII and stem fragments", "PROBLEM", 34, 71], ["a stable post-fusion hairpin structure", "PROBLEM", 99, 137], ["Exogenous DIII arrests", "PROBLEM", 216, 238], ["the fusion process", "TREATMENT", 239, 257], ["exogenous Gc fragments", "PROBLEM", 321, 343], ["a stable post-fusion structure", "PROBLEM", 468, 498], ["stem fragments", "OBSERVATION", 57, 71], ["stable", "OBSERVATION_MODIFIER", 101, 107], ["post-fusion", "OBSERVATION", 108, 119], ["hairpin structure", "OBSERVATION", 120, 137], ["fusion", "OBSERVATION", 243, 249], ["exogenous", "OBSERVATION_MODIFIER", 321, 330], ["Gc fragments", "OBSERVATION", 331, 343], ["stable", "OBSERVATION_MODIFIER", 470, 476], ["post-fusion", "OBSERVATION", 477, 488]]], ["The hemifusion intermediate is a stage that occurs between these fusion steps, in which the outer membranes of the virus and cell have fused, while the inner leaflets still remain apart.", [["outer membranes", "ANATOMY", 92, 107], ["cell", "ANATOMY", 125, 129], ["inner leaflets", "ANATOMY", 152, 166], ["outer membranes", "CELLULAR_COMPONENT", 92, 107], ["cell", "CELL", 125, 129], ["inner leaflets", "MULTI-TISSUE_STRUCTURE", 152, 166], ["these fusion steps", "TREATMENT", 59, 77], ["intermediate", "OBSERVATION_MODIFIER", 15, 27], ["fusion steps", "OBSERVATION", 65, 77], ["outer", "ANATOMY_MODIFIER", 92, 97], ["membranes", "ANATOMY_MODIFIER", 98, 107], ["virus", "OBSERVATION", 115, 120], ["inner leaflets", "ANATOMY", 152, 166]]], ["In order to test if the inhibition of ANDV by exogenous DIII occurs before or after the hemifusion intermediate state, we developed a hemifusion assay for the ANDV glycoproteins.", [["ANDV", "CHEMICAL", 38, 42], ["ANDV", "GENE_OR_GENE_PRODUCT", 38, 42], ["DIII", "GENE_OR_GENE_PRODUCT", 56, 60], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 159, 177], ["ANDV", "PROTEIN", 38, 42], ["exogenous DIII", "PROTEIN", 46, 60], ["ANDV glycoproteins", "PROTEIN", 159, 177], ["ANDV", "SPECIES", 38, 42], ["ANDV", "SPECIES", 159, 163], ["a hemifusion assay", "TEST", 132, 150], ["the ANDV glycoproteins", "PROBLEM", 155, 177]]], ["For this purpose, we took advantage of a previously developed cell-cell fusion assay between 293FT cells expressing the ANDV glycoproteins (effector cells) and CHO-K1 cells (target cells) [17] .", [["cell", "ANATOMY", 62, 66], ["cell", "ANATOMY", 67, 71], ["293FT cells", "ANATOMY", 93, 104], ["effector cells", "ANATOMY", 140, 154], ["CHO-K1 cells", "ANATOMY", 160, 172], ["cells", "ANATOMY", 181, 186], ["cell", "CELL", 62, 66], ["cell", "CELL", 67, 71], ["293FT cells", "CELL", 93, 104], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 120, 138], ["effector cells", "CELL", 140, 154], ["CHO-K1 cells", "CELL", 160, 172], ["cells", "CELL", 181, 186], ["293FT cells", "CELL_LINE", 93, 104], ["ANDV glycoproteins", "PROTEIN", 120, 138], ["effector cells", "CELL_TYPE", 140, 154], ["CHO-K1 cells", "CELL_LINE", 160, 172], ["target cells", "CELL_TYPE", 174, 186], ["cell-cell fusion assay", "TEST", 62, 84], ["CHO-K1 cells", "TEST", 160, 172], ["cell fusion", "OBSERVATION", 67, 78]]], ["In this assay, the low pH-triggered transfer of GM1 from effector cells to target cells was analyzed by confocal microscopy, which allows detection of GM1 at the cell surface in a single focal plane, with minimal sample intervention (Fig 7A) .", [["effector cells", "ANATOMY", 57, 71], ["cells", "ANATOMY", 82, 87], ["cell surface", "ANATOMY", 162, 174], ["focal plane", "ANATOMY", 187, 198], ["sample", "ANATOMY", 213, 219], ["GM1", "GENE_OR_GENE_PRODUCT", 48, 51], ["effector cells", "CELL", 57, 71], ["cells", "CELL", 82, 87], ["GM1", "GENE_OR_GENE_PRODUCT", 151, 154], ["cell surface", "CELLULAR_COMPONENT", 162, 174], ["GM1", "PROTEIN", 48, 51], ["effector cells", "CELL_TYPE", 57, 71], ["target cells", "CELL_TYPE", 75, 87], ["GM1", "PROTEIN", 151, 154], ["this assay", "TEST", 3, 13], ["the low pH", "PROBLEM", 15, 25], ["confocal microscopy", "TEST", 104, 123], ["minimal sample intervention", "TREATMENT", 205, 232], ["minimal", "OBSERVATION_MODIFIER", 205, 212]]], ["To allow unambiguous identification of GM1 transfer from effector cells to target cells, CHO-K1 cells were only defined as GM1 + when the label was detected on their full circumference (Fig 7A, red arrows) .", [["effector cells", "ANATOMY", 57, 71], ["cells", "ANATOMY", 82, 87], ["CHO-K1 cells", "ANATOMY", 89, 101], ["GM1", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 66, 71], ["cells", "CELL", 82, 87], ["CHO-K1 cells", "CELL", 89, 101], ["GM1 +", "SIMPLE_CHEMICAL", 123, 128], ["GM1", "PROTEIN", 39, 42], ["effector cells", "CELL_TYPE", 57, 71], ["target cells", "CELL_TYPE", 75, 87], ["CHO-K1 cells", "CELL_LINE", 89, 101], ["GM1", "PROTEIN", 123, 126], ["CHO-K1 cells", "TEST", 89, 101], ["GM1", "TEST", 123, 126]]], ["Conversely, target cells in contact with effector cells, but showing only partial or no GM1 stain, were defined as GM1 - (Fig 7A, yellow arrows) .", [["cells", "ANATOMY", 19, 24], ["effector cells", "ANATOMY", 41, 55], ["cells", "CELL", 19, 24], ["effector cells", "CELL", 41, 55], ["GM1", "GENE_OR_GENE_PRODUCT", 88, 91], ["GM1", "GENE_OR_GENE_PRODUCT", 115, 118], ["target cells", "CELL_TYPE", 12, 24], ["effector cells", "CELL_TYPE", 41, 55], ["GM1", "PROTEIN", 115, 118], ["effector cells", "PROBLEM", 41, 55], ["GM1 stain", "TEST", 88, 97], ["GM1", "TEST", 115, 118]]], ["Although this assay allows for the detection of lipid mixing between cells, it does not discriminate between full fusion and hemifusion of membranes.", [["cells", "ANATOMY", 69, 74], ["membranes", "ANATOMY", 139, 148], ["lipid", "SIMPLE_CHEMICAL", 48, 53], ["cells", "CELL", 69, 74], ["membranes", "CELLULAR_COMPONENT", 139, 148], ["this assay", "TEST", 9, 19], ["lipid mixing between cells", "PROBLEM", 48, 74], ["full fusion", "TREATMENT", 109, 120], ["hemifusion of membranes", "TREATMENT", 125, 148], ["fusion", "OBSERVATION", 114, 120]]], ["To obtain a quantitative measure of GM1 transfer from effector to target cells, we quantified the percentage of transfer in each condition.", [["cells", "ANATOMY", 73, 78], ["GM1", "GENE_OR_GENE_PRODUCT", 36, 39], ["cells", "CELL", 73, 78], ["GM1", "PROTEIN", 36, 39], ["target cells", "CELL_TYPE", 66, 78]]], ["At pH 7, a background level of transfer around 20% was observed in all conditions (Fig 7B) .", [["pH", "TEST", 3, 5]]], ["When glycoproteins were activated at pH 5.5, GM1-transfer from effector cells to target cells was detected in~70% of Mock control treatment ( Fig 7B) .", [["effector cells", "ANATOMY", 63, 77], ["cells", "ANATOMY", 88, 93], ["GM1", "SIMPLE_CHEMICAL", 45, 48], ["effector cells", "CELL", 63, 77], ["cells", "CELL", 88, 93], ["GM1", "PROTEIN", 45, 48], ["effector cells", "CELL_TYPE", 63, 77], ["target cells", "CELL_TYPE", 81, 93], ["glycoproteins", "TEST", 5, 18], ["pH", "TEST", 37, 39], ["GM1", "TEST", 45, 48], ["target cells", "TEST", 81, 93], ["Mock control treatment", "TREATMENT", 117, 139]]], ["However, when ANDV DIII was incorporated in the low pH incubation, the transfer of GM1 appeared to be less frequent, decreasing to below 40% (Fig 7B) .", [["ANDV DIII", "ORGANISM", 14, 23], ["GM1", "GENE_OR_GENE_PRODUCT", 83, 86], ["ANDV DIII", "PROTEIN", 14, 23], ["ANDV", "SPECIES", 14, 18], ["the low pH incubation", "TREATMENT", 44, 65]]], ["This value is still higher than the background level observed for GM1 transfer at neutral pH, indicating that this domain reduced lipid mixing in an incomplete manner.", [["GM1", "SIMPLE_CHEMICAL", 66, 69], ["lipid", "SIMPLE_CHEMICAL", 130, 135], ["This value", "TEST", 0, 10], ["this domain reduced lipid mixing", "PROBLEM", 110, 142], ["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["Most probably, exogenous ANDV DIII did not make contact with all fusion proteins during the short low pH incubation, which coincides with the results for blocking cell-cell fusion (see Fig 4A) .", [["cell", "ANATOMY", 163, 167], ["cell", "ANATOMY", 168, 172], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 25, 34], ["cell", "CELL", 163, 167], ["cell", "CELL", 168, 172], ["ANDV DIII", "PROTEIN", 25, 34], ["fusion proteins", "PROTEIN", 65, 80], ["ANDV", "SPECIES", 25, 29], ["all fusion proteins", "TREATMENT", 61, 80], ["the short low pH incubation", "PROBLEM", 88, 115], ["blocking cell-cell fusion", "TREATMENT", 154, 179]]], ["The impairment of GM1-transfer was highly specific, since the incorporation of PUUV hDIII, which has no crossinhibition activity against ANDV (see Figs 3 and 4A), did not abrogate the acid-induced GM1 transfer of~70% (Fig 7A and 7B ).", [["hDIII", "CHEMICAL", 84, 89], ["GM1", "GENE_OR_GENE_PRODUCT", 18, 21], ["PUUV", "ORGANISM", 79, 83], ["hDIII", "GENE_OR_GENE_PRODUCT", 84, 89], ["GM1", "SIMPLE_CHEMICAL", 197, 200], ["GM1", "PROTEIN", 18, 21], ["PUUV hDIII", "PROTEIN", 79, 89], ["ANDV", "SPECIES", 137, 141], ["the acid-induced GM1", "TEST", 180, 200], ["impairment", "OBSERVATION_MODIFIER", 4, 14], ["PUUV hDIII", "OBSERVATION", 79, 89]]], ["In summary, our results show that ANDV DIII arrests the fusion process after Gc trimerization, but before reaching a hemifusion intermediate.", [["ANDV DIII", "GENE_OR_GENE_PRODUCT", 34, 43], ["ANDV DIII", "PROTEIN", 34, 43], ["Gc", "PROTEIN", 77, 79], ["ANDV", "SPECIES", 34, 38], ["ANDV DIII arrests", "PROBLEM", 34, 51], ["the fusion process", "PROBLEM", 52, 70], ["Gc trimerization", "TREATMENT", 77, 93], ["fusion", "OBSERVATION", 56, 62]]], ["In this context, it seems likely that Gc fragments prevent the movement of the endogenous DIII or the stem region towards the core of the Gc trimer as described for other class II fusion proteins [39, 44] .DiscussionThe fusion of the viral membrane with a host cell membrane is a crucial step in the entry of enveloped viruses into cells.", [["stem region", "ANATOMY", 102, 113], ["membrane", "ANATOMY", 240, 248], ["cell membrane", "ANATOMY", 261, 274], ["cells", "ANATOMY", 332, 337], ["Gc fragments", "GENE_OR_GENE_PRODUCT", 38, 50], ["DIII", "GENE_OR_GENE_PRODUCT", 90, 94], ["Gc trimer", "GENE_OR_GENE_PRODUCT", 138, 147], ["cell membrane", "CELLULAR_COMPONENT", 261, 274], ["cells", "CELL", 332, 337], ["Gc fragments", "PROTEIN", 38, 50], ["endogenous DIII", "PROTEIN", 79, 94], ["stem region", "PROTEIN", 102, 113], ["Gc trimer", "PROTEIN", 138, 147], ["class II fusion proteins", "PROTEIN", 171, 195], ["Gc fragments", "PROBLEM", 38, 50], ["The fusion", "TREATMENT", 216, 226], ["the viral membrane", "TREATMENT", 230, 248], ["a host cell membrane", "TREATMENT", 254, 274], ["seems likely", "UNCERTAINTY", 20, 32], ["Gc fragments", "OBSERVATION", 38, 50], ["stem", "ANATOMY", 102, 106], ["region", "ANATOMY_MODIFIER", 107, 113], ["viral membrane", "OBSERVATION", 234, 248], ["host cell membrane", "OBSERVATION", 256, 274], ["viruses", "OBSERVATION", 319, 326]]], ["In the present study we demonstrated that predicted DIII and stem fragments blocked acid-induced fusion of ANDV within the endosomal entry pathway and with the cell surface.", [["stem fragments", "ANATOMY", 61, 75], ["endosomal", "ANATOMY", 123, 132], ["cell surface", "ANATOMY", 160, 172], ["DIII", "GENE_OR_GENE_PRODUCT", 52, 56], ["ANDV", "GENE_OR_GENE_PRODUCT", 107, 111], ["endosomal", "CELLULAR_COMPONENT", 123, 132], ["cell surface", "CELLULAR_COMPONENT", 160, 172], ["DIII", "PROTEIN", 52, 56], ["stem fragments", "PROTEIN", 61, 75], ["ANDV", "PROTEIN", 107, 111], ["the present study", "TEST", 3, 20], ["predicted DIII and stem fragments", "PROBLEM", 42, 75], ["acid-induced fusion", "TREATMENT", 84, 103], ["stem fragments", "OBSERVATION", 61, 75], ["acid-induced fusion", "OBSERVATION", 84, 103], ["endosomal", "ANATOMY_MODIFIER", 123, 132], ["entry pathway", "OBSERVATION", 133, 146], ["cell", "OBSERVATION_MODIFIER", 160, 164], ["surface", "OBSERVATION_MODIFIER", 165, 172]]], ["Fusion was allowed to proceed until Gc trimerization, but prevented membrane hemifusion and fusion pore formation.", [["membrane", "ANATOMY", 68, 76], ["pore", "ANATOMY", 99, 103], ["Gc", "GENE_OR_GENE_PRODUCT", 36, 38], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["pore", "CELLULAR_COMPONENT", 99, 103], ["Gc", "PROTEIN", 36, 38], ["Fusion", "TREATMENT", 0, 6], ["Gc trimerization", "TREATMENT", 36, 52], ["membrane hemifusion", "TREATMENT", 68, 87], ["fusion pore formation", "TREATMENT", 92, 113], ["fusion pore", "OBSERVATION", 92, 103]]], ["These results not only provide novel information about inhibitory strategies against ANDV and other hantaviruses, but also provide a proof of concept that Gc shares structural similarity with the overall fold of class II fusion proteins.DiscussionComparing the inhibition of hantaviruses by exogenous DIII with that of other class II fusion proteins, ANDV and PUUV hantaviruses were blocked by ANDV DIII without additional N-terminal His-tag or C-terminal residues, although containing seven N-terminal residues derived from the GST-tag.", [["hantaviruses", "DISEASE", 275, 287], ["hantaviruses", "DISEASE", 365, 377], ["His", "CHEMICAL", 434, 437], ["C", "CHEMICAL", 445, 446], ["N", "CHEMICAL", 492, 493], ["ANDV", "GENE_OR_GENE_PRODUCT", 85, 89], ["class II fusion proteins", "GENE_OR_GENE_PRODUCT", 212, 236], ["hantaviruses", "ORGANISM", 275, 287], ["DIII", "GENE_OR_GENE_PRODUCT", 301, 305], ["class II fusion proteins", "GENE_OR_GENE_PRODUCT", 325, 349], ["ANDV", "GENE_OR_GENE_PRODUCT", 351, 355], ["PUUV hantaviruses", "ORGANISM", 360, 377], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 394, 403], ["GST", "GENE_OR_GENE_PRODUCT", 529, 532], ["Gc", "PROTEIN", 155, 157], ["class II fusion proteins", "PROTEIN", 212, 236], ["exogenous DIII", "PROTEIN", 291, 305], ["class II fusion proteins", "PROTEIN", 325, 349], ["ANDV", "PROTEIN", 351, 355], ["ANDV DIII", "PROTEIN", 394, 403], ["N-terminal His-tag or C-terminal residues", "PROTEIN", 423, 464], ["N-terminal residues", "PROTEIN", 492, 511], ["GST-tag", "PROTEIN", 529, 536], ["ANDV", "SPECIES", 85, 89], ["ANDV", "SPECIES", 351, 355], ["PUUV", "SPECIES", 360, 364], ["ANDV", "SPECIES", 394, 398], ["inhibitory strategies", "TREATMENT", 55, 76], ["class II fusion proteins", "TREATMENT", 212, 236], ["other class II fusion proteins", "TREATMENT", 319, 349], ["ANDV", "TREATMENT", 351, 355], ["PUUV hantaviruses", "PROBLEM", 360, 377], ["C-terminal residues", "PROBLEM", 445, 464], ["seven N-terminal residues", "PROBLEM", 486, 511], ["PUUV hantaviruses", "OBSERVATION", 360, 377]]], ["While the addition of an N-terminal His-tag achieved a 100-fold improvement in blocking fusion of Semliki Forest virus [44] , ANDV DIII -with or without N-terminal His-tag -achieved similar inhibitory results.", [["His", "CHEMICAL", 36, 39], ["His", "CHEMICAL", 164, 167], ["Semliki Forest virus", "ORGANISM", 98, 118], ["ANDV DIII", "ORGANISM", 126, 135], ["N-terminal His-tag", "PROTEIN", 25, 43], ["ANDV DIII", "PROTEIN", 126, 135], ["N-terminal His-tag", "PROTEIN", 153, 171], ["Semliki Forest virus", "SPECIES", 98, 118], ["ANDV", "SPECIES", 126, 130], ["an N-terminal His-tag", "TREATMENT", 22, 43], ["blocking fusion", "TREATMENT", 79, 94], ["Semliki Forest virus", "PROBLEM", 98, 118], ["N-terminal His-tag", "TEST", 153, 171]]], ["For SFV DIII it has been proposed that this N-terminal tag may mimic the domain I-DIII linker region, thereby stabilizing the interaction with the fusion protein core [44] .", [["N", "CHEMICAL", 44, 45], ["SFV DIII", "ORGANISM", 4, 12], ["SFV DIII", "PROTEIN", 4, 12], ["N-terminal tag", "PROTEIN", 44, 58], ["domain I-DIII linker region", "PROTEIN", 73, 100], ["SFV", "SPECIES", 4, 7], ["this N-terminal tag", "TREATMENT", 39, 58], ["the domain I-DIII linker region", "PROBLEM", 69, 100], ["the fusion protein core", "TEST", 143, 166]]], ["On the other hand, it has been reported that the presence of C-terminal residues derived from the stem region is necessary for inhibition by exogenous DIII of DV2 and chikungunya virus E proteins [44, 72] .", [["stem region", "ANATOMY", 98, 109], ["chikungunya", "DISEASE", 167, 178], ["C", "CHEMICAL", 61, 62], ["DIII", "GENE_OR_GENE_PRODUCT", 151, 155], ["DV2", "GENE_OR_GENE_PRODUCT", 159, 162], ["chikungunya virus E", "ORGANISM", 167, 186], ["C-terminal residues", "PROTEIN", 61, 80], ["DIII", "PROTEIN", 151, 155], ["DV2", "PROTEIN", 159, 162], ["chikungunya virus E proteins", "PROTEIN", 167, 195], ["chikungunya virus", "SPECIES", 167, 184], ["C-terminal residues", "PROBLEM", 61, 80], ["DV2", "PROBLEM", 159, 162], ["chikungunya virus E proteins", "TEST", 167, 195], ["stem", "ANATOMY", 98, 102]]], ["More specifically, for chikungunya virus it has been shown that nine residues from the E stem region are required for DIII to bind to the fusion protein domain I-domain II core.", [["chikungunya", "DISEASE", 23, 34], ["chikungunya virus", "ORGANISM", 23, 40], ["DIII", "GENE_OR_GENE_PRODUCT", 118, 122], ["I-domain II", "GENE_OR_GENE_PRODUCT", 160, 171], ["E stem region", "DNA", 87, 100], ["DIII", "PROTEIN", 118, 122], ["fusion protein domain I-domain II core", "PROTEIN", 138, 176], ["chikungunya virus", "SPECIES", 23, 40], ["chikungunya virus", "PROBLEM", 23, 40], ["nine residues from the E stem region", "PROBLEM", 64, 100]]], ["Hence, the potency of inhibiting the ANDV fusion process through ANDV and PUUV DIII may be further improved in future studies by adding N-or C-terminal residues.DiscussionThe ANDV DIII, including the stem region, was largely insoluble and therefore this larger Gc fragment could not be tested in the ANDV entry assays.", [["stem region", "ANATOMY", 200, 211], ["N", "CHEMICAL", 136, 137], ["C", "CHEMICAL", 141, 142], ["ANDV", "GENE_OR_GENE_PRODUCT", 37, 41], ["ANDV", "GENE_OR_GENE_PRODUCT", 65, 69], ["PUUV DIII", "ORGANISM", 74, 83], ["ANDV DIII", "ORGANISM", 175, 184], ["ANDV", "SIMPLE_CHEMICAL", 300, 304], ["ANDV", "PROTEIN", 65, 69], ["PUUV DIII", "PROTEIN", 74, 83], ["N-or C-terminal residues", "PROTEIN", 136, 160], ["ANDV DIII", "PROTEIN", 175, 184], ["Gc fragment", "DNA", 261, 272], ["ANDV", "SPECIES", 65, 69], ["PUUV", "SPECIES", 74, 78], ["ANDV", "SPECIES", 175, 179], ["ANDV", "SPECIES", 300, 304], ["the ANDV fusion process", "TREATMENT", 33, 56], ["PUUV DIII", "PROBLEM", 74, 83], ["future studies", "TEST", 111, 125], ["terminal residues", "PROBLEM", 143, 160], ["Gc fragment", "PROBLEM", 261, 272], ["fusion", "OBSERVATION", 42, 48], ["PUUV", "OBSERVATION", 74, 78], ["stem", "ANATOMY", 200, 204], ["insoluble", "OBSERVATION", 225, 234], ["larger", "OBSERVATION_MODIFIER", 254, 260], ["fragment", "OBSERVATION", 264, 272]]], ["The R1 peptide spanning the first 17 N-terminal residues of the 44-residue stem region did not affect ANDV entry, while the R2 peptide spanning the last 20 C-terminal residues blocked ANDV infection to a similar extent as DIII.", [["infection", "DISEASE", 189, 198], ["N", "CHEMICAL", 37, 38], ["C", "CHEMICAL", 156, 157], ["ANDV", "SIMPLE_CHEMICAL", 102, 106], ["ANDV", "SIMPLE_CHEMICAL", 184, 188], ["DIII", "GENE_OR_GENE_PRODUCT", 222, 226], ["17 N-terminal residues", "PROTEIN", 34, 56], ["44-residue stem region", "PROTEIN", 64, 86], ["ANDV", "PROTEIN", 102, 106], ["last 20 C-terminal residues", "PROTEIN", 148, 175], ["DIII", "PROTEIN", 222, 226], ["ANDV", "SPECIES", 184, 188], ["The R1 peptide", "TEST", 0, 14], ["the R2 peptide", "TEST", 120, 134], ["terminal residues", "PROBLEM", 158, 175], ["ANDV infection", "PROBLEM", 184, 198], ["infection", "OBSERVATION", 189, 198]]], ["When we tested the two peptides R2.1 and R2.2, comprising either the N-or C-terminal half of the ANDV R2 stem peptide, the inhibitory activity against ANDV was largely retained by both peptides.", [["C", "CHEMICAL", 74, 75], ["ANDV", "SIMPLE_CHEMICAL", 151, 155], ["N-or C-terminal half", "PROTEIN", 69, 89], ["ANDV", "PROTEIN", 151, 155], ["ANDV", "SPECIES", 151, 155], ["the two peptides", "TEST", 15, 31]]], ["Hence, the R2 peptide seems to contain residues in these two regions that participate similarly during inhibition.", [["the R2 peptide", "TREATMENT", 7, 21], ["residues", "OBSERVATION", 39, 47]]], ["Similar to the C-terminal region of the ANDV stem region, the C-terminal region, but not the N-terminal, of DV2 E protein binds and blocks the fusion protein [47] .", [["ANDV stem region", "ANATOMY", 40, 56], ["C", "CHEMICAL", 15, 16], ["C", "CHEMICAL", 62, 63], ["N", "CHEMICAL", 93, 94], ["ANDV stem region", "CELLULAR_COMPONENT", 40, 56], ["DV2 E", "GENE_OR_GENE_PRODUCT", 108, 113], ["C-terminal region", "DNA", 15, 32], ["ANDV stem region", "DNA", 40, 56], ["C-terminal region", "DNA", 62, 79], ["N-terminal", "DNA", 93, 103], ["DV2 E protein", "PROTEIN", 108, 121], ["fusion protein", "PROTEIN", 143, 157], ["the C-terminal region", "PROBLEM", 58, 79], ["DV2 E protein binds", "TEST", 108, 127], ["the fusion protein", "TEST", 139, 157], ["terminal", "ANATOMY_MODIFIER", 17, 25], ["region", "ANATOMY_MODIFIER", 26, 32], ["ANDV stem", "ANATOMY_MODIFIER", 40, 49], ["region", "ANATOMY_MODIFIER", 50, 56], ["terminal", "ANATOMY_MODIFIER", 64, 72], ["region", "ANATOMY_MODIFIER", 73, 79]]], ["Interestingly, inhibitory peptides derived from membrane proximal regions (or stem regions) of diverse fusion proteins such as those of RVFV, DV2, SARS-coronavirus, Influenza virus, and Hepatitis C virus have been found likely to interact with membrane interfaces by a hydropathy segment [74] , which is predicted by the Wimley-White interfacial hydrophobicity scale (WWIHS) for the transfer of a peptide from an aqueous environment to a palmitoyl-oleoyl-phosphatidyl choline interface [75, 76] .", [["membrane", "ANATOMY", 48, 56], ["stem regions", "ANATOMY", 78, 90], ["membrane", "ANATOMY", 244, 252], ["SARS-coronavirus", "DISEASE", 147, 163], ["Influenza virus", "DISEASE", 165, 180], ["Hepatitis C", "DISEASE", 186, 197], ["palmitoyl-oleoyl-phosphatidyl choline", "CHEMICAL", 438, 475], ["palmitoyl-oleoyl-phosphatidyl choline", "CHEMICAL", 438, 475], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["RVFV", "ORGANISM", 136, 140], ["DV2", "GENE_OR_GENE_PRODUCT", 142, 145], ["SARS-coronavirus", "ORGANISM", 147, 163], ["Influenza virus", "ORGANISM", 165, 180], ["Hepatitis C virus", "ORGANISM", 186, 203], ["membrane", "CELLULAR_COMPONENT", 244, 252], ["palmitoyl-oleoyl-phosphatidyl choline", "SIMPLE_CHEMICAL", 438, 475], ["membrane proximal regions", "PROTEIN", 48, 73], ["fusion proteins", "PROTEIN", 103, 118], ["DV2", "PROTEIN", 142, 145], ["SARS-coronavirus", "SPECIES", 147, 163], ["Influenza virus", "SPECIES", 165, 180], ["Hepatitis C virus", "SPECIES", 186, 203], ["RVFV", "SPECIES", 136, 140], ["SARS-coronavirus", "SPECIES", 147, 163], ["Influenza virus", "SPECIES", 165, 180], ["Hepatitis C virus", "SPECIES", 186, 203], ["diverse fusion proteins", "PROBLEM", 95, 118], ["RVFV", "PROBLEM", 136, 140], ["DV2", "PROBLEM", 142, 145], ["SARS", "PROBLEM", 147, 151], ["coronavirus", "PROBLEM", 152, 163], ["Influenza virus", "PROBLEM", 165, 180], ["Hepatitis C virus", "PROBLEM", 186, 203], ["White interfacial hydrophobicity scale", "TEST", 328, 366], ["a peptide", "TREATMENT", 395, 404], ["a palmitoyl-oleoyl-phosphatidyl choline interface", "TREATMENT", 436, 485], ["membrane", "ANATOMY_MODIFIER", 48, 56], ["proximal", "ANATOMY_MODIFIER", 57, 65], ["regions", "ANATOMY_MODIFIER", 66, 73], ["stem", "ANATOMY_MODIFIER", 78, 82], ["diverse fusion", "OBSERVATION", 95, 109], ["Influenza virus", "OBSERVATION", 165, 180]]], ["A need for such a membrane-binding property for inhibitory activity coincides with studies on peptides derived from the stem region of alphavirus fusion proteins; these peptides generate WWIHS below values of 1 (S1 Table) , indicative of weak membrane binding [74] , and fail to block alphavirus fusion activity [44, 72] .", [["membrane", "ANATOMY", 18, 26], ["stem region", "ANATOMY", 120, 131], ["membrane", "ANATOMY", 243, 251], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["alphavirus", "ORGANISM", 135, 145], ["membrane", "CELLULAR_COMPONENT", 243, 251], ["alphavirus fusion proteins", "PROTEIN", 135, 161], ["WWIHS", "PROTEIN", 187, 192], ["such a membrane-binding property", "TREATMENT", 11, 43], ["inhibitory activity", "PROBLEM", 48, 67], ["studies on peptides", "TEST", 83, 102], ["alphavirus fusion proteins", "PROBLEM", 135, 161], ["these peptides", "TEST", 163, 177], ["weak membrane binding", "PROBLEM", 238, 259], ["fail to block alphavirus fusion activity", "PROBLEM", 271, 311], ["stem", "ANATOMY", 120, 124], ["alphavirus fusion", "OBSERVATION", 135, 152]]], ["In the case of the DV2 E protein, such a membrane-binding sequence is found at the C-terminal end of the peptide [48] with a high WWIHS value (S1 Table) .", [["membrane", "ANATOMY", 41, 49], ["C", "CHEMICAL", 83, 84], ["DV2 E", "GENE_OR_GENE_PRODUCT", 19, 24], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["DV2 E protein", "PROTEIN", 19, 32], ["membrane-binding sequence", "PROTEIN", 41, 66], ["C-terminal end", "PROTEIN", 83, 97], ["WWIHS", "PROTEIN", 130, 135], ["the DV2 E protein", "TEST", 15, 32], ["a membrane-binding sequence", "TEST", 39, 66]]], ["In fact, the stem peptides of the DV2 E protein have been shown to interfere with the fusion of the virus in the endosomal compartment by a two-step mechanism: first by binding to the viral membrane outside the cell, and next by binding against the E core trimer once fusion has been triggered in the endocytic compartment (47) .", [["endosomal compartment", "ANATOMY", 113, 134], ["membrane", "ANATOMY", 190, 198], ["cell", "ANATOMY", 211, 215], ["endocytic compartment", "ANATOMY", 301, 322], ["DV2 E", "GENE_OR_GENE_PRODUCT", 34, 39], ["endosomal compartment", "CELLULAR_COMPONENT", 113, 134], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["cell", "CELL", 211, 215], ["DV2 E protein", "PROTEIN", 34, 47], ["E core trimer", "PROTEIN", 249, 262], ["the DV2 E protein", "TEST", 30, 47], ["the virus", "PROBLEM", 96, 105], ["the E core trimer once fusion", "TREATMENT", 245, 274], ["fusion", "OBSERVATION", 86, 92], ["virus", "OBSERVATION", 100, 105], ["endosomal compartment", "OBSERVATION", 113, 134], ["viral membrane", "OBSERVATION", 184, 198], ["fusion", "OBSERVATION", 268, 274], ["endocytic", "ANATOMY_MODIFIER", 301, 310]]], ["Using the Wimley-White scale [77] , an interfacial hydropathy segment with a WWIHS vale >5 was predicted for the ANDV Gc stem region that coincides with the sequence of the R2 peptide (S1 Table) , indicative for moderate membrane partitioning [74] .", [["membrane", "ANATOMY", 221, 229], ["membrane", "CELLULAR_COMPONENT", 221, 229], ["ANDV Gc stem region", "DNA", 113, 132], ["an interfacial hydropathy segment", "PROBLEM", 36, 69], ["a WWIHS vale", "TEST", 75, 87], ["moderate membrane partitioning", "PROBLEM", 212, 242], ["interfacial hydropathy", "OBSERVATION", 39, 61], ["segment", "ANATOMY_MODIFIER", 62, 69], ["Gc stem", "ANATOMY", 118, 125], ["indicative for", "UNCERTAINTY", 197, 211], ["moderate", "OBSERVATION_MODIFIER", 212, 220], ["membrane partitioning", "OBSERVATION", 221, 242]]], ["If the ANDV R2 peptide would interact with membranes by a hydropathy segment, then such an interaction did not favor ANDV inhibition sufficiently in the endosomal route, since fusion impairment was most efficient when directly present in the fusion compartment; when applied at the same concentration, the R2 stem peptide blocked 45% of ANDV infection when entry occurred via the endocytic pathway, while R2 reached over 95% inhibition of ANDV infection when fusion occurred at the plasma membrane.", [["membranes", "ANATOMY", 43, 52], ["endosomal", "ANATOMY", 153, 162], ["plasma membrane", "ANATOMY", 482, 497], ["ANDV", "CHEMICAL", 337, 341], ["infection", "DISEASE", 342, 351], ["infection", "DISEASE", 444, 453], ["ANDV R2", "GENE_OR_GENE_PRODUCT", 7, 14], ["membranes", "CELLULAR_COMPONENT", 43, 52], ["ANDV", "SIMPLE_CHEMICAL", 117, 121], ["ANDV", "GENE_OR_GENE_PRODUCT", 337, 341], ["ANDV", "GENE_OR_GENE_PRODUCT", 439, 443], ["plasma membrane", "CELLULAR_COMPONENT", 482, 497], ["R2", "PROTEIN", 405, 407], ["ANDV", "SPECIES", 7, 11], ["ANDV", "SPECIES", 337, 341], ["ANDV", "SPECIES", 439, 443], ["a hydropathy segment", "PROBLEM", 56, 76], ["ANDV inhibition", "PROBLEM", 117, 132], ["fusion impairment", "PROBLEM", 176, 193], ["ANDV infection", "PROBLEM", 337, 351], ["ANDV infection", "PROBLEM", 439, 453], ["fusion", "TREATMENT", 459, 465], ["R2 stem", "ANATOMY", 306, 313], ["infection", "OBSERVATION", 342, 351], ["infection", "OBSERVATION", 444, 453], ["plasma membrane", "ANATOMY", 482, 497]]], ["In this sense, modifications to the R2 peptide that favor membrane interaction, such as those introduced to peptides derived from the West Nile virus E stem region [48] or the membrane proximal region of Influenza virus hemagglutinin and HIV gp41 [78, 79] , may help in the future to improve its inhibitory activity and to direct it towards the closed environment of endosomes.DiscussionThe ANDV DIII and stem peptides blocked not only fusion mediated by ANDV glycoproteins, but also the fusion activity of the glycoproteins of another hantavirus (PUUV).", [["membrane", "ANATOMY", 58, 66], ["membrane", "ANATOMY", 176, 184], ["endosomes", "ANATOMY", 367, 376], ["hantavirus", "DISEASE", 536, 546], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["West Nile virus", "ORGANISM", 134, 149], ["membrane", "CELLULAR_COMPONENT", 176, 184], ["Influenza virus hemagglutinin", "ORGANISM", 204, 233], ["HIV gp41", "ORGANISM", 238, 246], ["endosomes", "CELLULAR_COMPONENT", 367, 376], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 391, 400], ["ANDV glycoproteins", "GENE_OR_GENE_PRODUCT", 455, 473], ["hantavirus", "ORGANISM", 536, 546], ["PUUV", "ORGANISM", 548, 552], ["membrane proximal region", "DNA", 176, 200], ["HIV gp41", "PROTEIN", 238, 246], ["ANDV DIII", "PROTEIN", 391, 400], ["ANDV glycoproteins", "PROTEIN", 455, 473], ["glycoproteins", "PROTEIN", 511, 524], ["Nile virus", "SPECIES", 139, 149], ["Influenza virus hemagglutinin", "SPECIES", 204, 233], ["HIV", "SPECIES", 238, 241], ["West Nile virus", "SPECIES", 134, 149], ["Influenza virus hemagglutinin", "SPECIES", 204, 233], ["HIV", "SPECIES", 238, 241], ["ANDV", "SPECIES", 391, 395], ["ANDV", "SPECIES", 455, 459], ["PUUV", "SPECIES", 548, 552], ["membrane interaction", "PROBLEM", 58, 78], ["the West Nile virus E stem region", "TREATMENT", 130, 163], ["Influenza virus hemagglutinin", "TREATMENT", 204, 233], ["HIV gp41", "TEST", 238, 246], ["ANDV glycoproteins", "PROBLEM", 455, 473], ["proximal", "ANATOMY_MODIFIER", 185, 193], ["Influenza virus", "OBSERVATION", 204, 219]]], ["This result is in accordance with the high sequence identity of 72% between DIII of these viruses and also with reports on the cross-inhibition activity of DIII within the genus Alphavirus [72] , where DIII conservation is as high as 50%.", [["DIII", "GENE_OR_GENE_PRODUCT", 76, 80], ["DIII", "GENE_OR_GENE_PRODUCT", 156, 160], ["DIII", "GENE_OR_GENE_PRODUCT", 202, 206], ["DIII", "PROTEIN", 76, 80], ["DIII", "PROTEIN", 156, 160], ["DIII", "PROTEIN", 202, 206], ["viruses", "OBSERVATION", 90, 97], ["genus Alphavirus", "ANATOMY", 172, 188], ["high", "OBSERVATION_MODIFIER", 226, 230]]], ["However, the N-terminal His-tag of ANDV hDIII seemed to prevent the cross-inhibition of PUUV fusion activity, indicating that this tag may interfere in specific binding to Gc from heterologous species.", [["hDIII", "CHEMICAL", 40, 45], ["His", "CHEMICAL", 24, 27], ["ANDV", "GENE_OR_GENE_PRODUCT", 35, 39], ["PUUV", "ORGANISM", 88, 92], ["tag", "GENE_OR_GENE_PRODUCT", 131, 134], ["Gc", "GENE_OR_GENE_PRODUCT", 172, 174], ["N-terminal His-tag", "PROTEIN", 13, 31], ["ANDV hDIII", "PROTEIN", 35, 45], ["Gc", "PROTEIN", 172, 174], ["ANDV", "SPECIES", 35, 39], ["PUUV", "SPECIES", 88, 92], ["PUUV fusion activity", "TREATMENT", 88, 108], ["this tag", "PROBLEM", 126, 134], ["heterologous species", "PROBLEM", 180, 200], ["PUUV fusion", "OBSERVATION", 88, 99]]], ["It is likely that the histidines of the tag become positively charged in the low pH environment, which in turn may induce repulsion with positively charged residues in the Gc of hantaviruses.", [["histidines", "CHEMICAL", 22, 32], ["tag", "GENE_OR_GENE_PRODUCT", 40, 43], ["Gc", "PROTEIN", 172, 174], ["the histidines of the tag", "PROBLEM", 18, 43], ["positively charged residues", "PROBLEM", 137, 164], ["is likely", "UNCERTAINTY", 3, 12], ["low pH", "OBSERVATION_MODIFIER", 77, 83]]], ["Such repulsion may be overcome by a higher binding affinity of DIII to Gc from the same hantavirus, but not to heterologous viruses.", [["hantavirus", "DISEASE", 88, 98], ["DIII", "GENE_OR_GENE_PRODUCT", 63, 67], ["Gc", "GENE_OR_GENE_PRODUCT", 71, 73], ["DIII", "PROTEIN", 63, 67], ["Gc", "PROTEIN", 71, 73], ["the same hantavirus", "PROBLEM", 79, 98], ["heterologous viruses", "PROBLEM", 111, 131]]], ["In addition to the DIII of ANDV, peptides derived from the stem region of ANDV also cross-inhibited the PUUV fusion activity, which further corroborates the presence of conserved residues among hantavirus Gc proteins that are involved in the likely binding of this peptide.", [["stem region", "ANATOMY", 59, 70], ["hantavirus", "DISEASE", 194, 204], ["DIII", "GENE_OR_GENE_PRODUCT", 19, 23], ["ANDV", "GENE_OR_GENE_PRODUCT", 27, 31], ["ANDV", "GENE_OR_GENE_PRODUCT", 74, 78], ["hantavirus", "ORGANISM", 194, 204], ["Gc proteins", "GENE_OR_GENE_PRODUCT", 205, 216], ["DIII", "PROTEIN", 19, 23], ["ANDV", "PROTEIN", 27, 31], ["ANDV", "PROTEIN", 74, 78], ["Gc proteins", "PROTEIN", 205, 216], ["ANDV", "SPECIES", 27, 31], ["ANDV", "SPECIES", 74, 78], ["hantavirus", "SPECIES", 194, 204], ["the PUUV fusion activity", "PROBLEM", 100, 124], ["conserved residues among hantavirus", "PROBLEM", 169, 204], ["Gc proteins", "TEST", 205, 216], ["this peptide", "TREATMENT", 260, 272], ["stem", "ANATOMY_MODIFIER", 59, 63], ["PUUV fusion activity", "OBSERVATION", 104, 124]]], ["Cross-inhibition of fusion proteins by stem peptides has been previously reported for viruses from the genus Flavivirus; Dengue virus stem peptides blocked different Dengue virus serotypes but not other flaviviruses.", [["Dengue", "DISEASE", 121, 127], ["Dengue", "DISEASE", 166, 172], ["Dengue virus stem peptides", "ORGANISM", 121, 147], ["Dengue virus serotypes", "ORGANISM", 166, 188], ["fusion proteins", "PROTEIN", 20, 35], ["Dengue virus", "SPECIES", 121, 133], ["Dengue virus serotypes", "SPECIES", 166, 188], ["Dengue virus", "SPECIES", 121, 133], ["Dengue virus", "SPECIES", 166, 178], ["fusion proteins", "TREATMENT", 20, 35], ["stem peptides", "PROBLEM", 39, 52], ["viruses", "PROBLEM", 86, 93], ["the genus Flavivirus", "PROBLEM", 99, 119], ["Dengue virus stem peptides", "PROBLEM", 121, 147], ["different Dengue virus serotypes", "PROBLEM", 156, 188], ["other flaviviruses", "PROBLEM", 197, 215], ["fusion", "OBSERVATION", 20, 26], ["stem peptides", "OBSERVATION", 39, 52], ["genus Flavivirus", "ANATOMY", 103, 119]]], ["The absence of cross-inhibition in that case was related not to a poor interaction with the respective E protein, but rather to a poor interaction with the viral membrane [48] .", [["membrane", "ANATOMY", 162, 170], ["E", "GENE_OR_GENE_PRODUCT", 103, 104], ["E protein", "PROTEIN", 103, 112], ["the respective E protein", "TEST", 88, 112]]], ["Finally, stem peptides derived from the RVFV Gc protein have been reported to block the three different classes of viral fusion proteins [46] , acting as a broad-spectrum fusion inhibitor [80] .", [["RVFV", "ORGANISM", 40, 44], ["Gc", "GENE_OR_GENE_PRODUCT", 45, 47], ["RVFV Gc protein", "PROTEIN", 40, 55], ["viral fusion proteins", "PROTEIN", 115, 136], ["RVFV", "SPECIES", 40, 44], ["stem peptides", "TEST", 9, 22], ["the RVFV Gc protein", "TEST", 36, 55], ["viral fusion proteins", "TREATMENT", 115, 136], ["a broad-spectrum fusion inhibitor", "TREATMENT", 154, 187], ["viral fusion", "OBSERVATION", 115, 127]]], ["For the exogenous stem peptides from ANDV we did not observe cross-inhibition of other fusion proteins such as that of VSV at concentrations up to 60 \u03bcM.", [["ANDV", "SIMPLE_CHEMICAL", 37, 41], ["VSV", "ORGANISM", 119, 122], ["fusion proteins", "PROTEIN", 87, 102], ["ANDV", "SPECIES", 37, 41], ["VSV", "SPECIES", 119, 122], ["other fusion proteins", "TREATMENT", 81, 102], ["exogenous stem peptides", "OBSERVATION", 8, 31]]], ["Therefore, it is more likely that the ANDV stem fragments may be applied to inhibit similar viruses within the same genus, but not other viral fusion machineries.DiscussionTaken as a whole, our results demonstrate that strategies employed against class II fusion proteins allow for the inhibition of hantaviruses such as ANDV and PUUV.", [["stem fragments", "ANATOMY", 43, 57], ["PUUV", "DISEASE", 330, 334], ["hantaviruses", "ORGANISM", 300, 312], ["ANDV", "GENE_OR_GENE_PRODUCT", 321, 325], ["PUUV", "ORGANISM", 330, 334], ["ANDV stem fragments", "DNA", 38, 57], ["class II fusion proteins", "PROTEIN", 247, 271], ["ANDV", "SPECIES", 38, 42], ["ANDV", "SPECIES", 321, 325], ["PUUV", "SPECIES", 330, 334], ["the ANDV stem fragments", "PROBLEM", 34, 57], ["similar viruses", "PROBLEM", 84, 99], ["other viral fusion machineries", "PROBLEM", 131, 161], ["class II fusion proteins", "TREATMENT", 247, 271], ["hantaviruses", "TREATMENT", 300, 312], ["is more likely", "UNCERTAINTY", 14, 28], ["stem fragments", "OBSERVATION", 43, 57], ["viruses", "OBSERVATION", 92, 99], ["not other", "UNCERTAINTY", 127, 136], ["viral fusion", "OBSERVATION", 137, 149], ["PUUV", "OBSERVATION", 330, 334]]], ["Although targeting the endosomal site of virus fusion has not yet been optimized, it was possible to block fusion and infection under physiological virus entry conditions.", [["endosomal site", "ANATOMY", 23, 37], ["infection", "DISEASE", 118, 127], ["endosomal", "CELLULAR_COMPONENT", 23, 32], ["endosomal site", "DNA", 23, 37], ["virus fusion", "TREATMENT", 41, 53], ["block fusion", "PROBLEM", 101, 113], ["infection under physiological virus entry conditions", "PROBLEM", 118, 170], ["virus fusion", "OBSERVATION", 41, 53], ["infection", "OBSERVATION", 118, 127]]], ["Hopefully, the novel inhibitory strategy based on ANDV DIII and stem peptides will help in the future development of therapeutic strategies against different hantaviruses.DiscussionSupporting Information S1 Table.", [["hantaviruses", "DISEASE", 158, 170], ["ANDV DIII", "GENE_OR_GENE_PRODUCT", 50, 59], ["stem peptides", "GENE_OR_GENE_PRODUCT", 64, 77], ["ANDV DIII", "PROTEIN", 50, 59], ["ANDV", "SPECIES", 50, 54], ["the novel inhibitory strategy", "TREATMENT", 11, 40], ["ANDV DIII", "TREATMENT", 50, 59], ["stem peptides", "TREATMENT", 64, 77], ["therapeutic strategies", "TREATMENT", 117, 139], ["different hantaviruses", "PROBLEM", 148, 170]]], ["Prediction of hydropathy segments.", [["hydropathy segments", "PROBLEM", 14, 33], ["hydropathy", "OBSERVATION", 14, 24], ["segments", "ANATOMY_MODIFIER", 25, 33]]]], "PMC7102867": [["OverviewFetal thrombotic vasculopathy (FTV) is a vascular thrombotic condition causing obstruction of arteries and veins in the fetal circulation of the placenta, resulting in ischemic changes in the villi peripheral to the obstruction.", [["vascular", "ANATOMY", 49, 57], ["arteries", "ANATOMY", 102, 110], ["veins", "ANATOMY", 115, 120], ["fetal", "ANATOMY", 128, 133], ["placenta", "ANATOMY", 153, 161], ["villi", "ANATOMY", 200, 205], ["thrombotic vasculopathy", "DISEASE", 14, 37], ["FTV", "DISEASE", 39, 42], ["vascular thrombotic condition", "DISEASE", 49, 78], ["obstruction of arteries and veins", "DISEASE", 87, 120], ["obstruction", "DISEASE", 224, 235], ["vascular", "MULTI-TISSUE_STRUCTURE", 49, 57], ["arteries", "MULTI-TISSUE_STRUCTURE", 102, 110], ["veins", "MULTI-TISSUE_STRUCTURE", 115, 120], ["fetal circulation", "MULTI-TISSUE_STRUCTURE", 128, 145], ["placenta", "ORGAN", 153, 161], ["villi peripheral", "TISSUE", 200, 216], ["FTV", "SPECIES", 39, 42], ["OverviewFetal thrombotic vasculopathy", "PROBLEM", 0, 37], ["a vascular thrombotic condition", "PROBLEM", 47, 78], ["obstruction of arteries and veins in the fetal circulation of the placenta", "PROBLEM", 87, 161], ["ischemic changes in the villi peripheral to the obstruction", "PROBLEM", 176, 235], ["thrombotic", "OBSERVATION_MODIFIER", 14, 24], ["vasculopathy", "OBSERVATION", 25, 37], ["vascular", "ANATOMY", 49, 57], ["thrombotic", "OBSERVATION", 58, 68], ["obstruction", "OBSERVATION", 87, 98], ["arteries", "ANATOMY", 102, 110], ["veins", "ANATOMY", 115, 120], ["fetal", "ANATOMY_MODIFIER", 128, 133], ["circulation", "ANATOMY_MODIFIER", 134, 145], ["placenta", "ANATOMY", 153, 161], ["ischemic", "OBSERVATION", 176, 184], ["villi", "ANATOMY", 200, 205], ["peripheral", "ANATOMY_MODIFIER", 206, 216], ["obstruction", "OBSERVATION", 224, 235]]], ["When sufficiently extensive, FTV may cause a reduction in functional placental reserve or in other cases may be associated with additional thrombotic or thromboembolic events in the somatic vessels of the fetus itself.", [["placental", "ANATOMY", 69, 78], ["somatic vessels", "ANATOMY", 182, 197], ["fetus", "ANATOMY", 205, 210], ["thrombotic", "DISEASE", 139, 149], ["thromboembolic", "DISEASE", 153, 167], ["placental", "ORGAN", 69, 78], ["somatic vessels", "MULTI-TISSUE_STRUCTURE", 182, 197], ["fetus", "ORGAN", 205, 210], ["a reduction in functional placental reserve", "PROBLEM", 43, 86], ["additional thrombotic or thromboembolic events", "PROBLEM", 128, 174], ["may cause", "UNCERTAINTY", 33, 42], ["reduction", "OBSERVATION_MODIFIER", 45, 54], ["functional placental reserve", "OBSERVATION", 58, 86], ["may be associated with", "UNCERTAINTY", 105, 127], ["thrombotic", "OBSERVATION", 139, 149], ["thromboembolic", "OBSERVATION", 153, 167], ["somatic vessels", "OBSERVATION", 182, 197], ["fetus", "ANATOMY", 205, 210]]], ["When extensive, the former condition can lead to fetal growth restriction or stillbirth, whereas the latter may result in infarcts of various fetal structures, such as the brain, kidney, or, rarely, an extremity, such as an arm or leg.", [["fetal", "ANATOMY", 49, 54], ["fetal structures", "ANATOMY", 142, 158], ["brain", "ANATOMY", 172, 177], ["kidney", "ANATOMY", 179, 185], ["extremity", "ANATOMY", 202, 211], ["arm", "ANATOMY", 224, 227], ["leg", "ANATOMY", 231, 234], ["stillbirth", "DISEASE", 77, 87], ["infarcts", "DISEASE", 122, 130], ["fetal structures", "TISSUE", 142, 158], ["brain", "ORGAN", 172, 177], ["kidney", "ORGAN", 179, 185], ["extremity", "ORGANISM_SUBDIVISION", 202, 211], ["arm", "ORGANISM_SUBDIVISION", 224, 227], ["leg", "ORGANISM_SUBDIVISION", 231, 234], ["fetal growth restriction", "PROBLEM", 49, 73], ["stillbirth", "PROBLEM", 77, 87], ["infarcts of various fetal structures", "PROBLEM", 122, 158], ["infarcts", "OBSERVATION", 122, 130], ["various fetal structures", "OBSERVATION", 134, 158], ["brain", "ANATOMY", 172, 177], ["kidney", "ANATOMY", 179, 185], ["extremity", "ANATOMY", 202, 211], ["arm", "ANATOMY", 224, 227], ["leg", "ANATOMY", 231, 234]]], ["As with intravascular clotting in general, causal factors of FTV include a combination of the triad of stasis (by compression of cord or aberrant vessels); a thrombophilic state, both genetic (eg, protein S or factor V Leiden) and acquired (anticardiolipin antibody and so forth); and vascular injury (inflammatory and localized compression).", [["intravascular", "ANATOMY", 8, 21], ["cord", "ANATOMY", 129, 133], ["vessels", "ANATOMY", 146, 153], ["vascular", "ANATOMY", 285, 293], ["intravascular clotting", "DISEASE", 8, 30], ["FTV", "DISEASE", 61, 64], ["stasis", "DISEASE", 103, 109], ["vascular injury", "DISEASE", 285, 300], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 8, 21], ["cord", "ORGAN", 129, 133], ["vessels", "MULTI-TISSUE_STRUCTURE", 146, 153], ["protein S", "GENE_OR_GENE_PRODUCT", 197, 206], ["factor V Leiden", "GENE_OR_GENE_PRODUCT", 210, 225], ["anticardiolipin antibody", "GENE_OR_GENE_PRODUCT", 241, 265], ["vascular", "MULTI-TISSUE_STRUCTURE", 285, 293], ["protein S", "PROTEIN", 197, 206], ["factor V Leiden", "PROTEIN", 210, 225], ["anticardiolipin antibody", "PROTEIN", 241, 265], ["intravascular clotting", "PROBLEM", 8, 30], ["FTV", "PROBLEM", 61, 64], ["the triad of stasis", "PROBLEM", 90, 109], ["aberrant vessels)", "PROBLEM", 137, 154], ["a thrombophilic state", "PROBLEM", 156, 177], ["protein S", "TEST", 197, 206], ["factor V Leiden", "TEST", 210, 225], ["acquired (anticardiolipin antibody", "PROBLEM", 231, 265], ["vascular injury (inflammatory and localized compression)", "PROBLEM", 285, 341], ["intravascular", "OBSERVATION_MODIFIER", 8, 21], ["clotting", "OBSERVATION", 22, 30], ["stasis", "OBSERVATION", 103, 109], ["cord", "ANATOMY", 129, 133], ["vessels", "ANATOMY", 146, 153], ["thrombophilic", "OBSERVATION", 158, 171], ["vascular", "ANATOMY", 285, 293], ["injury", "OBSERVATION", 294, 300], ["inflammatory", "OBSERVATION_MODIFIER", 302, 314]]], ["The most serious outcomes include growth restriction, neurologic injury, and perinatal death.Key Features FTV: Potential Morphologic or Clinical Associations and SequelaeObstructive cord lesion or cord accident (common)Admit to neonatal ICU; normal at discharge (common)Neonatal encephalopathy (%)Cerebral palsy (rare); includes cerebral infarct, porencephalic cyst, hypoxic-ischemic encephalopathyStillbirth (uncommon)Intrauterine growth restriction (uncommon)OligohydramniosMaternal diabetes mellitus (common)Maternal autoimmune disease (lupus, anticardiolipin antibodies, and so forth) (uncommon)Severe acute respiratory syndrome (rare)Cytomegalovirus, Toxoplasma gondii (rare)Transverse limb reduction (rare)Maternal thrombophilic state (occurs equally in nonthrombophilic mothers)", [["neurologic", "ANATOMY", 54, 64], ["cord lesion", "ANATOMY", 182, 193], ["cord", "ANATOMY", 197, 201], ["Cerebral", "ANATOMY", 297, 305], ["cerebral", "ANATOMY", 329, 337], ["porencephalic cyst", "ANATOMY", 347, 365], ["limb", "ANATOMY", 691, 695], ["neurologic injury", "DISEASE", 54, 71], ["death", "DISEASE", 87, 92], ["cord lesion", "DISEASE", 182, 193], ["cord accident", "DISEASE", 197, 210], ["Neonatal encephalopathy", "DISEASE", 270, 293], ["Cerebral palsy", "DISEASE", 297, 311], ["cerebral infarct", "DISEASE", 329, 345], ["porencephalic cyst", "DISEASE", 347, 365], ["hypoxic-ischemic encephalopathy", "DISEASE", 367, 398], ["Stillbirth", "DISEASE", 398, 408], ["Intrauterine growth restriction", "DISEASE", 419, 450], ["Maternal diabetes mellitus", "DISEASE", 476, 502], ["Maternal autoimmune disease", "DISEASE", 511, 538], ["lupus", "DISEASE", 540, 545], ["acute respiratory syndrome", "DISEASE", 606, 632], ["Toxoplasma gondii", "DISEASE", 656, 673], ["Transverse limb reduction", "DISEASE", 680, 705], ["Maternal thrombophilic state", "DISEASE", 712, 740], ["cord", "ORGAN", 182, 186], ["cord", "ORGAN", 197, 201], ["cerebral", "ORGAN", 329, 337], ["anticardiolipin antibodies", "GENE_OR_GENE_PRODUCT", 547, 573], ["Cytomegalovirus", "ORGANISM", 639, 654], ["Toxoplasma gondii", "ORGANISM", 656, 673], ["limb", "ORGANISM_SUBDIVISION", 691, 695], ["anticardiolipin antibodies", "PROTEIN", 547, 573], ["Toxoplasma gondii", "SPECIES", 656, 673], ["Toxoplasma gondii", "SPECIES", 656, 673], ["growth restriction", "PROBLEM", 34, 52], ["neurologic injury", "PROBLEM", 54, 71], ["perinatal death", "PROBLEM", 77, 92], ["Clinical Associations", "PROBLEM", 136, 157], ["SequelaeObstructive cord lesion", "PROBLEM", 162, 193], ["Neonatal encephalopathy", "PROBLEM", 270, 293], ["Cerebral palsy (rare)", "PROBLEM", 297, 318], ["cerebral infarct", "PROBLEM", 329, 345], ["porencephalic cyst", "PROBLEM", 347, 365], ["hypoxic-ischemic encephalopathyStillbirth", "PROBLEM", 367, 408], ["Intrauterine growth restriction", "PROBLEM", 419, 450], ["OligohydramniosMaternal diabetes mellitus", "PROBLEM", 461, 502], ["Maternal autoimmune disease", "PROBLEM", 511, 538], ["lupus", "PROBLEM", 540, 545], ["anticardiolipin antibodies", "PROBLEM", 547, 573], ["Severe acute respiratory syndrome", "PROBLEM", 599, 632], ["Cytomegalovirus, Toxoplasma gondii", "PROBLEM", 639, 673], ["Transverse limb reduction", "PROBLEM", 680, 705], ["Maternal thrombophilic state", "PROBLEM", 712, 740], ["most serious", "OBSERVATION_MODIFIER", 4, 16], ["growth restriction", "OBSERVATION", 34, 52], ["neurologic injury", "OBSERVATION", 54, 71], ["cord", "ANATOMY", 182, 186], ["lesion", "OBSERVATION", 187, 193], ["cord", "ANATOMY", 197, 201], ["encephalopathy", "OBSERVATION", 279, 293], ["Cerebral", "ANATOMY", 297, 305], ["palsy", "OBSERVATION", 306, 311], ["cerebral", "ANATOMY", 329, 337], ["infarct", "OBSERVATION", 338, 345], ["porencephalic", "ANATOMY", 347, 360], ["cyst", "OBSERVATION", 361, 365], ["hypoxic", "OBSERVATION_MODIFIER", 367, 374], ["ischemic", "OBSERVATION_MODIFIER", 375, 383], ["encephalopathy", "OBSERVATION", 384, 398], ["Oligohydramnios", "OBSERVATION", 461, 476], ["autoimmune disease", "OBSERVATION", 520, 538], ["lupus", "OBSERVATION", 540, 545], ["Severe", "OBSERVATION_MODIFIER", 599, 605], ["acute", "OBSERVATION_MODIFIER", 606, 611], ["respiratory syndrome", "OBSERVATION", 612, 632], ["Cytomegalovirus", "OBSERVATION", 639, 654], ["limb", "ANATOMY", 691, 695], ["thrombophilic", "OBSERVATION", 721, 734]]]], "PMC7468344": [["IntroductionCardiopulmonary resuscitation (CPR) was developed in 1960 when the American Heart Association started a program to familiarize physicians with closed chest cardiac resuscitation as well as educating the general public.", [["Cardiopulmonary", "ANATOMY", 12, 27], ["chest cardiac", "ANATOMY", 162, 175], ["Cardiopulmonary resuscitation", "TREATMENT", 12, 41], ["closed chest cardiac resuscitation", "TREATMENT", 155, 189], ["chest", "ANATOMY", 162, 167]]], ["While CPR can be potentially life-saving, it can lead to unanticipated traumatic complications.", [["CPR", "TREATMENT", 6, 9], ["unanticipated traumatic complications", "PROBLEM", 57, 94], ["traumatic", "OBSERVATION_MODIFIER", 71, 80], ["complications", "OBSERVATION", 81, 94]]], ["Bony injuries, in particular fractures of the ribs and sternum, are the most frequently reported complications of chest compressions.", [["Bony", "ANATOMY", 0, 4], ["ribs", "ANATOMY", 46, 50], ["sternum", "ANATOMY", 55, 62], ["chest", "ANATOMY", 114, 119], ["Bony injuries", "DISEASE", 0, 13], ["fractures", "DISEASE", 29, 38], ["ribs", "ORGAN", 46, 50], ["sternum", "ORGAN", 55, 62], ["chest", "ORGANISM_SUBDIVISION", 114, 119], ["Bony injuries", "PROBLEM", 0, 13], ["particular fractures of the ribs and sternum", "PROBLEM", 18, 62], ["chest compressions", "TREATMENT", 114, 132], ["injuries", "OBSERVATION", 5, 13], ["fractures", "OBSERVATION", 29, 38], ["ribs", "ANATOMY", 46, 50], ["sternum", "ANATOMY", 55, 62], ["chest", "ANATOMY", 114, 119], ["compressions", "OBSERVATION", 120, 132]]], ["Vertebral body fractures can also occur, but they are seldom diagnosed and rarely reported in the literature [1].", [["Vertebral body", "ANATOMY", 0, 14], ["Vertebral body fractures", "DISEASE", 0, 24], ["Vertebral body", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Vertebral body fractures", "PROBLEM", 0, 24], ["body", "ANATOMY_MODIFIER", 10, 14], ["fractures", "OBSERVATION", 15, 24]]], ["We describe an extremely rare case of a COVID-19 positive, 79-year-old female who had a cardiac arrest with CPR, resulting in a widely diastatic spinal separation at the T12-L1 intervertebral disc space with L1 spinous process fracture.Case reportA 79-year-old female with a history of diabetes, hypertension, osteoarthritis, morbid obesity, and chronic lymphedema arrived to her local community hospital for multiple episodes of coffee ground emesis.", [["cardiac", "ANATOMY", 88, 95], ["spinal", "ANATOMY", 145, 151], ["cardiac arrest", "DISEASE", 88, 102], ["fracture", "DISEASE", 227, 235], ["diabetes", "DISEASE", 286, 294], ["hypertension", "DISEASE", 296, 308], ["osteoarthritis", "DISEASE", 310, 324], ["morbid obesity", "DISEASE", 326, 340], ["chronic lymphedema", "DISEASE", 346, 364], ["coffee ground emesis", "DISEASE", 430, 450], ["COVID-19", "CANCER", 40, 48], ["female", "ORGANISM", 71, 77], ["spinal", "ORGAN", 145, 151], ["female", "ORGANISM", 261, 267], ["a cardiac arrest", "PROBLEM", 86, 102], ["CPR", "TREATMENT", 108, 111], ["a widely diastatic spinal separation", "PROBLEM", 126, 162], ["L1 spinous process fracture", "PROBLEM", 208, 235], ["diabetes", "PROBLEM", 286, 294], ["hypertension", "PROBLEM", 296, 308], ["osteoarthritis", "PROBLEM", 310, 324], ["morbid obesity", "PROBLEM", 326, 340], ["chronic lymphedema", "PROBLEM", 346, 364], ["coffee ground emesis", "PROBLEM", 430, 450], ["cardiac", "ANATOMY", 88, 95], ["arrest", "OBSERVATION", 96, 102], ["widely", "OBSERVATION_MODIFIER", 128, 134], ["diastatic", "OBSERVATION", 135, 144], ["spinal", "ANATOMY", 145, 151], ["separation", "OBSERVATION", 152, 162], ["T12", "ANATOMY_MODIFIER", 170, 173], ["L1", "ANATOMY_MODIFIER", 174, 176], ["intervertebral", "ANATOMY_MODIFIER", 177, 191], ["disc", "ANATOMY", 192, 196], ["space", "ANATOMY_MODIFIER", 197, 202], ["L1", "ANATOMY_MODIFIER", 208, 210], ["spinous", "ANATOMY_MODIFIER", 211, 218], ["fracture", "OBSERVATION", 227, 235], ["diabetes", "OBSERVATION", 286, 294], ["hypertension", "OBSERVATION", 296, 308], ["osteoarthritis", "OBSERVATION", 310, 324], ["morbid", "OBSERVATION_MODIFIER", 326, 332], ["obesity", "OBSERVATION", 333, 340], ["chronic", "OBSERVATION_MODIFIER", 346, 353], ["lymphedema", "OBSERVATION", 354, 364], ["coffee ground emesis", "OBSERVATION", 430, 450]]], ["She was complaining of nausea, vomiting, abdominal pain, and had multiple abdominal hernia repairs in the past.", [["abdominal", "ANATOMY", 41, 50], ["abdominal hernia", "ANATOMY", 74, 90], ["nausea", "DISEASE", 23, 29], ["vomiting", "DISEASE", 31, 39], ["abdominal pain", "DISEASE", 41, 55], ["abdominal hernia", "DISEASE", 74, 90], ["abdominal", "ORGANISM_SUBDIVISION", 41, 50], ["abdominal hernia", "PATHOLOGICAL_FORMATION", 74, 90], ["nausea", "PROBLEM", 23, 29], ["vomiting", "PROBLEM", 31, 39], ["abdominal pain", "PROBLEM", 41, 55], ["multiple abdominal hernia repairs", "TREATMENT", 65, 98], ["abdominal", "ANATOMY", 41, 50], ["pain", "OBSERVATION", 51, 55], ["multiple", "OBSERVATION_MODIFIER", 65, 73], ["abdominal", "ANATOMY", 74, 83], ["hernia", "OBSERVATION", 84, 90], ["repairs", "OBSERVATION", 91, 98]]], ["The patient was diagnosed with a small bowel obstruction and taken for exploratory laparotomy by general surgery.", [["bowel", "ANATOMY", 39, 44], ["bowel obstruction", "DISEASE", 39, 56], ["patient", "ORGANISM", 4, 11], ["bowel", "ORGAN", 39, 44], ["patient", "SPECIES", 4, 11], ["a small bowel obstruction", "PROBLEM", 31, 56], ["exploratory laparotomy", "TEST", 71, 93], ["general surgery", "TREATMENT", 97, 112], ["small", "OBSERVATION_MODIFIER", 33, 38], ["bowel", "ANATOMY", 39, 44], ["obstruction", "OBSERVATION", 45, 56], ["laparotomy", "OBSERVATION", 83, 93]]], ["Postoperatively the patient required continued mechanical ventilation and was unable to be weaned off the ventilator for 7 days.Case reportA computed tomography (CT) scan of the chest/abdomen/pelvis (C/A/P) was done that showed a small right pleural effusion with associated passive atelectasis and possible right lower lobe pneumonia.", [["chest", "ANATOMY", 178, 183], ["abdomen", "ANATOMY", 184, 191], ["pelvis", "ANATOMY", 192, 198], ["right pleural effusion", "ANATOMY", 236, 258], ["right lower lobe", "ANATOMY", 308, 324], ["pleural effusion", "DISEASE", 242, 258], ["atelectasis", "DISEASE", 283, 294], ["right lower lobe pneumonia", "DISEASE", 308, 334], ["patient", "ORGANISM", 20, 27], ["chest", "ORGANISM_SUBDIVISION", 178, 183], ["abdomen", "ORGAN", 184, 191], ["pelvis", "ORGAN", 192, 198], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 314, 324], ["patient", "SPECIES", 20, 27], ["continued mechanical ventilation", "TREATMENT", 37, 69], ["the ventilator", "TREATMENT", 102, 116], ["Case reportA computed tomography", "TEST", 128, 160], ["CT) scan of the chest/abdomen/pelvis (C/A/P)", "TEST", 162, 206], ["a small right pleural effusion", "PROBLEM", 228, 258], ["passive atelectasis", "PROBLEM", 275, 294], ["right lower lobe pneumonia", "PROBLEM", 308, 334], ["mechanical ventilation", "OBSERVATION", 47, 69], ["chest", "ANATOMY", 178, 183], ["abdomen", "ANATOMY", 184, 191], ["pelvis", "ANATOMY", 192, 198], ["small", "OBSERVATION_MODIFIER", 230, 235], ["right", "ANATOMY_MODIFIER", 236, 241], ["pleural", "ANATOMY", 242, 249], ["effusion", "OBSERVATION", 250, 258], ["passive", "OBSERVATION_MODIFIER", 275, 282], ["atelectasis", "OBSERVATION", 283, 294], ["possible", "UNCERTAINTY", 299, 307], ["right lower lobe", "ANATOMY", 308, 324], ["pneumonia", "OBSERVATION", 325, 334]]], ["Severe degenerative changes were present throughout the spine consistent with diffuse idiopathic skeletal hyperostosis (DISH) and also demonstrated a significant kyphosis (Figs.", [["spine", "ANATOMY", 56, 61], ["skeletal", "ANATOMY", 97, 105], ["idiopathic skeletal hyperostosis", "DISEASE", 86, 118], ["DISH", "DISEASE", 120, 124], ["kyphosis", "DISEASE", 162, 170], ["spine", "ORGAN", 56, 61], ["skeletal", "ORGAN", 97, 105], ["Severe degenerative changes", "PROBLEM", 0, 27], ["diffuse idiopathic skeletal hyperostosis", "PROBLEM", 78, 118], ["a significant kyphosis (Figs", "PROBLEM", 148, 176], ["degenerative", "OBSERVATION", 7, 19], ["spine", "ANATOMY", 56, 61], ["consistent with", "UNCERTAINTY", 62, 77], ["diffuse", "OBSERVATION_MODIFIER", 78, 85], ["idiopathic", "OBSERVATION_MODIFIER", 86, 96], ["skeletal", "ANATOMY", 97, 105], ["hyperostosis", "OBSERVATION", 106, 118], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["kyphosis", "OBSERVATION", 162, 170]]], ["1a andb,Fig. 2).Case reportShe was initially successfully extubated to bilevel positive airway pressure (BiPAP), but 3 days later the patient became hypoxic and had a pulseless electrical activity cardiac arrest.", [["airway", "ANATOMY", 88, 94], ["cardiac", "ANATOMY", 197, 204], ["cardiac arrest", "DISEASE", 197, 211], ["airway", "MULTI-TISSUE_STRUCTURE", 88, 94], ["patient", "ORGANISM", 134, 141], ["cardiac", "ORGAN", 197, 204], ["patient", "SPECIES", 134, 141], ["bilevel positive airway pressure", "TREATMENT", 71, 103], ["BiPAP", "TREATMENT", 105, 110], ["hypoxic", "PROBLEM", 149, 156], ["a pulseless electrical activity cardiac arrest", "PROBLEM", 165, 211], ["airway pressure", "OBSERVATION", 88, 103], ["hypoxic", "OBSERVATION_MODIFIER", 149, 156], ["arrest", "OBSERVATION", 205, 211]]], ["The patient underwent 18 minutes of CPR with return of spontaneous circulation.Case reportAfter the patient's cardiac arrest, she was again unable to be weaned from the ventilator.", [["cardiac", "ANATOMY", 110, 117], ["cardiac arrest", "DISEASE", 110, 124], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 100, 107], ["cardiac", "ORGAN", 110, 117], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 100, 107], ["CPR", "TREATMENT", 36, 39], ["the ventilator", "TREATMENT", 165, 179], ["cardiac", "ANATOMY", 110, 117], ["arrest", "OBSERVATION", 118, 124]]], ["A Covid-19 swab was sent that resulted positive, and a repeat CT of the C/A/P was ordered.", [["swab", "ANATOMY", 11, 15], ["P", "DNA", 76, 77], ["A Covid-19 swab", "TEST", 0, 15], ["positive", "PROBLEM", 39, 47], ["a repeat CT", "TEST", 53, 64], ["the C/A/P", "TEST", 68, 77]]], ["CT now demonstrated a widely diastatic spinal separation at the T12/L1 intervertebral disc space with L1 spinous process fracture in the context of multilevel vertebral fusion, reflecting diffuse idiopathic skeletal hyperostosis (Fig. 3).", [["spinal", "ANATOMY", 39, 45], ["intervertebral disc space", "ANATOMY", 71, 96], ["vertebral", "ANATOMY", 159, 168], ["skeletal", "ANATOMY", 207, 215], ["fracture", "DISEASE", 121, 129], ["idiopathic skeletal hyperostosis", "DISEASE", 196, 228], ["vertebral", "ORGAN", 159, 168], ["skeletal", "ORGAN", 207, 215], ["CT", "TEST", 0, 2], ["a widely diastatic spinal separation at the T12/L1 intervertebral disc space", "PROBLEM", 20, 96], ["L1 spinous process fracture", "PROBLEM", 102, 129], ["multilevel vertebral fusion", "PROBLEM", 148, 175], ["diffuse idiopathic skeletal hyperostosis", "PROBLEM", 188, 228], ["widely", "OBSERVATION_MODIFIER", 22, 28], ["diastatic", "OBSERVATION", 29, 38], ["spinal", "ANATOMY", 39, 45], ["separation", "OBSERVATION", 46, 56], ["T12", "ANATOMY_MODIFIER", 64, 67], ["L1", "ANATOMY_MODIFIER", 68, 70], ["intervertebral", "ANATOMY_MODIFIER", 71, 85], ["disc", "ANATOMY", 86, 90], ["space", "ANATOMY_MODIFIER", 91, 96], ["L1", "ANATOMY_MODIFIER", 102, 104], ["spinous", "ANATOMY_MODIFIER", 105, 112], ["fracture", "OBSERVATION", 121, 129], ["multilevel", "OBSERVATION_MODIFIER", 148, 158], ["vertebral", "ANATOMY", 159, 168], ["fusion", "OBSERVATION", 169, 175], ["diffuse", "OBSERVATION_MODIFIER", 188, 195], ["idiopathic", "OBSERVATION_MODIFIER", 196, 206], ["skeletal", "ANATOMY", 207, 215], ["hyperostosis", "OBSERVATION", 216, 228]]], ["Multiple bilateral rib fractures compatible with sequela of chest compressions were also demonstrated.", [["rib", "ANATOMY", 19, 22], ["chest", "ANATOMY", 60, 65], ["fractures", "DISEASE", 23, 32], ["chest", "ORGANISM_SUBDIVISION", 60, 65], ["Multiple bilateral rib fractures", "PROBLEM", 0, 32], ["chest compressions", "PROBLEM", 60, 78], ["bilateral", "ANATOMY_MODIFIER", 9, 18], ["rib", "ANATOMY", 19, 22], ["fractures", "OBSERVATION", 23, 32], ["compatible with", "UNCERTAINTY", 33, 48], ["sequela", "OBSERVATION_MODIFIER", 49, 56], ["chest", "ANATOMY", 60, 65], ["compressions", "OBSERVATION", 66, 78]]], ["The patient's initial hospital was not equipped to perform magnetic resonance imaging (MRI) for an intubated patient and did not have neurosurgical specialty consultation available.", [["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 109, 116], ["magnetic resonance imaging", "TEST", 59, 85], ["MRI", "TEST", 87, 90]]], ["After discussion with the patient's family, she was subsequently transferred to our tertiary care facility for both neurosurgical evaluation and advanced imaging to include MRI.Case reportOn arrival, the patient's neurologic exam showed pupils were equal, round, and briskly reactive to light bilaterally, eye opening to voice, nonverbal secondary to intubation, and withdrawal to pain of all 4 extremities.", [["neurologic", "ANATOMY", 214, 224], ["eye", "ANATOMY", 306, 309], ["extremities", "ANATOMY", 395, 406], ["pain", "DISEASE", 381, 385], ["patient", "ORGANISM", 26, 33], ["patient", "ORGANISM", 204, 211], ["eye", "ORGAN", 306, 309], ["extremities", "ORGANISM_SUBDIVISION", 395, 406], ["patient", "SPECIES", 26, 33], ["patient", "SPECIES", 204, 211], ["both neurosurgical evaluation", "TEST", 111, 140], ["advanced imaging", "TEST", 145, 161], ["MRI", "TEST", 173, 176], ["the patient's neurologic exam", "TEST", 200, 229], ["intubation", "TREATMENT", 351, 361], ["withdrawal to pain of all 4 extremities", "PROBLEM", 367, 406], ["round", "OBSERVATION_MODIFIER", 256, 261], ["reactive", "OBSERVATION", 275, 283], ["bilaterally", "ANATOMY_MODIFIER", 293, 304], ["eye", "ANATOMY", 306, 309]]], ["The bilateral upper extremities briskly withdrew to painful stimulation, with the bilateral lower extremities only withdrawing minimally to painful stimulation.", [["upper extremities", "ANATOMY", 14, 31], ["lower extremities", "ANATOMY", 92, 109], ["upper extremities", "ORGANISM_SUBDIVISION", 14, 31], ["lower extremities", "ORGANISM_SUBDIVISION", 92, 109], ["painful stimulation", "TEST", 52, 71], ["painful stimulation", "TEST", 140, 159], ["bilateral", "ANATOMY_MODIFIER", 4, 13], ["upper extremities", "ANATOMY", 14, 31], ["painful stimulation", "OBSERVATION", 52, 71], ["bilateral", "ANATOMY_MODIFIER", 82, 91], ["lower extremities", "ANATOMY", 92, 109]]], ["The patient was diffusely hyporeflexic in all 4 extremities.", [["extremities", "ANATOMY", 48, 59], ["patient", "ORGANISM", 4, 11], ["extremities", "ORGANISM_SUBDIVISION", 48, 59], ["patient", "SPECIES", 4, 11], ["diffusely hyporeflexic in all 4 extremities", "PROBLEM", 16, 59], ["diffusely", "OBSERVATION_MODIFIER", 16, 25], ["hyporeflexic", "OBSERVATION", 26, 38], ["all 4", "ANATOMY_MODIFIER", 42, 47], ["extremities", "ANATOMY", 48, 59]]], ["Her exam was consistent with an ASIA C spinal cord injury.Case reportMRI of the lumbar spine was performed and showed severe cord compression at the level of the conus medullaris at T12-L1 secondary to displacement of the superior articular facets of L1 with a small ventral epidural hematoma, and abnormal soft tissue in the ventral epidural space at L2 suggesting some additional epidural hemorrhage.", [["spinal cord", "ANATOMY", 39, 50], ["lumbar spine", "ANATOMY", 80, 92], ["cord", "ANATOMY", 125, 129], ["conus medullaris", "ANATOMY", 162, 178], ["superior articular facets", "ANATOMY", 222, 247], ["ventral epidural hematoma", "ANATOMY", 267, 292], ["soft tissue", "ANATOMY", 307, 318], ["ventral epidural space", "ANATOMY", 326, 348], ["epidural", "ANATOMY", 382, 390], ["cord injury", "DISEASE", 46, 57], ["cord compression", "DISEASE", 125, 141], ["epidural hematoma", "DISEASE", 275, 292], ["epidural hemorrhage", "DISEASE", 382, 401], ["cord", "ORGAN", 46, 50], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 80, 92], ["cord", "ORGAN", 125, 129], ["conus medullaris", "MULTI-TISSUE_STRUCTURE", 162, 178], ["epidural hematoma", "PATHOLOGICAL_FORMATION", 275, 292], ["soft tissue", "TISSUE", 307, 318], ["ventral epidural space", "MULTI-TISSUE_STRUCTURE", 326, 348], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 382, 390], ["Her exam", "TEST", 0, 8], ["an ASIA C spinal cord injury", "PROBLEM", 29, 57], ["Case reportMRI of the lumbar spine", "TEST", 58, 92], ["severe cord compression", "PROBLEM", 118, 141], ["displacement of the superior articular facets of L1", "PROBLEM", 202, 253], ["a small ventral epidural hematoma", "PROBLEM", 259, 292], ["abnormal soft tissue in the ventral epidural space at L2", "PROBLEM", 298, 354], ["some additional epidural hemorrhage", "PROBLEM", 366, 401], ["consistent with", "UNCERTAINTY", 13, 28], ["spinal cord", "ANATOMY", 39, 50], ["injury", "OBSERVATION", 51, 57], ["lumbar spine", "ANATOMY", 80, 92], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["cord", "ANATOMY", 125, 129], ["compression", "OBSERVATION", 130, 141], ["conus medullaris", "ANATOMY", 162, 178], ["T12", "ANATOMY_MODIFIER", 182, 185], ["L1", "ANATOMY_MODIFIER", 186, 188], ["displacement", "OBSERVATION", 202, 214], ["superior", "ANATOMY_MODIFIER", 222, 230], ["articular", "ANATOMY_MODIFIER", 231, 240], ["facets", "ANATOMY_MODIFIER", 241, 247], ["L1", "ANATOMY", 251, 253], ["small", "OBSERVATION_MODIFIER", 261, 266], ["ventral", "ANATOMY_MODIFIER", 267, 274], ["epidural", "ANATOMY", 275, 283], ["hematoma", "OBSERVATION", 284, 292], ["abnormal", "OBSERVATION_MODIFIER", 298, 306], ["soft tissue", "OBSERVATION", 307, 318], ["ventral", "ANATOMY_MODIFIER", 326, 333], ["epidural space", "ANATOMY", 334, 348], ["L2", "ANATOMY_MODIFIER", 352, 354], ["some", "OBSERVATION_MODIFIER", 366, 370], ["additional", "OBSERVATION_MODIFIER", 371, 381], ["epidural", "ANATOMY", 382, 390], ["hemorrhage", "OBSERVATION", 391, 401]]], ["Rupture of the anterior longitudinal ligament at T12-L1, and rupture of the T12-L1 disc with macerated disc tissue and extensive edema in the disc space were also manifested (Fig. 4).Case reportOne day after the MRI was obtained, the patient was still requiring high levels of oxygen and positive end expiratory pressure with mechanical ventilation.", [["anterior longitudinal ligament", "ANATOMY", 15, 45], ["disc tissue", "ANATOMY", 103, 114], ["edema", "ANATOMY", 129, 134], ["disc space", "ANATOMY", 142, 152], ["rupture", "DISEASE", 61, 68], ["edema", "DISEASE", 129, 134], ["oxygen", "CHEMICAL", 277, 283], ["oxygen", "CHEMICAL", 277, 283], ["anterior longitudinal ligament", "MULTI-TISSUE_STRUCTURE", 15, 45], ["disc tissue", "TISSUE", 103, 114], ["edema", "PATHOLOGICAL_FORMATION", 129, 134], ["disc space", "MULTI-TISSUE_STRUCTURE", 142, 152], ["patient", "ORGANISM", 234, 241], ["oxygen", "SIMPLE_CHEMICAL", 277, 283], ["patient", "SPECIES", 234, 241], ["Rupture of the anterior longitudinal ligament at T12-L1", "PROBLEM", 0, 55], ["rupture of the T12-L1 disc", "PROBLEM", 61, 87], ["macerated disc tissue", "PROBLEM", 93, 114], ["extensive edema in the disc space", "PROBLEM", 119, 152], ["the MRI", "TEST", 208, 215], ["high levels of oxygen", "TREATMENT", 262, 283], ["positive end expiratory pressure", "TREATMENT", 288, 320], ["mechanical ventilation", "TREATMENT", 326, 348], ["anterior", "ANATOMY_MODIFIER", 15, 23], ["longitudinal", "ANATOMY_MODIFIER", 24, 36], ["ligament", "ANATOMY", 37, 45], ["T12", "ANATOMY_MODIFIER", 49, 52], ["L1", "ANATOMY_MODIFIER", 53, 55], ["rupture", "OBSERVATION", 61, 68], ["T12", "ANATOMY_MODIFIER", 76, 79], ["L1", "ANATOMY_MODIFIER", 80, 82], ["disc", "ANATOMY", 83, 87], ["macerated", "OBSERVATION_MODIFIER", 93, 102], ["disc tissue", "OBSERVATION", 103, 114], ["extensive", "OBSERVATION_MODIFIER", 119, 128], ["edema", "OBSERVATION", 129, 134], ["disc", "ANATOMY", 142, 146], ["space", "ANATOMY_MODIFIER", 147, 152], ["expiratory pressure", "OBSERVATION", 301, 320], ["mechanical ventilation", "OBSERVATION", 326, 348]]], ["She became hypotensive despite aggressive pressor support and suffered yet another cardiac arrest with the patient ultimately expiring.DiscussionThe CPR guidelines released in 2010 and 2015 by the American Heart Association endorsed performing chest compressions at a speed of at least 100-120 compressions per minute and to a depth of at least 5 cm for adult patients with cardiac arrest [2,3].", [["cardiac", "ANATOMY", 83, 90], ["chest", "ANATOMY", 244, 249], ["cardiac", "ANATOMY", 374, 381], ["hypotensive", "DISEASE", 11, 22], ["cardiac arrest", "DISEASE", 83, 97], ["cardiac arrest", "DISEASE", 374, 388], ["cardiac", "ORGAN", 83, 90], ["patient", "ORGANISM", 107, 114], ["chest", "ORGANISM_SUBDIVISION", 244, 249], ["patients", "ORGANISM", 360, 368], ["patient", "SPECIES", 107, 114], ["patients", "SPECIES", 360, 368], ["hypotensive", "PROBLEM", 11, 22], ["aggressive pressor support", "TREATMENT", 31, 57], ["another cardiac arrest", "PROBLEM", 75, 97], ["chest compressions", "TREATMENT", 244, 262], ["cardiac arrest", "PROBLEM", 374, 388], ["hypotensive", "OBSERVATION", 11, 22], ["cardiac", "ANATOMY", 83, 90], ["arrest", "OBSERVATION", 91, 97], ["chest", "ANATOMY", 244, 249], ["cardiac", "ANATOMY", 374, 381], ["arrest", "OBSERVATION", 382, 388]]], ["The faster and deeper chest compressions intend to augment the survival rate.DiscussionDespite CPR being potentially life-saving, it is a traumatic procedure which may result in unforeseen complications.", [["chest", "ANATOMY", 22, 27], ["chest", "ORGAN", 22, 27], ["The faster and deeper chest compressions", "TREATMENT", 0, 40], ["the survival rate", "TEST", 59, 76], ["CPR", "TREATMENT", 95, 98], ["a traumatic procedure", "TREATMENT", 136, 157], ["unforeseen complications", "PROBLEM", 178, 202], ["chest", "ANATOMY", 22, 27]]], ["Skeletal injuries, particularly fractures of the ribs and sternum, are common complications of chest compressions [1].", [["Skeletal", "ANATOMY", 0, 8], ["ribs", "ANATOMY", 49, 53], ["sternum", "ANATOMY", 58, 65], ["chest", "ANATOMY", 95, 100], ["Skeletal injuries", "DISEASE", 0, 17], ["fractures", "DISEASE", 32, 41], ["Skeletal", "ORGAN", 0, 8], ["ribs", "ORGAN", 49, 53], ["sternum", "ORGAN", 58, 65], ["chest", "ORGANISM_SUBDIVISION", 95, 100], ["Skeletal injuries", "PROBLEM", 0, 17], ["fractures of the ribs and sternum", "PROBLEM", 32, 65], ["chest compressions", "TREATMENT", 95, 113], ["injuries", "OBSERVATION", 9, 17], ["fractures", "OBSERVATION", 32, 41], ["ribs", "ANATOMY", 49, 53], ["sternum", "ANATOMY", 58, 65], ["chest", "ANATOMY", 95, 100]]], ["Spinal fractures as a complication of CPR are exceedingly rare and have been minimally reported in the literature.", [["Spinal", "ANATOMY", 0, 6], ["Spinal fractures", "DISEASE", 0, 16], ["Spinal fractures", "PROBLEM", 0, 16], ["CPR", "TREATMENT", 38, 41], ["fractures", "OBSERVATION", 7, 16], ["minimally", "OBSERVATION_MODIFIER", 77, 86]]], ["Of cases that have been described, the fractures are mid-thoracic vertebral compression fractures [5], [6], [7], [8], [9].", [["vertebral", "ANATOMY", 66, 75], ["fractures", "DISEASE", 39, 48], ["vertebral compression fractures", "DISEASE", 66, 97], ["[6], [7], [8]", "SIMPLE_CHEMICAL", 103, 116], ["the fractures", "PROBLEM", 35, 48], ["mid-thoracic vertebral compression fractures", "PROBLEM", 53, 97], ["fractures", "OBSERVATION", 39, 48], ["mid-thoracic", "ANATOMY_MODIFIER", 53, 65], ["vertebral", "ANATOMY", 66, 75], ["compression fractures", "OBSERVATION", 76, 97]]], ["The most common fracture location is at the mid-thoracic level because compressive forces during CPR are focused along the anterior and middle columns of the mid-thoracic curve [10].", [["anterior", "ANATOMY", 123, 131], ["middle columns", "ANATOMY", 136, 150], ["fracture", "DISEASE", 16, 24], ["anterior", "MULTI-TISSUE_STRUCTURE", 123, 131], ["The most common fracture location", "PROBLEM", 0, 33], ["compressive forces", "PROBLEM", 71, 89], ["CPR", "TREATMENT", 97, 100], ["most", "OBSERVATION_MODIFIER", 4, 8], ["common", "OBSERVATION_MODIFIER", 9, 15], ["fracture", "OBSERVATION", 16, 24], ["mid-thoracic", "ANATOMY", 44, 56], ["compressive", "OBSERVATION_MODIFIER", 71, 82], ["forces", "OBSERVATION_MODIFIER", 83, 89], ["anterior", "ANATOMY_MODIFIER", 123, 131], ["middle", "ANATOMY_MODIFIER", 136, 142], ["columns", "ANATOMY_MODIFIER", 143, 150], ["mid-thoracic curve", "ANATOMY", 158, 176]]], ["To our knowledge, a T12-L1 spinal injury with wide diastasis has not been published.DiscussionPrevious cases speculate that some degree of skeletal susceptibility such as osteoporosis, osteopenia, or kyphosis could be culpable for spinal fractures during CPR.", [["spinal", "ANATOMY", 27, 33], ["skeletal", "ANATOMY", 139, 147], ["spinal", "ANATOMY", 231, 237], ["spinal injury", "DISEASE", 27, 40], ["diastasis", "DISEASE", 51, 60], ["osteoporosis", "DISEASE", 171, 183], ["osteopenia", "DISEASE", 185, 195], ["kyphosis", "DISEASE", 200, 208], ["fractures", "DISEASE", 238, 247], ["skeletal", "ORGAN", 139, 147], ["spinal", "ORGAN", 231, 237], ["a T12-L1 spinal injury", "PROBLEM", 18, 40], ["wide diastasis", "PROBLEM", 46, 60], ["skeletal susceptibility", "PROBLEM", 139, 162], ["osteoporosis", "PROBLEM", 171, 183], ["osteopenia", "PROBLEM", 185, 195], ["kyphosis", "PROBLEM", 200, 208], ["spinal fractures", "PROBLEM", 231, 247], ["CPR", "TREATMENT", 255, 258], ["T12", "ANATOMY", 20, 23], ["L1", "ANATOMY_MODIFIER", 24, 26], ["spinal", "ANATOMY", 27, 33], ["injury", "OBSERVATION", 34, 40], ["wide", "OBSERVATION_MODIFIER", 46, 50], ["diastasis", "OBSERVATION", 51, 60], ["some degree", "OBSERVATION_MODIFIER", 124, 135], ["skeletal", "ANATOMY", 139, 147], ["susceptibility", "OBSERVATION", 148, 162], ["osteoporosis", "OBSERVATION", 171, 183], ["osteopenia", "OBSERVATION", 185, 195], ["kyphosis", "OBSERVATION", 200, 208], ["spinal", "ANATOMY", 231, 237], ["fractures", "OBSERVATION", 238, 247]]], ["Osteopenia is an important major risk factor for all different types of fractures.", [["Osteopenia", "DISEASE", 0, 10], ["fractures", "DISEASE", 72, 81], ["Osteopenia", "PROBLEM", 0, 10], ["fractures", "PROBLEM", 72, 81], ["fractures", "OBSERVATION", 72, 81]]], ["Dorsal kyphosis can increase the lumbar lordosis, therefore, exposing the spine to greater shearing forces during active chest compressions [6,8].", [["Dorsal", "ANATOMY", 0, 6], ["lumbar", "ANATOMY", 33, 39], ["spine", "ANATOMY", 74, 79], ["chest", "ANATOMY", 121, 126], ["kyphosis", "DISEASE", 7, 15], ["lumbar", "ORGANISM_SUBDIVISION", 33, 39], ["spine", "ORGAN", 74, 79], ["chest", "ORGANISM_SUBDIVISION", 121, 126], ["Dorsal kyphosis", "PROBLEM", 0, 15], ["the lumbar lordosis", "PROBLEM", 29, 48], ["active chest compressions", "TREATMENT", 114, 139], ["kyphosis", "OBSERVATION", 7, 15], ["lumbar lordosis", "ANATOMY", 33, 48], ["spine", "ANATOMY", 74, 79], ["chest", "ANATOMY", 121, 126]]], ["Although our patient was morbidly obese, her initial CT of the C/A/P demonstrated an almost fusion of her thoracolumbar spine from severe DISH, as well as a significant thoracic kyphosis.", [["thoracolumbar spine", "ANATOMY", 106, 125], ["thoracic", "ANATOMY", 169, 177], ["DISH", "DISEASE", 138, 142], ["thoracic kyphosis", "DISEASE", 169, 186], ["patient", "ORGANISM", 13, 20], ["thoracolumbar spine", "MULTI-TISSUE_STRUCTURE", 106, 125], ["thoracic", "ORGAN", 169, 177], ["patient", "SPECIES", 13, 20], ["morbidly obese", "PROBLEM", 25, 39], ["her initial CT of the C/A/P", "TEST", 41, 68], ["an almost fusion of her thoracolumbar spine", "PROBLEM", 82, 125], ["severe DISH", "PROBLEM", 131, 142], ["a significant thoracic kyphosis", "PROBLEM", 155, 186], ["fusion", "OBSERVATION", 92, 98], ["thoracolumbar spine", "ANATOMY", 106, 125], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["DISH", "OBSERVATION", 138, 142], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["thoracic", "ANATOMY", 169, 177], ["kyphosis", "OBSERVATION", 178, 186]]], ["The patient's underlying spine disease of severe DISH is a major contributing factor for this type of fracture as it functionally creates a long lever arm of the spine.DiscussionWe hypothesize that older age with decreased bone density, DISH, severe kyphosis, and forceful chest compressions during prolonged CPR all contributed to the T12-L1 separation.", [["spine", "ANATOMY", 25, 30], ["spine", "ANATOMY", 162, 167], ["bone", "ANATOMY", 223, 227], ["chest", "ANATOMY", 273, 278], ["DISH", "DISEASE", 49, 53], ["fracture", "DISEASE", 102, 110], ["DISH", "DISEASE", 237, 241], ["kyphosis", "DISEASE", 250, 258], ["patient", "ORGANISM", 4, 11], ["spine", "ORGAN", 25, 30], ["spine", "ORGAN", 162, 167], ["bone", "TISSUE", 223, 227], ["chest", "ORGANISM_SUBDIVISION", 273, 278], ["patient", "SPECIES", 4, 11], ["The patient's underlying spine disease", "PROBLEM", 0, 38], ["severe DISH", "PROBLEM", 42, 53], ["fracture", "PROBLEM", 102, 110], ["decreased bone density", "PROBLEM", 213, 235], ["DISH", "PROBLEM", 237, 241], ["severe kyphosis", "PROBLEM", 243, 258], ["forceful chest compressions", "PROBLEM", 264, 291], ["prolonged CPR", "TREATMENT", 299, 312], ["spine", "ANATOMY", 25, 30], ["disease", "OBSERVATION", 31, 38], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["DISH", "OBSERVATION", 49, 53], ["fracture", "OBSERVATION", 102, 110], ["spine", "ANATOMY", 162, 167], ["decreased", "OBSERVATION_MODIFIER", 213, 222], ["bone", "ANATOMY", 223, 227], ["density", "OBSERVATION", 228, 235], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["kyphosis", "OBSERVATION", 250, 258], ["chest", "ANATOMY", 273, 278], ["T12", "ANATOMY", 336, 339], ["L1", "ANATOMY", 340, 342]]], ["As the patient's initial CT of the C/A/P did not show any injury to the thoracic or lumbar vertebrae, we feel confident the T12/L1 spinal separation did in fact result from cardiopulmonary resuscitative efforts.", [["thoracic", "ANATOMY", 72, 80], ["lumbar vertebrae", "ANATOMY", 84, 100], ["spinal", "ANATOMY", 131, 137], ["patient", "ORGANISM", 7, 14], ["thoracic", "ORGAN", 72, 80], ["lumbar vertebrae", "MULTI-TISSUE_STRUCTURE", 84, 100], ["patient", "SPECIES", 7, 14], ["the patient's initial CT of the C/A/P", "TEST", 3, 40], ["any injury to the thoracic or lumbar vertebrae", "PROBLEM", 54, 100], ["the T12/L1 spinal separation", "PROBLEM", 120, 148], ["cardiopulmonary resuscitative efforts", "TREATMENT", 173, 210], ["injury", "OBSERVATION", 58, 64], ["thoracic", "ANATOMY", 72, 80], ["lumbar vertebrae", "ANATOMY", 84, 100], ["T12", "ANATOMY", 124, 127], ["L1 spinal", "ANATOMY", 128, 137]]], ["Because the patient was transferred to our facility, it is unknown if CPR was performed on a hospital bed mattress or if the patient was placed on a backboard.", [["patient", "ORGANISM", 12, 19], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 12, 19], ["patient", "SPECIES", 125, 132], ["a hospital bed mattress", "TREATMENT", 91, 114], ["a backboard", "TREATMENT", 147, 158]]], ["Much of the research about the performance of CPR on various support surfaces has been performed on manikins and it is unclear how the results could be translated to the CPR performed on humans.", [["humans", "ORGANISM", 187, 193], ["humans", "SPECIES", 187, 193], ["humans", "SPECIES", 187, 193], ["CPR", "TREATMENT", 46, 49], ["various support surfaces", "TREATMENT", 53, 77], ["manikins", "TREATMENT", 100, 108], ["the CPR", "TEST", 166, 173]]], ["Limited manikin studies have demonstrated a small benefit of increased chest compression depth when using a backboard.", [["chest", "ANATOMY", 71, 76], ["chest", "ORGANISM_SUBDIVISION", 71, 76], ["Limited manikin studies", "TEST", 0, 23], ["increased chest compression depth", "PROBLEM", 61, 94], ["a backboard", "TREATMENT", 106, 117], ["small", "OBSERVATION_MODIFIER", 44, 49], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["chest", "ANATOMY", 71, 76], ["compression", "OBSERVATION", 77, 88]]], ["The benefit was not enough to make a recommendation to routinely use a harder surface such as a backboard over the standard hospital bed mattress [11].DiscussionThe lumbosacral spinal cord starts at T9 and continues to L2.", [["surface", "ANATOMY", 78, 85], ["lumbosacral spinal cord", "ANATOMY", 165, 188], ["lumbosacral spinal cord", "ORGAN", 165, 188], ["a harder surface", "TREATMENT", 69, 85], ["a backboard over the standard hospital bed mattress", "TREATMENT", 94, 145], ["lumbosacral", "ANATOMY_MODIFIER", 165, 176], ["spinal cord", "ANATOMY", 177, 188], ["T9", "ANATOMY", 199, 201], ["L2", "ANATOMY", 219, 221]]], ["Therefore, the patient did suffer significant motor and sensory loss to her bilateral lower extremities.", [["lower extremities", "ANATOMY", 86, 103], ["motor and sensory loss", "DISEASE", 46, 68], ["patient", "ORGANISM", 15, 22], ["lower extremities", "ORGANISM_SUBDIVISION", 86, 103], ["patient", "SPECIES", 15, 22], ["significant motor and sensory loss to her bilateral lower extremities", "PROBLEM", 34, 103], ["sensory loss", "OBSERVATION", 56, 68], ["bilateral", "ANATOMY_MODIFIER", 76, 85], ["lower extremities", "ANATOMY", 86, 103]]], ["She was classified on The American Spinal Injury Association/International Spinal Cord Society Neurological Standard Scale (ASIA Impairment Scale) as ASIA C; motor function preserved but with more than half of the muscles in the lower extremities having a muscle grade of less than 3 [12].", [["muscles", "ANATOMY", 214, 221], ["lower extremities", "ANATOMY", 229, 246], ["muscle", "ANATOMY", 256, 262], ["muscles", "ORGAN", 214, 221], ["lower extremities", "ORGANISM_SUBDIVISION", 229, 246], ["muscle", "ORGAN", 256, 262], ["International Spinal Cord Society Neurological Standard Scale (ASIA Impairment Scale)", "TREATMENT", 61, 146], ["motor function", "TEST", 158, 172], ["Spinal", "ANATOMY", 35, 41], ["Injury", "OBSERVATION", 42, 48], ["Spinal Cord", "ANATOMY", 75, 86], ["muscles", "ANATOMY", 214, 221], ["lower extremities", "ANATOMY", 229, 246], ["muscle", "ANATOMY", 256, 262]]], ["The severe spinal cord injury, combined with older age, preexisting DISH, Covid-19, bilateral pneumonia, and morbid obesity all contributed to the patient's death.ConclusionCPR can be an important life-saving procedure, but strict attention to proper technique is of paramount importance as it can have many possible complications.", [["spinal cord", "ANATOMY", 11, 22], ["cord injury", "DISEASE", 18, 29], ["DISH", "DISEASE", 68, 72], ["pneumonia", "DISEASE", 94, 103], ["obesity", "DISEASE", 116, 123], ["death", "DISEASE", 157, 162], ["spinal cord", "ORGAN", 11, 22], ["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["The severe spinal cord injury", "PROBLEM", 0, 29], ["preexisting DISH", "PROBLEM", 56, 72], ["Covid", "TEST", 74, 79], ["bilateral pneumonia", "PROBLEM", 84, 103], ["morbid obesity", "PROBLEM", 109, 123], ["the patient's death", "PROBLEM", 143, 162], ["saving procedure", "TREATMENT", 202, 218], ["complications", "PROBLEM", 317, 330], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["spinal cord", "ANATOMY", 11, 22], ["injury", "OBSERVATION", 23, 29], ["bilateral", "ANATOMY_MODIFIER", 84, 93], ["pneumonia", "OBSERVATION", 94, 103], ["morbid", "OBSERVATION_MODIFIER", 109, 115], ["obesity", "OBSERVATION", 116, 123]]], ["While injuries to the spine seem to rarely occur following cardiopulmonary resuscitative efforts, they can be easily missed and a high index of suspicion by providers is necessary.Patient consent statementThe patient's family was able to see her over FaceTime prior to withdrawing care.", [["spine", "ANATOMY", 22, 27], ["injuries to the spine", "DISEASE", 6, 27], ["spine", "ORGAN", 22, 27], ["patient", "ORGANISM", 209, 216], ["Patient", "SPECIES", 180, 187], ["patient", "SPECIES", 209, 216], ["cardiopulmonary resuscitative efforts", "TREATMENT", 59, 96], ["withdrawing care", "TREATMENT", 269, 285], ["spine", "ANATOMY", 22, 27]]]]}